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Abstract 
 
Hepatocellular carcinoma (HCC) often arises on the background of chronic liver 
disease, and effective systemic treatments for HCC are limited. The disease is 
common globally and the majority of those affected survive less than 1 year. 
Expression of Sulfatase 2 (SULF2), an extracellular heparan sulfate 6-O-
endosulfatase which modulates growth factor/receptor tyrosine kinase and Wnt 
signalling, has been reported to be increased at the mRNA level in advanced HCC. 
This thesis has explored the potential of SULF2 as a candidate for targeted anti-
cancer therapy. 
Expression of SULF2 was compared at the mRNA and protein levels in 6 HCC cell 
lines. The impact of SULF2 silencing on signalling pathways and cell growth was 
assessed in vitro and in vivo using shRNA.  
Three of the 6 HCC cell lines showed high SULF2 expression at both the mRNA 
and protein level. The effect of SULF2 gene silencing in HCC cells was cell line-
dependent, with inhibition of Wnt-3a-induced β-catenin-dependent transcriptional 
activity in the HuH-7 cell line and inhibition of FGF-1/2-stimulated phosphorylation 
of ERK, and IGF-II-stimulated phosphorylation of AKT, in the SNU-182 cell line. 
SULF2 suppression significantly reduced cell growth and proliferation in both cell 
lines. Xenograft implantation using HuH-7 cells was completely abrogated by 
silencing of SULF2. Microarray gene expression analysis of HuH-7 cell lines 
showed that SULF2 suppression dramatically upregulated catalytically active 
angiotensin converting enzyme 2 (ACE2) at the mRNA and protein level. The level 
of the ACE2 product, the hepta-peptide angiotensin 1-7 that has been reported to 
have anti-proliferative and anti-angiogenic activities, was also increased.  
Recombinant SULF2 enzyme was produced and purified, and commercially 
available sulfatases were characterised, for screening of potential small-molecule 
inhibitors of SULF2. Together, the studies described in this thesis have shown that 
SULF2 is an attractive and tractable target for the treatment of HCC. 
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1. Chapter 1. Introduction 
 
1.1. Hepatocellular Carcinoma  
1.1.1. Incidence 
Hepatocellular carcinoma (HCC) is the leading primary malignancy of the liver in 
adults and accounts for about 85% of primary liver cancers. Globally, HCC is the 
fifth most widespread solid tumour and the third leading cause of cancer death 
(Parkin et al., 2005). During the last 30 years, the incidence and deaths from liver 
cancer have progressively increased in the United States and other western 
countries (Edwards et al., 2010). 
1.1.2. Aetiology  
HCC arises in the background of chronic hepatitis or cirrhosis in approximately 
80% of cases. Chronic infection with hepatitis B virus (HBV) or hepatitis C virus 
(HCV) are the commonest causes of chronic liver disease worldwide (Bosch et al., 
2005), while non-alcoholic fatty liver disease (NAFLD) is now the commonest 
cause in western societies (Starley et al. 2010). Other factors also contribute to the 
aetiology of liver disease and/or HCC, including alcohol ingestion (Ribes et al., 
2008), dietary exposure to aflatoxin B1 (AFB) (Wild and Gong, 2010) (Liu and Wu, 
2010), obesity, diabetes mellitus (Regimbeau et al., 2004), and oral contraceptives 
(El-Serag and Rudolph, 2007). All these risk factors either cause genetic 
aberrations and lead to the formation of HCC, or create an environment where the 
growth of cells with genetic aberrations conferring a survival advantage is 
encouraged. 
1.1.3. Chronologic sequence of HCC development 
Hepatocarcinogenesis in humans progresses through a process that could require 
>30 years following the first diagnosis of chronic infection with HBV or HCV (Figure 
 1.1). Only a proportion of patients with chronic hepatitis develop cirrhosis or HCC. 
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An increased incidence of HCC occurs in the setting of cirrhosis or chronic 
hepatitis (Figure  1.1), and in these two conditions several events are ongoing, 
including the presence of a large number of dead hepatocytes, infiltration of 
inflammatory cells and excessive deposition of connective tissue into the liver. All 
these events lead to highly modified matrix structure and hepatic microenvironment 
(Thorgeirsson and Grisham, 2002). 
Figure  1.1 depicts the sequence of events that precede the development of HCC. 
This sequence involves the formation of phenotypically altered hepatocytes that is 
followed by the development of dysplastic hepatocytes that form preneoplastic foci 
or nodules (Thorgeirsson and Grisham, 2002). 
 
Figure ‎1.1: Sequential changes in the human liver that lead to the development of 
HCC (adapted from Thorgeirsson and Grisham, 2002).  
 
1.1.4. Staging  
In general, staging is an essential process for predicting the prognosis and guiding 
the management of patients with cancer. A number of staging and prognostic 
systems for HCC are being used currently, though none is universally adopted or 
regularly employed in clinical trials. This diversity in staging systems is partly 
attributable to the heterogeneity of the disease, but also the significant impact that 
the underlying liver disease and function can have on outcome. A range of clinical 
and radiologic parameters are encompassed into HCC scoring schemes that 
define specific staging systems, such as the CLIP or CUPI scores, for example 
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(Table  1.1) (Gallo et al., 1998) (Clark et al., 2005). These systems are proposed 
replacements for the traditional TNM stage used commonly in other cancer types, 
and there are currently three well-validated systems, namely, BCLC, JIS and CLIP 
(Pons et al., 2005). All these three systems depend on the Child-Pugh score which 
is utilized to evaluate the prognosis of chronic liver disease, particularly cirrhosis. 
Table  1.1 lists the different staging systems of HCC with their evaluated 
parameters and classifications. 
Table ‎1.1: HCC staging systems and their evaluated variables (adapted from Pons 
et al., 2005). 
Classification Type Stages Variables 
Tumour Stage Liver Function 
Barcelona-
Clinic Liver 
Cancer 
(BCLC) 
Staging 0: Very Early 
A: Early 
B: Intermediate 
C: Advanced 
D: End-Stage 
Portal invasion 
Metastases 
Morphology 
Okuda 
Performance status 
Child-Pugh 
Portal hypertension 
Bilirubin 
The Cancer of 
the Liver 
Italian 
Program 
(CLIP) 
Score 0, 1, 2, 3, 4, 5, 6 Portal invasion 
</> 50% liver 
involvement 
Alpha-fetoprotein 
Child-Pugh 
Chinese 
University 
Prognostic 
Index (CUPI) 
Score Low risk: ≤1 
Intermediate: 2-
7 
High: ≥8 
TNM 
Alpha-fetoprotein 
Ascites 
Bilirubin 
Alkaline 
phosphatase 
Estrogen 
Receptor 
(E.R.) 
System 
  
E.R. wild-type 
E.R. variant 
Oestrogen receptor 
  
- 
  
French Score A: 0 points; 
B: 1-5 Points; 
C: ≥6 Points 
Portal invasion 
Alpha-fetoprotein 
Bilirubin 
Alkaline 
phosphatase 
Japan 
Integrated 
Staging (JIS) 
Score Stage I, II, III, IV TNM Child-Pugh 
Okuda Stage System Stage I, II, III 50% liver 
involvement 
Bilirubin 
Albumin 
Ascites 
Tumour-Node-
Metastasis 
(TNM) 
System Stage I, II, III Morphology 
Vascular invasion 
Metastases 
Fibrosis 
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1.1.5. Treatment approaches 
There have been many improvements in the prevention and management of HCC, 
including enhanced treatment of HCV (Tokita et al., 2005) (Kulik et al., 2006), lower 
frequency of HBV infection due to vaccination programs in some countries (Chang 
et al., 2009) (Beasley, 2009), improved screening and early detection of HCC in 
patients at high risk of developing the disease (Schutte et al., 2009), as well as the 
FDA approval of the multi-kinase inhibitor sorafenib for the treatment of patients 
with advanced HCC (Lang, 2008) (Kane et al., 2009). 
A number of treatment approaches are available for patients with HCC; however, 
the only curative treatments are surgical. Resection is often not possible because 
of the poor regenerative capacity of the underlying chronically diseased liver. 
Therefore, liver transplantation is often the only potential cure, but it is applicable to 
only a small percentage of patients. Surgical treatments are limited to those 
presenting with early stage disease, with little co-morbidity (Thomas et al., 2010).  
While liver transplantation is also preferred because it eradicates the risk of  
developing new primary tumours on the background of cirrhosis, the availability of 
donor organs is a severe limitation (Taura et al., 2007) (Nuzzo et al., 2007). Thus 
resection remains an option for those with cirrhosis which is not complicated by 
significant portal hypertension, and larger resections can be carried out in patients 
with healthy hepatic parenchyma, who do not have underlying chronic liver disease 
(Teh et al., 2005) (Cunningham et al., 2009). 
In cases where patients are not eligible for resection or transplantation, but with a 
liver-confined tumour, locoregional modalities might be employed. These 
modalities include radiofrequency ablation (RFA), percutaneous ethanol injection, 
transarterial chemoembolization (TACE) and cryotherapy. These approaches are 
not curative but help reduce or destroy tumour and may enable a more definitive 
treatment such as liver transplantation at a later stage (Heckman et al., 2008) 
(Pompili et al., 2008) (Belghiti et al., 2008). 
Clinically, HCC is resistant to chemotherapy as evidenced by the poor response to 
different chemotherapeutic agents. Impairment of liver function further limits the 
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usefulness of cytotoxic chemotherapy and both factors contribute to the lack of 
evidence that systemic treatment enhances overall survival (OS) of HCC patients 
(Simonetti et al., 1997). The multi-kinase inhibitor and anti-angiogenic agent 
sorafenib, which has manageable treatment-related adverse events (lethargy, 
gastrointestinal disturbances, hand and feet rash) has been shown to increase OS, 
albeit by only a few weeks (Llovet et al., 2008) (Cheng et al., 2009), and sorafenib 
provides “proof of concept” that targeting agents can have useful clinical activity in 
HCC. Therefore, there is an unequivocal requirement for safer and more effective 
systemic agents for advanced HCC, especially where there is liver dysfunction or 
sorafenib intolerance.  
One potential way to improve HCC therapy is to identify a cancer-causing gene 
with a cancer specific expression pattern and a protein product amenable, by virtue 
of location and biochemistry, to small molecule inhibition. Ideally, targeting the 
product of this gene would elicit either a cytotoxic tumour response (i.e. partial or 
complete regression) or sustained tumour growth inhibition (i.e. stable disease). 
One such promising candidate is sulfatase 2 (SULF2), which is a member of the 
sulfatase gene family containing 17 different enzymes. SULF2 catalyses the 
desulfation of its biological substrate heparan sulfate proteoglycans (HSPGs) 
extracellularly, thereby regulating different signalling pathways. The following four 
sections will describe the sulfatase family of enzymes, the natural substrate 
HSPGs of SULF2, the structure and characteristics of SULF2 and the reported role 
of SULF2 in different types of cancer.   
1.2. The Sulfatase Family 
Sulfatases are enzymes that catalyse the hydrolysis of sulfate esters (R-OSO3
-) 
and sulfamates (R-NHSO3
-) as illustrated in the reactions below (Diez-Roux and 
Ballabio, 2005) 
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This desulfating action is shared by all sulfatases, although each sulfatase has its 
own substrate specificity extending from complicated glycosaminoglycans (GAGs) 
to smaller hydroxysteroids and sulfolipids molecules (Diez-Roux and Ballabio, 
2005). Currently, studies have uncovered the presence of 17 different human 
genes coding for genuine sulfatases, while there are only 14 in rodents (Sardiello 
et al., 2005). Human sulfatases can be categorized into three groups based on 
their cellular localization and pH-dependent functions (Sardiello et al., 2005) 
(Buono and Cosma, 2010), and these are listed in Table 1.2. 
Table ‎1.2: Human sulfatases with their cellular localization and pH-dependent 
functions. 
Cellular localization 
pH-dependency 
Sulfatase name Symbol Cytogenetic 
location 
 
 
Lysosomal 
Acidic pH-dependent 
Arylsulfatase A ARSA 22q13.3 
Arylsulfatase B ARSB 5q14.1 
N-acetylgalactosamine-6-sulfatase GALNS 16q24.3 
N-acetylglucosamine-6-sulfatase   GNS  
(G6S) 
12q14.2–
12q14.3 
N-sulfoglucosamine sulfohydrolase 
(or heparan  N-sulfatase) 
SGSH 17q25.3 
Iduronate-2-sulfatase   IDS Xq28 
 
Non-
lysosomal 
Neutral pH-
dependent 
Microsomal Arylsulfatase  C 
(or steroid sulfatase) 
ARSC 
(STS) 
Xp22.3 
Endoplasmic 
reticulum 
Arylsulfatase  D ARSD Xp22.3 
Arylsulfatase  F ARSF Xp22.3 
Arylsulfatase  G ARSG 17q24.2 
Arylsulfatase  I ARSI 5q32 
Arylsulfatase  J ARSJ 4q26 
Golgi Arylsulfatase  E ARSE Xp22.3 
Not 
determined 
Arylsulfatase  H ARSH Xp22.3 
Arylsulfatase  K ARSK 5q15 
Extracellular 
Neutral–basic  
pH-dependent 
Sulfatase 1 SULF1 8q13.2–
8q13.3 
Sulfatase 2 SULF2 20q13.1 
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Regardless of their substrate specificity, sulfatases have sequence homology. Four 
domains constitute the protein structure: the highly conserved A, B and C and the 
less conserved D domains. Domains A, B and C contribute to form the N-terminus 
whereas D contains the C-terminus (Buono and Cosma, 2010). The active site is 
contained within the B domain where > 90% similarity has been found among all 
sulfatases, suggesting evolutionarily constrained regions (ECRs) which might be 
indispensable for the enzymatic activity of sulfatases (Sardiello et al., 2005). 
Essential for sulfatase activity and present in the catalytic active site is a Cα-
formylglycine (FGly) residue. FGly is produced posttranslationally from a cysteine 
residue that is contained within a consensus motif (Landgrebe et al., 2003). In 
eukaryotes, FGly generation occurs in the endoplasmic reticulum by the activity of 
FGly-generating enzyme (FGE) that is encoded by the SUMF1 (sulfatase 
modifying factor 1) gene (Dierks et al., 1997) (Dierks et al., 2003) (Cosma et al., 
2003). 
Sulfatases include asparagines which are glycosylated and are therefore regarded 
as glycoproteins. N-Glycosylation has been predicted for all sulfatases by 
bioinformatic methodology through identifying consensus sequences for N-
glycosylation (Buono and Cosma, 2010). However, no crystallography data have 
been generated for the majority of human sulfatases, with the exception of 
arylsulfatases A, B and C, and no structure biology evidence for glycosylation 
exists. Nevertheless, it has been reported that N-linked glycosylation can control 
the appropriate folding, stability and assembly of glycoproteins (Helenius, 1994) 
(Helenius and Aebi, 2001), and proper folding of human sulfatases could similarly 
rely on oligosaccharide modification. For example, expression of unglycosylated 
iduronate-2-sulfatase (IDS) led to unprocessed and catalytically inactive enzyme 
(Millat et al., 1997). 
1.3. Heparan Sulfate Proteoglycans  
1.3.1. Structure and characteristics 
Heparan sulfate proteoglycans (HSPGs) consist of one or more chains of heparan 
sulfate (HS) glycosaminoglycans (GAGs) that are attached to a core protein. 
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HSGAGs are sequences of polysaccharides made up of alternating uronic acid 
units (iduronic acid (IdoA) or glucuronic acid (GlcA)) and glucosamine units that are 
N-acetylated or N-sulfated to give N-acetylglucosamine (GlcNAc) and N-
sulfoglucosamine (GlcNS), respectively (Figure  1.2) (Lamanna et al., 2007) 
(Bishop et al., 2007). 
The HS chains are assembled in the Golgi apparatus and attached by the activity 
of different enzymes onto core proteins to form HSPGs. In the course of their 
formation, HS chains go through numerous modifications including C5 
epimerization of GlcA to IdoA, N-deacetylation and N-sulfation of GlcNAc, and O-
sulfation of uronic acids at C2 or of glucosamine at C6 and to a less extent at C3 
(denoted 2S, 6S and 3S, respectively) (Figure  1.2) (Bernfield et al., 1999) 
(Perrimon and Bernfield, 2000). Sulfation is catalysed by sulfotransferases in the 
lumen of Golgi apparatus where 3’-phosphoadenosine 5’-phosphosulfate is the 
sulfate donor (Abeijon et al., 1997) (Honke and Taniguchi, 2002). 
These modifications of HS chains lead to the formation of interspersed sulfated 
and non-sulfated fragments, and generates a high degree of heterogeneity with 
respect to chain stretch, location of modified fragments and the degree of 
epimerization and sulfation inside the fragments. Figure  1.3 depicts the three 
domains that contribute to HS chain structure with their compositions, namely, the 
highly-sulfated S domains that are flanked by the less-sulfated transition zones. 
Both domains are separated by non-sulfated domains (Gallagher, 2006) (Bishop et 
al., 2007). 
HSPGs differ in their cellular localization and can be divided into three groups: the 
first group spans the cell membrane and includes syndecans and betagylcan, 
whereas members of the second group are linked to glycosylphosphatidylinositol 
(GPI) and include glypicans. In contrast, the third group is secreted into the 
extracellular space and examples include perlecan, collagen XVIII and agrin 
(Figure  1.4) (Bernfield et al., 1999) (Bishop et al., 2007). 
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Figure ‎1.2: HS disaccharide composition: The main disaccharide alternating 
units are GlcNAc or GlcNS and a uronic acid either GlcA or IdoA. In the case of 
GlcNAc, it is always connected to GlcA (a). While GlcNS is predominantly linked to 
IdoA (b) where they are commonly sulfated at C6 and C2, respectively. GlcNAc 
can also undergo C6 sulfation when neighbouring a GlcNS-containing 
disaccharide. Additionally, C3 sulfation of GlcNS and C2 sulfation of GlcA may 
occur but to a less extent (adapted from Gallagher, 2006). 
 
 
Figure ‎1.3: HS domain structure: HS chains can undergo different modifications 
including epimerization, N- and O-sulfation leading to the formation of non-sulfated 
(NA) domains that disperse highly sulfated (NS) S-domains, and less sulfated 
(NA/NS) transition zones (adapted from Gallagher, 2006). 
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Figure ‎1.4: HSPG subgroups: HSPGs can be divided according to their cellular 
localization into three subgroups: the membrane spanning HSPGs such as 
syndecans, the GPI-linked glypicans, and the secreted extracellular HSPGs like 
perlecan (adapted from Lamanna et al., 2007). 
 
1.3.2. Functions 
The presence of uronic acid moieties and sulfate groups that are negatively 
charged in HS chains produces binding sites for a number of different proteins with 
diverse functions, as listed in Table  1.3. Consequently, HSPGs can perform a 
variety of signalling and structural functions (Bishop et al., 2007). HS can associate 
with extracellular matrix (ECM) components such as interstitial collagen, laminins 
and fibronectin, and it has been found to have indispensable roles in mediating 
interactions between cells or between cells and the ECM. Furthermore, the ability 
of HS to associate with different protein ligands (Table  1.3) makes the ligands 
more available to bind to the cell surface or ECM (Bernfield et al., 1999) 
(Vlodavsky et al., 2002). For example, the role of HS in facilitating the binding of 
fibroblast growth factors (FGFs) to their cognate receptors has been described 
extensively (Mohammadi et al., 2005) (Forsten-Williams et al., 2005). In contrast, 
the binding of HSPGs may also lead to sequestration of bioactive proteins, such as 
vascular endothelial growth factor (VEGF), thereby inhibiting their function. The 
association between HS and different ligands can also help to protect the latter 
from proteolytic cleavage, while in other instances HSPGs serve as co-receptors 
(Bernfield et al., 1999) (Vlodavsky et al., 2002).    
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Table ‎1.3: Protein ligands that interact with HS.  
General Class Examples 
Growth factors FGF-1, FGF-2, HGF, HB-EGF, VEGF, PDGF, amphiregulin 
Growth factor receptor FGFR 
ECM molecules Laminin, fibronectin, thrombospondin, fibrin, collagens, 
tenascin, vitronectin 
Morphogens TGF-β, BMPs, Wnts, Shh 
Enzymes Urokinase, hyaluronidase, elastase, superoxide dismutase, 
thrombin 
Enzyme inhibitor Antithrombin (protease inhibitor) 
Cytokines IL-7, IFN-g, IL-3, TNF-a, GM-CSF 
Chemokines IL-8, CXCL12, CCL21 
Adhesion molecules L-selectin, Mac-1, NCAM, PECAM-1 
 
Adapted from Rosen and Lemjabbar-Alaoui, 2010 and Bishop et al., 2007. 
FGF: fibroblast growth factor, HGF: hepatocyte growth factor, HB-EGF: heparin 
binding-epidermal growth factor, VEGF: vascular endothelial growth factor, PDGF: 
platelet-derived growth factor, ECM: extracellular matrix, FGFR: fibroblast growth 
factor receptor, TGF-β: transforming growth factor-β, BMPs: bone morphogenetic 
proteins, Shh: sonic hedgehog. 
 
1.3.3. Modifications  
Since HSPGs have numerous important functions, modification of HSPG structure 
provides the cells with a mechanism of response to variations in the extracellular 
compartment. For example, HSPGs can be modified and hence their function can 
be altered by the activity of heparanase that can cleave HS at specific sites by 
endoglycosidic activity (Vlodavsky et al., 2002). As a consequence, ligands 
sequestered by HSPGs, such as angiogenic factors, are released and access their 
receptors, thereby leading to phenotypic effects (Figure  1.5).     
Another modification of HS chains concerns the sulfate group at the 6-O position of 
glucosamine which has been reported to be essential for the binding of several 
proteins to HS (Gallagher, 2001) (Habuchi et al., 2004), and three HS 6-O-
sulfotransferases (HS6STs) have been found in humans and mice that catalyse the 
6-O sulfation (Figure 1.2) (Habuchi et al., 2000) (Habuchi et al., 2003). Two 
extracellular glucosamine 6-O endosulfatases SULF1 and SULF2 (collectively, 
referred to as SULF1/2) counteract the effect of HS6ST by postsynthetically 
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catalysing the removal of 6-O-sulfate from HS at the cell surface or the ECM 
(Dhoot et al., 2001) (Morimoto-Tomita et al., 2002) (Ohto et al., 2002). Therefore, 
the sulfation status at the 6-O position of HSPGs is controlled by two groups of 
enzymes (the SULF1/2 and HS6STs) whose combined functions modulate a 
variety of signalling pathways, and a large body of evidence has accumulated 
indicating the important role of SULF1/2 in cancer (see Section 1.5).  
 
Figure ‎1.5: Model for the different types of protein ligands that interact with HS and 
their release by heparanase (adapted from Vlodavsky et al., 2002). 
 
1.4. SULF1/2 
1.4.1. Cloning and characterisation of SULF1/2 
Dhoot et al. were the first to describe an avian gene termed QSulf1 in the quail 
embryo. This gene was thought to encode a sulfatase as it contained a domain 
similar to human lysosomal N-acetylglucosamine-6-sulfatase (GNS or G6S) 
enzyme. QSulf1 was subsequently shown to be expressed in somite muscle 
progenitors and to be involved in muscle specification in the quail embryo (Dhoot et 
al., 2001). The significance of QSulf1 discovery was underlined by its role in 
modulating the Wnt signalling pathway. An ortholog of QSulf1 was later identified in 
the rat embryo which was designated RSulfFP1 (‘floor plate 1’) because of its 
abundant expression in the floor plate of the evolving nervous system (Ohto et al., 
2002). In 2002, Morimoto-Tomita et al. reported the cloning of the human and 
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mouse orthologs SULF1 and MSulf1, and their homologues SULF2 and MSulf2, 
respectively. These mammalian SULF1/2 and MSulf1/2 proteins were reported to 
be secreted into the conditioned media of transfected cells and to be enzymatically 
active (Morimoto-Tomita et al., 2002). 
1.4.2. Structure of SULF1/2 
As described for QSulf1 (Dhoot et al., 2001), Sulf1 and Sulf2 proteins are 
comprised of approximately 870 amino acids (aa) in vertebrates. Sulf1/2 genes 
display 64% sequence similarity (Morimoto-Tomita et al., 2002) (Lamanna et al., 
2007) and share similar domain organization structure, which is depicted in Figure 
1.6, starting with a secretion signal sequence followed by an N-terminal domain 
and a C-terminal domain. Spanning the two N- and C-terminal sulfatase domains is 
a basic hydrophilic domain (HD) of 300-320 aa (Table  1.4) (Figure  1.6) (Figure  1.7) 
(Morimoto-Tomita et al., 2002) (Rosen and Lemjabbar-Alaoui, 2010). 
The N-terminal domain includes the conserved enzymatic domain that is shared by 
all sulfatases. Residues 415-871 (for SULF1)/416-870 (for SULF2), include the HD 
domain and C-terminal domain which are unique to SULF1/2 proteins, 
distinguishing them from other members of the sulfatase family (Figure  1.6). The 
C-terminal domain, however, shares a high degree of similarity with its counterpart 
in human lysosomal GNS (that also shares the same substrate with human 
SULF1/2, i.e., HS chains). This similarity of the C-terminal domain across these 
three enzymes may indicate a role for this domain in recognizing GlcNS/GlcNAc 
units of HS chains (Morimoto-Tomita et al., 2002) (Lai et al., 2008 c). 
Sulf1/2 orthologs between species also show a high degree of homology with 93% 
and 94% aa similarity for Sulf1 and Sulf2, respectively, between human and 
mouse. Sulf1/2 homologues (i.e., Sulf1 and Sulf2) within the same species show 
63-64% aa similarity (Morimoto-Tomita et al., 2002). As discussed earlier, the 
oxidation of a conserved cysteine to FGly is an early posttranslational event 
required to produce catalytically active SULF1/2, and takes place in a two-step 
reaction (Figure  1.8) (Dhoot et al., 2001) (Morimoto-Tomita et al., 2002). This 
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modification is vital for the enzymatic activity of SULF1/2, facilitating the hydrolysis 
of sulfate esters.   
Table ‎1.4: Structures of human SULF1/2 (Morimoto-Tomita et al., 2002). 
 SULF1 SULF2 
Length (aa) 871 870 
Signal peptide 1-22 1-24 
N-terminal (sulfatase) domain 42-414 43-415 
Hydrophilic domain (HD) 415-735 416-715 
GNS-related domain 736-843 717-824 
Number of N-glycosylation sites 10 11 
 
 
Figure ‎1.6: Structure of human SULF1/2: (From left to right) white: signal 
peptide, green: N-terminal sulfatase domain, orange line: FGly, red: HD and C-
terminal domains that include: yellow: polypeptide not similar to other sulfatases, 
blue: region with slight similarity between SULF1/2 proteins, brown: GNS-related 
region, purple: HS recognition sites, rich in arginine and lysine and mainly in the 
HD domain, are responsible for binding of SULF1/2 proteins to their sulfated 
substrates and to the cell surface (Adapted from Lai et al., 2008 c). 
 
SULF1
SULF2
100 200 300 400 500 600 700 800 871Amino acids
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Figure ‎1.7: Domain organization and processing of SULF1/2: First, the signal 
peptide is cleaved from the SULF1/2 pre-proprotein. Second, the resulting 
proprotein is processed by a furin-type proteinase in the HD domain (coloured in 
black) to give the 75 and 50 kDa domains that are linked by disulfide bonds in the 
mature protein. The asterisk indicates FGly residue that is essential for activity 
(adapted from Rosen and Lemjabbar-Alaoui, 2010).   
 
           
Figure ‎1.8: Conversion of cysteine to FGly of SULF1/2: The conversion is a 
two-step reaction starting with a dehydrogenase reaction followed by a hydrolysis 
step (Schmidt et al. 1995).   
 
 
 
1. Dehydrogenase reaction
2. Hydrolysis
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SULF1/2 enzymes are first produced as pre-proproteins from which the signal 
peptide is removed in the endoplasmic reticulum (ER) to give the pro-protein 
(Figure  1.7) (Tang and Rosen, 2009). Theoretically, the molecular mass of the 
human SULF1/2 proproteins should be ~ 100 kDa based on their amino acid 
sequence. However, by protein immunoblot the bands detected were of 132 kDa 
(Morimoto-Tomita et al., 2002) or 125 kDa (Tang and Rosen, 2009). This increase 
in mass from 100 to 132 kDa is ascribed to N-glycosylation as treating human 
SULF1/2 with N-glycanase gives the 100 kDa form (Morimoto-Tomita et al., 2002). 
Similar results have been reported in the rat after N-glycanase treatment 
(Nagamine et al., 2010). N-glycosylation of QSulf1 was shown to be necessary for 
its secretion and membrane targeting, as well as for binding to its substrate and 
endosulfatase activity (Ambasta et al., 2007), which may also apply to human 
SULF1/2.  
Tang and Rosen have reported that the 125 kDa human proprotein is further 
proteolytically processed by two furin-type proteinase-mediated cleavages that 
most probably occur in the trans Glogi (Tang and Rosen, 2009) (Thomas, 2002). 
The cleavage sites have been identified by Edman sequencing (Figure  1.9) and 
found to be in the HD domains in both human enzymes (Tang and Rosen, 2009) 
and those in other species such as the rat (Nagamine et al., 2010). This processing 
of human SULF1/2 leads to the formation of 75 and 50 kDa fragments that are 
linked by disulfide bonding to form the 125 kDa heterodimer (Figure  1.7). 
Therefore, by protein immunoblot and under reducing conditions, SULF1/2 can be 
detected as 75 and 50 kDa bands (Tang and Rosen, 2009). Notably, many cancer 
cell lines studied show additional processed forms of the enzymes (Morimoto-
Tomita et al., 2005) (Nawroth et al., 2007) (Lemjabbar-Alaoui et al., 2010). 
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Figure ‎1.9: Furin-type cleavage sites of SULF1/2: The underlined amino acid 
sequences identified by Edman sequencing are furin-type cutting sequences, and 
the sequence alignment shows that they are conserved among species. 
 
By immunofluorescence and protein immunoblot, the mature Sulf1/2 enzymes 
have been found to be secreted, but also to be localized to the cell membrane in 
both human and mouse (Morimoto-Tomita et al., 2002) (Lamanna et al., 2008) 
(Tang and Rosen, 2009). In contrast, QSulf1/2 enzymes are not secreted, being 
retained on the cell surface (Dhoot et al., 2001) (Ai et al., 2006). This association 
with the cell membrane is likely mediated by the HD domains, as deletion 
mutations in these domains increased the secretion of the enzyme (Dhoot et al., 
2001) (Ai el al., 2006) (Frese et al., 2009). Interestingly, membrane association is 
sensitive to high salt treatment (Morimoto-Tomita et al., 2002), revealing that it is 
mediated by electrostatic interactions between the negatively charged GAGs and 
the highly charged HD domains that are rich in arginine (R) and lysine (K), rather 
than trans-membrane integration (Ai et al., 2006) (Lamanna et al., 2008). The 
sequences that are highly rich in R and K correspond to heparin-binding motifs and 
serve as HS recognition sites (Figure  1.6). These HS recognition sites are included 
in Table  1.5 and are different between human SULF1 and SULF2 (Lai et al., 2008 
c). Also, membrane fractionation into detergent-soluble and insoluble fractions 
showed that SULF1/2 enzymes are enriched, particularly in the insoluble fraction, 
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suggesting an affinity for lipid raft domains (Lamanna et al., 2008). This localization 
is noteworthy because lipid rafts are fundamental in several signal transduction 
pathways (Lingwood and Simons, 2010). Essential for this localization is the furin-
type proteinase-mediated cleavage, as deletion mutation of the two furin cleavage 
sequences caused a significantly lower accumulation of mutant SULF1/2 into lipid 
rafts, without affecting the amount of secreted versus plasma membrane-retained 
SULF1/2 proteins (Tang and Rosen, 2009). 
Table ‎1.5: HS recognition sites of human SULF1/2 enzymes with their sequences 
and locations. 
Enzyme Sequence Location 
SULF1 RRRKKERKEKRRQRK 721-735 (HD domain) 
SULF2 KKKMR 
RRKKLFKKKYK 
KKKR 
KRKKKLRKLLKR 
402-406 (N-terminal) 
518-528 (HD domain) 
653-656 (HD domain) 
702-713 (HD domain) 
R: arginine, K: lysine, E: glutamic acid, Q: glutamine, M: methionine, L: leucine, F: 
phenylalanine, Y: tyrosine. 
 
1.4.3. Enzymatic activity of SULF1/2 
As reviewed above, SULF1 and SULF2 are glucosamine 6-O endosulfatases 
which release the sulfate group at position 6-O primarily from trisulfated 
disaccharide motifs (IdoA2S-GlcNS6S) present in the highly sulfated S-domains of 
HS chains or in heparin (Figure  1.10) (Morimoto-Tomita et al., 2002) (Ai et al., 
2003) (Saad et al., 2005) (Staples et al., 2011). 
 
Figure ‎1.10: SULF1/2 enzymes remove the 6-O-sulfate in preformed HSPGs. 
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Even though SULF1/2 and some lysosomal sulfatases share the same substrate 
(i.e., HS chains), there are differences in their activity. Firstly, SULF1/2 proteins are 
endosulfatases and have intra-chain activity, whereas lysosomal enzymes are 
exosulfatases and liberate sulfate groups during degradation of proteoglycans from 
the termini of the chains (Diez-Roux and Ballabio, 2005). However, Staples et al. 
have shown that human SULF2 acts not only on the internal regions of HS, but 
also on the non-reducing ends (Staples et al., 2011). Secondly, the pH optimum for 
the activity of SULF1/2 is pH 7 - 8 (i.e., in the neutral-basic range), while the 
lysosomal sulfatases work at an acidic pH (Morimoto-Tomita et al., 2002). These 
pH values are consistent with the cellular localization of these two types of 
enzymes, namely, the cell surface and the lysosomes, respectively. However, 
apart from SULF1/2, there are other non-lysosomal sulfatases that have maximal 
activity at neutral pH. These reside in the ER or Golgi (Table 1.2) (Hanson et al., 
2004) (Sardiello et al., 2005).    
SULF1/2 enzymes, like most sulfatases, are capable of hydrolysing 4-
methylumbelliferyl sulfate (4-MUS), which is a synthetic fluorogenic arylsulfatase 
substrate (Morimoto-Tomita et al., 2002). However, the affinity of 4-MUS for 
SULF1/2 is very low. The Michaelis constant (Km) defines an enzyme’s affinity for 
a substrate, and is the substrate concentration at which the reaction rate is half its 
maximum rate (Vmax). Thus, a high Km value means that the enzyme has a low 
affinity for the substrate, and a high concentration is needed for the reaction to 
operate at half its maximum rate. Accordingly, the Km of SULF1/2 4-MUS reaction 
was found to be approximately 10 mM (Uchimura et al., 2006 b) (Rosen and 
Lemjabbar-Alaoui, 2010). Nevertheless, an arylsulfatase activity assay using 4-
MUS as a substrate offers a method to measure the activity of SULF1/2 and could 
be used to screen for small-molecule inhibitors. In summary, SULF1/2 enzymes 
have both endosulfatase and arylsulfatase activities, where the former makes them 
unique and distinguishes them from other sulfatases. 
Although the catalytic active site of SULF1/2 is located in the 75 kDa N-terminal 
subunit (Morimoto-Tomita et al., 2002), this subunit has been reported to be 
inactive when expressed alone (Tang and Rosen et al., 2009). This observation 
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indicates that the 50 kDa C-terminal subunit is also essential for both enzymatic 
activities of SULF1/2 (i.e., endosulfatase and arylsulfatase activities). This is 
because the N-terminal subunit lacks the most C-terminal of the ECRs that are 
shared by all sulfatases (Tang and Rosen et al., 2009). 
With respect to the role of HD domains of SULF1/2, these are implicated in binding 
to the cell surface (Ai et al., 2006) (Frese et al., 2009). Also, the HD domains are 
involved in binding to the substrate HS; endosulfatase activity against HSPG is 
dependent on HS binding, as mutant SULF1/2 proteins that lack the HD domain 
demonstrate arylsulfatase activity against 4-MUS but not endosulfatase activity (Ai 
et al., 2006) (Frese et al., 2009) (Tang and Rosen, 2009). This binding of HD 
domains to the substrate was reported to be particularly dependent on 6-O 
sulfation, and hence sulfate hydrolysis facilitates the release of SULF1/2 enzymes 
enabling access to other regions (Frese et al., 2009). 
Endosulfatase assays using heparin or HSPGs as substrates have shown similar 
enzymatic activity of SULF1/2 (Morimoto-Tomita et al., 2002) (Lamanna et al., 
2008). Intriguingly, mutant SULF1/2 enzymes that cannot be cleaved by deletion of 
their furin cleavage sites maintain both arylsulfatase and endosulfatase activities, 
suggesting that processing of SULF1/2 proteins into their two subunits is not 
necessary for function (Tang and Rosen, 2009) (Nagamine et al., 2010). 
Nonetheless, unprocessed SULF1/2 proteins are rendered incapable of 
potentiating Wnt signalling, possibly due to impaired distribution of mutant SULF1/2 
into membranous lipid rafts, where many components of Wnt signalling are also 
localized (Tang and Rosen, 2009). 
Purified recombinant human SULF2 has been shown to have pro-angiogenic 
activity, promoting angiogenesis as evidenced by the chick chorioallantoic 
membrane assay. This activity of SULF2 was equivalent to that of VEGF165, used 
as a positive control (Morimoto-Tomita et al., 2005), and was suggested to be due 
to the mobilization of HSPG-sequestered angiogenic factors in the ECM, through 
desulfation of HS chains by SULF2. Thus, these factors become available to bind 
to their signal-transducing receptors and exert their biological activity. This result is 
consistent with the ability of human SULF2 to mobilize VEGF165 and reverse its 
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binding with immobilized heparin in an enzyme-linked immunosorbent assay 
(ELISA) (Uchimura et al., 2006 a).   
HS chains of HSPGs have been reported to be involved in binding to a number of 
growth factors (Table  1.3) and their associated receptor tyrosine kinases. Also, a 
requirement for 6-O sulfation of HS chains for cell-surface signalling by growth 
factors such as FGF-1 and FGF-2 has been described (Pye et al., 1998) (Pye et 
al., 2000). Using X-ray crystallography analysis, DiGabriele et al. demonstrated a 
direct role of 6-O sulfation and 2-O sulfation of heparin in its binding to FGF-1 
(DiGabriele et al., 1998), while no such requirement for 6-O sulfation was revealed 
for binding of FGF-2 to heparin (Faham et al., 1996). However, the 6-O sulfation of 
HS was shown to be necessary for promotion of FGF-2 activity (Guimond et al., 
1993) (Pye et al., 1998), indicating a role in the interaction between HS and 
FGFR1 (Kan et al., 1993) (Panteliano et al., 1994). In this latter case, it is 
envisaged that HS works as a bridge to form the ternary complex FGF-2/HS/FGFR 
(Rusnati et al., 1994). Also, it has been found that both chain length and sulfation 
pattern (including 6-O sulfation status) of HS is involved in differential activation of 
FGF-1/FGF-2 signalling (Pye et al., 2000). These data were further confirmed by 
the ability of human SULF2 to greatly reduce FGF-1 but not FGF-2 binding to 
immobilized heparin (Uchimura et al., 2006 a).   
Thus, 6-O sulfation of HSPGs can be modified by SULF1/2 enzymes which 
regulate different signalling pathways with implications for normal and pathological 
processes, including embryonic development, growth, chronic disease and cancer.  
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1.5. SULF1/2 in Cancer 
1.5.1. SULF1 in cancer 
The binding of a growth factor to its receptor can be inhibited by 6-O desulfation of 
HS chains of HSPGs by SULF1, and inhibition can abolish growth factor signalling 
in different types of cancers. Thus, overexpression of SULF1 in the human 
myeloma cell line CAG reduced tumour growth in vivo but not in vitro. This effect 
was attributed to inhibition of the assembly of the FGF-2 ternary signalling complex 
as shown in vitro (Dai et al., 2005). SULF1 expression was reported to be 
undetectable or extremely low in 77% (23 of 30) of primary ovarian carcinomas and 
in 71% (5 of 7) of ovarian cancer cell lines. SULF1 re-expression in ovarian cancer 
cell lines reduced proliferation in vitro and response to treatment with FGF-2 and 
HB-EGF, but not the response to heparinated FGF-2 or EGF (Lai et al., 2003). 
SULF1 expression in squamous cell carcinoma of the head and neck (SCCHN) cell 
lines downregulated MAPK/extracellular signal-regulated kinase (ERK) signalling 
pathway activation by either FGF-2 or HGF, and PI3K/AKT signalling pathway 
activation by HGF, with a subsequent reduction of proliferation and invasion in vitro 
(Lai et al., 2004 a). Also, SULF1 was downregulated in 60% of primary invasive 
breast cancer specimens, and SULF1 expression in MDA-MB-468 breast cancer 
cell line inhibited autocrine EGFR-mediated activation of ERK in vitro, which was 
restored after targeting SULF1 with shRNA (Narita et al., 2007). Also, in the same 
cell line, SULF1 expression reduced tumourigenicity and inhibited angiogenesis in 
nude mice in vivo (Narita et al., 2006). 
In hepatocellular carcinoma (HCC), SULF1 was found to be downregulated in 82% 
(9 of 11) of HCC cell lines as evidenced by RT-PCR (reverse transcription- 
polymerase chain reaction), and in 29% (9 of 31) of primary HCCs as revealed by 
RT-qPCR (reverse transcription-quantitative polymerase chain reaction). This 
downregulation of SULF1 was shown to be due to loss of one allele and/or DNA 
(deoxyribonucleic acid) hypermethylation, as treatment of SULF1-negative HCC 
cell lines with a DNA methylase inhibitor reactivated SULF1 expression (Lai et al., 
2004 b). As in SCCHN cell lines, SULF1 expression in HCC cell lines abrogated 
FGF-2- and HGF-mediated growth signalling pathways and increased sensitivity to 
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apoptosis (Lai et al., 2004 b). In another study, expression of SULF1 in two HCC 
cell lines (HuH-7 and Hep 3B) was shown to reduce tumourigenicity in xenograft 
models in vivo, while shRNA-mediated knockdown of the recombinant SULF1 in 
these two cell lines led to increased ERK and AKT phosphorylation (Lai et al., 
2006). Collectively, these results suggest that SULF1 is a negative regulator of 
MAPK/ERK and PI3K/AKT signalling pathways in HCC cell lines. 
Contrary to HCC, ovarian cancer and breast cancer, pancreatic cancer showed 
upregulation of SULF1 expression in 71% (22 of 31) of specimens by RT-qPCR, 
while SULF1 expression was absent in 50% (4 of 8) of pancreatic cancer cell lines. 
In spite of this pattern of expression, SULF1 re-expression in one of these SULF1-
negative cell lines reduced basal (uninduced) and FGF-2-mediated growth and 
invasion in vitro (Li et al., 2005). The role of SULF1 was also studied in 
oesophageal squamous cell carcinoma (ESCC). Membranous SULF1 staining by 
immunohistochemistry (IHC) was positive in 48% (42 of 87) of ESCC samples as 
opposed to the negative staining of neighbouring benign epithelium. RT-PCR 
showed an absence of SULF1 expression in 3 of 7 ESCC cell lines (Liu et al., 
2013). SULF1 re-expression in one of the SULF1-negative cell lines inhibited HGF 
signalling, as evidenced by western blot (WB), which showed inhibition of 
phosphorylation of the HGF receptor c-Met and the downstream mediator ERK1/2 
in response to exogenous HGF (Liu et al., 2013). This effect on HGF signalling was 
translated into reduced proliferation and dramatically diminished HGF-mediated 
invasiveness of SULF1-transfected cells. Clinically, SULF1 staining was found to 
be inversely correlated with both tumour size and invasion, but not tumour grading 
or metastasis (Liu et al., 2013).  
The aforementioned studies suggest that desulfation of HSPG by SULF1 abolishes 
growth factor signalling through interfering with the binding of growth factors with 
their receptors. Thus, SULF1 has a tumour suppressor effect in most types of 
cancer studied including myeloma, ovarian, head and neck, breast, liver, 
pancreatic and oesophageal cancers, even though it was found to be upregulated 
in pancreatic cancer and ESCC. 
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In another study, SULF1 mRNA was shown to be expressed in 50% (12 of 24) of 
pancreatic adenocarcinoma cell lines while the protein was detected only in one 
(HS766T) out of three cell lines that expressed SULF1 mRNA (messenger 
ribonucleic acid) as determined by WB. Also, SULF1 protein could be detected in 
the detergent lysate but not in the conditioned medium (CM) of HS766T cells 
(Nawroth et al., 2007). In the same study, a recombinant SULF1 protein was 
shown to promote Wnt signalling in SULF1-transfected Human Embryonic Kidney 
293T (HEK 293T) cells in response to either Wnt-1 or Wnt-4. Interestingly, the 
catalytically inactive form of SULF1 that was generated by a mutation in two 
cysteine residues in the active site (S1∆CC) reduced Wnt signalling by half in three 
cell lines that demonstrated autocrine Wnt activity even though native SULF1 
protein was only detected in one of these cell lines. However, all three cell lines 
expressed SULF2 protein and catalytically inactive SULF2 (S2∆CC) had the same 
effect of reducing Wnt signalling (Nawroth et al., 2007). These data suggest that 
SULF1 is a potentiator of autocrine Wnt signalling and that a functional redundancy 
between SULF1/2 enzymes exists at least in pancreatic cancer cell lines. The 
effect of SULF1 silencing on cell growth and tumourigenicity was not investigated 
in this latter study, and hence the role of SULF1 in pancreatic cancer has not been 
fully elucidated. 
Similar to pancreatic cancer, in non-small-cell lung carcinoma (NSCLC), SULF1 
expression was upregulated in 100% (10 of 10) of lung squamous carcinoma 
samples with an 18-fold change compared with the neighbouring non-malignant 
tissues as determined by microarray analysis. In line with the microarray data, RT-
qPCR of other cases showed SULF1 upregulation in both squamous carcinoma 
and adenocarcinoma by 12- and 3-fold, respectively. Also, SULF1 was expressed 
in 19% (3 of 16) of NSCLC cell lines (Lemjabbar-Alaoui et al., 2010). However, no 
further studies of SULF1 in this particular type of cancer have been performed. In 
another study, SULF1 expression was assessed in chondrosarcoma patient 
samples by IHC and was found to be strongly expressed in most cases but with no 
statistically significant relationship to the histological grade of tumour (Waaijer et 
al., 2012).  
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The role of SULF1 in gastric cancer has also been studied. Hur et al. showed 
upregulation of SULF1 mRNA levels in gastric cancer cell lines and in 30/30 
tumour tissues compared to their neighbouring benign tissues as assessed by RT-
qPCR, and this was attributed to hypomethylation of SULF1 promoter (Hur et al., 
2012). Also Tang et al. reported the upregulation of SULF1 in gastric cancer 
tissues at the mRNA level including cases that were Epstein-Barr virus-infected 
(Tang et al., 2012). Overexpression of SULF1 in one gastric cancer cell line 
increased tumourigenicity in vivo (Hur et al., 2012). Interestingly, SULF1 protein 
expression studied by IHC was found to be highly expressed in the stroma 
surrounding cancer cells, but only weakly expressed by the cancer cells 
themselves while very weakly or not expressed by normal mucosal cells. 
Furthermore, this study showed that SULF1 expression is a poor prognostic 
indicator for gastric cancer and correlates with increased recurrence rates and 
lymph node metastases (Hur et al., 2012).  
Overall, SULF1 has been reported to be upregulated in certain types of cancer 
including pancreatic, lung, chondrosarcoma and gastric cancer. However, it was 
not mechanistically studied in gastric cancer where it was found to have tumour-
promoting activity. Nevertheless, SULF1 acts a tumour suppressor in the majority 
of cancers and the effects of SULF1 are clearly tumour type- and cell line-
dependent. 
1.5.2. SULF2 in cancer 
1.5.2.1. SULF2 in myeloma, chondrosarcoma, breast, lung, pancreatic, 
glioblastoma, gastric and oesophageal cancers 
Similar to SULF1, SULF2 was shown to be an inhibitor of myeloma tumour growth, 
as forced expression in one human myeloma cell line reduced tumour growth in 
vivo but not in vitro through inhibiting the assembly of the FGF-2 ternary signalling 
complex, as evidenced by staining of tumour sections originating from injecting 
empty vector- or SULF2-transfected cells into immunocompromised mice (Dai et 
al., 2005). Also, SULF2 protein expression was found to be absent in most cases 
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of chondrosarcoma patient samples as assessed by IHC and staining was only 
focal in a small number of cases (Waaijer et al., 2012). 
In contrast to SULF1, SULF2 is upregulated 7-fold in ductal carcinoma (7 samples) 
compared with normal breast tissues (4 samples) as evidenced by SAGE analysis, 
and in 30% (6 of 20) of breast carcinomas as determined by complementary DNA 
(cDNA) microarray. Also, SULF2 was upregulated in mouse models of breast 
cancer and was expressed in 38% (3 of 8) of breast carcinoma cell lines as 
measured by RT-PCR. SULF2 protein was secreted into the medium of the 
SULF2-positive cell lines as determined by WB. The secreted SULF2 in one of 
these cell lines, namely, MCF-7 was purified and tested and was found to be 
enzymatically active as shown by arylsulfatase (ARS) activity assay using 4-MUS 
as a substrate. However, no further investigation of the function of the 
endogenously expressed SULF2 was carried out in these cell lines (Morimoto-
Tomita et al., 2005). In another study, SULF2 suppression in two breast 
adenocarcinoma cell lines (including MCF-7) and one mammary epithelial cell line 
was found to enhance proliferation and survival of the three cell lines and colony 
formation in the two adenocarcinoma cell lines (Hampton et al., 2009). Collectively, 
two studies (Dai et al., 2005) (Hampton et al., 2009) suggest that SULF2 works as 
a tumour suppressor, even though it is upregulated in breast cancer. However, as 
discussed below, studies suggesting that SULF2 is a tumour suppressor are in the 
minority. 
In NSCLC, SULF2 expression was upregulated in 80% (8 of 10) of lung squamous 
carcinoma samples with a 3-fold change compared with the adjacent non-
malignant tissues as determined by microarray analysis. In line with the microarray 
data, RT-qPCR of other samples showed SULF2 upregulation in both squamous 
carcinoma and adenocarcinoma, 4- and 3-fold upregulation, respectively. Also, 
SULF2 was expressed at the mRNA and protein levels in 31% (5 of 16) of NSCLC 
cell lines (Lemjabbar-Alaoui et al., 2010). Immunocytochemistry for SULF2 showed 
variable staining in 10 squamous cell carcinomas while no staining was seen in 10 
adenocarcinomas or in normal airway epithelium (Lemjabbar-Alaoui et al., 2010). 
Knockdown of SULF2 in NSCLC cell lines by shRNA decreased cell growth in vitro 
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and tumourigenicity in vivo. Expression of a dominant-negative form of SULF2, in 
which SULF2 is mutated at two cysteine residues in the catalytic domain (S2∆CC) 
that render it catalytically inactive, had the same effect of reducing cell growth in 
vitro. Also, either shRNA-mediated SULF2 knockdown or dominant-negative 
S2∆CC reduced autocrine Wnt signalling, comparable to the inhibition of Wnt 
signalling induced by soluble Wnt antagonists such as sFRP or WIF-1. SULF2 
overexpression in SULF2-positive NSCLC cell lines did not cause an increase in 
Wnt signalling activity while SULF2 expression in a SULF2-negative background 
showed a marked increase (Lemjabbar-Alaoui et al., 2010). Together, these data 
suggest a role for SULF2 in positively modulating Wnt signalling.  
In pancreatic adenocarcinoma, IHC showed that SULF2 was expressed in 57% (4 
of 7) of patient samples while RT-PCR showed that 88% (21 of 24) of pancreatic 
adenocarcinoma cell lines expressed SULF2 mRNA. Also, SULF2 protein was 
detected in four cell lines tested and was found in both the detergent lysate and the 
CM (Nawroth et al., 2007). As with SULF1, a recombinant SULF2 protein was 
shown to promote Wnt signalling in SULF2-transfected HEK 293T cells in response 
to either Wnt-1 or Wnt-4. Moreover, shRNA-mediated SULF2 knockdown or 
transfection with S2∆CC in 3 pancreatic adenocarcinoma cell lines with an active 
autocrine Wnt pathway reduced Wnt signalling, cell growth in vitro and 
tumourigenicity in vivo (Nawroth et al., 2007). Therefore, both studies (Lemjabbar-
Alaoui et al., 2010) (Nawroth et al., 2007) suggested that SULF2, like SULF1, is a 
potentiator of autocrine Wnt signalling. 
Consistent with the lung and pancreatic cancer data, SULF2 expression was 
shown to be upregulated by at least 2-fold in 46% (197 of 424) of human 
glioblastomas as compared to normal brain. Also, SULF2 protein was expressed in 
50% (29 of 57) of primary glioblastomas as demonstrated by IHC and in 67% (4 of 
6) astrocytoma cell lines as evidenced by WB. SULF2 suppression in one of 
these cell lines by shRNA decreased cell growth and viability in vitro and 
tumourigenicity in vivo. By using a human phospho-receptor tyrosine kinase array, 
it was found that SULF2 suppression reduced the phosphorylation of several 
receptor tyrosine kinases of which the most affected ones were PDGFRα and 
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insulin-like growth factor (IGF) receptor, IGF1Rβ. On the contrary, phospho-FGFR3 
was slightly increased and no effect on Wnt signalling was detected. SULF2 
suppression in another cell line caused the same effect of reduced phosphorylation 
of PDGFRα (Phillips et al., 2012). 
Similar to SULF1, SULF2 expression was found to be upregulated in gastric cancer 
cell lines and in tumour tissues as a result of hypomethylation of SULF2 promoter. 
Overexpression of SULF2 in one gastric cancer cell line increased tumourigenicity 
in vivo (Hur et al., 2012). Interestingly, this upregulation of SULF2 expression in 
gastric cancer and the effect on the tumourigenicity of gastric cells was less 
marked than for SULF1 (Hur et al., 2012). 
Lastly, SULF2 has been studied by IHC in invasive oesophageal cancer and found 
to be expressed in all squamous cell carcinoma cases (25 of 25) and in 91% of 
adenocarcinoma cases (68 of 75), with 49% and 36% of tumour cells staining 
positive for SULF2, respectively (Lui et al., 2012). Clinically, there was an inverse 
correlation between the percentage of SULF2-positive tumour cells and survival of 
patients (Lui et al., 2012). 
Taken together, the above studies demonstrate upregulation of expression and an 
oncogenic role for SULF2 in many types of cancer including lung, pancreatic, 
glioblastoma, gastric and oesophageal cancers, in addition to hepatocellular 
carcinoma which is discussed in detail below. 
1.5.2.2. SULF2 in HCC  
1.5.2.2.1. In vitro data 
SULF2 mRNA has been reported to be upregulated in 57% (79 of 139) of HCC 
specimens compared with neighbouring benign tissues and in 73% (8 of 11) of 
HCC cell lines as assessed by microarray and RT-qPCR (Lai et al., 2008 a). 
SULF2 protein was also upregulated in HCC as assessed by IHC and WB (Lai et 
al., 2010 a). 
By microarray analyses of gene expression, Lee et al. were able to define two 
discrete HCC subclasses (A and B) which were related to HCC patient survival. 
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Subclass A was associated with a poorer prognosis than subclass B (Lee et al., 
2004). In an independent study of SULF2 expression in the two HCC prognostic 
subclasses, tumours with a cluster A profile were predominant in the high SULF2 
group (93%) compared with the low SULF2 group (12.5%) (Lai et al., 2008 a). 
Also, the high SULF2 group was associated with higher proliferation and lower 
apoptosis indices as assessed by IHC using Ki-67 proliferation assay and TUNEL-
based apoptosis assay (Lai et al., 2008 a). Consistent with these results, forced 
SULF2 expression in the SULF2-negative Hep 3B cell line increased proliferation 
and migration while the opposite effect was shown after knockdown of SULF2 in 
SULF2-positive HuH-7 cell line using shRNA (Lai et al., 2008 a).  
SULF2 was reported to upregulate glypican 3 (GPC3) as shown by 
immunocytochemistry (ICC) and WB, and to promote both FGF-2 growth factor 
and Wnt/β-catenin signalling pathways (Lai et al., 2008 a) (Lai et al., 2010 b). With 
respect to FGF-2 signalling, forced expression of SULF2 was shown to increase 
FGF-2 binding to the cell surface as evidenced by flow cytometry. This binding was 
demonstrated to be significantly inhibited by heparin suggesting specific binding of 
FGF-2 to HS chains. Also, forced SULF2 expression increased the phosphorylation 
of FGF-2 signalling downstream mediators, ERK and AKT either at the basal level 
or after stimulation with FGF-2 (Lai et al., 2008 a), while SULF2 knockdown 
decreased AKT phosphorylation as shown by WB (Lai et al., 2010 a). Regarding 
the Wnt signalling pathway, the binding of Wnt-3a to Hep 3B cells was shown to be 
dependent on HS chains as demonstrated by flow cytometry (Lai et al., 2010 b). 
Forced expression of SULF2 in these cells upregulated Wnt-3a and promoted 
Wnt/β-catenin signalling pathway activity as shown by increased levels of Wnt-3a, 
β-catenin, cyclin D1 and the inactive phosphorylated form of GSK-3β (glycogen 
synthase kinase 3β) using WB and ICC. Wnt activation was assessed using the T-
cell factor (TCF)-luciferase reporter system. This role of SULF2 in promoting Wnt 
signalling was confirmed by downregulation of SULF2 in HuH-7 cells using shRNA, 
which showed inhibition of basal Wnt signalling (Lai et al., 2010 b). Interestingly, 
both FGF-2 and Wnt-3a binding to HCC cells was shown to be mediated by GPC3 
as shRNA-mediated knockdown of GPC3 decreased binding (Lai et al., 2008 a) 
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(Lai et al., 2010 b). This latter result suggests a requirement for GPC3 in the 
SULF2-mediated enhancement of FGF-2 and Wnt signalling pathways in vitro.  
Forced expression of SULF2 in HCC cells was also shown to improve their 
resistance to drug-induced apoptosis, whereas SULF2 knockdown demonstrated 
the opposite effect including downregulation of the anti-apoptotic protein Bcl-2 and 
upregulation of the pro-apoptotic protein BAD (Lai et al., 2010 a).  
1.5.2.2.2. In vivo data 
SULF2 expression in the SULF2-negative Hep 3B cells was found to increase 
tumourigenicity after implantation into immunocompromised mice as demonstrated 
by the faster growth of the tumours derived from SULF2-transfected cells 
compared to those established from empty vector-transfected cells. There was also 
upregulation of GPC3 levels as evidence by IHC analysis of xenograft sections 
from SULF2-transfected tumour (Lai et al., 2008 a). 
1.5.2.2.3. Clinical data 
Increased SULF2 expression was found to be associated with high proliferation 
and low apoptosis indices, and related to poor prognosis and high recurrence rate 
after resection (Lai et al., 2008 a).    
In summary SULF2, unlike SULF1, has an oncogenic effect in the majority of the 
cancer types studied, including HCC. This effect is ascribed to activation of two 
signalling pathways in particular, the first of which is growth factor and receptor 
tyrosine kinase (RTK) signalling leading to activation of downstream kinases ERK 
and AKT. The second is Wnt signalling which leads to β-catenin-dependent 
transcriptional activation (Figure  1.11). 
Unexpectedly, even though SULF1 and SULF2 demonstrate differing effects on 
RTK signalling, both activate Wnt signalling. While SULF1/2 proteins have a 
conserved N-terminal sulfatase domain, they diverge in the rest of their structures 
which contain distinct HS recognition sites between SULF1/2 enzymes as 
described earlier. These sites are implicated in binding to HS chains and could 
explain the dissimilarity in the functional activities of SULF1/2 enzymes in cancer. 
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This suggestion is in line with the reported effects of murine MSulf1/2 enzymes in 
knockout mouse models where, in spite of the existence of some degree of 
functional redundancy between MSulf1/2 enzymes, single knockouts have similar, 
but not equal, effect on phenotype and HS structure (Lamanna et al., 2008) (Kalus 
et al., 2009) (Nagamine et al., 2012). Neither MSulf1- nor MSulf2-knockout mice 
exhibited significant phenotypic or developmental abnormalities. In contrast, double 
knockout mice showed neonatal lethality accompanied with mild skeletal and renal 
defects (Holst et al., 2007) (Ratzka et al., 2008). MSulf2-knockout mice were in 
general viable and fertile but with strain-specific reduced body mass and mild lung 
or brain defects (Lum et al., 2007) (Kalus et al., 2009).  
 
 
Figure ‎1.11: The role of human SULF2 on signalling pathways in HCC: SULF2 
promotes FGF binding to the cell-surface, and FGF-induced ERK and AKT 
activation, and upregulates glypican 3 (GPC3) which promotes Wnt signalling. 
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1.6. Project Objective 
Molecular biology and functional studies were undertaken to further validate 
SULF2 as a therapeutic target in HCC, investigate mechanisms by which SULF2 
promotes cancer cell proliferation and tumourigenicity, and develop cell-free and 
cell-based assays to support the discovery and development of SULF2 inhibitors.  
Hypotheses to be tested 
 SULF2 knockdown in human cancer cells inhibits proliferation in vitro and 
tumourigenicity in vivo. 
 SULF2 inhibition inhibits signalling pathways in a cell-type dependent 
manner. 
Plan of investigation – 4 components 
1. Definition of the relative contributions of SULF1 and SULF2 to 
proliferation and tumourigenicity in HCC cell lines: 
SULF2 is one of two cell surface sulfatases. In contrast to SULF2, SULF1 can 
prevent cell growth in a tumour type dependent manner, i.e. SULF1 can reduce 
growth factor/receptor binding and signalling, cell growth and in vivo tumour 
growth. The role of SULF1 in liver cancer has not been clearly defined. While 
SULF1 mRNA is often undetectable in liver cancer cell lines, this most likely occurs 
as a result of acquired DNA methylation as loss of SULF1 mRNA expression is a 
relatively uncommon event in resected primary tumours (Lai et al., 2008 c). The 
possibility, however, that in some instances SULF1 loss contributes to loss of 
tumour suppressor activity in liver cancers (Lai et al., 2004 b) (Lai et al., 2006) 
needs to be carefully considered. SULF1 or SULF2 shRNA were transfected into 
HCC cell lines with pre-established SULF1 and SULF2 backgrounds, and effects 
on proliferation and tumourigenicity determined. An understanding of the relative 
roles of SULF2 and SULF1 in liver tumour cell proliferation and survival was used 
to inform the target compound profile for SULF2 inhibitor design, i.e. is a selective 
SULF2 or a dual SULF1/2 inhibitor preferable? 
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2. Investigation of the cellular signalling pathways relevant to SULF2-
mediated proliferation and tumourigenicity:  
SULF2 has been implicated in the regulation of two key cell signalling pathways 
that are involved in multiple tumour types: HSPG-binding growth factor signalling, 
notably FGF signalling, and the Wnt pathway. Small molecule FGF receptor 
tyrosine kinase, MEK and Wnt signalling inhibitors were used as positive controls 
in experiments to probe the role of FGF or Wnt signalling in SULF2-regulated HCC 
cell growth and survival. The HCC cell lines were selected from an existing panel 
(SNU-182, SNU-475, HuH-7, HepG2, Hep 3B, PLC/PRF/5) and includes those that 
have already been shown to be sensitive to SULF2 knockdown (Lai et al., 2008 a). 
3. Development of cell-free and cell-based assays to support the discovery 
and development of SULF2 inhibitors:  
The evaluation of potential small molecule SULF2 inhibitors developed by the CR 
UK Programme requires SULF1 and SULF2 enzyme assays and counter screens 
which were established using the fluorogenic substrate 4-methylumbelliferyl sulfate 
(Morimoto-Tomita et al., 2005) (Uchimura et al., 2006 b). Assays to study the 
effects of compounds on cell growth and tumourigenicity were established, 
supported by mechanistic studies.  
4. Development of predictive and pharmacodynamic biomarkers to support 
the preclinical and clinical development of SULF2 inhibitors:  
The successful development of targeted therapies requires a well-defined 
biomarker strategy and the cellular assays developed will be translated into 
biomarker assays as SULF1/2 inhibitors suitable for in vivo evaluation become 
available. Specifically, a microarray gene expression analysis was conducted after 
SULF2 knockdown to define possible markers. 
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2. Chapter 2. Materials and Methods 
 
2.1. Reagents 
4-Methylumbelliferyl sulfate (4-MUS) potassium salt (Sigma) (purity ≥ 99.95%, 
impurity ≤ 0.05% (w/w) by free 4-methylumbelliferone) was dissolved in H2O to give 
a stock solution at 15 mM. 4-Methylumbelliferyl-6-sulfo-N-acetyl-β-D-glucosaminide 
(MU-GlcNAc,6S) (Merck), 4-methylumbelliferyl-N-acetyl-β-D-glucosaminide (MU-
GlcNAc) (Merck) and 4-methylumbelliferyl β-D-galactopyranoside-6-sulfate (MU-
Gal,6S) (Sigma) were dissolved in H2O to give a stock solution at 10 mM. 4-
Methylumbelliferyl β-D-galactopyranoside (MU-Gal) (Sigma) was dissolved in 
DMSO at 100 mM. Oestrone 3-O-sulfamate (EMATE) (purity ≥ 98%, Sigma) was 
dissolved in DMSO to give a stock solution at 2 mM. P-Nitrocatechol sulfate 
(PNCS) (Sigma) was dissolved in H2O to give a stock solution at 6 mM. β-
Glucosidase was from almonds (Sigma) and β-galactosidase was from Escherichia 
coli (E. coli) (Sigma). FGF-1, FGF-2, IGF-I, IGF-II and VEGF-165 were from Cell 
Signalling. Angiotensin 1-7 and angiotensin II acetate salt hydrates (Sigma) were 
dissolved in PBS. 
2.2. Cell Culture  
Cells were incubated in a SANYO CO2 incubator (5% CO2, 37°C and 100% 
humidity) and were handled in a class II laminar flow BioMAT2 hood under sterile 
conditions. All HCC cell lines were cultured in DMEM (Dulbecco’s modified Eagle’s 
medium) nutrient mixture F-12 HAM with 15 mM HEPES (Sigma). All culture media 
were supplemented with 10% (v/v) foetal bovine serum (FBS) (Sigma), 2 mM L-
glutamine (Sigma), antibiotics (100 unit/ml penicillin and 100 µg/ml streptomycin) 
(Sigma). The medium was changed every two days and the cells were subcultured 
once a week. For the cell-based arylsulfatase (ARS) activity assay, the cells were 
cultured in phenol red-free DMEM with 1000 mg glucose/L (Sigma) with all the 
other supplements as described above. For transfection, Opti-MEM I reduced-
serum medium with GlutaMAX (Invitrogen) and without antibiotics was used. 
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Subculturing cells: The medium was aspirated and the adherent cells were 
washed with PBS followed by detaching the cells using trypsin-EDTA solution 
(Sigma) (0.5 g trypsin/L and 0.2 g EDTA/L in PBS). After incubation for 5 minutes 
(min), culture medium was added to block the trypsin and the cells were 
resuspended diluted and transferred into new culture plates or flasks.  
Freezing cells: After trypsinization and blocking trypsin, the cells were centrifuged 
at 1,000 xg for 5 min (Mistral 3000i, DJB Labcare) and the supernatant was 
aspirated. The cell pellet was resuspended in freezing medium (10% (v/v) DMSO 
in culture medium; freshly prepared), pipetted into cryovials (1 ml per vial each 
containing 1x106 cells), put in cryochamber filled with isopropyl alcohol (Cryo 1C 
freezing container, Nalgene) to achieve -1°C/min rate of cooling, stored at -70°C 
freezer for short-term storage and then transferred into liquid nitrogen for long-term 
storage. 
2.3. Transformation, Plasmid Propagation and Purification 
Transformation: 0.5 µg of plasmid DNA was mixed with one vial of One Shot 
TOP10 chemically competent E. coli (Invitrogen). The mixture was kept on ice for 
25 min, incubated for 1 min at 37°C and then placed on ice. 200 µl of S.O.C (Super 
Optimal broth with Catabolite repression) medium (Novagen) was added and 
following incubation for 1 hour at 37°C with shaking, transformed bacteria were 
streaked on an agar petri dish containing the appropriate selective antibiotic (25 
µg/ml kanamycin or 100 µg/ml ampicillin) and incubated overnight at 37°C. A single 
colony was picked and transferred into 2 ml LB (Luria Bertani) medium containing 
the appropriate antibiotic. LB medium was prepared by suspending 20 g of LB 
broth powder (Sigma) in 1 liter of distilled water followed by autoclaving. After an 
overnight incubation at 37°C in an orbital shaker, the culture was diluted 1:500 in 
200 ml LB medium with the selective antibiotic and incubated overnight with 
shaking. Bacteria were centrifuged at 6000 xg for 15 min at 4°C and then stored at 
-20°C after discarding the supernatant. 
Plasmid purification: This was performed using HiSpeed plasmid purification 
maxi kit (Qiagen) and according to the manufacturer’s protocol. 
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2.4. Transfection of Cells Using SULF1/2 Plasmids 
TrueORF Myc-DDK-tagged ORF clones of human SULF1 (RC216632) and human 
SULF2 (RC212675) were used as transfection-ready DNA (OriGene). The open 
reading frames (ORF) of SULF1 (ORF Size: 2616 bp) or SULF2 (ORF Size: 2613 
bp) were inserted at the multiple cloning site of the PrecisionShuttle pCMV6-Entry 
vector (Figure ‎2.1). Sgf I and Mlu I restriction enzymes were used for cloning. The 
ORF was inserted under a cytomegalovirus (CMV) promoter to allow for 
constitutive expression of the protein which was fused with a C-terminal MYC/DDK 
tag that can be used for antibody-based detection and purification. The plasmid 
confers resistance to neomycin (and its analogue, G418) and is used as a 
selectable marker. 
Lipofectamine (Invitrogen) or FuGENE HD (Promega) transfection reagents were 
used to transfect cells. A pCI-neo/EGFP plasmid that constitutively expresses 
EGFP (enhanced green fluorescent protein) was used for optimisation of 
transfection conditions. Transfection was performed by testing different ratios of 
transfection reagent to DNA and by scaling up the whole transfection mixture (i.e., 
transfection reagent plus DNA) to choose the condition that gave the highest 
transfection efficiency for each single cell line. 
 
Figure ‎2.1: Map for PrecisionShuttle pCMV6-Entry vector. The open reading 
frame of SULF1 or SULF2 were inserted at the multiple cloning site (MCS) of the 
vector. 
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Stable transfection: cells were cultured until they reach 80% confluency. The 
transfection reagent or the plasmid DNA were incubated separately for 5 minutes 
in 100 µl of serum- and antibiotic-free medium or Opti-MEM medium that was pre-
warmed to room temperature (RT). After incubating the transfection reagent/DNA 
mixture at RT for 25-45 minutes for lipofectamine or for up to 10 min for FuGENE, 
the mixture was added to the wells containing serum- and antibiotic-free culture 
medium which was changed into normal culture medium after 24 hours. G418 was 
used for selection at a concentration of 800 µg/ml and was added after 48 hours. 
The medium was changed every 3 days and the antibiotic was replenished with 
every medium change. At the end of the selection period, determined by the death 
of all control untransfected cells, different colonies were picked either by cloning 
cylinders (for HuH-7 and Hep 3B) or by dislodging colonies using the tip of 20 µl 
pipette set at 10 µl (for HepG2). The colonies were expanded under a selection 
pressure of 400 µg/ml G418.  
Transient transfection: The same protocol for stable transfection was performed 
where the transfection reagent/DNA mixture was added into Opti-MEM medium. 
The medium was changed into serum-containing medium after 24 hours. 
2.5. Generation of SULF2 Lentiviral Particles and Their Transduction into 
Cells 
Generation of SULF2 lentiviral particles: Three constructs were used for the 
generation of SULF2 recombinant vesicular stomatitis virus G protein (VSV-G)-
pseudotyped lentiviral particles. These were: (1) Precision LentiORF SULF2 clone 
(Open Biosystems) where SULF2 ORF was inserted into the pLOC vector with 
dual marker cassette that allows for the expression of SULF2, nuclear localized 
TurboGFP and blasticidin resistance gene from the same CMV promoter (Figure 
‎2.2); (2) envelope plasmid (pMD2.G); and (3) packaging plasmid (pCMV_dR8.91). 
The maps of all constructs are shown in Figure  2.2. Plasmid-containing bacteria 
were first amplified from glycerol stocks using 100 µg/ml ampicillin (Sigma) as a 
bacterial selection marker and then the plasmids were propagated and purified as 
described in Section 2.3. 
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HEK 293T cells were used to produce the lentiviral particles according to a 
published protocol (Naldini et al., 1996). 3x105 cells were cultured in a 10 cm dish 
and then co-transfected with a mixture of the three aforementioned plasmids (20 
μg of LentiORF SULF2 plasmid, 5 μg pMD2.G plasmid and 15 μg pCMV_dR8.91 
plasmid) using the calcium phosphate transfection method. After overnight 
incubation, cells were washed with PBS and fresh medium was added. Lentiviral 
particles-containing conditioned medium was collected after 3 days which 
approximately contains 10
6 
transducing units (TU)/ml. Following centrifugation at 
1,800 xg for 15 min at 4°C and filtration using a 0.45 μm filter to remove cell debris, 
the viral supernatant was concentrated 10-fold by centrifugation at 120,000 xg for 2 
hours at 4°C in an Optima
 
XL-100K ultracentrifuge (Beckman Coulter). The 
supernatant was discarded and viral pellet was resuspended in serum-containing 
medium and stored as aliquots at -80
 
°C. 
Transduction of SULF2 lentiviral particles into cells: 3x105 Hep 3B cells/well 
were seeded in a 6-well plate. Different volumes of lentiviral particles-containing 
medium with 8 µg/ml hexadimethrine bromide (Polybrene, Sigma) were added. 
After overnight incubation, the medium was replaced by a fresh medium and 24 
hours later cells were selected using 1 µg/ml blasticidin S hydrochloride (Sigma) 
until formation of colonies. Colonies were then picked by dislodging using the tip of 
20 µl pipette set at 10 µl and after bulk cultures were established analysed using 
WB, immunocytochemistry and ARS activity assay.    
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Figure ‎2.2: Maps of the plasmids used to generate SULF2 lentiviral particles: 
Top: Precision LentiORF SULF2 clone where the open reading frame of SULF2 
was inserted at the multiple cloning site of the pLOC vector. Bottom panel left: 
envelope plasmid (pMD2.G). Bottom panel right: packaging plasmid 
(pCMV_dR8.91). 
 
2.6. SULF1 and SULF2 Knockdown Using shRNA Lentiviral Particles 
A target set of 5 individual clones of mission TRC1 or TRC2 shRNA lentiviral 
particles (Sigma) for either SULF1 or SULF2 was used for gene silencing where 
different shRNA sequences (listed in Table ‎2.1 and Table ‎2.2) were inserted into 
the TRC1.5-pLKO.1-puro or TRC2-pLKO-puro vector and directed by the human 
U6 promoter. Figure ‎2.3 shows the map of the TRC2 vector which is only different 
from the TRC1.5 vector in that it contains the Woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) which enables enhanced expression of 
the shRNA (Zufferey et al., 1999). For inducible shRNA lentiviral particles, the 
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pLKO vector was designed to include a LacI (repressor) and a modified U6 
promoter with three LacO (operator) sequences (2 in the promoter and one 3' of it) 
(Figure ‎2.4).   
1x105 cells/well in a 12-well plate were infected with different multiplicities of 
infection (MOIs) values of either individual SULF1 or SULF2 shRNA lentiviral 
particles or TRC2-pLKO-puro non-targeting shRNA control transduction particles 
(Sigma) in the presence of 8 µg/ml hexadimethrine bromide (Sigma). For stable 
transduction, the medium was replaced after overnight incubation by a fresh 
medium. 1 day later, the transduced cells were selected using 1 µg/ml (for SNU-
182) or 2 µg/ml (for HuH-7 or HepG2) puromycin dihydrochloride (Sigma) until all 
control untransduced cells were killed.  
Non-targeting shRNA (NT shRNA) sequences have four base pair mismatches to 
any known human gene. The sequences of both constitutive and inducible NT 
shRNAs used are listed in Table  2.3.  
Table ‎2.1: shRNA sequences of mission TRC1 or TRC2 SULF1 shRNA 
lentiviral particles. 
TRC number Region Sequence  
TRCN0000051098* CDS CCGGCCCAAATATGAACGGGTCAAACTCGAGTTTGACC
CGTTCATATTTGGGTTTTTG 
TRCN0000051099* CDS CCGGCCAACACATAACTCCTAGTTACTCGAGTAACTAGG
AGTTATGTGTTGGTTTTTG 
TRCN0000373588 CDS CCGGGCGAGAATGGCTTGGATTAATCTCGAGATTAATCC
AAGCCATTCTCGCTTTTTG 
TRCN0000373589 3′ UTR CCGGTCTGGTGGACTGGACTAATTACTCGAGTAATTAGT
CCAGTCCACCAGATTTTTG 
TRCN0000373658 CDS CCGGGCCGACCATGGTTACCATATTCTCGAGAATATGGT
AACCATGGTCGGCTTTTTG 
Clones marked by asterisks are TRC1-version lentiviral particles while the rest are 
TRC2-version lentiviral particles. CDS: coding sequence; 3′ UTR: 3′ untranslated 
region. 
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Table ‎2.2: shRNA sequences of mission TRC2 SULF2 shRNA lentiviral 
particles. 
TRC number Region Sequence  
TRCN0000364454 CDS CCGGCCCACATCGTCCTCAACATTGCTCGAGCAATGTTGA
GGACGATGTGGGTTTTTG 
TRCN0000364517 CDS CCGGGGACAACACGTACATCGTATACTCGAGTATACGATG
TACGTGTTGTCCTTTTTG 
TRCN0000364518 3′ UTR CCGGGGGCGAAAGTCATTGGAATTTCTCGAGAAATTCCAA
TGACTTTCGCCCTTTTTG 
TRCN0000369076 CDS CCGGTGCACATCGACCACGAGATTGCTCGAGCAATCTCG
TGGTCGATGTGCATTTTTG 
TRCN0000376409 CDS CCGGTGCGGATATGGACGGGAAATCCTCGAGGATTTCCC
GTCCATATCCGCATTTTTG 
CDS: coding sequence; 3′ UTR: 3′ untranslated region. 
 
Table ‎2.3: shRNA sequences of mission TRC2 non-targeting shRNA lentiviral 
particles. 
TRC number Sequence  
Constitutive NT 
shRNA 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCT
TGTTGTTTTT 
Inducible 
iNT.shRNA 
CCGGGCGCGATAGCGCTAATAATTTCTCGAGAAATTATTAGCGCTAT
CGCGCTTTTT 
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Figure ‎2.3: TRC2-pLKO-puro vector map. 
 
                       
Figure ‎2.4: Inducible shRNA (pLKO-puro-IPTG-3xLacO) vector map. 
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2.7. RNA Extraction, Reverse Transcription and Polymerase Chain Reaction 
RNA extraction: RNA (ribonucleic acid) was extracted during the exponential 
phase of cell proliferation. After seeding 2x105 cells/well for 24 hours, the medium 
was removed and the cells were washed with PBS. RNA was isolated using 
RNeasy mini kit (Qiagen) and according to the manufacturer’s protocol. During the 
extraction and before RNA cleanup, contaminating DNA was removed by on-
column digestion using the RNase-free DNase set (Qiagen) and according to the 
manufacturer’s protocol. The RNA concentration was determined by measuring the 
optical density at 260 nm by Nanodrop, and the tubes were stored at -80°C. 
Reverse transcription: Reverse transcription system (Promega) was used to 
prepare cDNA according to the manufacturer’s protocol. 1 µg of RNA was 
incubated at 70°C for 10 min and then put on ice. The RNA was added to a 20 µl 
reaction mixture consisted of 4 µl of 25 mM MgCl2, 2 µl of reverse transcription 10x 
buffer, 2 µl of 10 mM dNTP mixture, 0.5 µl (20 u) of RNasin ribonuclease inhibitor, 
0.6 µl (15 u) of AMV reverse transcriptase, 1 µl (0.5 µg) of oligo-dT primer and the 
volume was adjusted to 20 µl with nuclease-free water. The samples were 
incubated at 42°C for 1 hour and at 95°C for 5 minutes, and then placed on ice for 
5 min. The samples were diluted 10 times in nuclease-free water and then stored 
at -20°C. 
Quantitative polymerase chain reaction (qPCR): cDNA was thawed on ice and a 
master mix was prepared for each set of primers which consisted of the following 
components for each 10 µl single reaction: 5 µl Platinum SYBR Green qPCR 
SuperMix-UDG with ROX (Invitrogen), 0.2 µl (final concentration 0.2 µM) of each 
primer (forward and reverse) and 3.6 µl of nuclease-free H2O. 1 µl of cDNA was 
added to each single reaction. The samples were loaded onto 384-well reaction 
plate (MicroAmp optical plate, Applied Biosystems) and the qPCR reaction was 
performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems) 
equipped with the SDS 2.3 software. The standard program was used (50°C for 2 
min, 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min). 
Each sample was prepared in triplicate and the results were analysed by the SDS 
RQ Manager software. The primer sequences are listed in Table  2.4 and the 
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SULF1 primer set was from Eurofines MWG Operon. All other primer sets were 
from Sigma. 
Polymerase chain reaction (PCR): The AmpliTaq Gold 360 DNA polymerase kit 
(Applied Biosystems) was used for this purpose. A master mix for each set of 
primers was prepared by adding the following components for each 25 µl reaction: 
2.5 µl of 25 mM MgCl2, 2.5 µl of 10x PCR buffer, 0.5 µl of 10 mM dNTP mixture, 
0.5 µl of 10 µM of each primer (forward and reverse), 0.5 µl of DNA polymerase 
and 15.5 µl of nuclease-free H2O (Ambion). 2.5 µl of cDNA samples were added 
into each PCR tube with 22.5 µl of the PCR master mix. The PCR reaction was 
performed using the GeneAmp PCR system 2700 thermal cycler (Applied 
Biosystems) and the standard program (94°C for 10 min followed by 20-40 cycles 
of 94°C for 1 min, 55°C for 1 min and 72°C for 1 min, and terminated by one hold 
at 72°C for 10 min).  
Agarose nucleic acid gel electrophoresis: 1% (w/v) agarose gel was prepared 
by adding 1.5 g of agarose (Fisher Scientific) to 150 ml of 0.5x TBE buffer. 5x TBE 
buffer was prepared by adding 57 g Tris base, 27.5 g boric acid and 20 ml of 0.5 M 
EDTA (pH 8) and adjusting the volume to 1 L with water. After dissolving agarose 
with heat using a microwave, 15 µl of 10,000x GelRed nucleic acid gel stain 
(Biotium) was added and the mixture was poured into a gel tray and left to cool at 
RT. Five µl of 6x loading dye was added to the 25 µl PCR reaction volume and the 
samples were loaded onto the gel with 5 µl of a 100 bp DNA ladder (Invitrogen). 
After running the samples at 153 V for 1 hour using a horizontal gel electrophoresis 
system (Horizon 11-14, Life Technologies), the gel was viewed using Bio-Rad 
imager equipped with Quantity One 4.5.2 software.   
2.8. Concentration of Conditioned Medium 
The conditioned medium (CM) was enriched 20 times using a Centricon-10 
centrifugal filter devise (Millipore) and according to the manufacturer’s protocol. In 
brief, 2 ml of CM was added into the sample reservoir attached to the filtrate vial 
and centrifuged at 5000 xg for 1 hour (hr). Subsequently, the filtrate vial was 
removed and the retentate vial was attached to the sample reservoir. The retentate 
was recovered by inverting the device and centrifuging at 1000 xg for 2 min.  
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Table ‎2.4: Primer sequences used for RT-PCR and RT-qPCR.  
GENE F Primer R Primer 
SULF2 ATGAGTTTGACATCAGGGTCCCGT ATGGATTTCCCGTCCATATCCGCA 
SULF1 GGTCCAAGTGTAGAACCAGGATC GACAGACTTGCCGTCCACATCA 
GAPDH CAATGACCCCTTCATTGACC GATCTCGCTCCTGGAAGATG 
B2M TGCTCGCGCTACTCTCTCTTT TCTGCTGGATGACGTGAGTAAAC 
SUMF1 CTCAACTGGCTATTTGACAGAGG TTTCACAGGTAACCACCAGGG 
GPC3 CCTTTGAAATTGTTGTTCGCCA CCTGGGTTCATTAGCTGGGTA 
CCND1 GCTGCGAAGTGGAAACCATC CCTCCTTCTGCACACATTTGAA 
MYC CAAATGCAACCTCACAACCTTGGC GCCCAAAGTCCAATTTGAGGCAGT 
TP53 CAGCACATGACGGAGGTTGT TCATCCAAATACTCCACACGC 
VEGFA AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 
FLT1 TTTGCCTGAAATGGTGAGTAAGG TGGTTTGCTTGAGCTGTGTTC 
KDR GGCCCAATAATCAGAGTGGCA CCAGTGTCATTTCCGATCACTTT 
GLI1 AACGCTATACAGATCCTAGCTCG GTGCCGTTTGGTCACATGG 
PTCH1 ACTTCAAGGGGTACGAGTATGT TGCGACACTCTGATGAACCAC 
PTCH2 GCTTCGTGCTTACTTCCAGGG CATGCGGAGACCTAATGCCA 
HHIP CCCTGCATAGTGGGGATGG AGGCTTAGCAGTCCTCTTTCAT 
FOXF1 CCCAGCATGTGTGACCGAAA ATCACGCAAGGCTTGATGTCT 
FOXM1 CGTCGGCCACTGATTCTCAAA GGCAGGGGATCTCTTAGGTTC 
BCL2 GGTGGGGTCATGTGTGTGG CGGTTCAGGTACTCAGTCATCC 
ACE2 ACAGTCCACACTTGCCCAAAT TGAGAGCACTGAAGACCCATT 
CEACAM7 GTTACCCACAATGACGCAGGA TCCACCGGATTGAAGTTGTTG 
HEPH TGCGATATGAAGCCTTTCAAGAT GGAGGCACGGTTGTAGAAGA 
PCDH20 AAAATGCACCTGTAAACACCCG GCGATAGGTCTGTACCCCATTA 
HOXB7 CGAGTTCCTTCAACATGCACT TTTGCGGTCAGTTCCTGAGC 
CTBP2 GAATTGCCGTGTGCAACATCC CGTGTTCCTCCGGTACAGG 
SLPI GAGATGTTGTCCTGACACTTGTG AGGCTTCCTCCTTGTTGGGT 
EDIL3 AGCATACCGAGGGGATACATT CAAGGCTCAACTTCGCATTCA 
SLFN11 AACCCCAACGCCCGATAAC TCATGCAAGCATAGCCATAGAG 
PRSS3 CCACCCTAAATACAACAGGGAC TCAGCACCAAAGCTCAGAGTG 
CEACAM6 TCAATGGGACGTTCCAGCAAT CACTCCAATCGTGATGCCGA 
TFPI2 CTGGGGCTGTCGATTCTGC TCTCCGCGTTATTTCCTGTTG 
BEX1 GCAGTAAACAGTCTCAGCATGG GGCTCCCCTTTATTAGCAACTT 
CTSE AGGCATCCGTCCCTCAAGAA CCTTGGCACTCTGGTCCATTG 
DLK1 CTTTCGGCCACAGCACCTAT TGTCATCCTCGCAGAATCCAT 
AHSG CTTCAACGCTCAGAACAACGG CCACATAGGTAGAAGGTGGGA 
MYCN CACGTCCGCTCAAGAGTGTC GTTTCTGCGACGCTCACTGT 
WNT5A TCGACTATGGCTACCGCTTTG CACTCTCGTAGGAGCCCTTG 
DKK1 ATAGCACCTTGGATGGGTATTCC CTGATGACCGGAGACAAACAG 
GPC4 GTGGGAAATGTGAACCTGGAA CGAGGGACATCTCCGAAGG 
MMP2 CCCACTGCGGTTTTCTCGAAT CAAAGGGGTATCCATCGCCAT 
MMP9 TGTACCGCTATGGTTACACTCG GGCAGGGACAGTTGCTTCT 
AGTR1 ATTTAGCACTGGCTGACTTATGC CAGCGGTATTCCATAGCTGTG 
ACE AACATGCAAATAGCCAACCACA TGCCCGTTCTAGGTCCTGAA 
CUX2 AGCGGGTGTTTGGGCATTA CCAGTACATTCTGCTCATCCG 
MAS1 ATGGATGGGTCAAACGTGACA CGATGTGCATTCCCGACTG 
FOXO1 TGATAACTGGAGTACATTTCGCC CGGTCATAATGGGTGAGAGTCT 
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2.9. Protein Extraction and Quantitation 
Protein extraction: Protein was extracted during the exponential phase of cell 
proliferation. 2x105 cells/well in a 6-well plate were cultured for 24 hours, medium 
removed and the cells washed with PBS. The PBS was aspirated completely and 
the plate was placed on ice. Two different protein extraction reagents were used 
depending on the downstream applications. For western blot application, 
PhosphoSafe extraction reagent (Novagen) (containing 4 phosphatase inhibitors, 
sodium fluoride, sodium vanadate, β-glycerophosphate and sodium 
pyrophosphate) to which protease inhibitor cocktail (Sigma) added in the ratio 
250:1 was used, while for immunoprecipitation applications, a non-denaturing NP-
40 buffer was used. This buffer consisted of 50 mM Tris (pH 7.4), 1% (v/v) NP-40, 
0.15 M NaCl, 2 mM EDTA, 10 mM sodium fluoride, 1 mM PMSF 
(phenylmethylsulfonyl fluoride) and 200 µl/50ml protease inhibitor cocktail. After 
adding the extraction reagent, the plate surface was scraped with a cell scraper 
and the content was transferred into an eppendorf tube. The samples were further 
lysed by sonication using Soniprep 150 plus at an amplitude of 4 for 10 seconds. 
The samples were then centrifuged at 16,100 xg for 10 min at 4°C using a table-
top eppendorf centrifuge 5415D to remove cell debris and the supernatant was 
stored at -70°C.  
Protein quantitation: protein was quantified using the bicinchoninic acid (BCA) 
assay. This is a colorimetric assay based on the ability of proteins (particularly the 
amino acids cysteine, cystine, tryptophan and tyrosine) to reduce cupric ion Cu+2 
(in reagent B) into cuprous ion Cu+1 in an alkaline solution (the biuret reaction). 
This is followed by detecting Cu+1 ions using BCA (in reagent A), leading to the 
formation of a purple colour that is proportional to protein concentration. First, 
diluted bovine serum albumin (BSA) standards of different concentrations ranging 
from 0.25 - 2 mg/ml were prepared and working reagent (WR) was prepared by 
mixing reagent A with reagent B in the ratio 50:1 (Pierce BCA protein assay kit, 
Thermo Scientific). Protein samples were diluted 1:5 and 10 µl of each sample or 
standard was added in triplicate in 96-well plate. 10 µl of H2O was added into the 
blank wells and 190 μl of the WR was added to each well. After mixing on a plate 
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shaker for 30 seconds, the plate was incubated at RT for 15 minutes and then the 
absorbance at 562 nm was read by FLUOstar Omega (BMG Labtech) plate reader 
using the Omega data analysis software. 
2.10. SDS-PAGE and Western Blot 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE): 
Denaturing and reducing gel electrophoreses was performed using NuPAGE 
Novex 4-12% Bis-Tris Gel 1.0 mm (Invitrogen). Samples were prepared by adding 
4x NuPAGE LDS (lithium dodecyl sulfate) sample buffer (Invitrogen), 10x NuPAGE 
sample reducing agent (Invitrogen) and incubation at 70°C for 10 min to denature 
and reduce the protein. After the denaturation step, the samples were placed on 
ice to prevent proteins from folding again and centrifuged shortly before loading 
onto the gel. The gel cassette was placed in the XCell SureLock Mini-Cell system 
(Invitrogen). The upper and lower buffer chambers of the system were filled with 1x 
SDS running (electrophoresis) buffer. The 20x NuPAGE MOPS SDS running buffer 
(Invitrogen) was used and the upper (inner) chamber was filled with 200 ml of 1x 
SDS running buffer containing 500 µl of NuPAGE antioxidant (Invitrogen). The 
samples and protein standard were loaded onto the gel which then ran at 200 V. 
The protein standard used was either the Novex sharp pre-stained protein 
standard (Invitrogen) or the HiMark pre-stained high molecular weight protein 
standard (Invitrogen). 
Western blot (WB): One nitrocellulose transfer membrane (HyBond-C Extra, 
Amersham Biosciences) and 4 filter papers were cut for each gel and soaked in 
transfer buffer (6.06 g Tris base, 28.28 g glycine, 200 ml methanol and dH2O made 
up to 2 liters). The gel was removed from its cassette and wetted in transfer buffer 
and then the following were placed in order over the cathode (black) core: 1 
blotting pad, 2 filter papers, the gel, transfer membrane and 2 filter papers. Air 
bubbles were removed by passing a roller and then another blotting pad was put 
on top and the transfer cassette was closed tightly using the anode (transparent) 
core. The cassette was slid into a transfer tank (Geneflow) and the tank was filled 
with transfer buffer. After running at 300 mAs for 90 min, the membrane was 
removed from its cassette and blocked in blocking buffer composed of 5% (w/v) 
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milk and 3% (w/v) BSA in Tris-buffered saline-Tween (TBS-T) for 1 hour with 
gentle agitation. 10x TBS-T was prepared by dissolving 60 g of Tris, 90 g of NaCl 
and 5 ml of Tween 20 in 1 L of H2O and the final pH was adjusted to 7.5 with 
concentrated HCl. Following blocking, the membrane was incubated with 1:1000 
(1:500 for SULF1) diluted primary antibody in blocking buffer overnight on a roller 
mixer (Stuart SRT6).  
Table ‎2.5 lists the different primary antibodies used. After decanting the primary 
antibody, the membrane was washed 3 times in TBS-T for 15 min each time and 
then incubated with 1:1000 diluted secondary antibody in blocking buffer for 1 hour. 
The secondary antibodies used were: polyclonal goat anti-rabbit immunoglobulins/ 
horseradish peroxidase (HRP) (dakocytomation), polyclonal goat anti-mouse 
immunoglobulins/HRP (dakocytomation) or donkey anti-goat IgG-HRP (Santa Cruz 
Biotechnology). After decanting the secondary antibody, the membrane was 
washed 4 times in TBS-T for 10 min each time. The chemiluminescence substrate, 
either Pierce ECL Western Blotting Substrate or SuperSignal West Dura Extended 
Duration Substrate (Thermo Scientific), was prepared by mixing the stable 
peroxide solution and the luminol/enhancer solution at a ratio of 1:1. Following 
incubation with the substrate for 2-5 min, the excess substrate was drained and the 
membrane was placed under a clear plastic cover in a film cassette and exposed 
to X-ray film. The film was developed using developing solution (RG X-ray 
developer, Champion) and fixative (RG X-ray fixer, Champion) in the Mediphot 937 
developing system. 
The membrane was stripped and reprobed when necessary. For stripping, the 
membrane was incubated with 10 ml stripping buffer at 50°C for 45 min with 
rotation using the Hybridiser HB-1 (Techne). Stripping buffer was prepared in a 
fume hood by adding 20 ml of 10% (w/v) SDS, 12.5 ml Tris HCl (pH 6.8) of the 
concentration 0.5 M and 0.8 ml β-mercaptoethanol and the volume was adjusted to 
100 ml with dH2O. After rinsing the membrane with water, it was washed once with 
TBS-T, blocked with blocking buffer for 1 hour and then reprobed with another 
primary antibody. 
 
49 
 
Table ‎2.5: List of the different primary antibodies used. 
Antibody Raised in 
/Clonality 
Immunogen Band 
size (kDa) 
SULF2  
(Abcam) 
Rabbit 
Polyclonal 
SULF2 C terminal amino acids 823-870 50  
SULF2  
(Abnova) 
Rabbit 
Polyclonal 
Rat SULF2 75-100 
SULF2  
(Thermo) 
Rabbit 
Polyclonal 
Synthetic peptide corresponding to SULF2  
SULF2 
(Aviva) 
Rabbit 
Polyclonal 
SULF2 C terminal amino acids 802-851  
SULF2  
(Sigma) 
Goat 
Polyclonal 
Internal region between the two furin cleavage sites 
(amino acids 545-560) of SULF2 
 
SULF2 (LR) Rabbit 
Polyclonal 
SULF2 HD amino acids 421-444  
SULF2 (NCL) Rabbit 
Polyclonal 
SULF2 HD amino acids 421-435  
SULF2  
(AbD Serotec) 
Mouse 
Monoclonal 
Epitope within SULF2 C-terminal subunit 37, 50, 
135 
SULF1  
(Abcam) 
Rabbit 
Polyclonal 
Amino acid 850 to the C-terminus of SULF1 58, 132 
 
SULF1  
(Abnova) 
Goat 
Polyclonal 
N-terminal amino acids 391-406 of mouse Sulf1 
that contains L
392
 instead of P
392
 in human SULF1 
 
β-Actin  
(Sigma) 
Mouse 
monoclonal 
β-Actin C-terminal peptide: Ser-Gly-Pro-Ser-Ile-Val-
His-Arg-Lys-Cys-Phe 
42 
STS/ARSC 
(Abcam) 
Rabbit 
Polyclonal 
Synthetic peptide corresponding to a region within 
internal sequence amino acids 396-445 of 
STS/ARSC 
63 
Total β-catenin 
(Cell Signalling) 
Rabbit 
Polyclonal 
Synthetic peptide corresponding to residues around 
Ser37 of β-catenin 
92 
Total β-catenin 
(Cell Signalling) 
Mouse 
Monoclonal 
Synthetic peptide corresponding to the carboxy 
terminus of β-catenin 
92 
Non-phospho- 
β-catenin 
(Cell Signalling) 
Rabbit 
Polyclonal 
Synthetic peptide corresponding to a region 
surrounding residue Ser37 of β-catenin 
92 
Phospho-
ERK1/2 
(Cell Signalling) 
Rabbit 
Monoclonal 
Synthetic phosphopeptide corresponding to 
residues surrounding Thr202/Tyr204 of human p44 
MAP kinase (ERK1) 
42, 44 
ERK1/2 
(Cell Signalling) 
Mouse 
Monoclonal 
Synthetic peptide corresponding to the sequence of 
p44/42 MAP kinase (ERK1/2) 
42, 44 
Phospho-AKT 
(Cell Signalling) 
Rabbit 
Monoclonal 
Synthetic phosphopeptide corresponding to 
residues around Ser473 of AKT 
60 
AKT  
(Cell Signalling) 
Rabbit 
Monoclonal 
Synthetic peptide corresponding to residues in the 
carboxy-terminal sequence of AKT 
60 
GAPDH 
(Cell Signalling) 
Rabbit 
Monoclonal 
Synthetic peptide corresponding to residues near 
the carboxy terminus of GAPDH 
37 
ACE2 
(Cell Signalling) 
Rabbit 
Polyclonal 
Synthetic peptide corresponding to residues near 
the amino terminus of ACE2 
120 
DLK1 
(R and D 
Systems) 
Mouse 
Monoclonal 
Recombinant human DLK1 long isoform Ala124-
Pro297 
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Antibody Raised in 
/Clonality 
Immunogen Band 
size (kDa) 
PCDH20 
(Santa Cruz) 
Rabbit 
Polyclonal 
Peptide mapping within an N-terminal extracellular 
domain of human PCDH20 
102 
Wnt-5a 
(R and D 
Systems) 
Rat 
Monoclonal 
Recombinant mouse Wnt-5a (Gln38-Lys380) 49 
TFPI2 
(R and D 
Systems) 
Mouse 
Monoclonal 
Recombinant human TFPI2 (Asp23-Phe235) 27 
SLPI 
(R and D 
Systems) 
Mouse 
Monoclonal 
Recombinant human SLPI 14 
  
2.11. Immunocytochemistry (ICC) 
4x105 cells/well were grown on glass coverslips in a 6-well plate. After 48 hours, 
the cells were rinsed with PBS and fixed in ice-cold methanol for 15 min at RT. The 
cells were washed twice with PBS and permeabilized by incubation with TBS-T for 
10 min. Following washing with PBS three times for 5 min each, the cells were 
incubated for 30 min with a blocking buffer composed of 3% (w/v) BSA and 10% 
(v/v) FBS in PBS. After that the cells were incubated with 1:100 diluted primary 
antibody in blocking buffer for 1 hr at RT. The antibody was decanted and the cells 
were washed in TBS-T three times for 5 min each. Cells were then incubated with 
the secondary antibody in blocking buffer (1:800 of Alexa Fluor 546 or Alexa Fluor 
488 goat anti-mouse or Alexa Fluor 488 goat anti-rabbit, Invitrogen) at RT for 1 hr 
in the dark followed by washing the cells in the dark with TBS-T three times for 5 
min each. The coverslips were then mounted with Vectashield mounting medium 
with DAPI (Vector Laboratories), sealed with nail polish and stored at 4°C. 
2.12. Immunoprecipitation 
200 µl of protein A agarose bead slurry (Calbiochem) was centrifuged at 400 xg for 
10 min. After discarding the supernatant, the remaining 100 µl of beads were 
washed with 1 ml of 1x HEPES (pH 8) and then centrifuged again. The supernatant 
was removed and an excess of SULF1 or 2 antibody (4 µg) was added. Following 
overnight incubation at 4°C under rotary agitation, the beads were centrifuged and 
the excess antibody was removed. Equal amounts of HCC cell lysates extracted by 
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NP-40 extraction buffer (1 mg for each 100 µl of beads) were added and incubated 
overnight at 4°C under rotary agitation. The beads were then centrifuged, the 
supernatant discarded, and the beads were washed twice with HEPES (1 ml each 
time), and resuspended in 100 µl of HEPES and stored at 4°C.   
2.13. Arylsulfatase Activity Assay 
The assay is based on the ability of sulfatase to convert 4-methylumbelliferyl 
sulfate (4-MUS) into the fluorescent product 4-methylumbelliferone (4-MU) by 
desulfation as shown in the reaction below. 
 
Cell-based assay: Cells were seeded in a 96-well plate. After 24 hours, the 
medium was removed and replaced by 100 µl phenol-free medium, and 
STS/ARSC was inhibited with 10 - 50 µM of oestrone 3-O-sulfamate (Sigma) for 1 
hour at 37°C. The remaining sulfatase activity was measured by incubation with 
the substrate 4-MUS for different time periods at 37°C after which the fluorescence 
of the product 4-MU was read at 460 nm following excitation at 355 nm using 
FLUOstar Omega (BMG Labtech) plate reader using the Omega data analysis 
software. 
Cell lysate- and immunoprecipitated enzyme-based assay: HCC cell lysates or 
SULF1/2-antibody immunoprecipitates (IPs) prepared in Section 2.12 were used in 
this assay by adding equal amounts of cell lysates or bead slurry in a 96-well black 
plate (Sterilin) in 50 µl reaction mixture of the following components: 5 µl of 10x 
(500 mM) HEPES reaction buffer (pH 8), 5 µl of 10x (100 mM) CaCl2, 4-MUS at the 
required concentration and made up to 50 µl with dH2O. The plate was incubated 
4-Methylumbelliferyl sulfate (4-MUS) 4-Methylumbelliferone (4-MU)
Fluorescence λex 355 nm; λem 460 nm
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for different time points at 37°C after which the fluorescence of the product 4-MU 
was read as described above. 
Recombinant sulfatase assays: Commercially available recombinant human 
sulfatases (ARSA and ARSB from R and D Systems, STS/ARSC, ARSD, ARSF, 
ARSG, IDS, GNS and GALNS from Origene) were diluted in reaction buffer as 
indicated above at different pH values and 4-MUS concentrations. After incubation 
at 37°C, the reaction was stopped using 100 µl of 1 M Tris (pH 10.5) and the 
fluorescence of 4-MU was read. 
2.14. Crystal Violet Staining 
Crystal violet is a protein dye that gives a reading at 595 nm that is proportional to 
cell count. For staining cells in 96-well plates, medium was removed and the plate 
was tapped onto paper towel to drain the medium completely. Each well was 
covered with 100 μl of crystal violet solution (0.4% (w/v) in distilled water). After 
incubation for 30 min at RT, the wells were washed under tap water flowing gently 
and then 3 times with 200 μl PBS with shaking on a plate shaker (Heidolph, 
Titramax 1000) for 5 min each time. Cells were solubilized by adding 100 μl/well of 
1% (w/v) SDS solution with shaking for 30 min at RT and the optical density at 595 
nm was measured using a FLUOstar Omega (BMG Labtech) plate reader.  
2.15. TCF Luciferase Reporter Assay 
Two different reporter plasmids were used. For transient transfection, the TCF 
reporter plasmid kit (Upstate, Millipore) was used to measure Wnt signalling. This 
kit contained two plasmids: a) TOPflash including 3 wild-type TCF binding sites 
and b) FOPflash including 2 wild-type and 1 mutated TCF binding site upstream of 
the thymidine kinase (TK) minimal promoter and luciferase ORF (Figure  2.5). 6x104 
cells/well in 24-well plates were transiently co-transfected in a reverse manner in 
Opti-MEM with 200 ng of either TOPflash or FOPflash along with 200 ng of β-
galactosidase reporter plasmid using FuGENE in the ratio 1:2 (µg total DNA: µl 
FuGENE). The β-galactosidase plasmid was used for internal normalization to 
correct for variable transfection efficiencies. 
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For stable transduction, the 7TFP lentiviral construct was used which was obtained 
from Addgene and was made and deposited by Prof. Roel Nusse (Fuerer and 
Nusse, 2010). This construct contains 7 TCF binding sites upstream of luciferase 
ORF in addition to puromycin as a selectable marker (Figure  2.6). Lentiviral 
particles were made using this construct as described in Section 2.5 and were 
used to infect HCC cells. Subsequently, cells were selected using puromycin. 
7TFP-transduced cells were seeded into 96-well plates at 10,000 cells/well. 
After overnight incubation of either transiently transfected or stably transduced 
cells in serum-free medium, cells were treated with recombinant human Wnt-3a (R 
and D Systems), 6-bromo-indirubin-3'-oxime (BIO) (Sigma) and/or the dishevelled 
(Dvl)-PDZ domain inhibitor II, compound 3289-8625 (Calbiochem) for different time 
periods. For TOPflash-transfected cells, cell lysates were prepared using reporter 
lysis buffer (RLB) (Promega) and luciferase and β-galactosidase activities were 
measured using a luciferase assay system (Promega) and a β-galactosidase 
enzyme assay system (Promega), according to the manufacturer’s protocol. For 
luciferase activity, a 96-well plate containing 10 µl cell lysate per well was placed in 
FLUOstar Omega plate reader which was programmed to dispense 50 µl of 
luciferase assay reagent per well followed immediately by reading the light 
produced for 10 seconds. For β-galactosidase activity, 10 µl of assay 2x buffer was 
added to a 96-well plate containing 10 µl cell lysate per well and incubated for 5 
min at 37°C or until the formation of a faint yellow colour. After that the reaction 
was stopped using 50 µl of 1 M sodium carbonate and the optical density at 420 
nm was measured. For 7TFP-transduced cells, luciferase activity was measured 
using ONE-Glo luciferase assay system (Promega) which uses 5’-fluoroluciferin as 
a substrate that is more stable than luciferin and gives more consistent 
luminescence following the reaction below.  
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100 µl of the reagent was added to the wells and incubated for 3 min at RT before 
measuring the luminescence using a FLUOstar Omega plate reader.    
 
 
Figure ‎2.5: TOPflash/FOPflash plasmid maps: Left: TOPflash plasmid including 
two sets of three copies of the full (wild-type) TCF binding site with the second set 
in the reverse orientation and Right: FOPflash plasmid including two full (in red) 
and one incomplete (mutated) copy (in blue) of the TCF binding site followed by 
three full copies in the reverse orientation. These two sets in each plasmid were 
upstream of the TK minimal promoter and luciferase ORF. 
 
Figure ‎2.6: 7TFP plasmid map: The plasmid includes 7 copies of the full (wild-
type) TCF binding site upstream of Firefly luciferase (FFluc) ORF. The puromycin 
resistance gene (PuroR) is under the SV40 promoter. 
 
2.16. Phospho-ERK, Phospho-AKT and Total‎β-catenin ELISA 
The ELISA assays were performed using PathScan phospho-p44/42 MAPK 
(Thr202/Tyr204), PathScan phospho-AKT1 (Ser473) or PathScan total β-catenin 
sandwich ELISA kits (Cell Signalling) that use 96-well plates coated with a capture 
antibody and according to the manufacturer’s protocol. In brief, 50 µg of cell lysates 
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were loaded into each well of the ELISA plate and the volume was completed to 
100 µl using sample diluent. The wells were sealed and incubated at 4°C overnight. 
The wells were then washed 4 times with washing buffer and incubated with 100 µl 
of detection antibody for 1 hr at 37°C. After washing the wells again as before, 100 
µl of HRP-linked secondary antibody was added for 30 min at 37°C. The wells were 
washed and 100 µl of TMB substrate was added for 10 - 20 min at RT. The 
reaction was stopped by adding 100 µl of stop solution and the optical density at 
450 nm was read using a FLUOstar Omega plate reader.  
2.17. Sulforhodamine B (SRB) Cell Growth Assay 
SRB stains proteins where the intensity of the staining is proportional to the 
number of cells. Cells were grown in 96-well plates (100 µl medium/well) for 
different periods and then fixed using 25 µl/well of ice-cold 50% (w/v) 
trichloroacetic acid (TCA). After incubation for 1 hour at 4°C, the liquid was 
removed and the wells were washed 5 times with dH2O. The plates were left to dry 
and then stored at 4°C until required. For SRB staining, the plates were allowed to 
reach room temperature and then stained with 100 µl of 0.4% (w/v) SRB solution in 
1% (v/v) acetic acid for 30 min. Subsequently, the unbound dye was discarded and 
the wells were washed 5 times with 1% acetic acid. The plates were left to dry 
overnight and then the dye was dissolved by adding 100 µl/well of 10 mM Tris (pH 
10.5). The plates were shaked for 20 min on a vibrating platform shaker (Titramax 
1000, Heidolph) and the absorbance at 510 or 570 nm was read using a FLUOstar 
Omega plate reader.   
2.18. Cell Proliferation Assay 
Cells were cultured in 96-well plates (100 µl medium/well) for different time points 
and then washed with PBS and trypsinized by 100 µl trypsin. The trypsin was 
blocked by adding 100 µl of serum-containing medium and the cells were 
transferred into counter pots, diluted 10 times using Isoton II solution and then 
counted using the Coulter Z1 (dual-threshold model) cell counter (Beckman 
Coulter) where the upper and lower size levels were set at 24 and 8 µm, 
respectively.  
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2.19. ELISA for RB4CD12-Based Detection of SULF1/2 Activity 
100 µl/well of 50 µg/ml biotinylated heparin was immobilized on streptavidin-coated 
96-well microplate (R and D systems, Minneapolis MN, USA). After incubation at 
4°C overnight, the plate was washed with PBS-T (0.1% (v/v) Tween-20 in PBS) 
three times and blocked with 200 µl of 3% (w/v) BSA for 2 hours at RT. The plate 
was washed again as indicated above and incubated with enzyme-antibody IPs of 
cell lysate for 2 hours at 37°C with 1x HEPES and 1x MgCl2 in 100 µl reaction 
mixture. Then the plate was washed and the c-Myc tagged RB4CD12 antibody 
(1:100 dilution in blocking solution) was added. RB4CD12 antibody was provided 
by Toin van Kuppevelt, Nijmegen, The Netherlands. After incubation for 1 hour at 
RT, the plate was washed 5 times in PBS-T for 10 minutes each with shaking and 
incubated with HRP-conjugated mouse monoclonal antibody to c-Myc (Abcam) 
(1:100 dilution of 1 mg/ml stock solution in blocking buffer) for 1 hour at RT. The 
plate was washed again and 100 µl/well of 1-Step Ultra TMB-ELISA (Thermo 
scientific) was added and incubated at RT until a blue colour developed. 50 µl of 2 
M sulfuric acid was added and the optical density at 450 nm was measured using a 
FLUOstar Omega plate reader. 
2.20. Tumourigenicity Assay 
All of the in vivo experiments were reviewed and approved by the local institutional 
animal welfare committee, and were performed according to the United Kingdom 
Coordinating Committee on Cancer Research Guidelines for the Welfare of 
Animals in Experimental Neoplasia (Second Edition) (Workman et al., 1998) and 
national law. 8 - 10 week-old female CD-1 athymic nude mice (Charles River 
Laboratories) or in house bred NOD scid gamma (NSG) mice (Comparative 
Biology Center, Medical School, Newcastle University) were implanted with a 
suspension of 1x107 HCC cells in 50 μl of culture medium or Matrigel basement 
membrane matrix (BD Biosciences) subcutaneously (s.c.) on the right flank. For 
inducible shRNA-transduced HuH-7 cells, 10 mice were implanted for each cell line 
(i.e., iNT.shRNA or iSULF2.shRNA-transduced cells). Half of the mice of each 
group were maintained on drinking water containing 12.5 mM IPTG (isopropyl β-D-
thiogalactoside).   
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Mice were monitored for tumour growth for 100 days post implantation and the size 
of any tumour that arose was measured in 2 dimensions using a digital caliper 
three times a week. Tumour volumes were determined from the two measurements 
using the formula (longest dimension/2) x (shortest dimension2). 
2.21. Quantification of small RNAs 
The QuantiMir RT system (Cambridge Bioscience) was used. The system converts 
small non-coding RNAs into quantifiable cDNA by tagging small RNA with poly A 
tag followed by annealing anchor oligo dT adaptor and reverse transcription 
reaction to create the first strand cDNA that can be used as a template for qPCR 
reaction using a 3’ universal reverse primer and a forward primer corresponding to 
the siRNA effector sequence of the shRNA of interest. The 5’ human U6 small 
nuclear RNA (snRNA) forward primer was used as an endogenous control. The 
sequences of the forward primers used in this assay are shown in Table  2.6. The 
assay was performed according to the manufacturer’s instructions. Total RNA was 
extracted from cell pellets by adding 100 µl of chilled cells-to-Cts lysis buffer 
followed by incubation at 45°C  for 10 min. Samples were then chilled on ice and 2 
µl of DNase I was added and samples incubated at 37°C for 15 min followed by 
inactivation of DNase by heating at 75°C  for 5 min. Five µl of each sample was 
then used in the reverse transcription reaction that was initiated by adding a poly A 
tail by incubating samples with 2 μl of 5x poly A buffer, 1 μl of 25 mM MnCl2, 1.5 μl 
of 5 mM ATP and 0.5 μl of poly A polymerase at 37°C  for 30 min. A 0.5 μl of oligo 
dT adaptor was then added and samples heated at 60°C for 5 min. cDNA was 
synthesized by adding 4 μl of 5x RT buffer, 2 μl of dNTP mix, 1.5 μl of 0.1 M DTT, 
1.5 μl of RNase-free H2O and 1 μl of reverse transcriptase followed by incubation 
at 42°C  for 60 min. Samples were then heated at 95°C for 10 min and resulting 
cDNAs stored at -20°C or used in qPCR reaction as described in Section 2.7. 
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Table ‎2.6: Forward primer sequences used for QuantiMir small RNA 
quantification. 
 Forward primer  Sequence 
5’ Human U6 snRNA CGCAAGGATGACACGCAAATTC 
Constitutive NT shRNA CAACAAGATGAAGAGCACCAA 
Constitutive and inducible SULF2 shRNA GGGCGAAAGTCATTGGAA 
Constitutive and inducible SULF1 shRNA TCTGGTGGACTGGACTAAT 
Inducible iNT.shRNA GCGATAGCGCTAATAATTT 
 
2.22. Affymetrix Microarray Gene Expression Analysis 
Biologically independent quadruplicates each containing 5x106 cells of HuH-7 
control untransduced cells or HuH-7 transduced with either NT shRNA or 
S2.shRNA_18 were harvested and resuspended in 300 µl RNAprotect Cell 
Reagent (Qiagen) and sent at RT for Affymetrix microarray analysis to the Center 
of Physiology and Pathophysiology, Institute of Neurophysiology, Cologne, 
Germany. The RNA was extracted and DNase-treated and then the quality of the 
RNA was tested by measuring the optical density (O.D.) at 260 nm/O.D. 280 nm 
and O.D. 260 nm/O.D. 230 nm ratios, RIN (RNA integrity number) using an Agilent 
Bioanalyzer 2100 and running RNA on a denaturing agarose gel to measure the 
ribosomal RNA species 28S/18S ratio.  
For transcriptional profiling, Affymetrix Human Genome U133 plus 2.0 arrays were 
used. Array hybridization and analysis were conducted by the Center of Physiology 
and Pathophysiology, Institute of Neurophysiology, Cologne, Germany as 
described in Appendix C. 
Analysis of affected pathways was completed by determining gene ontologies (GO) 
enriched with differentially expressed transcripts and by using Kegg pathways 
database (http://www.genome.jp/kegg/tool/search_pathway.html) and GeneSpring 
12.6 software (Agilent Technologies). 
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2.23. Flow Cytometry Analysis 
ImageStreamx (Amnis, Seattle) imaging flow cytometer was used, which has a 
high-speed automated microscope that can capture images of cells in flow and 
quantify the intensity and location of fluorescent probes. After trypsinization and 
blocking trypsin, the cells were centrifuged at 1,000 xg for 5 min, the supernatant 
aspirated and the cell pellet washed with PBS. The cells were then fixed in 1% 
(v/v) formalin in PBS for 20 min at RT. After centrifugation at 500 xg for 5 min, 
formalin was removed and cells resuspended in saponin-containing perm/wash 
buffer (BD Biosciences) for 1 hr at RT to permeabilize cells. Cells were centrifuged 
and gently resuspended in 100 µl of perm/wash buffer containing the primary 
antibody at dilution 1:100. After overnight incubation at 4°C, cells were centrifuged 
and resuspended in 100 µl of perm/wash buffer containing Texas Red secondary 
antibody (Invitrogen) at dilution 1:1000 for 1 hr at RT in the dark. Cells were then 
centrifuged and resuspended in 100 µl of perm/wash buffer and DAPI (1 µg/ml final 
concentration) was added to stain nuclei for 1 hr at RT. Cells were centrifuged at 
500 xg and re-suspended in an appropriate volume of PBS so that the sample ran 
at < 1000 objects/sec. Texas Red was excited at 561 nm and the emission at 595-
660 nm was measured. DAPI was excited at 405 nm and the emission was 
measured at 430-505 nm. Analysis was performed using the IDEAS software 
(version 5.0, Amnis, Seattle). To compensate for spectral overlap, cells labelled 
with a single-colour positive control for each fluorochrome were used. Round single 
cells (RSCs) were gated using a scatter plot of area versus aspect ratio of the 
brightfield image. The RSC population was then assessed for a sub-population of 
cells in best focus using the gradient Root Mean Square (RMS) feature. Gradient 
RMS calculates large changes in pixel values in the image. Cells with a gradient 
RMS > 50 are generally considered to be in best focus .The sub-population of 
RSCs in best focus was then assessed for the level of expression of proteins of 
interest by measuring the mean pixel intensity.  
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2.24. Measurement of ACE2 Activity 
Two fluorogenic peptide substrates were used, Mca-Tyr-Val-Ala-Asp-Ala-Pro-
Lys(Dnp)-OH (R and D systems) and Mca-Ala-Pro-Lys(Dnp)-OH (Enzo Life 
Sciences). The assay depends on the ability of ACE2 enzyme to cleave the amide 
bond between proline (Pro) and lysine (Lys) amino acids leading to the release of 
the fluorochrome Mca (7-methoxycoumarin-4-yl acetyl) from its quencher Dnp (2,4-
dinitrophenyl) group. Fifty µl of substrate diluted to 40 µM in 2x assay buffer (150 
mM Tris, 2M NaCl, pH 7.5) was added to 50 µl of cell lysates prepared in RLB 
buffer, or recombinant human ACE2 (R and D systems) and the fluorescence of 
the reaction was read at 405 nm after excitation at 320 nm using a FLUOstar 
Omega plate reader. 
2.25. Measurement of Ang-(1-7) Level 
The Ang-(1-7) ELISA (Uscn Life Science) was used which is a competitive 
inhibition enzyme immunoassay using a 96-well plate pre-coated with an Ang-(1-7) 
specific antibody. The Ang-(1-7) in the samples or the standards competes with a 
biotin-labelled Ang-(1-7) (reagent A) for binding to the Ang-(1-7) antibody. After 
washing the unbound conjugate, HRP-conjugated avidin (reagent B) is added 
where the bound amount of avidin is reversely proportional to Ang-(1-7) 
concentration. The assay was performed according to the manufacturer’s 
instructions. Fifty µl of each sample was added in each well to which equal volume 
of reagent A was added immediately. After incubation for 1 hr at 37°C, the wells 
were washed with 1x wash solution four times, 100 µl of detection reagent B added 
and the plate incubated for 30 min at 37°C. The wells were washed as before and 
90 µl of substrate solution added followed by incubation for 10 - 15 min at 37°C. 
Fifty µl of stop solution was added and the optical density at 450 nm was measured 
using a FLUOstar Omega plate reader.   
2.26. Statistical Analysis 
All graphs were generated using GraphPad Prism 6.00 software. To calculate p 
values after SULF1/2 knockdown, Minitab 16 statistical software was used. 2-
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sample t-test or one-way ANOVA were used for normally distributed samples. 
Homogeneity of variances was first determined using Levene’s test before 
conducting one-way ANOVA. When overall significant difference in group means 
was shown by one-way ANOVA, post-hoc pairwise comparisons tests were 
performed, including Tukey’s and Fisher’s tests.  
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3. Chapter 3. SULF1/2 Expression and Activity in HCC Cell Lines 
 
To study the biology of SULF1 and SULF2 in hepatocellular carcinoma, six HCC 
cell lines were chosen. The expression levels of SULF1/2 enzymes were first 
investigated at the mRNA and protein levels followed by measuring the sulfatase 
enzymatic activity of these cell lines. 
3.1. SULF1/2 mRNA Expression in HCC Cell Lines 
In order to characterise SULF1 and SULF2 mRNA levels in HCC cell lines, RT-
PCR was performed. DNA gel electrophoresis suggested that SULF2 was 
expressed at higher levels in three cell lines (SNU-182, HuH-7 and HepG2), lower 
levels in SNU-475, and was absent in Hep 3B and PLC/PRF/5 cell lines (Figure 
 3.1). For quantification of gene expression levels of SULF1 and SULF2, RT-qPCR 
was conducted. GAPDH and β2 microglobulin (B2M) were used as reference 
genes. Sequences of the primers used are listed in Table 2.1. First, the primers of 
GAPDH, B2M, SULF1 and SULF2 were validated using different quantities of 
cDNA for the HS766T pancreatic cancer cell line that is known to express high 
levels of both SULF1 and SULF2. The results showed that triplicate measurements 
of each gene had identical Ct (cycle threshold) values that inversely correlated with 
cDNA volumes (Figure  3.2; A) and the ratios of Ct values for each gene relative to 
that of GAPDH, used for normalization, remained constant (Figure  3.2; B). Also, 
the dissociation curve showed that the triplicate measurements for each gene had 
identical melting temperatures of the amplicon and no primer dimers were formed 
(Figure  3.2; C). Therefore, these primers were considered as suitable for 
measuring the expression level of SULF1 and SULF2.  
The RT-qPCR experiment presented in Figure  3.3 showed that SULF1 was only 
strongly expressed in 1 of 6 HCC cell lines (SNU-182) and weakly expressed in 
SNU-475 (Figure  3.3; B), while SULF2 was strongly expressed in 3 of 6 HCC cell 
lines (SNU-182, HuH-7 and HepG2), moderately expressed in SNU-475, weakly 
expressed in PLC/PRF/5 and was undetectable in Hep 3B cells (Figure  3.3; A). It 
was noteworthy that in SNU-182 cells SULF1 expression was 4-fold higher than 
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that of SULF2 as indicated by the Ct value of 22 for SULF1 compared with 24 for 
SULF2. In SNU-475 cells, Ct values were 33 for SULF1 compared with 29 for 
SULF2, i.e., the SULF2 transcript was 16-fold higher than the SULF1 transcript. 
 
Figure ‎3.1: Representative gel showing SULF2 mRNA levels in HCC cell lines: 
mRNA was harvested from 6 HCC cell lines and RT-PCR was performed using 
SULF2 primers, and the products were separated by agarose gel electrophoresis. 
GAPDH was used as the control. The experiment was performed in duplicate and 
a representative gel is shown. Data generated using the method described in 
Section 2.7.  
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Figure ‎3.2: Validation of RT-qPCR primers: A + B: RT-qPCR was performed 
using a range of HS766T cDNA volumes in triplicate. (A) The raw Ct values were 
plotted against the cDNA volume. Values are the mean of triplicates and error bars 
represent the standard error. (B) The relative expression of B2M, SULF1 and 
SULF2 using GAPDH as a reference gene. (C) Derivative dissociation curve of 1 µl 
of cDNA. The experiment was performed once. Data generated using the method 
described in Section 2.7. 
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Figure ‎3.3: Quantification of SULF1/2 mRNA levels by RT-qPCR in HCC cell 
lines: Data were normalized to the expression of GAPDH and presented relative to 
the expression level of PLC/PRF/5 cell line for SULF2 (A) or SNU-475 cell line for 
SULF1 (B). Values are the mean of three experiments each containing three 
biological replicates and error bars represent the standard error. Data generated 
using the method described in Section 2.7. 
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3.2. SULF1/2 Protein Expression in HCC Cell Lines 
To investigate whether SULF1/2 mRNA is translated into protein in HCC cell lines 
and to determine the localization of SULF1/2 proteins, western blot (WB) and 
immunocytochemistry (ICC) experiments were performed, respectively.  
3.2.1. SULF1/2 protein expression measured using western blot 
The performance of five commercially available antibodies (listed in Table  2.5) 
reportedly detecting SULF2 protein under reducing conditions was tested. 
However, none of these antibodies detected the appropriate SULF2 bands, namely 
the full-length protein along with one of its subunits (i.e., 75 or 50 kDa), depending 
on the immunogen to which the antibody (Ab) was raised. SULF2 Ab (LR) (kindly 
provided by Prof. Lewis Roberts, USA), raised against HD amino acids 421-444, 
gave better results. Blotting with this antibody was predicted to identify both the 
full-length 125 kDa and the 75 kDa bands that encompass the N-terminal domain. 
The 125 kDa band was detected in five HCC cell lines except Hep 3B cells (Figure 
 3.4; right), while the 75 kDa band was indistinguishable from a non-specific protein 
smear that appeared around that region. 
To generate a new SULF2 antibody, namely SULF2 Ab (NCL), the SULF2 HD 
amino acids 421-435 were used to which a cysteine residue was added as an 
immunogen in an attempt to generate a similar result to that obtained using SULF2 
Ab (LR). The peptide was designed and the antibody was raised in two rabbits by 
Eurogentec. The company provided the sera from the two rabbits, 1271 and 1272. 
After purification and testing the antibody specificity by ELISA, the antibody failed 
to detect the correct SULF2 bands by WB and gave unspecific binding. 
A new SULF2 Ab (Serotec) that was first reported by Lemjabbar-Alaoui et al. in 
2010 became commercially available. WB using this antibody showed the 
expression of SULF2 protein in the cell lines that expressed high levels of SULF2 
mRNA, namely SNU-182, HuH-7 and HepG2 (Figure  3.4; left). Moreover, this 
antibody gave less unspecific binding compared with SULF2 Ab (LR). However, 
the 50 kDa subunit could not be detected in any of the cells that endogenously 
expressed SULF2. 
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Regarding SULF1, two antibodies were tested and only the SULF1 antibody that 
was raised against the C-terminal domain, SULF1 Ab (Abcam), detected a 125 
kDa band, although not the 50 kDa band that encompasses the C-terminal domain 
(Figure  3.5). The results in Figure  3.5 were in line with the RT-qPCR data as a 125 
kDa band could be detected in the SNU-182 cell line but not the other HCC cell 
lines. HS766T pancreatic cancer cell line was used as a positive control for SULF1. 
                                       
Figure ‎3.4: SULF2 protein expression in HCC cell lines: Protein immunoblotting 
was performed on whole cell lysates with SULF2 Ab (Serotec) (Left), or SULF2 Ab 
(LR) (Right). The white arrows point to the band with the appropriate molecular 
weight for full-length SULF2 protein. The experiment was performed in triplicate 
and representative blots are shown. Data generated using the method described in 
Section 2.10. 
 
          
Figure ‎3.5: SULF1 protein expression in HCC cell lines: Protein immunoblotting 
was performed on whole cell lysates with SULF1 Ab (Abcam). The white arrow 
points to the band with the appropriate molecular weight for the full-length SULF1 
protein. The experiment was performed in triplicate and a representative blot is 
shown. Data generated using the method described in Section 2.10. 
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3.2.2. SULF1/2 protein expression analysed using immunocytochemistry 
In order to investigate the subcellular localization of SULF1/2 in HCC cell lines, ICC 
was performed. Three HCC cell lines (HuH-7, HepG2 and Hep 3B) and the 
HS766T pancreatic cancer cell line were studied using SULF2 Ab (LR) or SULF2 
Ab (Serotec) for SULF2 and SULF1 Ab (Abcam) for SULF1. These were the 
antibodies that gave the best results by WB. SULF2 Ab (LR) showed positive 
cytoplasmic and membranous staining for SULF2 in HuH-7 (Figure  3.6; 1B), 
HepG2 (Figure  3.6; 2B) and HS766T (data not shown) cells. However, this staining 
was similar to that in SULF2 non-expressing Hep 3B cells (Figure  3.6; 3B) 
indicating that this antibody is not suitable for ICC. 
In contrast, SULF2 Ab (Serotec) produced dotted-like staining of HuH-7 and 
HepG2 cells (Figure  3.7; 1-2B) rather than widespread staining of the whole cells. 
This pattern is in line with other studies reporting the enrichment of SULF2 in lipid 
raft domains on the cell surface (Tang and Rosen, 2009). Hep 3B cells were 
completely negative with this antibody (Figure  3.7; 3B). 
With respect to SULF1, no staining was detected in any of the tested cell lines 
except for weak staining in HS766T cells (data not shown), despite the very high 
level of protein expression of SULF1 in this cell line as measured by WB. 
Therefore, SULF1 Ab (Abcam) was regarded as unsuitable for ICC. Negative 
control samples stained with secondary antibody in the absence of primary 
antibody did not show staining in any of the cell lines (data not shown). 
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Figure ‎3.6: ICC staining of SULF2 in HCC cell lines using SULF2 Ab (LR): 
HCC cells were grown on glass coverslips and incubated with SULF2 Ab (LR) 
which was then stained green with Alexa Fluor 488 conjugated secondary 
antibody. Mounting medium with DAPI was used to counter-stain the nuclei in blue. 
(1) HuH-7, (2) HepG2, (3) Hep3B.  (A) blue channel for DAPI, (B) green channel 
for Alexa Fluor 488, (C) merge picture. The experiment was performed in duplicate. 
Data generated using the method described in Section 2.11. 
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Figure ‎3.7: ICC staining of SULF2 in HCC cell lines using SULF2 Ab 
(Serotec): HCC cells were grown on glass coverslips and incubated with SULF2 
Ab (Serotec) which was then stained green with Alexa Fluor 488 conjugated 
secondary antibody. Mounting medium with DAPI was used to counter-stain the 
nuclei in blue. (1) HuH-7, (2) HepG2, (3) Hep3B. (A) blue channel for DAPI, (B) 
green channel for Alexa Fluor 488, (C) merge picture. The experiment was 
performed in duplicate. Data generated using the method described in Section 
2.11. 
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3.3. Arylsulfatase Activity Assay in HCC Cell Lines 
SULF1/2 enzymes have been reported to have both endosulfatase as well as 
arylsulfatase (ARS) activities. To determine whether SULF1/2 proteins expressed 
in the different HCC cell lines were enzymatically active, their ARS activity was 
measured using the pseudo-substrate 4-MUS. 4-MUS is converted into the 
fluorescent product 4-MU by desulfation as described in Section 2.13. 
3.3.1. Optimisation of the conditions of the ARS activity assay 
The fluorescence of the product 4-MU is affected by the pH of the reaction mixture, 
with maximal fluorescence in alkaline solutions. This can be problematic if the pH 
optimum of the enzymes under investigation is in the acidic or neutral range. In 
such a case, the reaction would need to be stopped by increasing the pH of the 
reaction mixture to read the fluorescence of 4-MU, and as a result the assay would 
be discontinuous. Therefore, it was necessary to determine the sensitivity of 4-MU 
fluorescence at different pH values, as a continuous assay is optimal for studying 
the kinetics of SULF1/2 enzymatic reactions and the effects of inhibitors.  
Therefore, serial dilutions of 4-MU were added to HEPES solutions of different pH 
values ranging from 7 to 11, and the fluorescence intensity (FI) was measured. The 
results in Figure  3.8 show that FI values increased with increasing 4-MU 
concentrations to a peak of 4-MU fluorescence at a pH of 10 (Figure  3.8; A). 
However, 4-MU fluorescence could be detected at concentrations ≥ 0.1 µM 4-MU 
at all pH values studied (Figure  3.8; B). As the pH optimum for SULF1/2 activity is 
at 7 – 8, and in order to develop a continuous assay, the following conditions were 
used in all subsequent experiments: a pH of 7.4 was used for the cell-based assay 
which is the pH value of cell culture medium, and for all other cell-free assays a pH 
of 8 was used.  
The results presented in Figure  3.9 show that 4-MU readings are stable over at 
least a two-hour period, which was considered sufficient for performing a 
continuous assay and kinetic studies. 
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Figure ‎3.8: Effect of pH on the fluorescence of 4-MU: Serial dilutions of 4-MU 
were prepared in HEPES solutions of different pH and the fluorescence of 4-MU 
was measured at 460 nm following excitation at 355 nm. (A) Normal scale. (B) 
Logarithmic scale. The experiment was performed in triplicate. Data generated 
using the method described in Section 2.13. 
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Figure ‎3.9: Stability of the fluorescence of 4-MU over time: Serial dilutions of 4-
MU was prepared in pH 8 HEPES solution and the fluorescence of 4-MU was 
measured at 460 nm following excitation at 355 nm at different time points. The 
experiment was performed in triplicate. Data generated using the method 
described in Section 2.13. 
 
3.3.2. Cell-based assay 
In this assay, total ARS activity was measured and no differentiation was possible 
for either SULF1 or SULF2. Moreover, if other members of the sulfatase family are 
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For the cell-based assay, equal numbers of cells were cultured and then 
STS/ARSC was inhibited by incubation with EMATE. Remaining ARS activity was 
determined by incubation with the substrate 4-MUS and measurement of the 
fluorescent product 4-MU. The results in Figure  3.10 show that only two cell lines 
out of 6 tested exhibited ARS activity. HuH-7 had very high activity and HepG2 had 
lower but detectable activity while no significant activity was detected in any of the 
other four cell lines. These results suggested a poor correlation between SULF1/2 
mRNA and protein levels and sulfatase activity in HCC cell lines. Possible 
explanations include poor affinity of the substrate 4-MUS for SULF1/2 enzymes, or 
that SULF1/2 enzymes are present in some HCC cell lines in an inactive form.  
 
Figure ‎3.10: Cell-based arylsulfatase activity assay in HCC cell lines: 10,000 
cells/well were cultured in 96-well plate for 24 hours. STS/ARSC was then inhibited 
by incubation with 10 µM EMATE for 1 hour, and remaining sulfatase activity was 
measured by incubation with 0.5 mM 4-MUS for 4 hours after which the 
fluorescence of the product 4-MU was read at 460 nm following excitation at 355 
nm. Values are the mean of triplicates and error bars represent the standard error. 
The experiment was performed in triplicate. Data generated using the method 
described in Section 2.13. 
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and ARS activity was measured by incubation with the substrate 4-MUS and 4-MU 
fluorescence measured at different time points (Figure  3.11; A). The results 
showed that the majority of the sulfatase activity in HCC cell lines could be 
inhibited by the STS/ARSC inhibitor EMATE and only a low level of activity was not 
inhibited in both HuH-7 and HepG2 cell lines. Cell number at the time of the 
analysis was similar in the 3 cell lines and not affected by EMATE, as measured by 
crystal violet staining (Figure  3.11; B) 
 
 
Figure ‎3.11: Effect of EMATE on arylsulfatase activity assay in HCC cell lines: 
10,000 cells/well were cultured in a 96-well plate for 24 hours. Cells were then 
incubated with or without 10 µM EMATE for 1 hour. (A) Arylsulfatase activity was 
measured by incubation with 2.6 mM 4-MUS and reading the fluorescence of the 
product 4-MU at 460 nm following excitation at 355 nm. (B) Crystal violet staining 
of the same cells at the end of the ARS activity assay. Values are the mean of 
triplicates and error bars represent the standard error. The experiment was 
performed in triplicate. Data generated using the methods described in Section 
2.13 and Section 2.14. 
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3.3.3. Relationship between ARS activity and cell number   
To investigate the effect of cell number on the ARS activity, different numbers of 
HCC cells were seeded in 96-well plates and the EMATE-uninhibitable ARS 
activity was measured using the substrate 4-MUS, followed by staining of the cells 
with crystal violet. The results in Figure  3.12 show that the ARS activity of HuH-7 
and HepG2 cells is proportional to the number of seeded cells. No ARS activity 
was detected in the other 4 HCC cell lines (SNU-182, SNU-475, Hep 3B and 
PLC/PRF/5) even at 1x105 cells/well (data not shown). 
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Figure ‎3.12: Effect of cell number on arylsulfatase activity in HCC cell lines: 
Increasing numbers of cells/well were cultured in 96-well plates for 24 hours. 
Steroid STS/ARSC was then inhibited by incubation with 10 µM EMATE for 1 hour, 
and remaining sulfatase activity was measured by incubation with 0.5 mM 4-MUS 
for 4 hours. 100 µl of CM of HuH-7 (A) and HepG2 (B) was transferred into a new 
plate and 50 µl of 1 M Tris solution (pH 10.4) was added to increase 4-MU 
fluorescence which was read at 460 nm following excitation at 355 nm. Cells were 
then stained with crystal violet and the absorbance at 595 nm was read for HuH-7 
(C) and HepG2 (D). Values are the mean of triplicates and error bars represent the 
standard error. The experiment was performed in triplicate. Data generated using 
the methods described in Section 2.13 and Section 2.14. 
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3.3.4. ARS activity of HCC conditioned media 
Mature SULF1/2 can be retained on the cell surface or secreted into the 
extracellular fluid. To determine whether SULF1/2 proteins were secreted into the 
conditioned medium (CM), and whether the secreted proteins were enzymatically 
active, equal numbers of cells from the different cell lines (HuH-7, HepG2, Hep 3B 
and HS766T) were cultured in phenol red-free medium. After 48 hours, the CM 
was collected and concentrated 20 times. Then ARS activity was measured using 
4-MUS as a substrate. However, none of the cell lines tested showed any 
significant activity relative to control wells containing the substrate 4-MUS only 
(data not shown).   
3.3.5. ARS activity of HCC cell lysates 
In addition to the extracellular SULF1/2, enzymatically active SULF1/2 can be 
found in the ER and Golgi apparatus (Ai et al., 2003). Therefore, to compare the 
total level of SULF1/2 that could be present in different cellular compartments 
across HCC cell lines, ARS activity assays were performed using total cell lysates. 
Equal quantities of lysates were pre-incubated with EMATE to inhibit STS/ARSC 
before measuring the ARS activity using 4-MUS. The results in Figure  3.13 show 
that only HuH-7 and HepG2 cell lines had ARS activity and that no activity was 
detected in the other four cell lines. These results were consistent with the cell-
based assay data (Figure  3.10). The EMATE-uninhibitable activity of the cell 
lysates was ~ 40% and 60% of the total activity for HuH-7 and HepG2 cell lines, 
respectively (Figure  3.13). 
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Figure ‎3.13: Arylsulfatase activity assay of HCC cell lysates: 20 µg of HCC cell 
lysates extracted in RLB were incubated with or without 100 µM EMATE for 1 hour 
to inhibit STS/ARSC. After incubation with 3 mM 4-MUS for 3 hours at pH 7.5 the 
reaction was stopped and the fluorescence of the product 4-MU was read at 460 
nm following excitation at 355 nm. Values are the mean of triplicates and error bars 
represent the standard error. The experiment was performed in triplicate. Data 
generated using the method described in Section 2.13. 
 
3.3.6. ARS activity of SULF-antibody immunoprecipitates of HCC cell lysates   
ARS activity that was detected using cells or cell lysates could be due to the 
enzymatic activity of other members of the sulfatase family in addition to SULF1/2, 
as 4-MUS is a broad spectrum sulfatase substrate as discussed earlier. Therefore, 
SULF1/2 enzymes in HCC lysates were isolated by immunoprecipitation using 
SULF1 or SULF2 antibodies. Equal amounts of protein from lysates of HCC cell 
lines were incubated with protein A agarose beads that were pre-loaded with 
excess SULF1 Ab (Abcam) or SULF2 Ab (Abcam) to form SULF1/2-Ab 
immunoprecipitates (IPs) (see Section 2.12). These two antibodies were raised 
against the C-terminal domain of the corresponding SULF. The SULF2 Ab (Abcam) 
was initially chosen to avoid interference of the antibody-bead complex with the 
catalytic active site which is present in the N terminal domain of the SULF2 
enzyme. ARS activity of equal volumes of bead slurry was measured using the 
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substrate 4-MUS. For the SULF2-Ab (Abcam) IPs, the results showed that HuH-7 
cell lysate had the highest activity followed by HepG2 cell lysate while no activity 
was detected with the other HCC cell lysates (Figure  3.14; A).  
To confirm these results, the immunoprecipitation of SULF2 from HuH-7 and 
HepG2 cell lysates was repeated using a different antibody, namely SULF2 Ab 
(LR) that was raised against the HD domain. The results using the SULF2-Ab (LR) 
IPs were in line with the previous data using SULF2-Ab (Abcam) IPs and showed 
that both HuH-7 and HepG2 IPs had ARS activity which was higher in HuH-7 cell 
line (Figure  3.14; B). Furthermore, SULF2-Ab (Serotec) IPs showed similar results 
to SULF2-Ab (Abcam) IPs (data not shown). In all subsequent experiments 
SULF2-Ab (Abcam) IPs were used. 
With respect to SULF1, immunoprecipitation was performed using SNU-182 cell 
lysate only as this was the only HCC cell line that expressed SULF1. The HS766T 
cell line was also used as a positive control. No ARS activity was detected using 
SULF1-Ab IPs of SNU-182 cell lysate (data not shown), while a slight activity was 
detected for HS766T cell line (Figure  3.15). 
To investigate whether the ARS activity of SULF2-Ab IPs was lysate protein 
concentration dependent, SULF2 was immunoprecipitated by incubation of 
increasing quantities of HuH-7 cell lysate with the same volume of SULF2 
antibody-loaded beads. The HuH-7 cell line was used for this purpose as it had the 
highest ARS activity. The results in Figure  3.15 show that ARS activity increased 
with increasing quantities of lysate.  
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Figure ‎3.14: Arylsulfatase activity assay of SULF2-Ab IPs of HCC cell lysates: 
1 mg of HCC cell lysates was incubated with protein A agarose beads that were 
pre-loaded with excess SULF2 Ab (Abcam) (A), SULF2 Ab (LR) (B) or SULF1 Ab 
(Abcam) (C). Equal volumes of bead slurry were added to a 96-well plate and 
arylsulfatase activity was measured by incubation with 4-MUS for the time period 
indicated and reading the fluorescence of the product 4-MU at 460 nm following 
excitation at 355 nm. Values are the mean of triplicates and error bars represent 
the standard error. Each experiment was performed in triplicate. Data generated 
using the methods described in Section 2.12 and Section 2.13. 
 
Figure ‎3.15: Arylsulfatase activity of SULF2-Ab IPs generated using different 
quantities of HuH-7 cell lysate: Different amounts of HuH-7 cell lysate (0 - 500 
µg) were incubated with 25 µl of protein A agarose beads that were pre-loaded 
with excess SULF2 Ab (Abcam).The beads were washed and 1 mM 4-MUS was 
added and arylsulfatase activity was measured by reading the fluorescence of the 
product 4-MU at 460 nm following excitation at 355 nm. Values are the mean of 
duplicates and error bars represent the standard error. Data are from a single 
experiment. Data generated using the method described in Section 2.12 and 
Section 2.13. 
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3.3.7. Kinetics of the arylsulfatase activity of SULF2 using the substrate 4-
MUS 
One aim of these studies was to evaluate the use of the ARS activity assay of 
SULF2 with 4-MUS as a substrate in the screening of small-molecule inhibitors of 
SULF2. Therefore, it was important to study the kinetics of SULF2 with 4-MUS and 
to calculate the Michaelis constant (Km) of the reaction. For this purpose, SULF2-
Ab IPs of HuH-7 cell lysate were used and equal volumes of bead slurry were used 
and incubated with different concentrations of 4-MUS, and the fluorescence of the 
product 4-MU was read at different time points (Figure  3.16; A-G). The initial rates 
of the reactions were calculated and plotted against the substrate concentrations 
(Figure  3.16; H). The Km, defined as the concentration at half the maximum initial 
rate, was found to be 2.6 mM. The calculated Km was relatively high and indicates 
that 4-MUS is a poor SULF2 substrate. 
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Figure ‎3.16: Kinetics of arylsulfatase activity of SULF2-Ab IPs using 4-MUS: 
Equal volumes of bead slurry of SULF2-Ab IPs of HuH-7 cell lysate were added to 
a 96-well plate and arylsulfatase activity was measured by incubation with different 
concentrations of 4-MUS (A: 0.1 mM; B: 0.5 mM; C: 1 mM; D: 2 mM; E: 5 mM; F: 
7.5 mM; G: 10 mM) and reading the fluorescence of the product 4-MU at 460 nm 
following excitation at 355 nm. H: The initial velocity was plotted against 4-MUS 
concentration. GraphPad Prism was used to determine the Km using the model: 
Y = Vmax*X/(Km + X). The experiment was performed in duplicate. Data 
generated using the methods described in Section 2.12 and Section 2.13. 
 
3.3.8. Effect of EMATE on ARS activity of SULF2 
3.3.8.1. Effect of EMATE on ARS activity of SULF2-Ab IPs 
To investigate whether the enzyme purified by immunoprecipitation of HuH-7 cell 
lysate using SULF2 antibody was contaminated with STS/ARSC, a major 
component of cellular sulfatase activity in this cell line (Figure  3.13), SULF2-Ab IPs 
of HuH-7 cell lysate were pre-incubated with different concentrations of the 
STS/ARSC inhibitor EMATE for 1 hour, and the ARS activity measured using 4-
MUS as a substrate at different time points. The results showed no inhibition of the 
SULF2-Ab IP ARS activity even at 100 µM of EMATE (Figure  3.17). The results 
also showed that there was no linear increase of product formation over time 
(Figure  3.17).  
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Figure ‎3.17: Effect of EMATE on arylsulfatase activity of SULF2-Ab IPs: Equal 
volumes of bead slurry of SULF2-Ab IPs of HuH-7 cell lysate were incubated with 
EMATE for 1 hour and arylsulfatase activity measured by incubation with 2.6 mM 
4-MUS and reading the fluorescence of the product 4-MU at 460 nm following 
excitation at 355 nm. Values are the mean of triplicates and error bars represent 
the standard error. The experiment was performed in triplicate. Data generated 
using the methods described in Section 2.12 and Section 2.13. 
 
3.3.8.2. Effect of EMATE on the kinetics of ARS activity of SULF2 using 4-MUS 
To confirm that EMATE was not an inhibitor of SULF2, the effect of EMATE on the 
kinetics of SULF2 using 4-MUS as a substrate was investigated. Equal volumes of 
SULF2-Ab IPs of HuH-7 cell lysate were pre-incubated with EMATE followed by 
incubation with 4-MUS. The fluorescence of the product 4-MU was determined and 
the kinetics of the reaction was studied as described in Section 3.3.7. The results 
showed no effect of EMATE on the kinetics of the reaction as the slope after 
plotting the initial rate against the substrate concentration did not change in the 
presence (slope = 14.7) or absence (slope = 15.6) of EMATE (Figure  3.18). 
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Figure ‎3.18: EMATE effect on the kinetics of arylsulfatase activity of SULF2-
Ab IPs using 4-MUS: Equal volumes of bead slurry of SULF2-Ab IPs of HuH-7 cell 
lysate were added to a 96-well plate and incubated with 10 µM of EMATE for 1 
hour. After that ARS activity was measured by incubation with different 
concentrations of 4-MUS (A: 0.1 mM; B: 1 mM; C: 2.6 mM; D: 5 mM) and reading 
the fluorescence of the product 4-MU at 460 nm following excitation at 355 nm. E: 
The initial velocity was plotted against 4-MUS concentration. The experiment was 
performed in duplicate. Data generated using the methods described in Section 
2.12 and Section 2.13. 
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3.3.8.3. Effect of EMATE on ARS activity of whole cell lysate 
To determine the concentration of EMATE that should be used to inhibit 
STS/ARSC in all subsequent experiments, the effect of different concentrations of 
EMATE on ARS activity of whole cell lysate was investigated. HuH-7 cell lysate 
was used and the results in Figure  3.19 show that EMATE concentrations of 10-50 
µM inhibited the majority of the STS/ARSC activity. EMATE concentrations > 50 
µM did not markedly increase inhibition of STS/ARSC.  
 
Figure ‎3.19: Effect of EMATE on arylsulfatase activity of HuH-7 whole cell 
lysate: Equal quantities of HuH-7 cell lysate were incubated with EMATE for 1 
hour, and sulfatase activity measured by incubation with 2.6 mM 4-MUS and 
reading the fluorescence of the product 4-MU at 460 nm following excitation at 355 
nm. Values are the mean of triplicates and error bars represent the standard error. 
The experiment was performed in triplicate. Data generated using the method 
described in Section 2.13. 
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3.4. Determination of the Endosulfatase Activity of SULF1/2 Using the 
RB4CD12-Based ELISA  
In addition to the arylsulfatase activity of SULF1/2 enzymes, they possess 
oligosaccharide endosulfatase activity. To measure endosulfatase activity against 
heparin, the anti-HS phage display antibody RB4CD12 was used in an ELISA 
application as described in Section 2.19. The preferred sequence for RB4CD12 
binding is the trisulfated disaccharide composed of iduronic acid 2-O-sulfate and N-
sulfo-glucosamine-6-O-sulfate (Uchimura et al., 2010). Therefore, the binding of 
cMyc-tagged RB4CD12 primary antibody to immobilized heparin is inhibited on 
reduction of 6-O sulfation by SULF1/2. Reduced RB4CD12 binding leads to 
decreased levels of HRP-conjugated anti-cMyc secondary antibody binding and 
hence to less oxidization of the HRP substrate, TMB, which leads to lower optical 
density readings at 450 nm compared with untreated control wells. 
SULF1, SULF2 and STS/ARSC enzymes purified by immunoprecipitation were 
used in this assay. For SULF2, two different antibodies were used for 
immunoprecipitation, namely, the polyclonal SULF2 Ab (Abcam) and the more 
specific monoclonal SULF2 Ab (Serotec). Both STS/ARSC and SULF2 enzymes 
were purified from HuH-7 cell lysate as these cells had the highest ARS activity 
(Figure  3.10). SULF1 enzyme was purified from SNU-182 cell lysate as it is the 
only HCC cell line that expresses high level of SULF1.  
The ELISA results depicted in Figure  3.20 showed a decrease in the binding of 
RB4CD12 antibody as indicated by the optical density readings at 450 nm with 
increasing volumes of both SULF2-Ab IPs, but no change in the readings of the 
wells treated with STS/ARSC-Ab IPs. These results suggest that the SULF2-Ab 
IPs, but not STS/ARSC-Ab IPs, exhibited a concentration-dependent 
endosulfatase activity on immobilized heparin. Interestingly, the SULF1-Ab 
(Abcam) IPs also showed concentration-dependent endosulfatase activity (Figure 
 3.20). SULF2-Ab IPs from HepG2 or SNU-182 cell lysates were not tested due to 
the limited availability of the RB4CD12 antibody. 
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Figure ‎3.20: Endosulfatase activity measured using RB4CD12-based ELISA: 
SULF2-Ab (Serotec) IPs, SULF2-Ab (Abcam) IPs and STS/ARSC-Ab IPs from 
HuH-7 cell lysate and SULF1-Ab (Abcam) IPs from SNU-182 cell lysate were 
added in increasing volumes (1, 5, 10, 20 µl) to immobilised heparin in an ELISA 
plate. Following incubation with RB4CD12 antibody, the plate was incubated with 
HRP-conjugated cMyc antibody. HRP activity was detected by adding TMB 
substrate and reading the absorbance of the oxidized product at 450 nm. Total: 
untreated heparin. No 2o: cMyc secondary antibody omitted. No 1o: RB4CD12 
primary antibody omitted. Values are the mean of triplicates and error bars 
represent the standard error. The experiment was performed in duplicate. Data 
generated using the methods described in Section 2.12 and Section 2.19. 
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3.5. Summary 
In summary, a panel of six HCC cell lines were characterised for expression of 
SULF1 and SULF2 at the mRNA and protein levels and for arylsulfatase and 
endosulfatase enzymatic activities. Based on the pattern of expression, these cell 
lines constitute three groups, namely, SULF1 and SULF2-positive (SNU-182 and 
SNU-475), SULF2-positive (HuH-7 and HepG2) and SULF1 and SULF2 negative 
(Hep 3B and PLC/PRF/5). This allows studying the biology of SULF1/2 enzymes in 
different backgrounds.  
The arylsulfatase activity assay using 4-MUS as a substrate was also 
characterised. Only HuH-7 and HepG2 cells and cell lysates had arylsulfatase 
activity. Immunoprecipitated SULF2 from HuH-7 and HepG2 cell lysates but not 
SNU-182 cell lysate had arylsulfatase activity, and activity was not inhibited by the 
STS/ARSC inhibitor, EMATE. Immunoprecipitated SULF2 from HuH-7 cell lysate 
and immunoprecipitated SULF1 from SNU-182 cell lysate showed endosulfatase 
activity demonstrating that endogenous SULF1/2 proteins are enzymatically active 
in HCC cell lines.  
 
 
 
 
 
 
 
 
 
94 
 
4. Chapter 4. Generating Recombinant SULF1/2 Proteins and 
Characterisation of Commercially Available Sulfatases 
 
For screening small-molecule inhibitors of SULF2, it is important to generate 
recombinant SULF2 protein that can be easily and reliably purified, and used in an 
enzymatic assay or ELISA to screen inhibitors and to avoid contamination with 
other members of the sulfatase family. To generate recombinant protein, two 
different approaches were used to deliver the exogenous SULF2 DNA. The first 
approach was transfection of a SULF2 construct into cells. However, due to a low 
transfection efficiency, another approach was used, namely, transduction with 
SULF2-containing lentiviral particles. 
4.1. Gene Delivery of SULF2 by Transfection 
For transfection, the SULF1 or SULF2 open reading frame (ORF) was inserted 
under a CMV promoter to allow for constitutive expression of the protein which was 
fused with a C-terminal MYC/DDK tag for antibody detection and purification. Five 
different cell lines were transfected with these two constructs. Three of these were 
SULF1- and SULF2-negative, including Human Colon Tumour (HCT) cells and two 
HCC cell lines, Hep 3B and PLC/PRF/5. SULF1/2 expression in a negative 
background was designed to enable cell-based screening of inhibitors, by 
comparing effects in SULF1/2 non-expressing versus over-expressing cells, as well 
as to generate the recombinant SULF1/2 proteins. Two SULF2-positive HCC cell 
lines, HuH-7 and HepG2, were also evaluated, as these cells were known to be 
capable of producing and processing SULF2 protein (Chapter 3). As discussed 
earlier (Chapter 1), SULF1/2 enzymes are complex proteins that require different 
processing steps. 
4.1.1. Optimisation of transfection conditions 
Before attempting transfection of SULF1/2 constructs, transfection conditions were 
optimised. A pCI-neo/EGFP plasmid that constitutively expressed the fluorescent 
protein EGFP was used for this purpose. Transfection was performed by lipofection 
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using two different transfection reagents, namely, lipofectamine and FuGENE as 
described in Section 2.4. Optimisation was carried out by testing different ratios of 
transfection reagent to DNA, and by scaling up the whole transfection mixture (i.e., 
transfection reagent plus DNA) to identify the conditions that gave the highest 
transfection efficiency for each single cell line. The transfection efficiency was 
assessed by fluorescence microscopy and characterised by two criteria i.e., 
percentage of green cells to total cells and fluorescence intensity. In all tested cell 
lines, FuGENE was superior to lipofectamine but nevertheless overall transfection 
efficiency was low. Of the HCC cell lines, HuH-7 was the easiest cell line to 
transfect with 5% green cells (Figure ‎4.1) and more intense fluorescence than 
other cell lines followed by Hep 3B, while HepG2 was poorly transfected. For all 
cell lines, the ratio 2:1 (FuGENE:DNA) gave the best results.  
 
 
 
Figure ‎4.1: Optimisation of transfection conditions: HuH-7 cells were 
transfected in a 96-well plate with different ratios of FuGENE:DNA. After 24 hrs, 
the cells were examined under a fluorescence microscope. Right panel is EGFP 
channel: cells transfected in the ratio 2:1 (top); untransfected cells (bottom). Left 
panel is bright field of transfected (top) and untransfected (bottom) cells. The bar 
represents 100 pixels. Data are from a single experiment. Data generated using 
the method described in Section 2.4. 
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4.1.2. Screening of colonies 
After transfection with SULF1 or SULF2 constructs, G418 antibiotic was used to 
select for the successfully transfected antibiotic-resistant cells. Whole resistant 
HCT or PLC/PRF/5 cells were collected while for the other three HCC cell lines, 
resistant colonies were picked up: 20 colonies of each SULF1- or SULF2-
transfected HepG2, 9 colonies of each SULF1- or SULF2-transfected HuH-7 or 
Hep 3B. The colonies were expanded and screened using different methods. Only 
examples of the screened colonies are shown below.  
4.1.2.1. Screening of colonies using RT-qPCR 
mRNA was extracted from colonies of SULF1- or SULF2-transfected cells and 
SULF1/2 mRNA levels compared with those of control untransfected cells. Figure 
 4.2 shows a sample of screened HepG2 colonies. SULF2 expression was 4-fold 
and 80-fold higher in SULF2-transfected clone 13 and clone 15 cells, respectively, 
than in control untransfected HepG2 cells. SULF1-transfected cells had no 
increase in SULF2 expression over control. 
 
Figure ‎4.2: Screening of colonies using RT-qPCR: mRNA was extracted from 
control untransfected (Ctrl), SULF1- and SULF2-transfected HepG2 cells. RT-
qPCR was performed using SULF2 primers, and the data were normalized to the 
expression level of the control untransfected cells used as a calibrator. GAPDH 
was used as a reference gene. SULF2 (C13) and SULF2 (C15) are SULF2-
transfected clones 13 and 15. SULF1 (C13) is SULF1-transfected clone 13. Values 
are the mean of triplicates and error bars represent the standard error. Data are 
from a single experiment. Data generated using the methods described in Section 
2.4 and Section 2.7. 
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4.1.2.2. Screening of colonies using western blot 
Transfected cells were also screened for recombinant SULF1/2 proteins using WB. 
Two types of antibodies were used for this purpose; an anti-SULF1/2 antibody 
(either SULF2 or SULF1) or an anti-DDK antibody, as the recombinant proteins 
were C-terminally tagged with DDK. Both the CM and the cell lysate were 
screened. Figure  4.3 shows WB of the SULF2-transfected HCT cell line. In this 
case, the recombinant protein was purified from the conditioned medium using an 
anti-FLAG (DDK) M2 affinity column. A weak band corresponding to the full length 
SULF2 protein was detected in the first eluate. This result suggested the 
successful translation of the recombinant SULF2 protein and its secretion into the 
CM. However, no arylsulfatase activity was detected in any of the eluates using 4-
MUS as a substrate. The presence of recombinant proteins was also studied in the 
cell lysate, and Figure  4.4 depicts the analysis of a sample of HepG2 colonies 
transfected with SULF1 or SULF2 constructs and blotted using either SULF2 Ab 
(LR) or anti-DDK antibody. The results show the presence of the full-length protein 
in SULF2-transfected HepG2 clone 15, which had the highest SULF2 protein 
expression among all screened colonies, but not in the control untransfected 
HepG2 cells. However, ICC data showed that not all clone 15 cells were 
expressing SULF2 protein (Figure  4.5), consistent with the low transfection 
efficiency of HCC cells. 
 
Figure ‎4.3: Screening of SULF2-transfected HCT cells using WB: DDK-tagged 
SULF2 recombinant protein from CM of SULF2-transfected HCT cell line was 
purified using anti-FLAG M2 affinity column followed by WB using an anti-DDK 
antibody. C.M: the remaining conditioned medium from which the protein was 
purified. The white arrow points to a band with the appropriate molecular weight for 
the full-length SULF2 protein. The experiment was performed in duplicate. Data 
generated using the methods described in Section 2.4 and Section 2.10. 
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Figure ‎4.4: Screening of HepG2 colonies using WB: SULF1- or SULF2-
transfected HepG2 colonies were blotted with SULF2 Ab (LR) (top) and anti-DDK 
Ab (bottom). Ctrl: control untransfected HepG2. Data are from a single experiment. 
Data generated using the methods described in Section 2.4 and Section 2.10. 
 
 
Figure ‎4.5: ICC staining of SULF2 protein after transfection of the SULF2 
plasmid into HCC cells: HepG2 control untransduced cells or SULF2-transfected 
HepG2 clone 15 cells were grown on glass coverslips and incubated with SULF2 
Ab (Serotec) and then stained green with Alexa Fluor 488 conjugated secondary 
antibody. Mounting medium with DAPI was used to counter-stain the nuclei in blue. 
(1) control untransduced cells, (2) Clone 15. (A) blue channel for DAPI, (B) green 
channel for Alexa Fluor 488, (C) merge picture. Data are from a single experiment. 
Data generated using the methods described in Section 2.4 and Section 2.11. 
SULF2
DDK
125 kDa
125 kDa
DAPI SULF2 Merge
1A 1B 1C
2A 2B 2C
99 
 
4.1.2.3. Screening of colonies using an ARS activity assay 
Colonies were also screened using an arylsulfatase activity assay with 4-MUS as 
the substrate to investigate whether or not the recombinant protein was 
enzymatically active. Both whole cells and cell lysates were used for this purpose. 
For cell-based screening, equal numbers of cells from each clonal population were 
seeded and their ARS activities were compared with that of untransfected cells 
which served as a control. No significant ARS activity was detected over control in 
any of the tested colonies.  
For cell lysate screening, equal amounts of cell lysates from different clonal 
populations were screened for their ARS activities, which were compared with that 
of control untransfected cells. The transfected colonies in SULF-negative 
background (i.e., Hep 3B colonies) didn’t show significant ARS activity over control 
(data not shown). While transfected colonies in SULF-positive background (i.e., 
HuH-7 and Hep G2 colonies) showed a modest ≤ 2-fold increase in ARS activity 
over control. 
Notably, the SULF2-transfected HepG2 clone 15 cells that showed high level 
expression of recombinant SULF2 protein compared with control, still displayed 
only a 2-fold increase in ARS activity over that in untransfected HepG2 cells 
(Figure  4.6). Also, ARS activity of clone 15 cells was similar to that of clone 14 cells 
that had much lower levels of recombinant SULF2 protein. 
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Figure ‎4.6: Arylsulfatase activity of SULF2-transfected HepG2 clones: 30 µg 
of cell lysates were incubated with 50 µM EMATE for 1 hr to inhibit STS/ARSC, 
and then ARS activity was measured by adding 2.6 mM of 4-MUS and reading the 
fluorescence of the product 4-MU. HepG2: untransfected cells, SULF2 (C14) and 
SULF2 (C15) are SULF2-transfected clones 14 and 15, respectively. Values are 
the mean of triplicates and error bars represent the standard error. The experiment 
was performed in triplicate. Data generated using the method described in Section 
2.13. 
 
4.1.2.4. Screening of colonies using SULF1/2-Ab IPs 
Screening was performed using SULF2-transfected HepG2 clone 15 to investigate 
whether or not the recombinant SULF2 protein was active, as the ARS activity 
assay of the cell lysate showed only a 2-fold increase in activity over control 
(Figure  4.6). SULF2 Ab (LR) was used for immunoprecipitation, equal volumes of 
bead slurry were added, and ARS activity was measured using the substrate 4-
MUS. The results in Figure  4.7 show no significant difference in the ARS activity of 
IPs between clone 15 and control cells suggesting that the ARS activity of both 
cells was due to endogenous SULF2 and that the recombinant SULF2 protein in 
clone 15 was not active.  
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Figure ‎4.7: Arylsulfatase activity assay of SULF2-Ab IPs of control 
untransfected HepG2 and SULF2-transfected HepG2 clone 15 cell lysates: 
1mg of HCC cell lysates were incubated with protein A agarose beads that were 
pre-loaded with excess SULF2 Ab (LR). Equal volumes of bead slurry were added 
to a 96-well plate and arylsulfatase activity was measured by incubation with 2.6 
mM 4-MUS and reading the fluorescence of the product 4-MU at 460 nm following 
excitation at 355 nm. Values are the mean of triplicates and error bars represent 
the standard error. Data are from a single experiment. Data generated using the 
methods described in Section 2.12 and Section 2.13. 
 
4.2. Gene Delivery of SULF2 by Transduction 
Given the low transfection efficiency of HCC cells, another approach to expressing 
SULF2 protein was investigated, namely transduction with SULF2 lentiviral 
particles into HCC cells. SULF2 lentiviral particles were generated as described in 
Section 2.5 where the expression of both SULF2 and a blasticidin selectable 
marker were driven by the same promoter. This design allowed for enrichment of 
SULF2-expressing cells after selection with blasticidin. Hep 3B cells were 
transduced with different volumes of SULF2 lentiviral particles-containing CM 
followed by selection of transduced cells using blasticidin. WB analysis was 
performed using a SULF2 Ab (Serotec) that was raised against a region in the C-
terminal domain. WB data revealed the expression of a 125 kDa protein consistent 
with full-length SULF2 in addition to a 50 kDa protein consistent with the C-terminal 
subunit of SULF2 protein, in the SULF2-transduced cells. No SULF2 protein was 
detected in the control untransduced Hep 3B cells. The expression of SULF2 
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protein was dependent on the volume of SULF2 lentiviral particle-containing CM 
added to the cells (Figure  4.8). To determine what percentage of cells were 
expressing SULF2 protein, ICC was performed which confirmed intense staining 
for SULF2 protein in the majority of the transduced cells, and no visible staining in 
the control untransduced cells (Figure  4.9). However, no arylsulfatase activity 
detected of the cell lysates of the transduced cells using 4-MUS as the substrate 
(data not shown). Therefore, individual colonies were picked to screen for cells 
enriched in catalytically active SULF2. WB was performed using the SULF2 Ab 
(Serotec), which identified clones 10 and 26 as the most highly expressing clones 
followed by clones 17 and 19 (Figure  4.10). This SULF2 expression was confirmed 
by ICC, and Figure  4.11 shows SULF2 staining in clones 10, 17 and 26 but not in 
the control untransduced Hep 3B cells. Unfortunately, as for the SULF2-transfected 
cells, none of the SULF2-transduced clonal population cell lysates showed any 
detectable activity against 4-MUS in comparison to Hep 3B control untransduced 
cells. HuH-7 cell lysate was used as positive control in this assay (Figure  4.12) 
 
Figure ‎4.8: WB analysis of SULF2 protein expression after transduction of 
SULF2 lentiviral particles into HCC cells: Hep 3B cells were transduced with 
either 100 µl or 500 µl SULF2 lentiviral particle-containing conditioned medium. 
WB was performed using SULF2 Ab (Serotec). The experiment was performed in 
triplicate and a representative blot is shown. Data generated using the methods 
described in Section 2.5 and Section 2.10. 
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Figure ‎4.9: ICC staining of SULF2 protein after transduction of SULF2 
lentiviral particles into HCC cells: Hep 3B control untransduced cells or those 
transduced with 500 µl SULF2 lentiviral particle-containing CM were grown on 
glass coverslips and incubated with SULF2 Ab (Serotec) and then incubated with 
Alexa Fluor 488 conjugated secondary antibody. Mounting medium with DAPI was 
used to counter-stain the nuclei in blue. (1) control untransduced cells, (2) SULF2-
transduced cells. (A) blue channel for DAPI, (B) green channel for Alexa Fluor 488, 
(C) merge picture. The experiment was performed in duplicate. Data generated 
using the methods described in Section 2.5 and Section 2.11. 
 
Figure ‎4.10: SULF2 protein expression in SULF2-transduced clones of Hep3B 
cells: Hep 3B cells were transduced with SULF2 lentiviral particles followed by 
selection with blasticidin and picking of colonies. WB was performed using SULF2 
Ab (Serotec). M: Marker, Ctrl: control untransduced cells. The experiment was 
performed in duplicate and representative blots are shown. Data generated using 
the methods described in Section 2.5 and Section 2.10. 
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Figure ‎4.11: ICC staining of SULF2-transduced clones of Hep3B cells: Cells 
were grown on glass coverslips and incubated with SULF2 Ab (Serotec) and then 
incubated with Alexa Fluor 546 conjugated secondary antibody. Mounting medium 
with DAPI was used to counter-stain the nuclei in blue. (1) control untransduced 
cells, (2) Clone 10, (3) Clone 17, (4) Clone 26. (A) blue channel for DAPI, (B) red 
channel for Alexa Fluor 546, (C) merge picture. The experiment was performed in 
duplicate. Data generated using the method described in Section 2.11. 
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Figure ‎4.12: Arylsulfatase activity of SULF2-transduced Hep 3B clones: 30 µg 
cell lysates were incubated with 50 µM EMATE for 1 hr to inhibit STS/ARSC, and 
ARS activity was then measured by adding 2.6 mM of 4-MUS and reading the 
fluorescence of the product 4-MU. Ctrl: control untransduced Hep 3B cells. Ctrl (4-
MUS): substrate control with no lysate added. Values are the mean of triplicates 
and error bars represent the standard error. The experiment was performed in 
triplicate. Data generated using the method described in Section 2.13. 
 
The lack of enzymatic activity of the SULF2 protein generated was potentially due 
to the production of an inactive form due to insufficient Cα-formylglycine generating 
enzyme (FGE) activity that is required for the conversion of a cysteine residue in 
the catalytic active site into Cα-formylglycine. To test this hypothesis the SUMF1 
gene that encodes for the FGE enzyme was co-expressed. 
4.3. Overexpression of SUMF1 in SULF2-Expressing Cells 
Prior to attempting overexpression of SUMF1, the endogenous level of SUMF1 in 
HCC cell lines was investigated by RT-qPCR. The results showed that all six HCC 
cell lines express a similar level of SUMF1 ranging from 25 - 28 fold higher than the 
GAPDH endogenous control gene (Figure  4.13). 
To investigate whether SUMF1 co-expression could activate the over-expressed 
recombinant SULF2 protein, a SUMF1 construct was transfected into cells. 
However, the SUMF1 construct has no selectable marker, thus it was either 
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transiently transfected or co-transfected with the SULF2 construct for stable 
transfection. 
Both Hep 3B and HEK 293T cells were transfected, the latter having a relatively 
high transfection efficiency, and expression of SUMF1 was investigated at the 
mRNA level by RT-PCR. The results showed the successful expression of SUMF1 
mRNA after transient transfection in both HEK 293T and Hep 3B cells; however, 
SUMF1 was lost when it was stably transfected with the SULF2 construct in Hep 
3B cells (Figure  4.14). Therefore, SULF2 and SUMF1 constructs were transiently 
co-transfected into HEK 293T cells and the expression of both proteins was 
confirmed at the protein level by WB (Figure  4.14). Also, SULF2-expressing 
HepG2 clone 15 was transiently transfected with the SUMF1 construct. However, 
none of these cells showed any arylsulfatase activity in cell lysates or conditioned 
medium (data not shown). 
 
Figure ‎4.13: SUMF1 expression in HCC cell lines: RT-qPCR was performed on 
mRNA extracted from HCC cells. GAPDH was used as a reference gene. Error 
bars represent standard error of the mean of triplicates. Values are the mean of 
triplicates and error bars represent the standard error. Data are from a single 
experiment. Data generated using the method described in Section 2.7. 
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Figure ‎4.14: Overexpression of SUMF1 in HEK 293T and Hep 3B cells: (A) RT-
PCR of HEK 293T or Hep 3B cells that were transfected with the SUMF1 construct. 
The reaction was performed for 30 cycles using SUMF1 primers (right) or GAPDH 
(left) as a reference gene. (B) WB of control untransfected or SULF2 and SUMF1-
transiently co-transfected HEK 293T cells using SULF2 (left) or SUMF1 (right) 
antibodies. Control: untransfected cells, SUMF1 (T): SUMF1-transiently transfected 
cells, SULF2+SUMF1 (S): SULF2 and SUMF1-stably co-transfected cells, 
SULF2+SUMF1 (T): SULF2 and SUMF1-transiently co-transfected cells. All 
experiments were performed in duplicate and representative images and blots are 
shown. Data generated using the methods described in Section 2.4, Section 2.7 
and Section 10. 
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4.4. Transient Transfection and Production of SULF2  
The experiments in the preceding sections demonstrated that it was possible to 
express recombinant SULF2 at very high level. However, there was no enzymatic 
activity associating with the SULF2 protein. It is plausible that high levels of 
catalytically active SULF2 enzyme are toxic to the cells, and the focus was 
changed to transient transfection of other previously reported SULF2 constructs. A 
simple SULF2 construct was used for this purpose, which was described by the 
first group that cloned human SULF2. The wild-type SULF2 ORF was cloned into 
the pcDNA3.1 vector backbone and was tagged by Myc and His (polyhistidine 
metal-binding tag) at the C-terminal end (Morimoto-Tomita et al., 2002). Also, the 
catalytically inactive mutated form of SULF2 (also called S2∆CC) that was 
generated by conversion of the cysteine at residue 88 in the active site into alanine 
was used as negative control for enzymatic activity. Both constructs were 
deposited by Prof. Steven Rosen on Addgene. WB of the conditioned medium of 
cells transiently transfected with either the wild-type or the mutated SULF2 showed 
the expression of both full-length protein and the 50 kDa subunit to which the 
SULF2 Ab (Serotec) was raised (Figure  4.15; A), indicating appropriate processing 
of the expressed proteins and their secretion into the medium. Arylsulfatase activity 
assays showed that only the CM of cells transfected with wild-type SULF2 had 
activity, while no activity was detected for either the mock transfected or the 
S2ΔCC-transfected cells (Figure  4.15; B). The active SULF2 could be purified and 
enriched about 160-fold from the CM using nickel affinity gel to which the His tag of 
the SULF2 protein binds, while no activity was detected in the flow-through (Figure 
 4.15; C). However, it was not possible to remove the protein from the beads using 
the standard reagents imidazole or EDTA because both inhibited the ARS reaction. 
Therefore, the SULF2-bound beads were used for screening SULF2 inhibitors.     
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Figure ‎4.15: Transient expression and enzymatic activity of SULF2 in the CM 
of transfected HEK 293T cells: HEK 293T cells were transfected with wild-type 
SULF2 plasmid (lane 1: WT SULF2), mock transfected without plasmid (lane 2: 
Mock), or transfected with a catalytically inactive SULF2 plasmid (lane 3: S2ΔCC). 
CM was collected after 3 days. (A) WB was performed using SULF2 Ab (Serotec). 
(B) ARS activity of 20 µl CM was measured by adding 8 mM of 4-MUS and reading 
the fluorescence of the product 4-MU. (C) SULF2 was purified using nickel affinity 
gel, and the ARS activity of CM (starting material before purification), SULF2-
bound beads and flow-through (FT) from the column after purification was 
measured. Ctrl (4-MUS): substrate control with no CM added. For (B and C) values 
are the mean of triplicates and error bars represent the standard error. All 
experiments were performed in triplicate and a representative blot is shown for (A). 
Data generated using the methods described in Section 2.4, Section 2.10 and 
Section 2.13. 
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4.5. Characterisation of Commercially Available Sulfatases for Counter-
Screening SULF2 Inhibitors 
It was anticipated that in addition to testing against active SULF2, potential SULF2 
inhibitors would be tested against other members of the sulfatase family to 
determine selectivity. Therefore, all sulfatases that are commercially available were 
purchased and their activity with the substrate 4-MUS was characterised in terms 
of pH optimum, concentration and time dependency. The Km values of the reaction 
were measured whenever possible and when 4-MUS was a particularly poor 
substrate, other substrates were used where available. 
4.5.1. Characterisation of arylsulfatase A (ARSA) 
ARSA activity has an acidic pH optimum (Figure  4.16), which is consistent with its 
lysosomal subcellular localization. Concentration-dependent activity with 4-MUS 
exhibited a good dynamic range (Figure  4.17) (Table  4.1). The Km value was 
calculated as 2.2 mM at pH 4.5 (Figure  4.18), while the reported value is 12.5 mM 
at pH 5.7 (Hanson et al., 2004). 
 
Figure ‎4.16: pH-dependent ARS activity of ARSA: 100 ng ARSA was incubated 
with 3 mM 4-MUS at different pH values for 2 hrs. The reaction was stopped using 
1 M Tris (pH 10.4) and the fluorescence of the product 4-MU was read at 460 nm 
after excitation at 355 nm. Values are the mean of triplicates and error bars 
represent the standard error. The experiment was performed in duplicate. Data 
generated using the method described in Section 2.13. 
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Figure ‎4.17: Concentration-dependent ARS activity of ARSA: Different 
concentrations of ARSA were incubated with 3 mM 4-MUS at pH 4.5 for 2 hrs. The 
reaction was stopped using 1 M Tris (pH 10.4) and the fluorescence of the product 
4-MU was read at 460 nm after excitation at 355 nm. Values are the mean of 
triplicates and error bars represent the standard error. The experiment was 
performed in duplicate. Data generated using the method described in Section 
2.13. 
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Figure ‎4.18: Determination of the Km of 4-MUS for ARSA: (A) 75 ng ARSA was 
incubated with different concentrations of 4-MUS at pH 4.5 for different time points. 
The reaction was stopped using 1 M Tris (pH 10.4) and the fluorescence of the 
product 4-MU was read at 460 nm after excitation at 355 nm. Values are the mean 
of triplicates and error bars represent the standard error. (B) Initial velocity was 
plotted against 4-MUS concentration. GraphPad Prism was used to determine the 
Km using the model: Y = Vmax*X/(Km + X). The experiment was performed in 
duplicate. Data generated using the method described in Section 2.13. 
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4.5.2. Characterisation of arylsulfatase B (ARSB) 
As for ARSA, ARSB showed an acidic pH optimum (Figure  4.19), consistent with 
its lysosomal localization. Concentration-dependent activity with 4-MUS also 
exhibited a good dynamic range (Figure  4.20) (Table  4.1). The Km value was 
calculated as 415 µM at pH 4.5 (Figure  4.21), whereas the reported value is 1,180 
µM at pH 5.6 (Hanson et al., 2004). 
 
Figure ‎4.19: pH-dependent ARS activity of ARSB: 100 ng ARSB was incubated 
with 3 mM 4-MUS at different pH values for 2 hrs. The reaction was stopped using 
1 M Tris (pH 10.4) and the fluorescence of the product 4-MU was read at 460 nm 
after excitation at 355 nm. Values are the mean of triplicates and error bars 
represent the standard error. The experiment was performed in duplicate. Data 
generated using the method described in Section 2.13. 
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Figure ‎4.20: Concentration-dependent ARS activity of ARSB: Different 
concentrations of ARSB were incubated with 3 mM 4-MUS at pH 4.5 for 2 hrs. The 
reaction was stopped using 1 M Tris (pH 10.4) and the fluorescence of the product 
4-MU was read at 460 nm after excitation at 355 nm. Values are the mean of 
triplicates and error bars represent the standard error. The experiment was 
performed in duplicate. Data generated using the method described in Section 
2.13. 
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Figure ‎4.21: Determination of the Km of 4-MUS for ARSB: (A) 75 ng ARSB was 
incubated with different concentrations of 4-MUS at pH 4.5 for different time points. 
The reaction was stopped using 1 M Tris (pH 10.4) and the fluorescence of the 
product 4-MU was read at 460 nm after excitation at 355 nm. Values are the mean 
of triplicates and error bars represent the standard error. (B) Initial velocity of the 
reaction was plotted against 4-MUS concentration. GraphPad Prism was used to 
determine the Km using the model: Y = Vmax*X/(Km + X). The experiment was 
performed in duplicate. Data generated using the method described in Section 
2.13. 
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4.5.3. Characterisation of steroid sulfatases/arylsulfatase C (STS/ARSC) 
STS/ARSC showed a pH optimum of 7.5 (Figure  4.22), in line with localization in 
the microsomes. Concentration-dependent activity against 4-MUS exhibited a good 
dynamic range (Figure  4.23) (Table  4.1). The Km value was 82 µM at pH 7.5 
(Figure  4.24), compared to the reported value of 800 µM at pH 7 (Hanson et al., 
2004). 
 
Figure ‎4.22: pH-dependent ARS activity of STS/ARSC: 100 ng STS/ARSC was 
incubated with 3 mM 4-MUS at different pH values for 2 hrs. The reaction was 
stopped using 1 M Tris (pH 10.4) and the fluorescence of the product 4-MU was 
read at 460 nm after excitation at 355 nm. Values are the mean of triplicates and 
error bars represent the standard error. The experiment was performed in 
duplicate. Data generated using the method described in Section 2.13. 
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Figure ‎4.23: Concentration-dependent ARS activity of STS/ARSC: Different 
concentrations of STS/ARSC were incubated with 3 mM 4-MUS at pH 7.5 for 2 hrs. 
The reaction was stopped using 1 M Tris (pH 10.4) and the fluorescence of the 
product 4-MU was read at 460 nm after excitation at 355 nm. Values are the mean 
of triplicates and error bars represent the standard error. The experiment was 
performed in duplicate. Data generated using the method described in Section 
2.13. 
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Figure ‎4.24: Determination of the Km of 4-MUS for STS/ARSC: (A) 75 ng 
STS/ARSC was incubated with different concentrations of 4-MUS at pH 7.5 for 
different time points. The reaction was stopped using 1 M Tris (pH 10.4) and the 
fluorescence of the product 4-MU was read at 460 nm after excitation at 355 nm. 
Values are the mean of triplicates and error bars represent the standard error. (B) 
Initial velocity of the reaction was plotted against 4-MUS concentration. GraphPad 
Prism was used to determine the Km using the model: Y = Vmax*X/(Km + X). The 
experiment was performed in duplicate. Data generated using the method 
described in Section 2.13. 
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4.5.4. Characterisation of neutral pH-dependent sulfatases 
In addition to STS/ARSC, other neutral pH-dependent sulfatases were tested; the 
ER sulfatases ARSD, ARSF and ARSG. These three enzymes showed very weak 
activity using 4-MUS (Figure  4.25), with no more than 1.4-, 1.5- and 6.7-fold 
increase over substrate-only control, using 500 ng of ARSD, ARSF and ARSG, 
respectively (Table  4.1). This lack of activity made it difficult to measure the Km 
values for these enzymes. Also, this result indicated that 4-MUS is not a suitable 
substrate for assaying the activity of these three enzymes. 
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Figure ‎4.25: Concentration-dependent ARS activity of ARSD (A), ARSF (B) 
and ARSG (C): Different concentrations of the enzymes were incubated with 3 mM 
4-MUS at pH 7.5 for 2 hrs. The reaction was stopped using 1 M Tris (pH 10.4) and 
the fluorescence of the product 4-MU was read at 460 nm after excitation at 355 
nm. Values are the mean of triplicates and error bars represent the standard error. 
The experiment was performed in duplicate. Data generated using the method 
described in Section 2.13. 
 
4.5.5. Characterisation of acidic pH-dependent sulfatases 
In addition to ARSA and ARSB, the activity of three other lysosomal enzymes, 
namely, GALNS, GNS and IDS was measured using 4-MUS as the substrate. Of 
these three enzymes only IDS showed weak activity, with a 2.5-fold increase over 
control using 500 ng of the enzyme (Figure  4.26) (Table  4.1). No activity was 
detected for GALNS or GNS using 4-MUS (Figure  4.26). Therefore, other 
substrates were tested for these lysosomal enzymes. One was the chromogenic 
substrate p-nitrocatechol sulfate, where the removal of the sulfate groups by 
lysosomal arylsulfatases (e.g., ARSA and ARSB) leads to the formation of p-
nitrocatechol. The absorbance of p-nitrocatechol can be measured in alkaline 
solution at 510 nm (van der Pal et al., 1991). IDS, GALNS and GNS enzymes 
failed to show any detectable activity, even at high enzyme concentrations (data 
not shown). Another indirect assay was therefore explored, which was the 
glucosidase- and galactosidase-coupled assays for GNS and GALNS, respectively. 
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Figure ‎4.26: Concentration-dependent ARS activity of IDS (A), GALNS (B) and 
GNS (C): Different concentrations of the enzymes were incubated with 3 mM 4-
MUS at pH 4.5 for 2 hrs. The reaction was stopped using 1 M Tris (pH 10.4) and 
the fluorescence of the product 4-MU was read at 460 nm after excitation at 355 
nm. Values are the mean of triplicates and error bars represent the standard error. 
The experiment was performed in duplicate. Data generated using the method 
described in Section 2.13. 
 
4.5.5.1. Characterisation of GNS using the glucosidase-coupled assay 
GNS is a lysosomal exosulfatase that removes the 6-O-sulfate group from N-
sulfated or N-acetylated glucosamine residues at the non-reducing end of HS 
chains, or N-acetylated glucosamine residues of keratan sulfate (Parenti et al., 
1997). To measure GNS activity a glucosidase-coupled assay can be used, which 
depends on the intrinsically poor ability of β-glucosidase to hydrolyse the glycosidic 
bond between 4-MU and N-acetyl glucosamine when the latter is modified by a 6-
O-sulfate as depicted in Figure  4.27 (Myette et al., 2009). In this assay, 4-
methylumbelliferyl-6-sulfo-N-acetyl-β-D-glucosaminide (MU-GlcNAc,6S) is used, 
with 4-methylumbelliferyl-N-acetyl-β-D-glucosaminide (MU-GlcNAc) serving as a 
positive control for the activity of β-glucosidase. By performing the glucosidase-
coupled assay at pH 4.5, the pH optimum of GNS, an assay was performed to 
confirm that β-glucosidase had minimal activity against MU-GlcNAc,6S compared 
with its activity against MU-GlcNAc. GNS alone had no activity against either 
G N S  (n g )
F
lu
o
r
e
s
c
e
n
c
e
 i
n
te
n
s
it
y
 (
a
.u
.)
0 2 0 0 4 0 0 6 0 0
0
1 0 0 0 0
2 0 0 0 0
3 0 0 0 0
C
124 
 
substrate (Figure  4.28; A). The minimal activity of β-glucosidase against MU-
GlcNAc,6 was slightly increased by pre-incubation of the substrate with 250 ng of 
GNS for two hours, followed by adding β-glucosidase (Figure  4.28; B). This result 
suggested that the activity of GNS was the rate-limiting step of the glucosidase-
coupled assay, as reported previously (Myette at al., 2009). Therefore, incubation 
of MU-GlcNAc,6S with high quantities of GNS and for a longer time was required to 
achieve the dynamic range needed for counter-screening of inhibitors (Figure  4.29; 
A). Under these conditions, it was found that GNS retained some activity at pH 7.5 
(Figure  4.29; B). 
 
Figure ‎4.27: Principle of the glucosidase-coupled assay 
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Figure ‎4.28:‎Activity‎of‎β-glucosidase and/or GNS against MU-GlcNAc,6S and 
MU-GlcNAc: 2 mM MU-GlcNAc,6S and MU-GlcNAc were incubated with 250 ng 
GNS for 2 hrs at 37°C in a reaction buffer containing HEPES and MgCl2 followed 
by adding 40 units of β-glucosidase for 1 hr. The reaction was stopped using 1 M 
Tris (pH 10.4) and the fluorescence of the product 4-MU was read at 460 nm after 
excitation at 355 nm. (B) is the same as (A) with MU-GlcNAc data excluded for 
clarity. Values are the mean of triplicates and error bars represent the standard 
error. The experiment was performed in triplicate. 
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Figure ‎4.29: Glucosidase-coupled assay of GNS activity: 2 mM MU-GlcNAc,6S 
was incubated with 500 ng GNS for 3 hrs at 37°C followed by adding 40 units β-
glucosidase for 1 hr. The reaction was stopped using 1 M Tris (pH 10.4) and the 
fluorescence of the product 4-MU was read at 460 nm after excitation at 355 nm. 
(B) is the same as (A) with the data at pH 4.5 excluded for clarity. Values are the 
mean of triplicates and error bars represent the standard error. The experiment 
was performed in triplicate. 
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4.5.5.2. Characterisation of GALNS using the galactosidase-coupled assay   
GALNS is a lysosomal exosulfatase that removes 6-sulfate group from N-
acetylated galactosamine residues of chondroitin sulfate or from galactosamine 
residues in keratan sulfate (Parenti et al., 1997). In a similar approach to that used 
for measuring GNS activity, the galactosidase-coupled assay was used for 
GALNS. This assay depends on the intrinsically poor ability of β-galactosidase to 
hydrolyse the glycosidic bond between 4-MU and galactosamine when the latter is 
modified by a 6-O-sulfate (van Diggelen et al., 1990). For this assay, 4-
methylumbelliferyl β-D-galactopyranoside-6-sulfate (MU-Gal,6S) was used and 4-
methylumbelliferyl β-D-galactopyranoside (MU-Gal) served as a positive control for 
the activity of β-galactosidase. The assay showed that β-galactosidase has no 
activity against MU-Gal,6S at pH 4.5, the pH optimum of GALNS, although it has 
some activity at pH 7.5 (Figure  4.31; A) and very high activity against MU-Gal at 
pH 4.5 (Figure  4.30; A). GALNS alone had no activity against either substrate 
(Figure  4.30). Pre-incubation of the MU-Gal,6S with 500 ng GNS at pH 4.5 for 4 
hours followed by adding β-galactosidase was not associated with any measurable 
activity (Figure  4.31; B), suggesting either that this commercial GALNS enzyme is 
not active, or that MU-Gal,6S is not a substrate for this enzyme. 
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Figure ‎4.30:‎Activity‎of‎β-galactosidase and/or GALNS against MU-Gal,6S and 
MU-Gal: 2 mM MU-Gal,6S and MU-Gal were incubated with 250 ng GALNS for 1 
hrs at 37°C in a reaction buffer containing HEPES (pH 4.5) and MgCl2 followed by 
adding 40 units β-galactosidase for 1 hr. The reaction was stopped using 1 M Tris 
(pH 10.4) and the fluorescence of the product 4-MU was read at 460 nm after 
excitation at 355 nm. (B) is the same as (A) with MU-Gal data excluded for clarity. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. 
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Figure ‎4.31: Galactosidase-coupled assay of GALNS activity: 2 mM MU-
Gal,6S was incubated with 500 ng GALNS for 4 hrs at 37°C followed by adding 40 
units β-galactosidase for 1 hr. The reaction was stopped using 1 M Tris (pH 10.4) 
and the fluorescence of the product 4-MU was read at 460 nm after excitation at 
355 nm. (B) is the same as (A) with the data at pH 7.5 excluded for clarity. Values 
are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. 
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Table ‎4.1: Relative ARS activity of sulfatases against 4-MUS. 
Enzyme 
 (ng) 
Ratio of activity to control (no enzyme)   
ARSA ARSB 
STS/ 
ARSC ARSD ARSF ARSG IDS GNS GALNS 
0 1 1 1 1 1 1 1 
  
25 2 3 1 1 1 1.3 1.1 
50 7 6 4 1 1 1.8 1.2 
75 10 9 6     
100 12 11 9 1 1.1 2.5 1.4 
250 20 42 20 1.3 1.3 4.4 1.9 
500 28 59 36 1.4 1.5 6.7 2.5 
Km (µM) 2,200 415  82  N/A N/A N/A N/A N/A N/A 
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4.6. Summary 
Recombinant SULF2 protein could be stably expressed at high levels but did not 
show any catalytic activity using 4-MUS as the substrate even after co-expression 
with the FGE enzyme that is responsible for sulfatase activation. In contrast, 
transient expression of SULF2 did produce catalytically active enzyme that was 
secreted into conditioned medium. The failure to generate SULF2 by stable 
expression could possibly be due to toxicity resulting from high levels of active 
SULF2 enzyme in the stably transfected cells, such that only cells with inactive 
SULF2 and/or low levels of active SULF2 survive. The inactivity of SULF2 could be 
due to defective post-translational processing independent of the FGE enzyme, 
and the inability to detect low levels of active SULF2 could be due to the poor 
affinity of the SULF2 enzyme for the substrate 4-MUS. The transiently expressed 
active SULF2 could be enriched from CM using affinity binding but could not be 
eluted. Thus, SULF2 bound to beads was identified as the only viable source of 
enzyme for screening of inhibitors.  
Setting up the sulfatase counter-screens was more straightforward. Three 
commercially available sulfatases, ARSA, ARSB and STS/ARSC, have high affinity 
to 4-MUS so these can be used in the initial counter-screening of potential 
inhibitors of SULF2. ARSD, ARSF, ARSG and IDS did have weak activity against 
4-MUS substrate, but as large amounts of enzyme would need to be purchased 
these sulfatases would only be used for counter-screening of inhibitors inactive in 
the initial counter screen with ARSA, ARSB and STS/ARSC. A similar approach 
was proposed for GNS, where the glucosidase-coupled assay could be used for 
highly selected inhibitors, as a high concentration of the enzyme is required. 
 
 
 
 
132 
 
5. Chapter 5. Effects of Constitutive SULF1/2 Suppression in 
HCC Cell Lines 
 
Numerous signalling pathways are recognized as playing a part in 
hepatocarcinogenesis. Two of the most important and best characterised are the 
growth factor/receptor tyrosine kinase (RTK) signalling pathway and the Wnt 
signalling pathway. Key growth factors involved in the RTK pathway include FGF-
1, FGF-2, IGF-I, IGF-II and VEGF-165 (Yang et al., 2011) (Min et al., 2011) (Wu 
and Zhu, 2011) (Cornellà et al., 2011) (Zhang et al., 2012). The 6-O sulfation of 
HSPGs is reportedly important for these two signalling pathways and 6-O sulfation 
is post-synthetically modified by the activity of SULF1/2. Thus, these pathways 
were characterised in HCC cell lines and the effect of SULF2 gene silencing on 
these pathways investigated. 
5.1. Characterisation of Wnt Signalling in HCC Cell Lines 
Secreted Wnt ligands can activate two signalling pathways. The first is the 
canonical Wnt signalling pathway in which ligands bind to frizzled (FZD) receptors 
and this leads to activation of T-cell factor/lymphocyte enhancer factor (TCF/LEF) 
transcription factors (Gordon and Nusse, 2006). The second is the non-canonical 
signalling pathway, which regulates cytoskeletal reorganization and calcium 
mobilization (Veerman et al., 2003). The canonical pathway is better characterised 
and is generally considered the more pertinent to carcinogenesis (Polakis et al., 
2012). While a number of ways of measuring the canonical signalling pathway 
have been developed, there is a shortage of assays to study the non-canonical 
pathway (van Amerongen and Nusse, 2009). The focus here will be on the 
canonical Wnt signalling pathway. 
Canonical Wnt signalling is mediated by the protein β-catenin. In the absence of 
Wnt ligands (Figure  5.1; left), β-catenin is kept at a low level through association 
with the destruction complex composed of the adenomatous polyposis coli (APC) 
protein, axin and two kinases, namely glycogen synthase kinase 3β (GSK-3β) and 
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casein kinase 1α (CK-1α). The degradation cascade of β-catenin is initiated after 
phosphorylation at Ser45 by CK-1α (Amit et al., 2002) (Liu et al., 2002). This initial 
event leads to its subsequent further phosphorylation at Ser33, Ser37 and Thr41 
by GSK-3β (Wu and He, 2006), which leads to degradation of β-catenin by the 
ubiquitin-proteasome pathway, involving the ubiquitin ligase β-TrCP (Willert and 
Nusse, 1998) (Nusse, 2012).  
Upon signalling (Figure  5.1; right), Wnt ligands bind to fizzled receptors and low-
density lipoprotein receptor-related protein 5 and 6 (LRP5/6) co-receptors, and this 
leads to the rearrangement of the receptors. The LRP tail is phosphorylated by CK-
1γ which also requires frizzled and the scaffolding protein dishevelled (Dvl). 
Subsequently, LRP recruits axin and disrupts the destruction complex (Mao et al., 
2001) (Bilic et al., 2007). In another model, it was proposed that frizzled receptors 
recruit Dvl through binding with the PDZ domain of Dvl (Umbhauer et al., 2000) 
(Wong et al., 2003) (Cong et al., 2004). The similarity between the N terminus of 
Dvl and the DIX domain of axin leads to their interaction and to the formation of a 
Dvl, axin and GSK-3β complex upon Wnt binding (Schwarz-Romond et al., 2007) 
(Nusse et al., 2012). As a result, β-catenin is no longer phosphorylated by GSK-3β, 
and it accumulates in the cytoplasm followed by translocation to the nucleus. In the 
nucleus β-catenin forms a complex with TCF/LEF transcription factors and other 
elements including BCL9, pygopus (Pygo), and CBP to drive the transcription of 
downstream genes such as MYC and CCND1 (Willert and Nusse, 1998) 
(Grigoryan et al., 2008) (Nusse, 2012). 
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Figure ‎5.1: Diagram representing the canonical Wnt signalling pathway: Left: 
Inactive Wnt signalling: In the absence of Wnt ligand, β-catenin is targeted for 
degradation by the destruction complex (axin, APC, CK-1α and GSK-3β). Right: 
Active Wnt signalling: Binding of Wnt ligand to its frizzled receptor and LRP5/6 co-
receptor recruits the scaffolding protein dishevelled and this leads to the disruption 
of the destruction complex and stabilization of β-catenin which translocates to the 
nucleus and activates transcription of target genes. 
 
 
 
 
 
 
 
 
135 
 
There are numerous means of monitoring canonical Wnt signalling. These include 
detecting changes in the levels or activity of β-catenin as detected by performing 
WB, ICC or ELISA using antibodies against total β-catenin or active β-catenin 
(ABC); β-catenin lacking phosphates at Ser33/37/Thr41. Changes in β-
catenin/TCF activity can be detected using luciferase reporter assays, as described 
in Section 2.15. The format can involve transiently transfecting cells with a plasmid 
vector containing a ‘TOPflash’ reporter, or stably transducing cells with 7TFP 
lentiviral particles. The TOPflash plasmid has three TCF binding sites upstream of 
the luciferase coding sequence, promoting the expression of luciferase following 
activation of Wnt signalling. The activity of the expressed luciferase is measured by 
a chemiluminescent reaction using luciferin as the substrate. The 7TFP construct 
has seven TCF binding sites upstream of Firefly luciferase making it more robust 
for detecting changes in Wnt signalling, as the greater number of sites available for 
binding enhances the signal to noise ratio. The 7TFP lentiviral particle reporter has 
been previously characterised (Fuerer and Nusse, 2010) and offers the advantage 
of being integrated within the majority of the cells, rather than a subset of cells, as 
is the case using transient transfection.  
For stimulation of Wnt signalling in HCC cell lines, the canonical Wnt-3a ligand was 
used, which modulates cell proliferation and survival via a β-catenin-dependent 
signalling pathway (Galli et al., 2006). β-Catenin is not only involved in Wnt 
signalling but also has other functions in the cells, including a role in cell adhesion 
at the cell surface (Brembeck et al., 2006). As levels of β-catenin can be very high 
in HCC cell lines, and only a proportion of β-catenin will be involved in Wnt 
signalling, subtle or small changes in β-catenin levels were difficult to detect by WB 
in HuH-7 and Hep 3B cells (data not shown). Furthermore, the functional 
consequences are unknown. Therefore, the TCF luciferase reporter assay was 
established. For screening of cell lines the TOPflash construct was used, co-
transfected with a β-galactosidase construct. The activity of β-galactosidase was 
measured and used for normalization, thereby correcting for variation in 
transfection efficiency. Treatment of HCC cell lines with Wnt-3a showed that only 
HuH-7 and Hep3B cells were responsive to Wnt-3a treatment, leading to increased 
luciferase activity, while HepG2 cells were not responsive but had very high basal 
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level (data not shown). For further studies, the HuH-7 cell line was chosen and the 
cells were treated with increasing concentrations of Wnt-3a for different durations. 
The results showed a Wnt-3a concentration-dependent increase in TCF activity at 
all time points. However, 6 hours of treatment was found to give the highest 
luciferase activity in response to Wnt-3a (Figure  5.3; A). 
As a positive control for stimulation of the canonical Wnt signalling, 6-bromo-
indirubin-3'-oxime (BIO) was used, the structure of which is shown in Figure  5.2. 
BIO is a potent and selective inhibitor of GSK-3α/β (Meijer et al., 2003) 
(Polychronopoulos et al., 2004). TCF reporter activity showed BIO concentration-
dependent stimulation up to 1 µM, while higher concentrations were toxic to cells 
(Figure  5.3; B). To confirm that the activation of Wnt signalling following Wnt-3a 
treatment was due to Wnt-3a binding to frizzled receptor, and hence via the 
canonical Wnt signalling pathway, the Dvl-PDZ domain inhibitor II, compound 
3289-8625 was used (structure shown in Figure  5.2). This compound disrupts the 
interaction between Dvl and FZD and thus blocks Wnt-3a-induced β-catenin-
dependent transcriptional activity (Grandy et al., 2009). Also, this compound serves 
as a positive control for the inhibition of Wnt signalling. HuH-7 cells were incubated 
with increasing concentrations of compound 3289-8625 for 1 hr, followed by 
stimulation with 100 ng/ml of Wnt-3a and the results showed concentration-
dependent inhibition of luciferase reporter activity (Figure ‎5.3; C). 
       
Figure ‎5.2: The structure of BIO (6-bromo-indirubin-3'-oxime) (Left) and of 
compound 3289-8625 (Dvl-PDZ Domain Inhibitor II) (Right). 
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Figure ‎5.3: Characterisation of the TCF reporter assay in HuH-7 cells: HuH-7 
cells were transiently co-transfected with TOPflash and β-galactosidase constructs. 
The cells were then stimulated with different concentrations of Wnt-3a (A) or BIO 
(B) for different time points or treated with different concentrations of compound 
3289-8625 for 1 hour followed by treatment with 100 ng/ml Wnt-3a for 6 hours (C). 
The cell lysates were extracted and the TOPflash luciferase activity was measured 
and normalized to the activity of β-galactosidase. Values are the mean of triplicates 
and error bars represent the standard error. The experiment was performed in 
triplicate. Data generated using the method described in Section 2.15. 
 
5.2. Characterisation of Growth Factor/Receptor Tyrosine Kinase Signalling 
in HCC Cell Lines 
Growth factors act through binding to their cognate receptor tyrosine kinases which 
then transduce the signal, predominantly via the MEK/MAPK/ERK or the PI3K/AKT 
cascades, depending on the type of the growth factor and the cells being studied. 
Transduction leads to the phosphorylation of ERK1/2 and/or AKT that can be 
detected by WB or quantified by an ELISA for phospho-ERK (p-ERK) or phospho-
AKT (p-AKT).  
P-ERK and p-AKT stimulation was studied in three cell lines; SNU-182, HuH-7 and 
Hep 3B. Responsiveness to different growth factors, and the optimal concentration 
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SNU-182 cells were serum-starved overnight and then stimulated with FGF-1, 
FGF-2, IGF-I, IGF-II or VEGF-165. These five growth factors were selected given 
the reported involvement of FGF, IGF and VEGF signalling and downstream 
mediators (i.e., MAPK/ERK and PI3K/AKT signalling pathways) in HCC (Min et al., 
2011) (Wu and Zhu, 2011) (Cornellà et al., 2011).  
To determine the optimal concentrations of the growth factors required to achieve 
maximal phosphorylation of ERK and/or AKT, the cells were treated with a range of 
growth factor concentrations for 10 min, and then WB was performed. The blots 
showed that FGF-1, FGF-2, IGF-I cause phosphorylation of both ERK and AKT at 
concentrations as low as 0.1 nM. Only 10 nM of IGF-II caused phosphorylation of 
AKT but not ERK after 10 min, while VEGF-165 did not cause any increase in 
phosphorylation of either ERK or AKT in the SNU-182 cell line even at a high 
concentration (Figure  5.4). 
To determine optimal exposure times for SNU-182 cells to the different growth 
factors, the cells were treated with 10 nM of the growth factors for different time 
periods followed by extraction of cell lysates and WB. The blots showed that the 
stimulation of p-ERK and p-AKT was highest after 10 min exposure to FGF-1, 5-10 
min exposure to FGF-2 and 5 min exposure to IGF-I. IGF-II caused 
phosphorylation of AKT after 10 min and of ERK after 5 min only, possibly 
explaining why stimulation of ERK phosphorylation could not be detected in the 
experiment where an exposure time of 10 min was used. Again, VEGF-165 failed 
to cause any phosphorylation of ERK or AKT up to 10 min exposure to this growth 
factor (Figure  5.5).  
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Figure ‎5.4: Optimisation of p-ERK and p-AKT stimulation in response to 
different concentrations of growth factors in SNU-182 cells: SNU-182 cells 
were serum-starved overnight and then treated with 0.1, 1 or 10 nM of FGF-1, 
FGF-2, IGF-I, IGF-II or VEGF-165 for 10 min. Cell lysates were prepared, 15 
µg/lane loaded and WB performed using antibodies against p-ERK and p-AKT. 
Then WB membranes were stripped and re-probed using total ERK and total AKT 
antibodies to serve as loading controls. The experiment was performed in duplicate 
and representative blots are shown. Data generated using the method described in 
Section 2.10. 
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Figure ‎5.5: Optimisation of p-ERK and p-AKT stimulation in response to 
different exposure times of growth factors in SNU-182 cells: SNU-182 cells 
were serum-starved overnight and then treated with 10 nM of FGF-1, FGF-2, IGF-I, 
IGF-II or VEGF-165 for 2, 5 or 10 min. Cell lysates were prepared, 15 µg/lane 
loaded and WB performed using antibodies against p-ERK and p-AKT. Then WB 
membranes were stripped and re-probed using total ERK and total AKT antibodies 
to serve as loading controls. The experiment was performed in duplicate and 
representative blots are shown. Data generated using the method described in 
Section 2.10. 
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To further characterise growth factor/RTK signalling in SNU-182 cells, the potent 
and selective inhibitor of the FGF receptor (FGFR1 and FGFR3) PD173074 was 
used (Mohammadi et al., 1998) (Kunii et al., 2008) (Pardo et al., 2009). The 
structure of PD173074 is shown in Figure  5.6. SNU-182 cells were incubated with 
increasing concentrations of PD173074 for 1 hr, followed by treatment with 10 nM 
of FGF-1 or FGF-2 for 10 min. An ELISA for p-ERK was performed and the results 
demonstrated concentration-dependent inhibition of basal, FGF-1- and FGF-2-
induced ERK phosphorylation (Figure ‎5.7; A). The IC50 for inhibition of FGF-
stimulated p-ERK by PD173074 was found to be 84 nM for FGF-1 and 27 nM for 
FGF-2 (Figure  5.7; B). Also, the MEK inhibitor PD0325901 (Barrett et al., 2008) 
was used at 1 µM and caused complete inhibition of basal, FGF-1- and FGF-2-
induced ERK phosphorylation (data not shown). The structure of PD0325901 is 
shown in Figure  5.6. HuH-7 and Hep 3B cells showed similar results to SNU-182 
cells (G. Beale personal communication).   
     
Figure ‎5.6: The structure of the FGFR inhibitor PD173074 (Left) and the MEK 
inhibitor PD0325901 (Right). 
PD173074 PD0325901
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Figure ‎5.7: Characterisation of p-ERK stimulation in SNU-182 cells in 
response to FGF-1 and FGF-2 and inhibition by PD173074: SNU-182 cells were 
serum-starved overnight and treated with different concentrations of PD173074 for 
1 hr followed by stimulation with 10 nM of FGF-1 or FGF-2 for 10 min. Cell lysates 
were prepared and the p-ERK ELISA was performed using 50 µg cell lysate/well. 
(A) Raw data. Values are the mean of triplicates and error bars represent the 
standard error. (B) Data expressed as a percentage of FGF-1- or FGF-2-stimulated 
PD173074-untreated cells. The experiment was performed in triplicate. Data 
generated using the method described in Section 2.16. 
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5.3. Knockdown of SULF1/2 Genes and Effects on Signalling, Cell Growth 
and Tumourigenicity 
To study the biology of SULF1/2 in HCC cell lines, SULF1 and SULF2 were 
knocked down using shRNA and the subsequent signalling and phenotypic 
consequences examined. SULF2 suppression can also serve as a positive control 
or surrogate for SULF2 inhibition using small molecule inhibitors, providing a 
means of exploring the consequences of inhibition of SULF2 over SULF1 and other 
sulfatases.    
5.3.1. Identification of the optimal shRNA sequence to induce gene silencing 
To identify the optimal shRNA sequence to suppress SULF2 expression, HuH-7 
cells were used as they endogenously express high level of SULF2 that is also 
enzymatically active (Chapter 3). Non-targeting shRNA (NT shRNA) (containing 
four base pair mismatches to any known human gene) or five commercially 
available clones of SULF2-targeting shRNA lentiviral particles each containing a 
different shRNA sequence (Table  2.2) were either transiently or stably transduced 
at different multiplicities of infection (MOIs). All shRNAs were constitutively 
expressed under the U6 promoter. MOI is defined as the number of lentiviral 
particles per cell. The MOI was optimised for stable transduction at 0.5 as using a 
higher MOI caused detrimental effects on infected cells including increased cell 
death and inability of remaining viable cells to proliferate. This effect could be due 
to the multiple integration sites per cell at high MOI which could lead to the 
insertion of the construct within the coding sequences of important genes and 
hence disruption of their functions.  
RNA was extracted after 24 or 48 hrs for transient transduction, or after selection 
with puromycin until all control untransduced cells were killed for stable 
transduction. SULF2 expression was quantified using RT-qPCR. The analysis 
showed that shRNA sequence TRCN0000364518 (S2.shRNA_18) caused the 
greatest SULF2 gene silencing compared to NT shRNA after either transient or 
stable transduction (Figure  5.8).  
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To test the specificity of SULF2 knockdown, the expression levels of B2M, TP53 
and KLF6 were analysed after stable SULF2 knockdown in HuH-7 cells using 
S2.shRNA_18. The RT-qPCR data showed marked suppression of SULF2 
expression in the S2.shRNA_18-transduced cells (97% decrease versus NT 
shRNA-transduced cells) with no effect on the mRNA levels of B2M, TP53 or KLF6 
(Figure  5.9). SULF1 mRNA level remained undetectable in HuH-7 cells after 
SULF2 knockdown as in control cells. The specificity and consistency of SULF2 
targeting was also confirmed by knockdown of SULF2 using S2.shRNA_18 in 
HepG2 cells (Figure  5.10) that do not express SULF1 and in SNU-182 cells (Figure 
 5.11) that endogenously express both SULF1 and SULF2. Importantly, the results 
showed no effect on SULF1 expression in SNU-182 cells after SULF2 gene 
silencing. Collectively, the data of SULF2 gene silencing in the three cell lines 
tested showed the lack of any stimulation of the expression of SULF1 in response 
to the loss of SULF2.  
A similar procedure was followed to identify the optimal SULF1-targeting shRNA. 
The SNU-182 cell line was used for this purpose as it was the only HCC cell line 
that expressed a high level of SULF1. The results showed that shRNA sequence 
TRCN0000373589 (S1.shRNA_89) caused the greatest gene silencing of SULF1 
after transient or stable transduction (Figure  5.12) without affecting the expression 
level of four other genes including SULF2 (Figure  5.13). The non-targeting (NT) 
shRNA caused a slight upregulation of SULF2 expression in HuH-7 (Figure  5.9) 
and HepG2 cells (Figure  5.10), but not in SNU-182 cells (Figure  5.11) (Figure 
 5.13). Expression levels of all other genes tested were unchanged in NT shRNA 
cells relative to control untransduced cells in all tested cell lines (Figure  5.9) 
(Figure  5.10) (Figure  5.11) (Figure  5.13). S2.shRNA_18 and S1.shRNA_89 were 
used in all subsequent experiments and these are referred to as SULF2 shRNA 
and SULF1 shRNA, respectively, throughout the rest of the thesis. All resulting 
stable cell lines which constitutively expressed SULF2 shRNA and SULF1 shRNA 
were analysed for the downstream consequences of SULF1 or SULF2 gene 
silencing. The effect of gene silencing on cell functionality was tested using 
different phenotypic and mechanistic assays according to the cascade shown in               
Figure  5.144. 
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Figure ‎5.8: Identification of the optimal SULF2-targeting shRNA: HuH-7 cells 
were transiently transduced with 1 or 5 MOI for 24 or 48 hrs or stably transduced 
with different SULF2 targeting shRNA lentiviral particles or NT shRNA lentiviral 
particles. RT-qPCR was performed and the data normalized to the expression of 
GAPDH and presented relative to the SULF2 mRNA expression level in cells 
transduced with NT shRNA. Data are from a single experiment. Data generated 
using the methods described in Section 2.6 and Section 2.7. 
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Figure ‎5.9: Effect of SULF2 gene silencing on the expression of selected 
genes in the HuH-7 cell line: HuH-7 cells were stably transduced with either 
S2.shRNA_18 or NT shRNA lentiviral particles. RT-qPCR was performed and the 
data normalized to the expression of GAPDH. Values are the mean of triplicates 
and error bars represent the standard error. The experiment was performed in 
triplicate. Data generated using the methods described in Section 2.6 and Section 
2.7. 
 
 
Figure ‎5.10: Effect of SULF2 gene silencing on the expression of selected 
genes in the HepG2 cell line: HepG2 cells were stably transduced with either 
S2.shRNA_18 or NT shRNA lentiviral particles. RT-qPCR was performed and the 
data normalized to the expression of GAPDH. Values are the mean of triplicates 
and error bars represent the standard error. The experiment was performed in 
duplicate. Data generated using the methods described in Section 2.6 and Section 
2.7. 
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Figure ‎5.11: Effect of SULF2 gene silencing on the expression of selected 
genes in the SNU-182 cell line: SNU-182 cells were stably transduced with either 
S2.shRNA_18 or NT shRNA lentiviral particles. RT-qPCR was performed and the 
data normalized to the expression of GAPDH. Values are the mean of triplicates 
and error bars represent the standard error. The experiment was performed in 
duplicate. Data generated using the methods described in Section 2.6 and Section 
2.7. 
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Figure ‎5.12: Identification of the optimal SULF1-targeting shRNA: SNU-182 
cells were transiently transduced with 1 MOI for 48 hrs or stably transduced with 
different SULF1 targeting shRNA lentiviral particles or NT shRNA lentiviral 
particles. RT-qPCR was performed and the data normalized to the expression of 
GAPDH and presented relative to the SULF2 mRNA expression level in cells 
transduced with NT shRNA. Ctrl: control untransduced cells. Data are from a single 
experiment. Data generated using the methods described in Section 2.6 and 
Section 2.7. 
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Figure ‎5.13: Effect of SULF1 gene silencing on the expression of selected 
genes in the SNU-182 cell line: SNU-182 cells were stably transduced with 
different SULF1 targeting shRNA lentiviral particles or NT shRNA lentiviral 
particles. RT-qPCR was performed and the data normalized to the expression of 
GAPDH and presented relative to the expression level in cells transduced with NT 
shRNA. Ctrl: control untransduced cells. Data are from a single experiment. Data 
generated using the methods described in Section 2.6 and Section 2.7. 
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              Figure ‎5.14: SULF1/2 knockdown evaluation cascade (each assay was repeated at least 3 times) 
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5.3.2. SULF2 gene silencing in HuH-7 cells and effects on signalling, cell 
growth and tumourigenicity  
5.3.2.1. Effects of SULF2 gene silencing on signalling pathways in HuH-7 cells 
5.3.2.1.1. Effect of SULF2 gene silencing on growth factor/RTK signalling in HuH-7 
cells 
HuH-7 cells that were stably transduced with NT shRNA or SULF2 shRNA (Figure 
 5.9) were serum-starved overnight and then stimulated with different 
concentrations of FGF-1, FGF-2 or IGF-I for 10 or 60 min. The cell lysates were 
extracted and WB was performed with antibodies against SULF2, p-ERK and p-
AKT. WB membranes were then stripped and re-probed using total ERK and total 
AKT antibodies to serve as loading controls. WB showed expression of SULF2 
protein in the NT shRNA-transduced cells but complete absence of SULF2 protein 
in the cells transduced with SULF2 shRNA, confirming the knockdown of SULF2 at 
the protein level in this cell line (Figure  5.15).  
Both FGF-1- and FGF-2-stimulated p-ERK and p-AKT, while IGF-I stimulated p-
AKT but not p-ERK in this cell line. Stimulation of p-ERK and p-AKT was 
concentration-dependent for all three ligands; however, no clear effect of SULF2 
gene silencing was found on basal or stimulated ERK or AKT phosphorylation with 
any of the tested ligands after either 10 min (Figure  5.15) or 60 min (data not 
shown). The effect of SULF2 knockdown on IGF-II-stimulated ERK and AKT 
phosphorylation was also tested in this cell line and no clear effect was detected 
(data not shown). 
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Figure ‎5.15: Effect of SULF2 gene silencing on FGF-1, FGF-2 and IGF-I 
signalling pathways in the HuH-7 cell line: HuH-7 cells were stably transduced 
with either NT shRNA or SULF2 shRNA lentiviral particles. The cells were serum-
starved overnight and then treated with different concentrations of FGF-1 (A), FGF-
2 (B) or IGF-I (C) for 10 min. Whole cell lysates were prepared and WB was 
performed using antibodies against SULF2, p-ERK1/2 and p-AKT. The membranes 
were stripped and reprobed with antibodies against total ERK1/2 and total AKT 
serving as loading controls. The experiment was performed in triplicate and 
representative blots are shown. Data generated using the methods described in 
Section 2.6 and Section 2.10. 
 
5.3.2.1.2. Effect of SULF2 gene silencing on Wnt signalling in HuH-7 cells  
To study the effect of SULF2 gene silencing on Wnt signalling, HuH-7 cells stably 
transduced with NT shRNA or SULF2 shRNA (Figure  5.9) were transiently co-
transfected with TOPflash and β-galactosidase constructs, and then stimulated 
with 100 ng/ml Wnt-3a for 6 hours. The cell lysates were extracted and the 
TOPflash luciferase activity was measured and normalized to the activity of β-
galactosidase. The results showed that SULF2 gene silencing in this cell line 
caused a marked inhibition of Wnt-3a-induced β-catenin-dependent transcriptional 
activity (50% decrease and p value = 0.027, Figure  5.16).  
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Effect of SULF2 knockdown on Wnt signalling was confirmed by infecting the cells 
transduced with NT shRNA or SULF2 shRNA with the 7TFP lentiviral particles. The 
cells were treated with different concentrations of Wnt-3a for 6 hrs and the results 
showed marked inhibition of Wnt-3a-induced luciferase activity in the SULF2 
knockdown cells (Figure ‎5.17; A). The Dvl-PDZ domain inhibitor II, compound 
3289-8625, was used as positive control for inhibition. Incubation of the cells with 
3289-8625 before treatment with 100 ng/ml Wnt-3a showed complete inhibition of 
luciferase activity (Figure ‎5.17; A).  
To determine whether the effect of SULF2 knockdown on Wnt signalling was due 
to interfering with Wnt-3a ligand binding at the cell surface or downstream of the 
FZD/LRP receptors, the NT shRNA- and SULF2 shRNA-transduced cells were 
treated with BIO which inhibits GSK-3β, and hence activates Wnt signalling 
downstream of Wnt ligand receptor activation. The results showed that there was 
slight decrease of BIO-stimulated luciferase activity in the SULF2 knockdown cells 
(Figure  5.17; B), but much less than the decrease in Wnt3a-stimulated luciferase 
activity. This result suggests that SULF2 suppression led to reduced Wnt signalling 
predominantly by affecting Wnt-3a binding at the cell surface.   
In an attempt to confirm the effect of SULF2 knockdown on Wnt signalling by 
another method, the level of total β-catenin was measured by sandwich ELISA 
both before and after stimulation with Wnt-3a for 24 hours, allowing enough time 
for the degradation of β-catenin. The results showed no change in the level of total 
β-catenin after SULF2 suppression (Figure  5.18; A). The lack of effect was possibly 
due to the high level of β-catenin that is present at the cell membrane in HuH-7 
cells, where it has a role in cell-cell adhesion (Sangkhathat et al., 2006), masking 
changes in cytoplasmic/nuclear β-catenin. This hypothesis was confirmed by ICC, 
which showed that the majority of total β-catenin staining was at the cell surface 
with no detectable translocation of β-catenin to the nucleus after treatment with 
Wnt-3a in this cell line notwithstanding the changes in TCF reporter gene activity 
(Figure  5.19).    
Therefore, the level of active β-catenin (ABC) was investigated by WB. WB showed 
that the increase in ABC levels in the NT shRNA-transduced cells was much higher 
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than that in the SULF2 shRNA-transduced cells after treatment with Wnt-3a for 
either 6 or 24 hrs (Figure ‎5.18; B). Unfortunately, the ABC antibody did not work for 
ICC or ELISA so it was not possible to visualize the cells or use ELISA to quantify 
the changes. 
SULF2 knockdown in HuH-7 cells showed lack of an effect on the expression level 
of CCND1 and MYC, which are transcriptional targets of β-catenin-TCF complex, 
or on the expression of GPC3 (data not shown), which was previously reported to 
be affected by SULF2 gene silencing and to be required by Wnt signalling (Lai et 
al., 2008 a). However, signalling pathways other than Wnt signalling can regulate 
CCND1 and MYC, including the MAPK/ERK and PI3K/AKT signalling pathways, 
and these may have compensated for reduced Wnt signalling in the HuH-7 cells. 
 
Figure ‎5.16: Effect of SULF2 gene silencing on Wnt signalling pathway in 
HuH-7 cells measured by the TOPflash reporter assay: HuH-7 cells were stably 
transduced with either NT shRNA or SULF2 shRNA lentiviral particles. The cells 
were then transiently co-transfected with TOPflash and β-galactosidase constructs 
in Opti-MEM medium followed by treatment with 100 ng/ml Wnt-3a for 6 hours. 
Whole cell lysates were prepared using RLB and luciferase activity was measured. 
Values are the mean of four different experiments and error bars represent the 
standard error. * p = 0.027, 2-sample t-test. Data generated using the methods 
described in Section 2.6 and Section 2.15. 
 
 
 
%
 T
O
P
fl
a
s
h
 l
u
c
if
e
r
a
s
e
 a
c
ti
v
it
y
n o  W n t 1 0 0  n g /m l W n t-3 a
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
N T  s h R N A
S U L F 2  s h R N A
*
158 
 
    
 
Figure ‎5.17: Effect of SULF2 gene silencing on Wnt signalling pathway in 
HuH-7 cells measured by the 7TFP reporter assay: HuH-7 cells were stably 
transduced with either NT shRNA or SULF2 shRNA lentiviral particles followed by 
transduction with 7TFP lentiviral particles. The cells were serum-starved overnight 
and then treated with different concentrations of Wnt-3a (A) or BIO (B) for 6 hours. 
ONE-Glo reagent was added and luciferase activity was measured. Values are the 
mean of triplicates and error bars represent the standard error. The experiment 
was performed in triplicate. * p = 0.004, ** p = 0.001, *** p < 0.0001, 2-sample t-
test. Data generated using the methods described in Section 2.6 and Section 2.15. 
W n t-3 a  (n g /m l)
L
u
c
if
e
r
a
s
e
 a
c
ti
v
it
y
 (
li
g
h
t 
u
n
it
s
)
0 5 0 1 0 0 1 5 0 2 0 0
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0
N T  shR N A
S U L F 2  sh R N A*
* * * * * *
N T  s h R N A + 3 2 8 9 -8 6 2 5
S U L F 2  s h R N A + 3 2 8 9 -8 6 2 5
* *
A
0.0 0.5 1.0
0
1000
2000
3000
4000
NT shRNA
SULF2 shRNA
B
BIO (M)
L
u
c
if
e
ra
s
e
 a
c
ti
v
it
y
 (
li
g
h
t 
u
n
it
s
)
159 
 
 
 
Figure ‎5.18: Effect of SULF2 knockdown on total‎β-catenin and ABC levels in 
HuH-7 cells: Control untransduced HuH-7 cells or those stably transduced with 
either NT shRNA or SULF2 shRNA lentiviral particles were serum-starved 
overnight and then treated with 100 ng/ml Wnt-3a for 6 or 24 hours. Cell lysates 
were prepared. (A) Total β-catenin ELISA was performed after treatment of cells 
with Wnt-3a for 24 hours. No1o/no2o: detection and secondary antibodies omitted. 
No 1o: detection antibody omitted. Values are the mean of triplicates and error bars 
represent the standard error. (B) WB was performed using an ABC antibody. 
GAPDH was used as loading control. NT: NT shRNA-transduced cells. S2: SULF2 
shRNA-transduced cells. The experiment was performed in duplicate. Data 
generated using the methods described in Section 2.10 and Section 2.16. 
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Figure ‎5.19: ICC staining of β-catenin in the HuH-7 cell line: Control 
untransduced HuH-7 cells or those stably transduced with either NT shRNA or 
SULF2 shRNA lentiviral particles were grown on glass coverslips and serum-
starved overnight followed by treatment with or without 100 ng/ml Wnt-3a for 24 
hours. The cells were incubated with total β-catenin antibody and then incubated 
with Alexa Fluor 488 conjugated secondary antibody. Mounting medium with DAPI 
was used to counter-stain the nuclei in blue. 1, 2: control untransduced cells. 3, 4: 
NT shRNA-transduced cells. 5, 6: SULF2 shRNA-transduced cells. (A) blue 
channel for DAPI, (B) green channel for Alexa Fluor 488, (C) merge picture. The 
experiment was performed in duplicate. Data generated using the method 
described in Section 2.11. 
 
5.3.2.2. Effects of SULF2 gene silencing on growth of HuH-7 cells in vitro 
To determine the effect of SULF2 knockdown and consequent Wnt signalling 
suppression on cell growth and proliferation, HuH-7 cells that were stably 
transduced with NT shRNA or SULF2 shRNA (Figure  5.9) were cultured in a 96-
well plate and cell proliferation was evaluated by cell counting and measuring 
cellular protein content using sulforhodamine B (SRB) assay. The results showed 
that SULF2 suppression significantly inhibited the proliferation of HuH-7 cells as 
evidenced by a doubling time of 58 hours as opposed to 43 hours for both control 
untransduced and NT shRNA-transduced cells (Figure  5.20).  
The effect of exogenous Wnt-3a on the growth of control untransduced and NT 
shRNA- and SULF2 shRNA-transduced HuH-7 cells was then investigated. The 
cells were cultured in 10% (v/v) FBS-containing medium due to the detrimental 
effect of the lack of FBS on the growth of HuH-7 cells. The SRB assay showed no 
effect of either Wnt-3a or BIO on cell growth of any of the three HuH-7 tested cell 
lines where BIO was used as a positive control for stimulation of Wnt signalling 
(Figure  5.21; A, B). The lack of an effect of Wnt-3a or BIO on cell growth could be 
due to the presence of growth factors in the FBS masking any stimulation resulting 
from the exogenous Wnt-3a. On the other hand, treating the cells with the Wnt 
signalling inhibitor, compound 3289-8625 completely inhibited the growth of all 
three HuH-7 cell lines (Figure ‎5.21; C). Inhibition of growth by 3289-8625 was 
partially rescued by the addition of BIO, but not Wnt-3a (Figure ‎5.21; D, E), 
presumably because compound 3289-8625 works downstream of Wnt-3a binding 
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to its receptors but not downstream of BIO-mediated inhibition of GSK-3β. 
Interestingly, and consistent with the proposed role of SULF2 in Wnt signalling, the 
BIO-rescued cells showed similar growth rates regardless of SULF2 expression 
status. Overall, these data suggest that Wnt signalling is involved in regulating the 
growth of HuH-7 cells, and that SULF2 has a role in controlling Wnt-3a binding at 
the cell surface. 
 
        
Figure ‎5.20: Effect of SULF2 gene silencing on cell growth and proliferation 
in HuH-7 cells: HuH-7 cells were stably transduced with either NT shRNA or 
SULF2 shRNA lentiviral particles. 2,000 cells were seeded per well for different 
time points and then either counted (A) or stained with SRB (B). Values are the 
mean of triplicates for (A) and six replicates for (B) and error bars represent the 
standard error. The experiment was performed in quadruplicate. * p = 0.002, ** p = 
0.001, *** p value < 0.0001, one-way ANOVA for (A) and 2-sample t-test for (B). 
Data generated using the methods described in Section 2.17 and Section 2.18. 
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Figure ‎5.21: Effect of modulators of Wnt signalling on cell growth of HuH-7 
cells after SULF2 knockdown: 2,000 HuH-7 cells (control untransduced and 
stably transduced with either NT shRNA or SULF2 shRNA lentiviral particles) were 
seeded per well in 96-well plates. The cells were treated with 100 ng/ml Wnt-3a 
(A), 1 µM BIO (B), 100 µM compound 3289-8625 (C), a combination of Wnt-3a and 
compound 3289-8625 (D) or a combination of BIO and compound 3289-8625 (E). 
Cells were fixed at different time points, stained using SRB and the optical density 
at 570 nm was measured. Values are the mean of triplicates and error bars 
represent the standard error. The experiment was performed in triplicate. ** p value 
= 0.001, *** p value < 0.0001, one-way ANOVA between untreated cell lines in (A), 
between untreated and 3289-8625-treated cell lines in (C) and between cell lines 
treated with 3289-8625 alone and cell lines treated with both 3289-8625 and BIO in 
(E). Data generated using the method described in Section 2.17. 
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5.3.2.3. Effects of SULF2 gene silencing on tumourigenicity of HuH-7 cells in vivo  
After demonstrating the effect of SULF2 knockdown on HuH-7 cell signalling and 
growth in vitro, the impact on the tumourigenicity of HuH-7 cells in vivo was 
examined. A pilot study was conducted in which HuH-7 cells were implanted 
subcutaneously into CD1 female nude mice using cells that were stably transduced 
with either NT shRNA or SULF2 shRNA (5 mice per group). The results showed 
that within 32 days after implantation all 5 animals in the NT shRNA-transduced 
cells group had developed tumours (median time to tumour detection 28 days, 
range 25-32). The median time to reach a volume of 500 mm3 was 35 days (range 
28-42) from implantation or 8 days (range 5-10) from the first day tumours were 
measurable. In contrast, over a 100-day period, none of the animals implanted with 
the SULF2 shRNA-transduced cells developed tumours (Figure  5.22). 
To confirm the pilot study data, the in vivo experiment was repeated and 10 mice 
were implanted per group. In addition to the two cell lines mentioned above, 
untransduced HuH-7 cells were also used serving as an additional control. The 
results showed that both control untransduced and NT shRNA-transduced cells 
formed tumours (8/10 and 9/10 mice, respectively) (Figure  5.23; A) with no 
difference in the mean time to reach a tumour volume of 500 mm3 from 
implantation between the two groups (Figure  5.23; B). Importantly, SULF2 shRNA-
transduced cells failed to form any tumours as before. 
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Figure ‎5.22: Pilot study of the effect of SULF2 gene silencing on 
tumourigenicity of HuH-7 cells in mice: 1x107 NT shRNA- or SULF2 shRNA-
transduced cells were implanted subcutaneously into the right flank of five CD1 
female nude mice each, and the tumour volume was measured 3 times a week 
using a digital caliper. The data represent the tumour incidence and growth rate in 
mice. Data generated using the method described in Section 2.20. 
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Figure ‎5.23: Repeat study of the effect of SULF2 gene silencing on 
tumourigenicity of HuH-7 cells in mice: 1x107 control untransduced, NT shRNA-
transduced or SULF2 shRNA-transduced cells were implanted subcutaneously into 
the right flank of ten CD1 female nude mice and the tumour volume was measured 
3 times a week using a digital caliper. (A) Tumour incidence and growth rate in 
mouse. (B) Mean time to reach a volume size of 500 mm3. The horizontal lines are 
the mean of the replicates and error bars represent the standard error. Data 
generated using the method described in Section 2.20. 
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5.3.3. SULF1/2 gene silencing in SNU-182 cells and effects on signalling, cell 
growth and tumourigenicity 
SNU-182 is a poorly differentiated HCC cell line that expresses both SULF1 and 
SULF2 at high and comparable levels. Therefore, knocking down SULF1 and 
SULF2 in this cell line was investigated, in order to compare the biology and the 
roles of SULF1 and SULF2 in the context of HCC.  
SNU-182 cells were stably transduced with NT shRNA, SULF1 shRNA or SULF2 
shRNA. RT-qPCR results showed that after two weeks of selection of transduced 
cells with puromycin there was a 94% decrease of SULF2 and 85% decrease of 
SULF1 mRNA levels in the SULF2 shRNA-transduced cells and the SULF1 
shRNA-transduced cells, respectively, as compared to NT shRNA-transduced cells 
(Figure  5.24; A). After two months of growing cells under selection (i.e., in 
puromycin) there was more suppression of the expression of SULF2 and SULF1 in 
their respective shRNA-transduced cells (98% and 89%, respectively) (Figure  5.24; 
B). However, there was also a 50% decrease of SULF2 expression in the SULF1 
shRNA-transduced cells as compared to NT shRNA-transduced cells, suggesting a 
late effect of SULF1 suppression on the expression of SULF2 (Figure  5.24; B). 
However, no effect was detected on the expression of other genes tested, for 
example B2M, TP53 and KLF6, after either SULF1 or SULF2 knockdown in SNU-
182 cells (data not shown). 
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Figure ‎5.24: SULF1/2 mRNA levels in SNU-182 cells after transduction with 
shRNA lentiviral particles: SNU-182 cells were stably transduced with NT 
shRNA, SULF2 shRNA or SULF1 shRNA lentiviral particles. RT-qPCR was 
performed and the data were normalized using GAPDH as a reference gene. (A) 
Early effect (2 weeks) of transduction. (B) Late effect (2 months) of transduction. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. Data generated using the methods 
described in Section 2.6 and Section 2.7.  
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5.3.3.1. Effects of SULF1/2 gene silencing on signalling pathways in SNU-182 cells 
5.3.3.1.1. Effect of SULF1/2 gene silencing on growth factor/RTK signalling in 
SNU-182 cells 
SNU-182 cells that were stably transduced with NT shRNA, SULF2 shRNA or 
SULF1 shRNA and grown for ≥ 2 months (Figure  5.24; B) were serum-starved 
overnight and then treated with or without the FGFR inhibitor PD173074 or the 
MEK inhibitor PD0325901 for 1 hour before stimulation with 10 nM FGF-1 or FGF-2 
for 10 min. The cell lysates were extracted and WB was performed with antibodies 
against SULF1, SULF2, p-ERK1/2, p-AKT or actin. WB membranes were then 
stripped and re-probed using total ERK and total AKT antibodies as a loading 
control. WB showed the absence of SULF2 protein in the cells transduced with 
SULF2 shRNA (Figure  5.25; A) and the absence of SULF1 protein in the cells 
transduced with SULF1 shRNA (Figure  5.25; B). 
There was no effect on the basal level of p-ERK or p-AKT as a result of SULF1 or 
SULF2 knockdown. However, both FGF-1 and FGF-2 could stimulate p-ERK in all 
cell lines except the SULF2 knockdown cells which showed marked inhibition of 
FGF-1- or FGF-2-stimulated p-ERK levels (Figure  5.25). Both PD173074 and 
PD0325901 reduced basal and FGF-1- or FGF-2-stimulated p-ERK levels without 
affecting p-AKT levels, and thus served as positive controls for inhibition of p-ERK 
(Figure  5.25). As WB is a semi-quantitative technique, a p-ERK1/2 sandwich 
ELISA was performed to quantify p-ERK levels. The results showed significant 
lower p-ERK levels after stimulation with either FGF-1 or FGF-2 in SULF2 
knockdown cells (p value < 0.02, Figure  5.26). The positive controls for inhibition, 
PD173074 and PD0325901 treatment completely abrogated the phosphorylation of 
ERK in response to FGF-1 or FGF-2 in all 4 SNU-182 cell lines (Figure  5.26).  
A similar approach was used to examine the effect of SULF1/2 knockdown on the 
IGF-I and IGF-II signalling pathways. The main downstream transducer of the IGF 
growth factors is the PI3K/AKT pathway resulting in the phosphorylation of AKT. 
Therefore, a p-AKT ELISA was used and the results showed no effect of SULF1/2 
knockdown on the basal level of p-AKT or on IGF-I-stimulated p-AKT level (Figure 
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 5.27; A). However, there was significant inhibition of IGF-II-stimulated p-AKT in the 
SULF2 knockdown cells only (p value < 0.05, Figure  5.27; B). Collectively, these 
results demonstrated the important role of SULF2, but not SULF1, in the SNU-182 
cell line in the regulation of the signalling consequent to FGF-1, FGF-2 and IGF-II, 
but not IGF-I, treatment.  
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Figure ‎5.25: Effect of SULF1/2 gene silencing on FGF-1 and FGF-2 signalling 
pathways in SNU-182 cells measured by WB: SNU-182 cells were stably 
transduced with NT shRNA, SULF2 shRNA or SULF1 shRNA lentiviral particles. 
The cells were serum-starved overnight and then treated with 100 nM PD173074 
or 1 µM PD0325901 for 1 hour before stimulation with 10 nM FGF-1 (A) or FGF-2 
(B) for 10 min. Whole cell lysates were prepared and WB was performed using 
antibodies against SULF2, SULF1, p-ERK1/2, p-AKT or actin. The membranes 
were stripped and reprobed with antibodies against total ERK1/2 and total AKT 
serving as loading controls. The experiment was performed in triplicate and 
representative blots are shown. Data generated using the methods described in 
Section 2.6 and Section 2.10. 
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Figure ‎5.26: Effect of SULF1/2 gene silencing on FGF-1 and FGF-2 signalling 
pathways in SNU-182 cells measured by ELISA: SNU-182 cells were stably 
transduced with NT shRNA, SULF2 shRNA or SULF1 shRNA lentiviral particles. 
The cells were serum-starved overnight and then treated with 100 nM PD173074 
or 1 µM PD0325901 for 1 hour before stimulation with 10 nM FGF-1 (A) or FGF-2 
(B) for 10 min. Whole cell lysates were prepared and p-ERK1/2 sandwich ELISA 
was performed. 50 µg of cell lysates were loaded of each sample. Values are the 
mean of 5 different experiments for (A) and 3 different experiments for (B) and 
error bars represent the standard error. * p value < 0.05, 2-sample t-test. Data 
generated using the methods described in Section 2.6 and Section 2.16. 
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Figure ‎5.27: Effect of SULF1/2 gene silencing on IGF-I and IGF-II signalling 
pathways in SNU-182 cells measured by ELISA: SNU-182 cells were stably 
transduced with NT shRNA, SULF2 shRNA or SULF1 shRNA lentiviral particles. 
The cells were serum-starved overnight and then treated with 10 nM IGF-I (A) for 5 
min or IGF-II (B) for 10 min. Whole cell lysates were prepared and p-AKT sandwich 
ELISA was performed. 50 µg of cell lysates were loaded of each sample. Values 
are the mean of 3 different experiments and error bars represent the standard 
error. * p value = 0.014, ** p value ≤ 0.005, 2-sample t-test. Data generated using 
the methods described in Section 2.6 and Section 2.16. 
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5.3.3.1.2. Effect of SULF1/2 gene silencing on Wnt signalling in SNU-182 cells 
SNU-182 cells that were transduced with NT shRNA, SULF2 shRNA or SULF1 
shRNA were transduced with 7TFP lentiviral particles, prior to stimulation with Wnt-
3a. None of these cell lines were responsive to Wnt-3a (Figure  5.28), in keeping 
with a report that TCF activity was not detected in SNU-182, even after transfecting 
the cells with mutant β-catenin (Yuzugullu et al., 2009). 
Neither SULF1 nor SULF2 knockdown in SNU-182 cells affected the expression 
level of CCND1 or MYC, two transcriptional targets of the β-catenin-TCF complex. 
However there was a late, rather than early, effect of SULF1 and SULF2 
suppression on the expression of GPC3, resulting in 4- and 11-fold downregulation 
of GPC3, respectively (Figure  5.29).  
 
Figure ‎5.28: Effect of SULF2 gene silencing on Wnt signalling pathway in 
SNU-182 cells using 7TFP reporter assay: SNU-182 cells were stably 
transduced with either NT shRNA or SULF2 shRNA lentiviral particles followed by 
transduction with 7TFP lentiviral particles. The cells were serum-starved and then 
treated with different concentrations of Wnt-3a for 6 hours. ONE-Glo reagent was 
added and luciferase activity was measured. Values are the mean of triplicates and 
error bars represent the standard error. The experiment was performed in 
duplicate. Data generated using the methods described in Section 2.6 and Section 
2.15. 
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Figure ‎5.29: Effect of SULF2 gene silencing on Wnt signalling pathway-
related genes in SNU-182 cells: SNU-182 cells were stably transduced with NT 
shRNA, SULF2 shRNA or SULF1 shRNA lentiviral particles. RT-qPCR was 
performed and the data were normalized using GAPDH as a reference gene. (A) 
Early effect (2 weeks) of transduction. (B) Late effect (2 months) of transduction. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. Data generated using the methods 
described in Section 2.6 and Section 2.7. 
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5.3.3.2. Effects of SULF1/2 gene silencing on growth of SNU-182 cells in vitro 
To investigate the effect of SULF2 knockdown and subsequent growth factor 
signalling suppression on cell proliferation, SNU-182 cells that were stably 
transduced with NT shRNA, SULF2 shRNA or SULF1 shRNA (Figure  5.24) were 
cultured in 96-well plates and cell proliferation was evaluated by cell counting. The 
results showed that SULF2 suppression increased the doubling time of 50 hours 
for both control untransduced and NT shRNA-transduced cells to 62 hours for the 
SULF2 knockdown cells. Interestingly, SULF1 suppression also reduced the 
proliferation of SNU-182 cells, and the doubling time of SULF1 knockdown cells 
was 60 hours (Figure  5.30). 
 
Figure ‎5.30: Effect of SULF1/2 gene silencing on cell proliferation in SNU-182 
cells: SNU-182 cells were stably transduced with NT shRNA, SULF2 shRNA or 
SULF1 shRNA lentiviral particles. 1,000 cells were seeded per well and counted at 
different time points. Values are the mean of triplicates and error bars represent 
the standard error. The experiment was performed in quadruplicate. * p value < 
0.05, 2-sample t-test between control untransduced or NT shRNA-transduced cells 
vs. SULF2 shRNA- or SULF1 shRNA-transduced cells. Data generated using the 
method described in Section 2.18.  
 
 
 
 
 
0 4 8 1 2
0
4 0 0 0
8 0 0 0
1 2 0 0 0
C o n tro l u n tra n s d u c e d
N T .shR N A
S U L F 2  sh R N A
S U L F 1  sh R N A
D a y
C
e
ll
 n
u
m
b
e
r
/w
e
ll
*
*
*
178 
 
5.3.3.3. Effects of SULF1/2 gene silencing on tumourigenicity of SNU-182 cells in 
vivo 
None of the SNU-182 cell lines formed tumour xenografts in nude mice, even after 
re-suspending the cell pellet before injection in Matrigel basement membrane 
matrix. Matrigel contains a variety of growth factors and was used to promote cell-
cell contact and enhance growth, with the goal of increasing the tumour-forming 
potential of the cells. Also, no tumours were formed when the cells were implanted 
into the more immunocompromised NSG (NOD scid gamma) mice. Therefore, it 
was not possible to investigate the effect of SULF1/2 knockdown on the 
tumourigenicity of SNU-182 cells. 
5.3.4. SULF2 gene silencing in HepG2 cells and effects on signalling, cell 
growth and tumourigenicity 
HepG2 cells express SULF2 at high level but not SULF1. To study the role of 
SULF2 in this cell line, SULF2 knockdown was performed using SULF2 shRNA 
(Figure  5.10) and the effect of SULF2 suppression on growth factor and Wnt 
signalling studied.  
5.3.4.1. Effects of SULF2 gene silencing on signalling pathways in HepG2 cells 
5.3.4.1.1. Effect of SULF2 gene silencing on growth factor/RTK signalling in 
HepG2 cells 
To study the effect of SULF2 gene silencing on growth factor signalling pathway, 
the phosphorylation status of ERK1/2 and AKT was assessed by WB after 
stimulation with 10 nM FGF-1 or FGF-2 for 10 min, or IGF-I for 5 min, either in 
serum-free or serum-containing medium. WB showed no clear effect of SULF2 
suppression on the basal or growth factor-stimulated levels of p-ERK1/2 or p-AKT 
(Figure  5.31). 
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Figure ‎5.31: Effect of SULF2 gene silencing on growth factor signalling in 
HepG2 cells: HepG2 cells were stably transduced with either NT shRNA or SULF2 
shNRA lentiviral particles. The cells were incubated in either serum-free medium 
(FBS -) or serum-containing medium (FBS +) overnight. Cells were then treated 
with 10 nM FGF-1 (A; left) or FGF-2 (B; right) for 10 min or IGF-I for 5 min (B; 
left). Whole cell lysates were prepared and WB was performed using antibodies 
against SULF2, p-ERK1/2 and p-AKT. Total ERK1/2 and total AKT were used as 
loading controls. * denotes samples that were incubated with serum-free medium 
overnight and then treated with 10% FBS for 10 min. FBS: foetal bovine serum. 
The experiment was performed in duplicate and representative blots are shown. 
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5.3.4.1.2. Effect of SULF2 gene silencing on Wnt signalling in HepG2 cells 
HepG2 cells have a wild-type and a truncated form of β-catenin that is 
constitutively active (Carruba et al., 1999). When these cells were treated with 
Wnt-3a, there was a small Wnt-3a concentration-dependent increase in the level of 
the wild type β-catenin as detected by WB (data not shown). Therefore, to 
determine whether there is any effect of SULF2 suppression on wild type β-
catenin-dependent TCF activity, the TCF luciferase reporter assay was performed 
using the TOPflash reporter system. 
The results showed that there was a very high luciferase activity in all 3 cell lines 
(i.e., control untransduced, NT shRNA or SULF2 shRNA-transduced cells) that was 
≥ 9-fold the background level measured by the FOPflash construct that contains 
mutant TCF binding sites (Figure  5.32). The TOPflash TCF-dependent activity was 
not increased by treatment with Wnt-3a (data not shown), and the basal activity 
was not affected by SULF2 knockdown (Figure  5.32).  Furthermore, no change 
was detected in the expression level of either CCND1 or GPC3 after SULF2 
knockdown in this cell line (data not shown). 
 
Figure ‎5.32: Effect of SULF2 gene silencing on Wnt signalling pathway in 
HepG2 cells: HepG2 cells were stably transduced with either NT shRNA or SULF2 
shRNA lentiviral particles. The cells were then transiently co-transfected with either 
TOPflash or FOPflash and β-galactosidase constructs in Opti-MEM medium. 
Whole cell lysates were prepared using RLB and luciferase activity was measured. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. Data generated using the methods 
described in Section 2.6 and Section 2.15. 
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5.3.4.2. Effects of SULF2 gene silencing on growth of HepG2 cells in vitro 
Although SULF2 knockdown did not affect growth factor or Wnt signalling, SULF2 
could still alter other signalling pathways and affect proliferation in HepG2 cells. 
The SRB assay was, therefore, performed to measure cell growth; however, the 
results showed no change in the growth of HepG2 cells after SULF2 gene silencing 
(Figure  5.33). 
 
Figure ‎5.33: Effect of SULF2 gene silencing on the growth of HepG2 cells: 
HepG2 cells were stably transduced with either NT shRNA or SULF2 shRNA 
lentiviral particles. 1,000 cells were seeded per well for different time points and 
then stained with SRB. Values are the mean of quadruplicates and error bars 
represent the standard error. The experiment was performed in triplicate. Data 
generated using the methods described in Section 2.6 and Section 2.17. 
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5.4. Summary 
Two of the most important signalling pathways that are involved in 
hepatocarcinogenesis were characterised in a panel of HCC cell lines; the Wnt and 
the growth factor/RTK signalling pathways. Well-validated inhibitors of these 
pathways were also tested; compound 3289-8625 and PD173074 that inhibit Wnt 
and RTK signalling pathways, respectively. These inhibitors were thus used as 
positive controls for inhibition of their respective pathways. The optimal shRNA 
sequences for gene silencing of either SULF2 or SULF1 were selected, and these 
were stably transduced into HCC cells and the downstream consequences were 
investigated. Mechanistically, the effect of SULF2 knockdown was cell-type 
specific, with inhibition of Wnt signalling in HuH-7 cell line, inhibition of FGF-1, 
FGF-2 and IGF-II signalling in SNU-182 cell line and no effect on either pathway in 
HepG2 cell line. Phenotypically, SULF2 knockdown had a detrimental effect on the 
proliferation of HuH-7 and SNU-182 cells in vitro and inhibited the tumourigenicity 
of HuH-7 cells in vivo. There was no effect of SULF2 knockdown on the 
proliferation of HepG2 cells. 
SULF1 knockdown inhibited the proliferation of SNU-182 cells, but it did not affect 
the growth factor/RTK signalling pathway, in contrast to SULF2 knockdown in this 
cell line. 
 
 
 
 
 
 
 
 
 
 
 
 
183 
 
6. Chapter 6. Effects of Inducible SULF1/2 Suppression in HCC 
Cell Lines 
 
The data presented in Chapter 5 demonstrated that SULF2 has a role in the 
regulation of cellular signalling and growth in HCC cell lines. The experiments 
described in this chapter were designed to further characterise the function of 
SULF1 and SULF2 by using inducible shRNAs to regulate expression. The 
S2.shRNA_18 and S1.shRNA_89 sequences were cloned into an isopropyl β-D-
thiogalactoside (IPTG)-inducible shRNA lentiviral vector by Sigma. This vector 
contains one LacI and a U6 promoter with three LacO sequences (Figure  2.4). 
IPTG is an analogue of lactose and binds to the LacI protein, changing its 
conformation and releasing it from the LacO site, which promotes the expression of 
the shRNA. These non-targeting (NT), SULF2 and SULF1 inducible shRNA 
constructs were provided in the form of lentiviral particles, and will be referred to as 
iNT.shRNA, iSULF2.shRNA and iSULF1.shRNA throughout the rest of the thesis.    
6.1. Optimisation of the Conditions for the Inducible Knockdown 
To choose the best conditions to achieve maximum knockdown of SULF1/2, HuH-7 
cells were stably transduced with either iNT.shRNA or iSULF2.shRNA and then 
treated with different concentrations of IPTG for different time periods with daily 
medium changes and replenishment of IPTG. WB showed that 1-2 mM IPTG 
caused silencing of SULF2 in the iSULF2.shRNA-transduced cells as early as one 
day after treatment with maximum reduction in SULF2 protein levels achieved after 
3 days (Figure  6.1). No effect on the levels of SULF2 protein was detected in the 
iNT.shRNA-transduced cells even after 5 days (data not shown). In the SNU-182 
cell line, 1 mM IPTG for 1-2 days caused almost complete absence of SULF1 or 
SULF2 proteins, and as in the HuH-7 cell line IPTG caused no change in the 
protein levels of either SULF1 or SULF2 in the iNT.shRNA-transduced cells (data 
not shown).  
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Figure ‎6.1: Optimisation of conditions for inducible SULF2 shRNA in HuH-7 
cells: The inducible SULF2 shRNA-transduced HuH-7 cells were treated with 
different concentrations of IPTG for 1-3 days and WB was performed on whole cell 
lysates with SULF2 Ab (Serotec) or actin Ab (loading control). The experiment was 
performed in triplicate and a representative blot is shown. Data generated using 
the methods described in Section 2.6 and Section 2.10. 
 
The duration of the effect of IPTG was assessed by RT-qPCR after treatment of 
iNT.shRNA- and iSULF2.shRNA-transduced HuH-7 cells with 1 mM of IPTG 
without any medium change or replenishment of IPTG. The results showed 75% 
and 86% decreases of SULF2 expression after treatment of iSULF2.shRNA-
transduced HuH-7 cells with IPTG for 3 and 8 days, respectively. No effect on 
SULF2 expression was shown after treatment of iNT.shRNA-transduced cells with 
IPTG for 3 days, while there was a 2-fold upregulation after 8 days of treatment 
(Figure  6.2). In inducible iSULF2.shRNA-transduced SNU-182 cells, IPTG 
treatment caused 92% and 99% decreases of SULF2 expression after 3 and 8 
days, while IPTG treatment caused 71% and 91% decreases of SULF1 expression 
in iSULF1.shRNA-transduced cells after 3 and 8 days, respectively. Interestingly, 
IPTG treatment for 8 days caused downregulation of SULF1 in iSULF2.shRNA-
transduced cells (78%) and of SULF2 in iSULF1.shRNA-transduced cells (81%). 
However, no effect of IPTG on SULF1 or SULF2 mRNA levels was observed in 
iNT.shRNA-transduced cells (Figure  6.3). These data demonstrate that the effect 
of IPTG persists for at least 8 days, and that SULF1/2 knockdown increases over 
time during incubation of cells with IPTG.     
To determine the specificity of knockdown, the expression of B2M was evaluated in 
both HuH-7 and SNU-182 cells transduced with the different inducible shRNAs. 
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The results showed no change in the expression of B2M in any of the cell lines 
tested before and after IPTG treatment (Figure  6.2) (Figure  6.3). 
Finally, to confirm that iNT.shRNA was expressed after IPTG treatment and to 
compare the level of the inducibly expressed shRNAs to that of the constitutively 
expressed shRNAs previously used (Section 5.3), the expression of the different 
shRNAs was tested in SNU-182 cell line using the QuantiMir small RNA 
quantification system as described in Section 2.21 Using a forward primer 
corresponding to the siRNA effector sequence of S2.shRNA_18 and a universal 
reverse primer, the RT-qPCR results showed that the iSULF2.shRNA was 
expressed at high levels after treatment of SNU-182 cells with 1 mM of IPTG for 8 
days. This expression level was close to that of the constitutively expressed SULF2 
shRNA (6.4-fold for iSULF2.shRNA vs. 9.3-fold for SULF2 shRNA) (Figure  6.4).  
However, the sequence of the constitutively expressed NT shRNA differed from 
that of the inducibly expressed iNT.shRNA. Using a forward primer corresponding 
to the siRNA effector sequence of NT shRNA, the RT-qPCR results showed 39-
fold upregulation of NT shRNA while using a specific primer for iNT.shRNA, the 
analysis showed only 4-fold upregulation after IPTG treatment for 8 days (Figure 
 6.4). Regarding iSULF1.shRNA, the forward primer corresponding to the siRNA 
effector sequence of S1.shRNA_89 did not give any signal despite trying different 
optimisation conditions including changes to the qPCR program and the amount of 
cDNA used. 
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Figure ‎6.2: RT-qPCR analysis after treatment of inducible shRNA-transduced 
HuH-7 cells with IPTG: The iNT.shRNA- or iSULF2.shRNA-tranduced HuH-7 cells 
were treated with 1 mM IPTG for 3 days (A) or 8 days (B) without medium change, 
and RT-qPCR was performed using SULF2 and B2M primers. GAPDH was used 
as an endogenous control for normalization. Values are the mean of triplicates and 
error bars represent the standard error. The experiment was performed in triplicate. 
Data generated using the methods described in Section 2.6 and Section 2.7. 
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Figure ‎6.3: RT-qPCR analysis after treatment of inducible shRNA-transduced 
SNU-182 cells with IPTG: The iNT.shRNA-, iSULF2.shRNA- or iSULF1.shRNA-
tranduced SNU-182 cells were treated with 1 mM IPTG for 3 days (A) or 8 days (B) 
without medium change and RT-qPCR was performed using SULF2, SULF1 and 
B2M primers. GAPDH was used as an endogenous control for normalization. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. Data generated using the methods 
described in Section 2.6 and Section 2.7. 
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Figure ‎6.4: Comparison of shRNA expression in constitutive and inducible 
shRNA-transduced SNU-182 cells using RT-qPCR: RNA was extracted from the 
constitutively expressed shRNA-transduced SNU-182 cells and the inducibly 
expressed shRNA-transduced SNU-182 cells that were incubated with or without 1 
mM IPTG for 8 days. RT-qPCR was performed using forward primers representing 
the siRNA sequences of S2.shRNA_18 (A), NT shRNA (B) and iNT.shRNA (C) 
and the QuantiMir 3’ universal reverse PCR primer. 5’ human U6 snRNA forward 
primer was used as an endogenous control for normalization. Values are the mean 
of triplicates and error bars represent the standard error. The experiment was 
performed in triplicate. Data generated using the method described in Section 2.21. 
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Subsequently, the cell lines with inducible shRNAs were analysed for the effect of 
inducible SULF1 or SULF2 gene silencing by measuring cell signalling and 
proliferation. 
6.2. Inducible SULF2 Gene Silencing in HuH-7 Cells and Effects on 
Signalling, Cell Growth and Tumourigenicity  
6.2.1. Effects of inducible SULF2 gene silencing on signalling pathways in 
HuH-7 cells 
As shown in Section 5.3.2, constitutive SULF2 knockdown resulted in inhibition of 
Wnt signalling in HuH-7 cell line, and hence the effect of inducible SULF2 
suppression was investigated. 
As measured by the TCF reporter gene assay, inducible SULF2 knockdown 
caused inhibition of Wnt-3a-induced β-catenin-dependent transcriptional activity (p 
value = 0.05, Figure  6.5; A). No effect on Wnt signalling was seen in the 
iNT.shRNA-transduced cells (Figure  6.5; A). This effect of SULF2 knockdown was 
attributed to the interaction of the Wnt-3a ligand with its receptor at the cell surface, 
as inducible SULF2 suppression did not diminish BIO-induced luciferase activity 
(BIO activates Wnt signalling by inhibiting GSK-3β, i.e. downstream of the frizzled 
receptor, as described in Section 5.1) (Figure  6.5; B). 
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Figure ‎6.5: Effect of inducible SULF2 gene silencing on Wnt signalling 
pathway in HuH-7 cells: HuH-7 cells were stably transduced with either 
iNT.shRNA or iSULF2.shRNA lentiviral particles. The cells were treated with 1mM 
IPTG for 3 days, serum-starved overnight and then treated with 100 ng/ml Wnt-3a 
(A) or 1 µM BIO (B) for 6 hours. Whole cell lysates were prepared using RLB and 
luciferase activity was measured. Values are the mean of triplicates and error bars 
represent the standard error. The experiment was performed in triplicate. * p = 
0.015, 2-sample t-test. Data generated using the methods described in Section 2.6 
and Section 2.15. 
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6.2.2. Effects of inducible SULF2 gene silencing on growth of HuH-7 cells in 
vitro 
The effect of inducible SULF2 knockdown on the growth of HuH-7 cells was 
investigated. The cells were treated with IPTG to induce shRNA expression. 
However, the results showed no effect of inducible SULF2 suppression on cell 
growth after treatment with IPTG at day 0 (data not shown) or at day 4 (Figure  6.6) 
following seeding cells.  
      
      
Figure ‎6.6: Effect of inducible SULF2 gene silencing on cell growth in HuH-7 
cells: HuH-7 cells were stably transduced with either iNT.shRNA (A) or 
iSULF2.shRNA (B) lentiviral particles. 2000 cells/well were seeded in 96-well 
plates. Cells were treated with IPTG at day 4, or not (control), and stained with 
SRB every two days. Values are the mean of six replicates and error bars 
represent the standard error. The experiment was performed in triplicate. Data 
generated using the methods described in Section 2.6 and Section 2.17. 
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6.2.3. Effects of inducible SULF2 gene silencing on tumourigenicity of HuH-7 
cells in vivo 
Despite the lack of effect on growth in vitro, and given that the microenvironment 
in vivo is quite different from that in culture, the effect of inducible SULF2 
knockdown was also investigated in vivo. iNT.shRNA- or iSULF2.shRNA-
transduced cells were each implanted into 10 mice and 5 mice per cell line were 
given IPTG in the drinking water. IPTG was added from day 0 at a final 
concentration of 12.5 mM in the drinking water. This concentration was reported 
to strongly induce expression of tested genes as early as 24 hours in liver cell 
lines when implanted subcutaneously in mice (Wu et al., 1997). The mice 
developed tumour xenografts as follows: 2/5 of iNT.shRNA with no IPTG, 4/5 of 
iNT.shRNA with IPTG, 4/5 of iSULF2.shRNA with no IPTG, and 5/5 of 
iSULF2.shRNA with IPTG (Figure  6.7; A). Furthermore, there was no difference 
in the mean time to reach a tumour volume of 500 mm3 between the four groups 
(Figure  6.7; B). The tumours were examined and SULF2 knockdown was 
confirmed in those tumours originating from iSULF2.shRNA-transduced cells 
after IPTG treatment (76% decrease of mRNA level vs. tumours from IPTG 
untreated iSULF2.shRNA-transduced cells), while no effect was detected on the 
expression level of B2M after IPTG treatment (Figure  6.7; C). 
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Figure ‎6.7: Effect of inducible SULF2 gene silencing on the tumourigenicity 
of HuH-7 cells: 1x107 iNT.shRNA- or iSULF2.shRNA-transduced cells were 
implanted subcutaneously into the right flank of ten CD1 female nude mice each. 5 
mice per group were supplied with drinking water containing 3 g/L (12.5 mM) IPTG 
that was prepared fresh every week. Tumour incidence and volume were 
measured 3 times a week using a digital caliper. (A) Tumour incidence and growth 
rate in mouse. (B) Mean time to reach a volume size of 500 mm3 from 
implantation. The horizontal lines are the mean of the replicates and error bars 
represent the standard error. (C) RT-qPCR analysis using primers for SULF2 and 
B2M in tumours from each group removed when tumour volume reached 500 mm3. 
GAPDH was used as a reference gene for normalization. Values are the mean of 
replicates and error bars represent the standard error. Data generated using the 
methods described in Section 2.7 and Section 2.20. 
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6.3. Inducible SULF1/2 Gene Silencing in SNU-182 Cells and Effects on 
Signalling and Cell Growth 
6.3.1. Effects of inducible SULF1/2 gene silencing on signalling pathways in 
SNU-182 cells 
As shown in Section 5.3.3, constitutive SULF2 knockdown resulted in inhibition of 
growth factor/RTK signalling in SNU-182 cell line, and hence the effect of inducible 
SULF2 suppression was investigated. 
Constitutive SULF2 knockdown caused marked inhibition of FGF-1- and FGF-2-
induced ERK and IGF-II-induced AKT phosphorylation in SNU-182 cells. However, 
inducible SULF2 knockdown failed to cause any effect on p-ERK levels induced by 
FGF-1 or FGF-2, or on p-AKT levels induced by IGF-I (Figure  6.8) or IGF-II (data 
not shown).  
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Figure ‎6.8: Effect of inducible SULF1/2 gene silencing on FGF-1, FGF-2 and 
IGF-I signalling pathways in SNU-182 cells: SNU-182 cells stably transduced 
with iNT.shRNA, iSULF2.shRNA or iSULF1.shRNA lentiviral particles were treated 
with 1 mM IPTG for two days. The cells were serum-starved overnight and then 
treated with 10 nM FGF-1 (A) or FGF-2 (B) for 10 min, or IGF-I (C) for 5 min. 
Whole cell lysates were prepared and WB was performed using antibodies against 
SULF2, p-ERK1/2 or p-AKT. The membranes were stripped and reprobed with 
antibodies against total ERK1/2 and total AKT serving as loading controls. The 
experiment was performed in triplicate and representative blots are shown. Data 
generated using the method described in Section 2.10. 
 
6.3.2. Effects of inducible SULF1/2 gene silencing on growth of SNU-182 cells 
in vitro 
The effect of inducible SULF1/2 knockdown on the growth of SNU-182 cells was 
also investigated. The cells were treated with IPTG at day 4 to induce shRNA 
expression. The results showed that neither SULF1 nor SULF2 suppression 
altered cell growth in 10% (v/v) FBS-containing medium (Figure  6.9) or 1% (v/v) 
FBS-containing medium (data not shown).  
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Figure ‎6.9: Effect of inducible SULF1/2 gene silencing on cell growth in SNU-
182 cells: SNU-182 cells were stably transduced with iNT.shRNA (A), 
iSULF2.shRNA (B) or iSULF1.shRNA (C) lentiviral particles. 1000 cells/well were 
seeded into 96-well plates. Cells were treated with IPTG at day 4 and stained with 
SRB every two days. Values are the mean of six replicates and error bars 
represent the standard error. The experiment was performed in triplicate. Data 
generated using the method described in Section 2.17. 
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6.4. Summary 
In summary, the data in Chapter 5 demonstrated that SULF2 plays a role in 
regulating the growth of HCC cell lines. Further characterisation of the impact of 
SULF2 suppression using inducible knockdown of either SULF1 or SULF2 was 
therefore investigated. First, the conditions for inducing the expression of the 
different shRNAs using IPTG were optimised. The inducible SULF1/2 knockdown 
was confirmed at the mRNA and protein levels using RT-qPCR and WB. Second, 
the consequences of inducible SULF1/2 knockdown on signalling and cell growth 
were explored in HuH-7 and SNU-182 cell lines as these were the two cell lines 
where constitutive SULF2 knockdown reduced signalling and growth.  
In the HuH-7 cell line, inducible SULF2 knockdown inhibited Wnt-3a-stimulated β-
catenin-dependent transcriptional activity to a limited extent but had no effect on 
cell growth in vitro or tumourigenicity in vivo. In the SNU-182 cell line, neither 
SULF1 nor SULF2 inducible knockdown affected the growth factor/RTK signalling 
or cell growth in vitro. These results suggest that SULF2 knockdown should be 
maintained for long time before signalling or phenotypic effects are produced.  
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7. Chapter 7. Microarray Gene Expression Analysis Following 
SULF2 Knockdown in HCC Cell Lines 
 
The data in the preceding chapters demonstrated that SULF2 suppression is 
clearly associated with biological effects in HCC cell lines. To explore the effect of 
SULF2 knockdown in HCC cells at the molecular level, as well as potentially 
identifying biomarkers for SULF2 inhibition, microarray gene expression analysis 
was performed, using Affymetrix human genome U133 plus 2.0 arrays, consisting 
of > 54,000 probe sets for the analysis of about 47,400 transcripts and variants 
including 38,500 characterised genes. 
7.1. Effect of SULF2 Knockdown on Gene Expression in HuH-7 Cell Line 
Control untransduced HuH-7 cells or the cells that were stably transduced with 
either NT shRNA or SULF2 shRNA were cultured for 48 hours before being 
harvested and sent for microarray analysis. The results represent the average of 
four biologically independent replicates. First, SULF2 knockdown was confirmed by 
RT-qPCR, and 97% decrease of SULF2 in the SULF2 shRNA-transduced cells 
demonstrated compared to SULF2 expression in NT shRNA-transduced cells. As 
noted before, there was upregulation (3-fold in this experiment) of SULF2 in NT 
shRNA-transduced cells compared to control untransduced cells (Figure  7.1; A), 
indicating that SULF2 expression may be induced by transducing cells with 
lentiviral particles or simply reflecting heterogeneity. 
Analysis of the microarray experiment, as described in Section 2.22, showed that 
of the more than 54,000 tested probe sets: 
 1529 probe sets were differentially expressed between NT shRNA-transduced 
cells and control untransduced cells with ≥ 2-fold change and an adjusted p 
value ≤ 0.01. 
 2561 probe sets were differentially expressed between SULF2 shRNA-
transduced cells and control untransduced cells with ≥ 2-fold change and an 
adjusted p value ≤ 0.01. 
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 703 probe sets were differentially expressed between SULF2 shRNA-
transduced cells and NT shRNA-transduced cells with ≥ 2-fold change and an 
adjusted p value ≤ 0.01. 
These data suggest that there were considerable changes in the expression levels 
of many genes due to transduction with lentiviral particles and/or selection with 
puromycin, regardless of the expression level of SULF2, as shown by the principal 
component analysis, reflecting transcriptome differences among the samples 
(Figure  7.1; B). Therefore, only the genes that were differentially expressed in the 
SULF2 knockdown cells with ≥ 2-fold change and adjusted p value ≤ 0.01, 
compared to both NT shRNA and control untransduced cells, were taken into 
consideration for further analysis. This approach identified 444 differentially 
expressed probe sets, and of these 146 probe sets (representing 111 genes) were 
downregulated and 298 probe sets (representing 211 genes) were upregulated 
after SULF2 knockdown (Figure  7.2). A complete list of these differentially 
expressed probe sets that were downregulated or upregulated after SULF2 
knockdown in HuH-7 cells can be found in Appendices A and B, respectively. 
As one gene can be involved in more than one pathway, investigation of affected 
pathways was performed, using GeneSpring 12.6 software, based on 
WikiPathways analysis (Analysis, Reactome, GenMAPP and Other). 
Unsurprisingly, given the number of genes affected, SULF2 suppression was found 
to affect the transcript level of genes belonging to many different pathways (Table 
 7.1).  
The most differentially expressed genes after SULF2 knockdown as compared to 
both NT shRNA-transduced cells and control untransduced cells are listed with 
their putative pathways in Table  7.2 (n = 26). To verify the microarray data prior to 
further study, the most differentially expressed genes that have a potential link to 
cancer were selected for RT-qPCR analysis (n = 18). These genes are listed in 
Table  7.2 and labelled in Figure  7.2; B. The RT-qPCR results confirmed the 
microarray data for all the genes tested, and genes with a potential role in liver 
carcinogenesis were selected for analysis at the protein level. Seven genes were 
chosen, five that were upregulated and two that were downregulated after SULF2 
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knockdown. The upregulated genes were ACE2 (angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 2), PCDH20 (protocadherin 20), SLPI (secretory leukocyte 
peptidase inhibitor), TFPI2 (tissue factor pathway inhibitor 2) and WNT5A 
(wingless-type MMTV integration site family, member 5A). The two genes that 
were downregulated after SULF2 suppression were MYCN (v-myc 
myelocytomatosis viral related oncogene, neuroblastoma derived (avian)) and 
DLK1 (delta-like 1 homolog (Drosophila)). 
Unfortunately, only the antibodies for ACE2 and MYCN performed satisfactorily in 
WB analysis (Figure  7.4). ACE2 was the most differentially expressed gene after 
SULF2 knockdown, with gene expression inversely correlated with SULF2, as 
evidenced by both microarray and RT-qPCR data (Figure  7.3; A and B). This effect 
was confirmed at the protein level, where ACE2 protein was only detected in the 
SULF2 knockdown cells (Figure  7.4). The expression of MYCN correlated with the 
expression of SULF2, with downregulation of MYCN mRNA levels (Figure  7.3; A 
and C) and a reduction in MYCN protein expression (Figure  7.4) after SULF2 
knockdown. 
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Figure ‎7.1: SULF2 expression and principal component analysis of HuH-7 
cell lines: Control untransduced, NT shRNA-transduced and SULF2 shRNA-
transduced HuH-7 cells were cultured for 2 days followed by mRNA extraction. (A) 
RT-qPCR analysis of SULF2 expression using GAPDH as a reference gene. 
Horizontal lines are the mean of 4 separate replicates of each cell line. (B) 
Principal component analysis plot provided as a 2-dimensional plot showing the 
transcriptome difference (variation in gene profile) of the samples. Each point is 
from a separate microarray analysis with 4 separate replicates for each cell line. 
Data generated using the methods described in Section 2.7 and Section 2.22. 
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Figure ‎7.2: Scatter plot display of differentially expressed genes with ≥‎2-fold 
change and adjusted p value‎≤‎0.01‎after SULF2 knockdown in HuH-7 cells as 
compared to both NT shRNA-transduced cells and control untransduced 
cells: (A) Fold change (SULF2 shRNA vs. NT shRNA) was plotted against fold 
change (SULF2 shRNA vs. Control untransduced). Each dot represents one gene 
and the colour represents average expression where red colour represents high 
expression, yellow colour represents medium expression and blue colour 
represents low expression. (B) Fold change (SULF2 shRNA vs. NT shRNA) was 
plotted against average expression. Genes that were chosen for RT-qPCR 
analysis are labelled. Data generated using the method described in Section 2.22. 
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Table ‎7.1: Gene ontolgies enriched with differentially expressed transcripts after 
SULF2 knockdown in HuH-7 cell line with ≥ 2-fold change and adjusted p value ≤ 
0.01 (only the pathways that contain ≥ two affected transcripts are listed). 
Pathway Matched Entities 
(S2 vs. NT and Ctrl) 
Hs muscle cell TarBase 10 
Hs epithelium TarBase 9 
Hs lymphocyte TarBase 9 
Hs focal adhesion 8 
Hs neural crest differentiation 6 
Hs myometrial relaxation and contraction pathways 6 
Hs calcium regulation in the cardiac cell 5 
Hs adipogenesis 4 
Hs integrated pancreatic cancer pathway 4 
Hs prostate cancer 4 
Hs SIDS susceptibility pathways 4 
Hs spinal cord injury 4 
Hs metapathway biotransformation 3 
Hs EGF-EGFR signalling pathway 3 
Hs Wnt signalling pathway and pluripotency 3 
Hs G protein signalling pathways 3 
Hs GPCRs, class A rhodopsin-like 3 
Hs Toll-like receptor signalling pathway 3 
Hs microRNAs in cardiomyocyte hypertrophy 3 
Hs leukocyte TarBase 3 
Hs folate metabolism 3 
Hs endochondral ossification 3 
Hs GPCR ligand binding 2 
Hs senescence and autophagy 2 
Hs inflammatory response pathway 2 
Hs BDNF signalling pathway 2 
Hs regulation of actin cytoskeleton 2 
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Pathway Matched Entities 
(S2 vs. NT and Ctrl) 
Hs cell cycle 2 
Hs TCR signalling pathway 2 
Hs DNA damage response 2 
Hs DNA damage response (only ATM dependent) 2 
Hs TGF beta signalling pathway 2 
Hs ErbB signalling pathway 2 
Hs RANKL-RANK signalling pathway 2 
Hs GPCR downstream signalling 2 
Hs miRNA regulation of DNA damage response 2 
Hs selenium pathway 2 
Hs cytoplasmic ribosomal proteins 2 
Hs integrated breast cancer pathway 2 
Hs signalling pathways in glioblastoma 2 
Hs vitamin B12 metabolism 2 
Hs synaptic vesicle pathway 2 
Hs nuclear receptors in lipid metabolism and toxicity 2 
Hs matrix metalloproteinases 2 
Hs drug induction of bile acid pathway 2 
Hs integrin cell surface interactions 2 
Hs sphingolipid metabolism 2 
Hs Phase II conjugation 2 
Hs response to elevated platelet cytosolic Ca2+ 2 
Ctrl: control untransduced cells; NT: NT shRNA-transduced cells; S2: SULF2 
shRNA-transduced cells. Hs: Homo sapiens. SIDS: Sudden infant death syndrome. 
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Table ‎7.2: Summary of genes that were most differentially expressed at the mRNA 
level after SULF2 knockdown in HuH-7 cell line with their fold change values as 
measured by microarray and RT-qPCR analyses. The minus (-) symbol in front of 
the fold change value demonstrates gene downregulation. The data represent the 
mean of quadruplicate determinations. 
Gene 
Symbol 
 
Fold Change 
(Microarray) 
Fold Change 
(qPCR) 
Pathway 
NT vs. 
Ctrl 
S2 vs. 
Ctrl 
S2 vs. 
NT 
NT vs. 
Ctrl 
S2 vs. 
Ctrl 
S2 vs. 
NT 
ACE2* -1.5 47 70 -2.4 67 161 Renin-angiotensin system 
CEACAM7 -1.2 42 46 
high expression for S2 
while undetermined 
expression for NT and Ctrl 
Integral to membrane 
HEPH -1.9 20 37 -12 24 289 Mineral absorption 
PCDH20 1.5 27 18 1.1 27 24 Cell adhesion 
HOXB7* 1.1 15 15 -1.4 86 121 N/A 
CA4* -1.2 10 13 
   
Nitrogen metabolism 
CTBP2* -2.5 4.4 11 -14 9.1 123 
Notch and Wnt signalling 
pathways 
GCC2 1.2 19 15 
   
Golgi 
PI3* -1.9 7.7 14 
   
Extracellular region 
SLPI -1.3 11 15 -2.2 38 83 Extracellular region 
EDIL3 -1.0 14 14 -1.4 20 27 Cell adhesion 
SLFN11 1.4 20 14 7.1 367 52 Nucleus 
FAM198B -2.0 7.1 14 
   
Golgi membrane 
PRSS3* 1.8 21 11 3.1 65 21 
Protein digestion and 
absorption 
CEACAM6* 1.0 11 10 -1.5 237 350 Integral to membrane 
MUC13* -1.1 8.6 9.0 
   
Extracellular region 
HOXB3 1.0 9.8 9.6 
   
Nucleus 
TFPI2* 1.0 7.7 7.6 -1.2 13 15 Extracellular region 
CCL3 
//CCL3L1 
//CCL3L3 
1.0 8.9 8.6 
   
Senescence and 
autophagy 
ESRP1 1.1 9.5 8.5 
   
N/A 
WNT5A* -2.3 3.3 7.5 -4.4 5.2 23 
Wnt and Hedgehog 
signalling pathways 
MYCN 1.1 -4.2 -4.7 1.1 -4.0 -4.5 
Transcriptional 
misregulation in cancer 
AHSG* 1.1 -4.7 -5.0 -1.0 -5.8 -5.7 N/A 
DLK1 1.8 -3.8 -6.9 1.7 -6.7 -11 N/A 
CTSE 1.0 -9.2 -9.5 1.2 -54 -67 Lysosome 
BEX1 -1.6 -20 -13 -1.7 -75 -44 N/A 
SULF2* 2.8 -4.2 -12 3.0 -11 -34 N/A 
* The values are the average of the fold change for the different probe sets used to 
detect the same gene in the microarray experiment. Ctrl: control untransduced 
cells; NT: NT shRNA-transduced cells; S2: SULF2 shRNA-transduced cells. 
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Figure ‎7.3: mRNA levels of ACE2 and MYCN after SULF2 knockdown in HuH-
7 cells: mRNA expression analysis of control untransduced, NT shRNA-
transduced and SULF2 shRNA-transduced HuH-7 cells by Affymetrix microarray or 
RT-qPCR. For RT-qPCR, GAPDH was used as a reference gene. (A) SULF2, (B) 
ACE2, (C) MYCN. Values are the average of the fold change for the different probe 
sets used to detect the same gene in the microarray experiment, and values are 
the mean of the fold change for 4 separate replicates in the RT-qPCR experiment. 
Error bars represent the standard error. Data generated using the methods 
described in Section 2.7 and Section 2.22. 
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Figure ‎7.4: Protein levels of ACE2 and MYCN after SULF2 knockdown in HuH-
7 cells: Analysis of control untransduced, NT shRNA-transduced and SULF2 
shRNA-transduced HuH-7 cells by WB using antibodies against SULF2, ACE2 and 
MYCN. GAPDH was used as a loading control and samples were loaded as 
biological triplicates. The experiment was performed in triplicate and a 
representative blot is shown. Data generated using the method described in 
Section 2.10. 
 
7.2. Effect of SULF2 Knockdown on Gene Expression in Other Cancer Cell 
Lines 
To determine whether the effects of SULF2 knockdown in the HuH-7 cell line were 
cell type-specific, studies were performed in three additional cell lines. The first 
was the HCC cell line SNU-182, where there was inhibition of growth factor/RTK 
signalling pathway after SULF2 knockdown, and reduced cell proliferation after 
either SULF1 or SULF2 knockdown. The second cell line was the pancreatic 
cancer cell line BxPC3 that expresses high level of SULF2 but a low level of 
SULF1. SULF2 knockdown in this cell line was shown at the mRNA (Figure  7.6; A) 
and protein level (Figure  7.6; B). Cell growth in vitro was inhibited (Figure  7.6; C 
and D) and tumour growth was slightly delayed after SULF2 knockdown (Figure 
 7.6; E), in line with the findings of a previous study (Nawroth et al., 2007). The third 
cell line was the HCC cell line SNU-475. This cell line expresses both SULF1 and 
SULF2
ACE2
GAPDH
Control
untransduced
1         2         3
NT shRNA
1        2         3
SULF2 shRNA
1        2        3
MYCN
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SULF2 at low levels, and knockdown of either SULF1/2 genes had no effect on the 
proliferation of the SNU-475 cells (data not shown). 
RT-qPCR analysis was performed in the 3 additional cell lines using primers for the 
genes that were differentially expressed after SULF2 knockdown in HuH-7 cell line, 
and had potential links to cancer. In the SNU-182 cell line, a small upregulation of 
SULF2 was observed in the NT shRNA-transduced cells in comparison to control 
untransduced cells (1.7-fold). SULF2 was markedly downregulated in the SULF2 
shRNA-transduced cells, and there was a small downregulation of SULF2 
expression in the SULF1 shRNA-transduced cells (98% and 68% vs. NT shRNA-
transduced cells, respectively). Only SULF1 was downregulated in the SULF1 
shRNA-transduced cells (70% vs. NT shRNA-transduced cells) (Table  7.3). SULF2 
knockdown was confirmed at the protein level in these samples by WB (Figure 
 7.5).  
Of these genes that were downregulated after SULF2 knockdown in the HuH-7 cell 
line, only three genes were affected in the SNU-182 cell line (i.e., ACE2, MYCN 
and DLK1). ACE2 was upregulated (≥ 1.5-fold) after SULF2 suppression and 
downregulated (≥ 1.9-fold) after SULF1 suppression in SNU-182 cell line, while 
both MYCN and DLK1 were downregulated (≥ 1.5-fold) after both SULF1 and 
SULF2 suppression (Table  7.3).  
Other genes that have been reported to have role in liver carcinogenesis were also 
examined in SNU-182 cell line. GPC3 was dramatically downregulated after either 
SULF1 or SULF2 suppression, while GPC4 was downregulated (2-fold) and matrix 
metalloproteinase 9 (MMP9) was upregulated (> 2-fold) after SULF1 suppression 
only (Table  7.3). In addition, the gene encoding the angiotensin II type 1 receptor, 
AGTR1, was downregulated (> 2-fold), while the hedgehog-interacting protein 
(HHIP) that antagonizes hedgehog (Hh) signalling was upregulated (≥ 1.9-fold) 
after SULF2 knockdown (Table  7.3). 
With respect to BxPC3 and SNU-475 cell lines, of the genes tested the only one 
that showed differential expression in either HuH-7 or SNU-182 cell lines that 
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showed any change after SULF1/2 knockdown was ACE2, and then only in BxPC3 
cells where it was upregulated ≥ 2.2-fold after SULF2 knockdown (Figure  7.6; A). 
 
Table ‎7.3: RT-qPCR analysis of the effect of SULF2 knockdown in SNU-182 cells. 
The minus (-) symbol in front of the fold change value demonstrates gene 
downregulation. The data represent the mean of quadruplicate determinations, and 
numbers in bold indicate the genes that were discussed in the thesis. 
Gene 
Symbol 
 
Fold Change (qPCR) 
Pathway NT vs. 
Ctrl 
S2 vs. 
Ctrl 
S2 vs. 
NT 
S2 vs. 
S1 
S1 vs. 
Ctrl 
S1 vs. 
NT 
ACE2 1.9 2.7 1.5 5.3 -1.9 -3.6 
Renin-angiotensin 
system 
CEACAM7 Not expressed 
Integral to 
membrane 
HEPH Not expressed Mineral absorption 
PCDH20 Weakly expressed Cell adhesion 
HOXB7 1.4 1.0 -1.4 -1.3 1.3 -1.1 N/A 
CTBP2 1.2 1.2 1.0 1.2 -1.1 -1.2 
Notch and Wnt 
signalling pathways 
SLPI -1.6 -1.8 -1.1 1.2 -2.1 -1.3 Extracellular region 
EDIL3 1.1 1.2 1.1 -1.2 1.4 1.3 Cell adhesion 
SLFN11 Not expressed Nucleus 
PRSS3 Weakly expressed 
Protein digestion 
and absorption 
CEACAM6 Not expressed 
Integral to 
membrane 
TFPI2 1.2 -1.0 -1.3 -2.1 2.1 1.7 Extracellular region 
WNT5A 1.5 1.3 -1.2 1.2 1.1 -1.5 
Wnt and Hedgehog 
signalling pathways 
MYCN -1.2 -1.7 -1.5 1.2 -2.1 -1.8 
Transcriptional 
misregulation in 
cancer 
AHSG Not expressed N/A 
DLK1 1.4 -1.5 -2.1 1.5 -2.1 -3.0 N/A 
CTSE Not expressed Lysosome 
BEX1 -7.9 -11 -1.4 -2.2 -4.9 1.6 N/A 
SULF2 1.7 -40 -66 -22 -1.9 -3.1 N/A 
SULF1 -1.3 -1.4 -1.1 3.1 -4.3 -3.3 N/A 
GPC3 -1.6 -23 -15 2.8 -65 -41 
Proteoglycans in 
cancer 
GPC4 -1.2 -1.3 -1.1 2.0 -2.7 -2.2 
Wnt signalling 
pathway 
MYC 1.0 1.5 1.4 -1.0 1.5 1.4 Pathways in cancer 
CCND1 1.3 1.0 -1.3 1.3 -1.3 -1.6 Pathways in cancer 
ACE 1.2 1.3 1.0 1.5 -1.2 -1.4 
Renin-angiotensin 
system 
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AGTR1 1.8 -2.4 -4.3 -2.6 1.1 -1.6 
Renin-angiotensin 
system 
FOXO1 -1.0 1.0 1.1 -1.2 1.2 1.2 
Transcriptional 
misregulation in 
cancer 
VEGFA 1.3 2.4 1.9 1.5 1.6 1.2 
VEGF signalling 
pathway 
Gene 
Symbol 
Fold Change (qPCR) 
Pathway NT vs. 
Ctrl 
S2 vs. 
Ctrl 
S2 vs. 
NT 
S2 vs. 
S1 
S1 vs. 
Ctrl 
S1 vs. 
NT 
MMP2 1.2 -1.1 -1.3 -1.4 1.3 1.1 Pathways in cancer 
MMP9 -1.0 -1.5 -1.5 -3.9 2.7 2.7 Pathways in cancer 
HHIP 1.0 2.4 2.4 1.9 1.2 1.2 
Hedgehog 
signalling pathway 
GLI1 -1.9 -1.9 1.0 -1.1 -1.6 1.1 
Hedgehog 
signalling pathway 
Ctrl: control untransduced cells; NT: NT shRNA-transduced cells; S2: SULF2 
shRNA-transduced cells. 
 
 
Figure ‎7.5: SULF2 protein levels after SULF1/2 knockdown in SNU-182 cells: 
Cell lysates were prepared from control untransduced, NT shRNA-transduced, 
SULF2 shRNA-transduced and SULF1 shRNA-transduced SNU-182 cells and WB 
was performed using antibody against SULF2 (Serotec). Actin was used as a 
loading control and samples were loaded as biological triplicates. The experiment 
was performed in triplicate and a representative blot is shown. Data generated 
using the method described in Section 2.10. 
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Figure ‎7.6:  Effect of SULF2 gene silencing in BxPC3 cells: BxPC3 cells were 
stably transduced with either NT shRNA or SULF2 shRNA lentiviral particles. (A) 
RT-qPCR analysis using SULF2 and ACE2 primers. GAPDH was used as a 
reference gene for normalization. Values are the mean of triplicates and error bars 
represent the standard error. (B) WB analysis of cell lysates using SULF2 Ab 
(Serotec). Actin was used as a loading control. Samples were loaded as biological 
triplicates. (C and D) SRB assay of cell growth in 10% FBS (C) or 1% FBS (D) 
containing medium. Values are the mean of six replicates and error bars represent 
the standard error. ** p value = 0.003, *** p value < 0.0001, one-way ANOVA. 
Experiments (A-D) were performed in triplicate. (E) 5x106 cells were resuspended 
in Matrigel and implanted subcutaneously into the right flank of 5 nude mice for 
each cell line, and the tumour volume measured 3 times a week using a digital 
caliper. The horizontal lines are the mean of replicates and error bars represent the 
standard error. * p value = 0.017, 2-sample t-test. Data are from a single 
experiment. Data generated using the methods described in Sections 2.6, 2.7, 
2.10, 2.17 and 2.20. 
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7.3. Effect of the ACE2/Ang-(1-7)/Mas Receptor Axis in HuH-7 Cells 
As shown in Section 7.1, there was a pronounced upregulation of ACE2 in SULF2 
knockdown HuH-7 cells at both the mRNA and protein levels, hence experiments 
were performed to (1) determine the percentage of SULF2 knockdown cells 
overexpressing ACE2; (2) establish if the overexpressed ACE2 enzyme was 
catalytically active; and (3) explore the role of ACE2 in mediating the downstream 
biological consequences observed after prolonged SULF2 knockdown in HuH-7 
cells.  
ACE2 is an ectoenzyme that is present at the cell surface and can also be 
secreted. To determine the percentage of ACE2-positive cells and to explore the 
localization of the enzyme, cells were examined using the ImageStreamX imaging 
flow cytometer, as described in Section 2.23. Unfortunately, none of the SULF2 
antibodies available were suitable for analysis using this equipment; however, the 
anti-ACE2 antibody worked well. Forty-five % of the SULF2 knockdown cells were 
ACE2-positive with a mean fluorescence intensity (FI) of 135,400 (median 
105,195). This percentage was much higher than that of ACE2-positive cells in the 
control untransduced cells (10%), which had a mean FI of 110,753 (median 
60,404), and also much higher than the NT shRNA-transduced cells (4%), which 
had a mean FI of 107,524 (median 60,199) (Figure  7.7; B-D). In addition, the 
analysis confirmed the membranous localization of ACE2 enzyme in all ACE2-
positive cells (Figure  7.7; F). 
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Figure ‎7.7: Flow cytometry analysis of the expression and localization of 
ACE2 after SULF2 knockdown in HuH-7 cells: Control untransduced, NT 
shRNA-transduced and SULF2 shRNA-transduced cells were trypsinized and a 
single cell suspension fixed, permeabilized, incubated with ACE2 antibody and 
then stained with Texas Red secondary antibody followed by analysis using 
ImageStreamX imaging flow cytometer. (A-D) Left panel is gating for round single 
cells (RSCs) using aspect ratio of cells on the y axis and cell area on the x axis. 
Right panel is frequency histograms of RSCs using frequency on the y axis and 
fluorescence intensity of Texas Red on the x axis. (A) Secondary antibody only 
control used to set the gate for ACE2 expression. (B) Control untransduced cells. 
(C) NT shRNA-transduced cells. (D) SULF2 shRNA-transduced cells. (E) 
Representative images of ACE2-negative SULF2 knockdown cells. (F) 
Representative images of ACE2-positive SULF2 knockdown cells. BF: Bright field, 
DAPI: Blue channel for DAPI staining of nuclei. The experiment was performed in 
triplicate. Data generated using the method described in Section 2.23. 
 
218 
 
Angiotensin II (Ang II) is a proliferation-promoting peptide that acts on the Ang II 
type 1 receptor (AT1R). ACE2 converts Ang II into another biologically active 
peptide called angiotensin 1-7 or Ang-(1-7). Ang-(1-7) stimulates the Mas receptor 
which is associated with an anti-proliferative effect (Santos et al., 2003) (Tallant 
and Clark, 2003) (Tallant et al., 2005). To test the enzymatic activity of ACE2 in 
HuH-7 cells, the fluorogenic peptide substrate Mca-Tyr-Val-Ala-Asp-Ala-Pro-
Lys(Dnp)-OH was used as described in Section 2.24. This substrate has a highly 
fluorescent group, Mca (7-methoxycoumarin-4-yl acetyl), that is quenched by a 
Dnp (2,4-dinitophenyl) group. ACE2 can cleave the peptide bond between proline 
and lysine amino acids of the fluorogenic peptide, producing measurable 
fluorescence (Vickers et al., 2002). Firstly, this substrate was tested against 
recombinant human ACE2 (rhACE2). The experiment confirmed a concentration- 
and time-dependent increase in fluorescence, in keeping with ACE2 activity, that 
reached a plateau when a high concentration of the enzyme was used (Figure  7.8; 
A). Next, cell lysates of control untransduced, NT shRNA-transduced and SULF2 
shRNA-transduced HuH-7 cells were incubated with this substrate and 
fluorescence was read in a kinetic mode. Assessment of the data revealed higher 
enzymatic activity of SULF2 knockdown cell lysate as compared to the control 
untransduced or NT shRNA-transduced cell lysates (Figure  7.8; B). As the Mca-
Tyr-Val-Ala-Asp-Ala-Pro-Lys(Dnp)-OH substrate can also be cleaved by caspase-1 
and interleukin-converting enzyme (Enari et al., 1996), a more specific ACE2 
substrate was used, namely Mca-Ala-Pro-Lys (Dnp)-OH (Vickers et al., 2002). This 
latter substrate has a shorter peptide sequence and the same fluorochrome as the 
longer peptide substrate. The results were in line with the previous data and 
showed that SULF2 knockdown cells had higher ACE2 activity, in keeping with the 
overexpressed ACE2 being active in these cells (Figure  7.8; C).  
Given that ACE2 converts Ang II into Ang-(1-7), the control untransduced HuH-7 
cells and those transduced with NT shRNA or SULF2 shRNA were treated with or 
without Ang II and the level of Ang-(1-7) was measured in culture medium as 
described in Section 2.25. Serum-free medium was used to avoid any effect due to 
enzymes present in FBS that might metabolise Ang II. The study showed that 
basal levels of Ang-(1-7) were not detected in the culture medium of any of the 3 
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HuH-7 cell lines. However, in the cells treated with Ang II, the concentration of 
Ang-(1-7) was 3-fold higher in the culture medium from SULF2 knockdown cells 
(154 pg/ml) in comparison to medium from control untransduced cells (56 pg/ml) or 
NT shRNA-transduced cells (48 pg/ml) (Figure  7.9), further supporting the 
catalytically active nature of the overexpressed ACE2 enzyme in the SULF2 
knockdown cells.  
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Figure ‎7.8: The activity of ACE2 after SULF2 knockdown in HuH-7 cells: 
100,000 control untransduced HuH-7 cells or those transduced with NT shRNA or 
SULF2 shRNA were cultured in 12-well plate and cell lysates prepared. Substrate, 
either Mca-Tyr-Val-Ala-Asp-Ala-Pro-Lys(Dnp)-OH (A and B) or Mca-Ala-Pro-
Lys(Dnp)-OH (C), was diluted in assay buffer to give a concentration of 40 µM and 
added to recombinant ACE2 protein or cell lysates and the fluorescence was read 
at 450 nm after excitation at 355 nm. (A) rhACE2 at 1 or 10 ng/µl final 
concentration. (B and C) cell lysates. Blank is samples containing no cell lysates. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. * p value < 0.05, one-way ANOVA. Data 
generated using the method described in Section 2.24. 
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Figure ‎7.9: Metabolism of exogenous Ang II by the HuH-7 cell lines: 100,000 
control untransduced HuH-7 cells or those transduced with NT shRNA or SULF2 
shRNA were cultured in 6-well plates and serum-starved overnight followed by 
treatment with 10 µM Ang II for 1 hour. Culture medium was collected and filtered 
through a cellulose membrane with 10,000 kDa molecular weight cut-off. The Ang-
(1-7) levels were measured using a competitive inhibition enzyme immunoassay. 
(A) Standard curve of Ang-(1-7) where the optical density readings at 450 nm were 
plotted against the log of standard concentrations in pg/ml. (B) Concentration of 
Ang-(1-7) in culture medium. Blank is medium that was not incubated with cells. 
Values are the mean of quadruplicates and error bars represent the standard error. 
The experiment was performed in triplicate. Data generated using the method 
described in Section 2.25. 
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The effect of Ang II and Ang-(1-7) on the growth of HuH-7 cells was investigated. It 
was hypothesized that Ang II would promote the proliferation of control 
untransduced and NT shRNA-transduced cells, but not SULF2 knockdown cells 
owing to its conversion into the anti-proliferative peptide Ang-(1-7) by ACE2 in 
these cells. Conversely, Ang-(1-7) would inhibit the proliferation of all 3 HuH-7 cell 
lines; control untransduced cells, NT shRNA-transduced cells and SULF2 
knockdown cells. In fact, neither Ang II nor Ang-(1-7) had an effect on the 
proliferation of any of the HuH-7 cell lines, in 10% (v/v) or 1% (v/v) FBS-containing 
medium, at concentrations up to 10 µM of either peptide (Figure  7.10). It was not 
possible to culture these cells in serum-free medium due to the poor growth and 
survival of HuH-7 cells in the absence of FBS.  
One possible explanation for the lack of effect of Ang-(1-7) in these cells is the low 
level of expression of the MAS1 gene, which encodes the Mas receptor, in the 
HuH-7 cell line, as shown by RT-qPCR analysis (Ct value of 36 for MAS1 
compared to Ct value of 17 for GAPDH). However, the ACE2 enzyme expressed 
by SULF2 knockdown HuH-7 cells and its product Ang-(1-7) could still affect 
endothelial cells in vivo, and hence angiogenesis and this may explain the 
complete inhibition of tumourigenicity of SULF2 knockdown HuH-7 cells in nude 
mice.  
Neither inducible nor transient SULF2 knockdown in the HuH-7 cell line caused 
any increase in ACE2 expression as assessed by RT-qPCR (data not shown), and 
this could explain, in addition to the weak inhibition of Wnt signalling resulting from 
inducible SULF2 suppression, the lack of inducible SULF2 knockdown effect on the 
tumourigenicity of HuH-7 cells in vivo.  
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Figure ‎7.10:  Effect of Ang II or Ang-(1-7) on the growth of HuH-7 cells: 2,000 
control untransduced HuH-7 cells or those transduced with NT shRNA or SULF2 
shRNA were cultured in 96-well plates in 10% (v/v) FBS-containing medium. The 
cells were treated with different concentrations of Ang II or Ang-(1-7) for 3 or 6 
days. Cells were stained with SRB stain and the optical density at 570 nm was 
measured. (A) Control untransduced cells. (B) NT shRNA-transduced cells. (C) 
SULF2 shRNA-transduced cells. (1) Ang II-treated cells. (2) Ang-(1-7)-treated cells. 
Values are the mean of triplicates and error bars represent the standard error. The 
experiment was performed in triplicate. Data generated using the method 
described in Section 2.17. 
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7.4. Summary 
Microarray gene expression analysis was performed in the HuH-7 cell line model to 
further understand the biology of SULF2 knockdown and also to identify 
biomarkers for SULF2 inhibition. Three hundred and twenty-two genes were found 
to be differentially expressed in the SULF2 knockdown cells as compared to both 
control untransduced and NT shRNA-transduced cells, with ≥ 2-fold change and 
adjusted p value ≤ 0.01. The changes in levels of mRNA from 18 genes most 
differentially expressed with a potential link to cancer were confirmed by RT-qPCR. 
Seven genes with a potential role in liver carcinogenesis were studied by WB. The 
gene most highly affected by SULF2 knockdown, ACE2, was further studied and 
ACE2 expression was found to be inversely related to SULF2 at the mRNA and 
protein levels. ACE2 expressed in SULF2 knockdown HuH-7 cells was 
enzymatically active and produced a higher level of its product, the anti-
proliferative peptide Ang-(1-7), in medium from SULF2 knockdown cell cultures. 
Upregulation of ACE2 gene, albeit to a much lower level, was also shown after 
SULF2 suppression in SNU-182 and BxPC3 cell lines, suggesting a general role 
for SULF2 in controlling ACE2 expression.       
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8. Chapter 8. Discussion 
 
One of the main goals of this project was to study the biology of SULF1/2 proteins 
in hepatocellular carcinoma (HCC) with particular focus on SULF2, which has 
previously been reported to be involved in hepatocarcinogenesis (Lai et al., 2008 
a) (Lai et al., 2008 b) (Lai et al., 2010 a) (Lai et al., 2010 b). In order to do so, 
methods to investigate signalling pathways that are regulated by SULF1/2 were 
established, and as model systems a panel of HCC cell lines with differential 
patterns of SULF1/2 expression was established and characterised.  
Characterisation of mRNA and protein expression in HCC cell lines  
Six HCC cell lines were used in this study in which the expression of endogenous 
SULF1/2 was investigated at the mRNA and protein level. RT-PCR and RT-qPCR 
were performed using validated primers (Figure  3.2). The results showed that 
SULF2 was highly expressed in 3 cell lines (i.e., SNU-182, HuH-7 and HepG2), 
moderately expressed in the SNU-475 cell line, while it was weakly expressed in 
PLC/PRF/5 cell line and under the level of detection in the Hep 3B cell line (Figure 
 3.1) (Figure  3.3; A). With respect to SULF1, RT-qPCR showed that SULF1 was 
highly expressed in the SNU-182 cell line whereas modest expression was 
detected in the SNU-475 cell line, and no expression was detected in any of the 
other four cell lines (Figure  3.3; B).  
This pattern of mRNA expression for SULF1/2 across cell lines was consistent with 
that reported in the literature (Lai et al., 2008 a) (Lai et al., 2008 c). It is noteworthy 
that the only cell lines that expressed SULF1 (i.e., SNU-182 and SNU-475) were 
derived from poorly differentiated HCC tumours and that they also expressed 
SULF2. None of the cell lines derived from well-differentiated tumours expressed 
SULF1. In the SNU-182 cell line, SULF1 expression was higher than that of SULF2 
by 4-fold, while in the SNU-475 cell line SULF2 expression was higher than SULF1 
expression by 16-fold. 
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Nawroth et al., reported that SULF1 protein was not detected in certain pancreatic 
cancer cell lines even though SULF1 mRNA was expressed (Nawroth et al., 2007). 
Therefore, to investigate whether or not the mRNA for SULF1/2 was translated into 
proteins in HCC cell lines, western blot (WB) analysis was carried out using SULF1 
and SULF2 antibodies. A panel of commercially available antibodies for both 
enzymes raised to different immunogens was used, and these antibodies are listed 
in Table 2.2. However, most of these antibodies were unsatisfactory, with multiple 
non-specific bands despite many attempts to optimise the concentration of the 
antibodies or the conditions of WB. Only one SULF1 antibody (Ab), namely SULF1 
Ab (Abcam) that was raised against a peptide in the C-terminal domain, gave a 
band by WB corresponding to the full-length 125 kDa SULF1 protein. This band 
was detected only in SNU-182 cell lysates and not in the other 5 HCC cell lines 
(Figure  3.5). A similar band was detected in the lysate of HS766T pancreatic 
cancer cells that was used as a positive control in this experiment as this cell line 
expresses SULF1 at a high level (Nawroth et al., 2007) (Figure  3.5). However, the 
50 kDa subunit that encompasses the C-terminal domain could still not be 
detected, even though SDS-PAGE was performed under reducing conditions (see 
Section 2.10). 
As none of the commercially available SULF2 antibodies were satisfactory, a 
SULF2 antibody kindly provided by Prof. Lewis Roberts (Lai et al., 2008 a) was 
used in WB. This antibody, SULF2 Ab (LR), was generated in rabbits and raised 
against amino acids 421-444 within the hydrophilic domain (HD) of SULF2. The 
full-length 125 kDa SULF2 protein was detected in all HCC cell lysates except for 
Hep 3B (Figure  3.4; right). As WB was performed under reducing conditions, this 
antibody should also have detected the 75 kDa subunit that encompasses the N-
terminal domain; however, it was not possible to distinguish the 75 kDa band from 
a large non-specific protein smear in this region (Figure  3.4; right). 
According to the expression levels of SULF1/2 mRNAs and proteins that were 
revealed by RT-qPCR and WB, the panel of HCC cell lines that were tested could 
be divided into three groups: SULF1(+)/SULF2(+) - SNU-182 and SNU-475, 
SULF1(-)/SULF2(+) - HuH-7 and HepG2, and SULF1(-)/SULF2(-) - Hep 3B and 
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PLC/PRF/5. This pattern of expression was exploited to study the biology of 
SULF1/2, and in developing cell-based screening assays for small-molecule 
inhibitors of SULF2. 
To generate a new SULF2 antibody, a somewhat similar peptide to that used to 
raise the SULF2 Ab (LR) was synthesized. The peptide included amino acids 421-
435 of the HD domain of human SULF2 and, as the sequence did not have a 
cysteine residue, a terminal cysteine was added to the C-terminus to form the 
immunogen. The cysteine residue was added to conjugate the small peptide to 
carrier proteins to enhance the immune response and to immobilize the peptide on 
an affinity matrix for purification of the antibody. The production of this antibody, 
designated as SULF2 Ab (NCL), was performed by Eurogentec. Two rabbits were 
immunized and sera collected (1271 and 1272). These sera underwent affinity 
purification and were then tested by ELISA against the immunogen to which they 
were raised. However, neither purified antibody was suitable for WB. 
During the course of these studies, a SULF2 Ab (Serotec) that was generated 
against the C-terminal domain by Lemjabbar-Alaoui et al. in 2010 became 
commercially available. Using this antibody in WB showed the expression of the 
full-length SULF2 protein in the cell lines that expressed high levels of SULF2 
mRNA (i.e. SNU-182, HuH-7 and HepG2) with reduced non-specific binding 
compared with SULF2 Ab (LR) (Figure  3.4; left). However, the 50 kDa subunit 
could still not be detected in the cells that express endogenous SULF2. 
To determine the subcellular localization of SULF1/2 proteins, 
immunocytochemistry (ICC) of permeabilized cells was performed using the 
antibodies that performed well for WB, namely, SULF1 Ab (Abcam) for SULF1 and 
SULF2 Ab (LR) and SULF2 Ab (Serotec) for SULF2. Immunofluorescence staining 
for SULF1 in the high SULF1-expressing HS766T cell line gave weak staining and 
there was no staining in the SNU-182 cell line, suggesting low affinity and 
unsuitability of this antibody for ICC. SULF2 Ab (LR) gave membranous but also 
non-specific cytoplasmic staining in HCC cells as indicated by the similar staining 
of SULF2-positive cell lines, HuH-7 and HepG2, and the SULF2-negative cell line, 
Hep 3B (Figure  3.6). However, SULF2 Ab (Serotec) produced dot-like 
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membranous staining of HuH-7 and HepG2 cells (Figure  3.7; 1B, 2B), rather than 
widespread staining of whole cells. This pattern of expression is in line with 
published data and the enrichment of SULF2 in lipid raft domains on the cell 
surface (Tang and Rosen, 2009). Hep 3B cells were completely negative on ICC 
with the SULF2 Ab (Serotec) (Figure  3.7; 3B). 
Characterisation of the sulfatase enzymatic activities of HCC cell lines 
After characterisation of SULF1/2 mRNA and protein expression in HCC cell lines, 
the next step was to evaluate catalytic activity, and in so doing explore potential 
test systems for screening small-molecule inhibitors of SULF2. SULF1/2 enzymes 
are known to have both arylsulfatase (ARS) and glucosamine 6-O endosulfatase 
activities (Morimoto-Tomita et al., 2002) (Uchimura et al., 2006 b). First, a 
fluorometric ARS assay using the fluorogenic substrate 4-methylumbelliferyl sulfate 
(4-MUS) was investigated. Upon desulfation of 4-MUS it is converted into the 
fluorescent product 4-methylumbelliferone (4-MU), whose fluorescence at 460 nm 
can be measured after excitation at 355 nm. Therefore, an ARS assay using 4-
MUS as a substrate might represent a rapid method for screening inhibitors. 
However, a major drawback for this assay is related to the fluorescence of the 
product 4-MU which requires alkalization of the reaction mixture for complete 
ionization of 4-MU and optimal fluorescence. Hence, this alkalization leads to a 
discontinuous assay because the pH optimum for SULF1/2 activity is between pH 
7 - 8, a drawback that prevents kinetic studies (Bilban et al., 2000) (Ahmed et al., 
2005).  
Therefore, the effect of pH on the fluorescence intensity (FI) and stability of 4-MU 
was investigated to determine whether it was possible to measure 4-MU 
fluorescence at a pH range of 7 - 8 with acceptable sensitivity. As expected, there 
was maximal 4-MU fluorescence at pH 10, that decreased gradually at lower pH 
values. However, the fluorometer was still able to detect 4-MU fluorescence at 
concentrations ≥ 0.1 µM in the pH range of 7 - 11 (Figure  3.8). Also, the 
fluorescence of 4-MU was found to be stable over at least 2 hours in aqueous 
solutions (Figure  3.9). Collectively, these observations indicated that it would be 
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possible to perform a continuous cell-based ARS activity assay at pH 7.4, the pH of 
culture medium, and a continuous cell-free ARS assay at pH value of 8. 
After optimising the conditions for ARS activity measurement, the activity of 
SULF1/2 in HCC cells was investigated. It is important to note that the cell-based 
ARS assay does not differentiate between the ARS activity resulting from either 
SULF1/2 enzymes. Also, other members of the sulfatase family could contribute to 
the measured activity if these members are present at the cell surface or secreted 
into the medium, or if the substrate 4-MUS is internalized into the cells. Lysosomal 
sulfatases have been reported to be secreted and then re-internalized through the 
mannose-6-phosphate receptor (Buono and Cosma, 2010), while uptake of 4-MUS 
was reported to take place in isolated hepatocytes where it was hydrolysed by 
arylsulfatases (Kauffman et al., 1991). Therefore, to distinguish SULF1/2 activity, it 
would be necessary to inhibit other sulfatases before measuring the activity of 
SULF1/2. However, well-validated inhibitors are only available for steroid sulfatase 
(STS), also called ARSC, which is reported to be present in nearly all membrane 
compartments including the plasma membrane (Willemsen et al., 1988) (Stein et 
al., 1989). Deficiency of seven sulfatases (ARSA, ARSB, GALNS, GNS, SGSH, 
IDS, and ARSE) cause inherited disorders, for example lysosomal storage 
diseases, and inhibitors are not available (Hanson et al., 2004). STS/ARSC is 
implicated in steroid hormone biochemistry and, in addition to deficiency causing 
an inherited disorder; upregulation of STS/ARSC is involved in hormone-
dependent breast cancer (Miyoshi et al., 2003) (Suzuki et al., 2003 b). Therefore, 
inhibitors of STS/ARSC have been developed. One of these STS/ARSC inhibitors 
is the irreversible inhibitor oestrone 3-O-sulfamate (EMATE) (Howarth et al., 1994) 
(Poirier et al, 1999), and HCC cells were incubated with EMATE for 1 hour before 
adding 4-MUS in all experiments to remove sulfatase activity due to STS/ARSC.  
When equal numbers of cells were incubated with 4-MUS, ARS activity remaining 
after STS/ARSC inhibition was shown to be high in HuH-7 cells, HepG2 had some 
activity and no activity was detected in SNU-475, Hep 3B or PLC/PRF/5 cells 
(Figure  3.10). Surprisingly, SNU-182 cells did not show any ARS activity, even 
though both SULF1/2 proteins were highly expressed in this cell line. As only 
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SULF2, but not SULF1, was expressed in HuH-7 and HepG2 cells, the ARS 
activity that was measured in these two cell lines could be in part due to SULF2, 
and activity was also found to be proportional to the number of cells (Figure  3.12). 
No ARS activity was detected in any of the other 4 HCC cell lines even at very high 
cell densities. This result suggests that in some cell lines either SULF1/2 proteins 
are not presented on the cell membrane, or that SULF1/2 proteins are partially or 
completely inactive, i.e. ARS activity or both ARS and endosulfatase activities are 
absent, respectively. Lack of activity could be due to the complexity of SULF1/2 
enzyme biosynthesis and the requirement for several processing steps for 
sulfatase activity. The absence of functional SULF1/2 on the cell membrane in 
SNU-182 cells could be investigated by measuring the ARS activity of SNU-182 
cell lysates and membrane preparations. The results also showed that most of the 
ARS activity in HuH-7 and HepG2 cells was inhibitable by EMATE, and hence is 
attributed to STS/ARSC, while the remaining ARS activity that could result from 
SULF2 comprised about one third of the total activity only (Figure  3.11). This high 
level of STS/ARSC activity in selected HCC cell lines is consistent with other 
studies that have reported the expression of STS/ARSC in HepG2 cells (Hammer 
et al., 2005).  
It is known that SULF1/2 proteins are extracellular enzymes that can be retained 
on the cell surface or secreted into the medium (Dhoot et al., 2001) (Morimoto-
Tomita et al., 2002) (Ohto et al., 2002). However, no ARS activity was detected in 
the concentrated conditioned medium (CM) from cultures of HCC cell lines that 
exhibited cellular ARS activity (i.e., HuH-7 and HepG2), even though SULF2 
protein could be detected by WB in the CM (data not shown). This result could be 
due to that the levels of SULF2 protein in the CM being insufficient to give 
detectable ARS activity with 4-MUS as a substrate, consistent with the low affinity 
of 4-MUS for SULF2 (Km = 2.6) (Figure  3.16).  
As discussed in Section 1.4.2, SULF1/2 enzymes are synthesized in the 
endoplasmic reticulum (ER) where the signal peptide is removed (Tang and 
Rosen, 2009) and the Cα-formylglycine (FGly) is formed to generate a catalytically 
active protein (Dierks et al., 1997) (Dierks et al., 2003) (Cosma et al., 2003). 
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SULF1/2 enzymes are subsequently transported to the trans Golgi where they 
undergo cleavage by a furin-type proteinase to form a heterodimer that is linked by 
disulfide bonds (Thomas, 2002) (Tang and Rosen, 2009). At the same time, N-
glycosylastion takes place in the ER and/or Golgi which is necessary for secretion 
of the protein, and possibly for endosulfatase activity (Morimoto-Tomita et al., 
2002) (Ambasta et al., 2007). Ai et al. reported that SULF1/2 enzymes that were 
targeted to the ER or to the Golgi apparatus showed endosulfatase activity, and 
were as active as cell surface SULF1/2 against a heparan sulfate (HS) substrate 
(Ai et al., 2003). This latter observation is not surprising as the FGly residue 
required for the catalytic activity is generated early in the ER as a co-translational 
or early post-translational event. Therefore, to investigate the activity of total 
SULF1/2 proteins in HCC cell lines, and to explore whether some cell lines such as 
SNU-182 can express catalytically active SULF1/2 enzymes that are not localized 
to the cell surface, HCC total cell lysates were screened for ARS activity. The 
pattern of cell lysate activity using 4-MUS was not different from that of intact cell-
based ARS activity. Thus, only HuH-7 and HepG2 cell lysates exhibited ARS 
activity while no activity was detected in any of the other 4 HCC cell lysates 
including SNU-182 (Figure  3.13). These data suggest that both SULF1/2 proteins 
in SNU-182 cell line do not have any arylsulfatase activity, although they may still 
possess endosulfatase activity. 
Investigating ARS activity of cells or cell lysates using 4-MUS as a substrate does 
not exclude the possibility of members of the sulfatase family other than SULF1/2 
contributing to the measured ARS activity. Therefore, it was important to attempt to 
purify SULF1/2 enzymes from HCC cell lysates before measuring their ARS 
activity. Purification was carried out by immunoprecipitation using SULF1/2 
antibodies, namely, SULF1 Ab (Abcam) for SULF1 and SULF2 Ab (Abcam), 
SULF2 Ab (LR) or SULF2 Ab (Serotec) for SULF2, to give SULF1- and SULF2-Ab 
immunoprecipitates (IPs). These antibodies were used as they were raised against 
the C-terminal or HD domains that are unique to SULF1/2 enzymes and distinguish 
them from other sulfatases (Lai et al., 2008 c). Also, using antibodies that are 
raised against the N-terminal domain could block the enzymatic activity of 
SULF1/2.   
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ARS activity detected using SULF2-Ab (Abcam) IPs of HCC cell lysates were 
consistent with the ARS activity data generated using cells or cell lysates. The ARS 
activity of SULF2-Ab (Abcam) IPs showed that HuH-7 cells had the highest activity 
followed by HepG2 cells, with no activity detected in any of the other 4 HCC cell 
lines (Figure  3.14; A). These results suggest that the EMATE-uninhibited ARS 
activity measured in HuH-7 and HepG2 cells or cell lysates can possibly be 
attributed in part to SULF2. To confirm these results, SULF2 purification by 
immunoprecipitation using a different antibody, namely SULF2 Ab (LR) that was 
raised against the HD domain of SULF2, was performed. The results obtained 
were in line with the previous data and SULF2 Ab (LR) IPs of HuH-7 and HepG2 
cell lysates showed ARS activity that was higher in HuH-7 (Figure  3.14; B). Also, 
the ARS activity of the purified SULF2 enzyme was concentration-dependent in 
SULF2 Ab (Abcam) IPs of HuH-7 cell lysates (Figure  3.15). Using the SULF2 Ab 
(Serotec) that was raised against the C-terminal domain, ARS activity similar to 
that found with SULF2-Ab (Abcam) IPs was observed (data not shown).  
For SULF1 Ab (Abcam) IPs, IPs of SNU-182 cell lysates showed no ARS activity, 
consistent with the cellular and cell lysate data, and only a low level of activity was 
detected for IPs of HS766T cell lysates (Figure  3.14; C), even though the HS766T 
cell line expresses a very high level of SULF1 protein. These data are consistent 
with other studies showing that 4-MUS is a poorer substrate for SULF1 than 
SULF2 (Morimoto-Tomita et al., 2002). 
Since it is possible to perform ARS activity assays using 4-MUS in a 96-well plate, 
this assay is a suitable fluorescence-based format for high-throughput screening of 
small-molecule inhibitors of SULF2. Therefore, the kinetics of the reaction between 
SULF2 and 4-MUS were investigated using this format with SULF2 Ab (Abcam) 
IPs of HuH-7 cell lysates as the enzyme source. The Michaelis constant (Km) of 4-
MUS for SULF2 was calculated and found to be 2.6 mM (Figure  3.16). This value 
is not dissimilar to the Km value of 10 mM reported in other studies (Uchimura et 
al., 2006 b) (Rosen and Lemjabbar-Alaoui, 2010), and the high Km reflects the low 
affinity of SULF2 for 4-MUS. 
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The effect of the STS/ARSC inhibitor, EMATE, on SULF2 enzyme was investigated 
to determine whether it could also inhibit SULF2. The results showed that there 
was no effect of up to 100 µM EMATE on enzyme activity when SULF2 Ab IPs 
were used (Figure  3.17), and EMATE did not affect the kinetics of the reaction of 
purified SULF2 with 4-MUS (Figure  3.18). These results not only confirm that 
SULF2 is not inhibited by EMATE but also provide evidence that the ARS activity 
remaining in HCC cells or cell lysates after pre-incubation with EMATE is in part or 
totally due to SULF2, although the possibility that other sulfatases contribute to the 
measured ARS activity cannot be excluded. Thus, pre-incubation of HuH-7 cell 
lysate with up to 400 µM EMATE failed to inhibit at least one third of the total ARS 
activity measured without EMATE treatment (Figure  3.19). It is noteworthy that an 
EMATE concentration of 400 µM is high relative to the inhibition constant (Ki) for 
EMATE against purified human STS/ARSC (0.67 µM), and the IC50 of EMATE 
against STS/ARSC-expressing CHO cells (0.03 µM) using 4-MUS as a substrate 
(Nussbaumer et al., 2003) (Horvath and Billich, 2005). 
In addition to arylsulfatase activity, the purified SULF1/2 proteins were shown to 
have endosulfatase activity using immobilized heparin as a substrate. This analysis 
was performed using the cMyc-tagged RB4CD12 phage display antibody whose 
preferred binding sequence is the trisulfated disaccharide composed of iduronic 
acid and glucosamine (Dennissen et al., 2002) (Jenniskens et al., 2002) (Uchimura 
et al., 2010). Removal of the 6-O sulfate by the endosulfatase activity of SULF1/2 
prevents the binding of RB4CD12, which is detected using an HRP-conjugated 
cMyc secondary antibody. The results showed that both SULF1-Ab IPs of SNU-
182 cell lysate and SULF2-Ab IPs of HuH-7 cell lysate using either SULF2 Ab 
(Serotec) or SULF2 Ab (Abcam) exhibited a concentration-dependent 
endosulfatase activity, while no activity was detected using STS/ARSC-Ab IPs of 
HuH-7 cell lysate (Figure  3.20). Interestingly, these results indicated that even 
though purified SULF1 from SNU-182 cell lysate had no ARS activity using 4-MUS 
as a substrate, it did have endosulfatase activity. SULF2 from HuH-7 cell lysate, on 
the other hand, had both activities. A summary of HCC cell lines used in this thesis 
with their characteristics and sulfatase activities is given in Table  8.1. 
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Table ‎8.1: Summary of HCC cell lines used in this thesis with their characteristics. 
Cell line SULF2 
mRNA 
levels 
SULF1 
mRNA 
levels 
SULF2 
protein 
levels 
SULF1 
protein 
levels 
Arylsulfatase 
activity 
Endosulfatase 
activity 
SNU-182 +++ +++ ++ ++ - ++ (SULF1) 
SNU-475 + + - - - n.t. 
HuH-7 ++ - ++ - ++ ++ (SULF2) 
HepG2 ++ - ++ - + n.t. 
Hep 3B - - - - - n.t. 
PLC/PRF/5 +/- - - - - n.t. 
SULF2 protein levels tested using the SULF2 Ab (Serotec). n.t. = not tested.  
Level or activity: +++, very high, ++, high; +, detectable; +/-, weak; -, absent. 
 
Endosulfatase activity assays could be used to screen potential inhibitors of 
SULF2, with counter-screening of inhibitors using SULF1, in an ELISA format. 
However, there are two drawbacks to using this assay for screening. First, the 
RB4CD12 antibody detects an epitope, trisulfated disaccharide IdoA2S-GlcNS6S, 
which is not solely metabolised by SULF2 (Jenniskens et al., 2000), and SULF2 
specificity could not be assumed as removal of the 6-O-sulfate by SULF2 or any of 
the other two sulfates by other sulfatases could affect the binding of the antibody to 
heparin, rendering the assay not specific for SULF2 activity unless purified enzyme 
is used. Second, current contractual limitations on the use of the RB4CD12 
antibody would have to be resolved.  
There are two other methods to measure the endosulfatase activity of SULF2 that 
do not require the RB4CD12 antibody, involving the use of either 35S-radiolabelled 
or unlabelled synthetic heparan sulfates. The first approach measures the level of 
35S [SO4] in the case of radiolabelled HS (Ai et al., 2003), and the second 
measures disaccharide fragments following enzymatic degradation in the case of 
unlabelled HS. The sulfation of the disaccharide fragments is measured using high 
performance liquid chromatography (HPLC) and compared with authentic 
disaccharide markers (Morimoto-Tomita et al., 2002). However, both methods 
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would require development and optimisation, and modification for use in the high 
throughput screening of inhibitors. 
Generation of recombinant SULF2 enzyme 
Although endogenous HuH-7 cell SULF2 activity could be measured, the level was 
low, and enrichment by SULF2-Ab IP was considered insufficiently robust for 
inhibitor screening. The specificity of the IP could not be assumed and because 
cell lysate and not CM was used for immunoprecipitation, the precipitate could be 
contaminated with other sulfatases with arylsulfatase activity not inhibited by 
EMATE. Ideally, recombinant SULF1/2 proteins should be generated that can be 
purified and used in an enzymatic assay for the screening of inhibitors. 
In an attempt to generate recombinant SULF1/2 proteins, cells were transfected 
with two different constructs, one for each SULF. The open reading frame of either 
SULF1 or SULF2 was inserted under a CMV promoter in the pCMV6-Entry vector 
(Figure  2.1) to allow constitutive expression of SULF1/2 proteins which were fused 
with a C-terminal MYC/DDK tag for antibody detection and purification. A range of 
different cell lines were transfected including HCT (which is a human colon 
carcinoma cell line that grows quickly and is easy to transfect), Hep 3B and 
PLC/PRF/5 cell lines which are SULF1- and SULF2-negative and hence would 
allow SULF1/2 expression in a SULF-negative background. SULF2-transfected 
cells could also be used for the cell-based screening of inhibitors. As SULF1/2 
enzymes are complex proteins, and their production requires a number of 
processing steps as discussed earlier, the SULF1/2 constructs were also 
transfected into the SULF2-positive HuH-7 and HepG2 cell lines, i.e. cells that had 
been shown to produce active SULF2 protein. 
Transfection was performed using lipofection with two different transfection 
reagents (i.e., lipofectamine or FuGENE). Transfection conditions were optimised 
using the pCI-neo/EGFP plasmid that constitutively expresses EGFP, and 
FuGENE was shown to be superior to lipofectamine giving better transfection 
efficiency; however, transfection was in general poor. HuH-7 cells gave the highest 
transfection but only 5% of cells were successfully transfected (Figure  4.1). 
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However, the low transfection efficiency was circumvented to some extent by the 
use of SULF1/2 constructs containing a selectable marker that confers resistance 
to neomycin or its analogue G418. 
After transfection with SULF1/2 constructs, cells were selected using G418 and 
multiple colonies were picked and expanded for each construct and each cell line. 
First, the clones were screened for SULF1/2 mRNA using RT-PCR or RT-qPCR. 
RT-PCR was used for cells that have a SULF-negative background while RT-
qPCR was used for cells that express endogenous SULF1/2. For example, the RT-
qPCR data showed the upregulation of SULF2 mRNA levels in two of SULF2-
transfected HepG2 clones (4- and 80-fold increase) compared with untransfected 
control cells (Figure  4.2).  
Additionally, the clones were screened for DDK-tagged recombinant SULF1/2 
proteins by performing WB using an anti-DDK antibody. Either the secreted 
SULF1/2 proteins that were purified from the CM (Figure  4.3) or the total cell 
lysates of clones (Figure  4.4) were screened. In both cases, recombinant SULF1/2 
proteins could be detected. 
The SULF2-transfected HepG2 clone 15 showed 80-fold upregulation of SULF2 
mRNA level over control untransfected HepG2 cells by RT-qPCR (Figure  4.2). The 
clone 15 cell lysate also showed high levels of recombinant SULF2 protein as 
demonstrated by WB using both anti-DDK and SULF2 (LR) antibodies (Figure  4.4), 
while WB of control untransfected HepG2 cell lysate showed no band and a much 
weaker band for SULF2 using anti-DDK Ab and SULF2 (LR) Ab, respectively 
(Figure  4.4). ICC showed membranous and cytoplasmic staining of SULF2 in 
HepG2 clone 15. However, only about 50% of the cells were SULF2 positive 
(Figure  4.5).   
To investigate whether the recombinant SULF1/2 proteins were active. Clones 
were screened for their ARS activity using 4-MUS. Either cells or cell lysates were 
used; however, no more than a two-fold increase in ARS activity in transfected 
clones was detected, compared with that of corresponding untransfected cells. 
Furthermore, an increase in SULF2 activity was only seen in HuH-7 and HepG2 
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clones, i.e. in cells that express endogenous SULF2. Even the HepG2 SULF2-
expressing clone 15 cell lysate did not show more than a 2-fold increase in ARS 
activity compared to untransfected HepG2 cell lysate (Figure  4.6).  
Collectively, these results indicated that the recombinant SULF1/2 proteins 
generated were mostly inactive. Lack of activity was confirmed by measuring the 
ARS activity of purified SULF2 enzymes generated using SULF2-Ab IPs from 
equal quantities of clone 15 or untransfected HepG2 cell lysates (Figure  4.7). The 
slight increase in ARS activity of some cell lysates of HuH-7 and HepG2 clones 
compared with that of control untransfected cell lysates could be due to an 
increase in the level of endogenous SULF2 due to the different culture conditions, 
as the clones were maintained under a selection pressure of 400 µg/ml G418. 
However, another possibility for the slight increase in ARS activity is the presence 
of low levels of active recombinant SULF1/2 proteins in HuH-7 and HepG2 cells. 
Nevertheless, the amount of active recombinant protein was not enough for 
purification and subsequent applications such as screening of inhibitors. 
Given that even the best SULF2-expressing clone, as assessed by RT-qPCR and 
WB, had only 50% SULF2-positive cells by ICC (Figure  4.5), another gene delivery 
method was used to improve the efficiency of gene delivery, namely, SULF2-
containing lentiviral particles. The lentiviral construct used allows the expression of 
SULF2 and the blasticidin resistance gene under the same CMV promoter. This 
construct design ensures that all blasticidin-resistant cells are expressing SULF2. 
Infecting the SULF-negative Hep 3B cell line with SULF2 lentiviral particles led to 
high-level expression of SULF2 protein with full-length protein and the 50 kDa 
subunit detected by WB using the SULF2 Ab (Serotec) which was raised against 
the C-terminal domain. No SULF2 protein was detected in the control 
untransduced cells (Figure  4.8). ICC staining showed that the majority of the 
infected cells were SULF2-positive with no staining of the untransduced cells 
(Figure  4.9). Surprisingly, however, the cell lysates of the SULF2-transduced cells 
showed no ARS activity using 4-MUS as a substrate. Thus, colonies were picked 
to obtain clones that were highly enriched for catalytically active SULF2-expressing 
cells, and might therefore have enzymatic activity against 4-MUS. However, even 
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though the expression of SULF2 protein was confirmed by WB and ICC (Figure 
 4.10) (Figure  4.11), none of the clones showed any measurable ARS activity 
(Figure  4.12). 
The production of inactive recombinant SULF1/2 proteins could be due to defective 
post-translational processing, including insufficient cellular levels of the Cα-
formylglycine generating enzyme (FGE) required to convert the cysteine residue 
into FGly at the active site of nascent SULF1/2 proteins. It has been reported that 
in arylsulfatase A (ARSA)-overexpressing cells a proportion of the ARSA 
generated enzyme still has the cysteine instead of FGly (Schmidt et al., 1995). 
Also, Anson et al. demonstrated that overexpression of arylsulfatase B (ARSB) led 
to a significant decline in the measured activities of other endogenous sulfatases 
(Anson et al., 1993), and these two studies suggest that the conversion of cysteine 
to FGly is carried out by a saturable mechanism, and that the level of FGE in the 
cells can be a limiting factor for sulfatase activity. A way to circumvent FGE 
insufficiency is by double transfection of cells with an FGE-expressing construct. A 
similar strategy has been described in other studies where the ARSA activity of 
ASRA-transfected COS-7 fibroblast-like cells or HepG2 cells was increased 
substantially by co-transfection of an FGE-expressing construct with the ARSA 
construct, compared with transfecting cells with the ARSA construct alone (Cosma 
et al., 2003) (Takakusaki et al., 2005). 
The expression of endogenous SUMF1(sulfatase modifying factor 1), the gene 
encoding FGE, was measured and the results showed comparable expression of 
SUMF1 in all the HCC cell lines at a level that was about 25 - 28 fold higher than 
the expression of GAPDH (Figure  4.13). Therefore, to increase the expression of 
SUMF1 in the cells, a SUMF1 construct was co-transfected with the SULF2 
construct either transiently or stably. The stably, but not the transiently, co-
transfected cells rapidly lost the expression of SUMF1 as shown by RT-PCR 
(Figure  4.14; A), while the transiently co-transfected cells expressed both SULF2 
and SUMF1 protein as evidenced by WB (Figure  4.14; B). However, no ARS 
activity was detected in these transiently co-transfected cells. Also, the HepG2 
SULF2-expressing clone 15 showed no increase in ARS activity when it was 
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transiently transfected with the SUMF1 construct. A possible explanation for these 
results is that a high level of recombinant active SULF2 protein may affect or even 
kill cells in which it is present for a long time. Alternatively, the low transfection 
efficiency might have prevented any increase in ARS activity following transient 
transfection of SUMF1 into the SULF2-expressing clone 15. It may be possible to 
circumvent these two potential drawbacks by the transduction of inducible SUMF1 
lentiviral constructs into cells or the expression of SUMF1 and SULF2 in alternative 
biological systems such as bacteria or insect cells.  
Active SULF2 enzyme has been successfully generated using a plasmid supplied 
by the group that first cloned human SULF2 (Morimoto-Tomita et al., 2002). 
Transient expression of the wild-type SULF2 or a mutated form in which the 
cysteine in the active site is replaced by alanine, rendering the enzyme inactive, 
was performed in HEK 293T cells. Both forms were secreted into the conditioned 
medium (CM) at comparable levels as shown by WB (Figure  4.15; A). However, 
only the wild-type SULF2 had ARS activity against 4-MUS (Figure  4.15; B). This 
active SULF2 could be purified and enriched from CM by approximately 160-fold 
(Figure  4.15; C), but could not be eluted from agarose beads by standard 
conditions as these were found to inhibit SULF2 activity. Therefore, SULF2-bound 
beads will be used for screening of SULF2 inhibitors, and an analogous approach 
is being explored for the production of SULF1.  
Characterisation of commercially available sulfatases for counter-screening 
SULF2 inhibitors 
In the development of SULF2 inhibitors, it will be important to identify selective 
SULF2 inhibitors rather than general sulfatase inhibitors, given the important 
physiological roles of sulfatases as evidenced by the diseases resulting from their 
deficiency (Hanson et al., 2004). Where available, commercially produced 
sulfatases will be used for counter-screening of SULF2 inhibitors, and 9 members 
of the sulfatase family are available. These enzymes were purchased and activity 
using 4-MUS as a substrate was characterised in terms of pH optimum, 
concentration and time dependency. The Km values of the reaction were 
measured when possible. Three sulfatases could readily convert 4-MUS to 4-MU 
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(i.e., ARSA, ARSB, STS/ARSC) with pH optima in the acidic range for ARSA and 
ARSB (Figure  4.16) (Figure  4.19) consistent with their lysosomal localization, and 
in the neutral range for STS/ARSC (Figure  4.22) consistent with its localization in 
the microsomes (Hanson et al., 2004). The three enzymes showed concentration-
dependent activities (Figure  4.17) (Figure  4.20) (Figure  4.23) and time-dependent 
activities with 4-MUS Km values of 2.2 mM, 415 µM and 82 µM for ARSA, ARSB 
and STS/ARSC, respectively (Figure  4.18) (Figure  4.21) (Figure  4.24) (Table  4.1). 
Other neutral pH-dependent sulfatases (i.e., ARSD, ARSF and ARSG) were also 
tested, but 4-MUS was not an efficient substrate (Figure  4.25) (Table  4.1). Only 
IDS of three acidic pH-dependent sulfatases tested showed any activity with 4-
MUS as a substrate, while GNS and GALNS had no activity at all (Figure  4.26) 
(Table  4.1). Therefore, other assays were investigated for the latter two enzymes. 
GNS is an exosulfatase that removes the 6-O-sulfate group from N-sulfated or N-
acetylated glucosamine residues at the non-reducing end of HS chains or the N-
acetylated glucosamine residues of keratan sulfate (Parenti et al., 1997). 
Therefore, a glucosidase-coupled assay which had been used before with 
flavobacterial 6-sulfatase (Myette et al., 2009) was evaluated. This assay depends 
on the intrinsically poor ability of β-glucosidase to hydrolyse the glycosidic bond 
between 4-MU and N-acetylglucosamine (GlcNAc) when the latter is 6-O-sulfated 
(Figure  4.27) (Figure  4.28). However, the activity of β-glucosidase is increased 
when the substrate MU-GlcNAc,6S is pre-incubated with GNS (Figure  4.29), and 
this two-stage assay could be used for GNS counter-screening of SULF2 inhibitors. 
A similar strategy was evaluated for GALNS which is another exosulfatase that 
removes the 6-O-sulfate group from N-acetylated galactosamine residues of 
chondroitin sulfate or from galactosamine in keratan sulfate (Parenti et al., 1997). 
The galactosidase-coupled assay has been used before with human GALNS (van 
Diggelen et al., 1990) and depends on the ability of GALNS to remove the 6-O-
sulfate from galactosamine-6-sulfate (Gal,6S) allowing β-galactosidase to liberate 
4-MU from the substrate MU-Gal,6S (Figure  4.30). However, the data generated 
showed no activity with commercial GALNS using MU-Gal,6S as a substrate in the 
coupled reaction (Figure  4.31). 
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In summary, the sulfatases ARSA, ARSB and STS/ARSC have sufficient affinity for 
4-MUS to be used in the initial counter-screening of inhibitors of SULF2. ARSD, 
ARSF, ARSG and IDS have only weak affinity for 4-MUS, and large amounts of the 
enzymes would be required. These latter enzymes could only be used for limited 
counter-screening. Similarly, the glucosidase-coupled GNS assay could be used 
for testing selected inhibitors, as a high concentration of the enzyme is again 
required. 
Biology of SULF1/2 enzymes in cancer 
A complementary approach to SULF2 inhibition using small-molecule inhibitors in 
target validation is SULF2 knockdown using shRNA. In the studies described in 
this thesis, knockdown of SULF2 was performed to (1) understand the biology of 
SULF2, (2) serve as a positive control for the effects of SULF2 inhibition using 
small-molecule inhibitors and (3) validate the selectivity of SULF2 inhibitors by 
treating cells where the SULF2 gene had been silenced with the inhibitors and 
confirming the lack of any effect of the inhibitors under conditions of SULF2 
knockdown.  
Given that the response of cells to a particular stimulus is cell-type and hence 
context dependent, the effect of SULF2 knockdown in an HCC cell line depends on 
the dominant signalling pathways and the genetic changes that drive the 
proliferation and growth of the cell line. Also, it is important to note that signal 
transduction pathways are not linear but sophisticated networks of protein 
interactions with cross-talk between different signalling pathways. Therefore, the 
response to SULF2 suppression is expected to be variable and different between 
cell lines.  
Two of the most important and well-characterised signalling pathways in HCC are 
the Wnt signalling pathway (Pez et al., 2013) and the growth factor/receptor 
tyrosine kinase (RTK) signalling pathway. Some of the most important growth 
factors that are involved in HCC are FGFs, IGFs and VEGF (Yang et al., 2011) 
(Min et al., 2011) (Wu and Zhu, 2011) (Cornellà et al., 2011) (Zhang et al., 2012). It 
has been reported that the 6-O sulfation of heparin sulfate proteoglycans (HSPGs) 
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is important for regulating Wnt and RTK signalling pathways in HCC, and in other 
types of cancer. 
SULF2 has been shown to modify Wnt signalling both at the basal level and after 
stimulation with different Wnt ligands, such as Wnt-1, Wnt-3a and Wnt-4. 
Overexpression of SULF2 was shown to promote Wnt signalling in response to 
Wnt-1 or Wnt-4 in HEK 293T cells (Nawroth et al., 2007), and SULF2 suppression 
by knocking down the gene using shRNA or expressing a dominant-negative form 
of SULF2 was found to inhibit autocrine Wnt signalling in both pancreatic cancer 
and NSCLC (non-small-cell lung carcinoma) cell lines (Nawroth et al., 2007) 
(Lemjabbar-Alaoui et al., 2010). Directly relevant to the studies described in this 
thesis, in HCC SULF2 overexpression in Hep 3B cells increased Wnt-3a binding to 
the cell surface and upregulated basal and Wnt-3a-stimulated Wnt signalling (Lai et 
al., 2010 b). 
In growth factor/RTK signalling, SULF2 has been shown to modify FGF-2 signalling 
in myeloma and HCC. Overexpressing SULF2 inhibited FGF-2-stimulated p-ERK 
levels in one myeloma cell line (Dai et al., 2005), but had the opposite effect in the 
HCC cell line Hep 3B, increasing FGF-2 binding to cells and promoting basal and 
FGF-2-stimulated ERK and AKT phosphorylation (Lai et al., 2008 a). In 
glioblastoma, SULF2 suppression reduced the phosphorylation of the receptor 
tyrosine kinases, PDGFRα and IGF1Rβ (Phillips et al., 2012). 
In HEK 293T cells, overexpression of SULF1 was demonstrated to promote Wnt-1- 
or Wnt-4-stimulated Wnt signalling (Nawroth et al., 2007), whereas overexpression 
of SULF1 inhibited activation of growth factor/RTK signalling pathway in response 
to FGF-2, HB-EGF (heparin binding-epidermal growth factor) and HGF. For 
example, SULF1 overexpression inhibited FGF-2 and HB-EGF signalling in ovarian 
cancer, as evidenced by reduced HB-EGF-stimulated phosphorylation of EGFR 
(epidermal growth factor receptor), and FGF-2- and HB-EGF-stimulated p-ERK 
levels (Lai et al., 2003). In SCCHN (squamous cell carcinoma of the head and 
neck) and HCC, SULF1 overexpression also inhibited FGF-2 and HGF signalling, 
as shown by reduced FGF-2-stimulated p-ERK, HGF-stimulated p-ERK and p-AKT 
levels, and phosphorylation of the HGF receptor, c-Met (Lai et al., 2004 a) (Lai et 
al., 2004 b). Also, SULF1 overexpression inhibited FGF-2 signalling in pancreatic 
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cancer and myeloma cells (Li et al., 2005) (Dai et al., 2005), and HGF signalling in 
oesophageal cancer cells (Liu et al., 2013). Furthermore, SULF1 overexpression 
inhibited autocrine p-EGFR and p-ERK levels in breast cancer (Narita et al., 2007). 
Hence, in the above settings, SULF1 has functions normally associated with 
tumour suppressor, as opposed to oncogenic signalling. 
The above studies emphasise the tumour- and cell type-dependency of the role of 
SULF1/2 in cancer, and hence the Wnt and growth factor/RTK pathways were 
characterised in the HCC cell lines used in this thesis, and then the effect of 
SULF1/2 gene silencing on these pathways was investigated. 
Wnt signalling pathway in HCC 
The canonical Wnt signalling is strongly implicated in hepatocarcinogenesis. β-
catenin aberrant accumulation and activation is reported in a high percentage of 
HCCs ranging from 50-80% (Laurent-Puig and Zucman-Rossi, 2006) (Thompson 
and Monga, 2007) (Takagi et al., 2008). A small fraction of this activation is 
attributed to mutations in downstream mediators of Wnt signalling, such as the β-
catenin-encoding gene CTNNB1 which is seen in 19% (610 of 3234) of cases, and 
mutations in the AXIN1 and APC genes are also uncommon, with 14% (64 of 458) 
and 4% (5 of 116) of cases, respectively (de La Coste et al., 1998) (Kondo et al., 
1999) (Legoix et al., 1999) (Taniguchi et al., 2002) (Ishizaki et al., 2004) (Wellcome 
Trust Sanger Institute, COSMIC database, 2013). Additionally, no mutations in the 
AXIN2 gene were reported in HCC. These results suggest that other components 
of the Wnt signal transduction cascade are responsible for β-catenin activation. 
Dysregulation of the upstream elements of Wnt signalling are reported to be 
frequent in HCC, including upregulation of Wnt ligands (e.g., Wnt-3, Wnt-4 and 
Wnt-5a) and their frizzled (FZD) receptors such as FZD-3, FZD-6 and FZD-7, or 
downregulation of the Wnt antagonists secreted frizzled-related proteins (sFRP-1, 
sFRP-2, sFRP-5) (Merle et al., 2004) (Bengochea et al., 2008) (Takagi et al., 
2008). These events increase the levels of Wnt ligands available to bind to the 
cells in the case of Wnt ligand overexpression or sFRP downregulation, or increase 
the sensitivity of cells to Wnt ligands in the case of frizzled receptor 
overexpression. SULF2 has been shown to increase the levels of Wnt ligands and 
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affect Wnt signalling by either removing the 6-O-sulfate from storage-type HSPGs, 
and hence releasing Wnt ligands (Lai et al., 2010 b), and/or by decreasing the 
affinity of Wnt binding to the co-receptor-type HSPGs (Ai et al., 2003) making Wnt 
ligands more available to bind to frizzled receptors. Therefore, SULF2 inhibition 
could potentially benefit a high percentage of HCCs. 
In the panel of HCC cell lines studied in this thesis, HuH-7 cells were reported to 
have wild-type β-catenin and AXIN1, with β-catenin reportedly showing 
membranous staining with no cytosolic accumulation (Satoh et al., 2000) (Cagatay 
and Ozturk, 2002). However, HuH-7 cells were shown to have high levels of FZD-7 
mRNA compared to other HCC cell lines and normal hepatocytes (Merle et al., 
2004) (Yuzugullu et al., 2009). Also, expression of a dominant-negative mutant 
form of FZD-7 that lacks the intracellular domain in HuH-7 cells decreased β-
catenin activation and cell motility (Merle et al., 2004). Thus, the HuH-7 cells were 
used in the studies reported here to characterise Wnt signalling, given the 
importance of Wnt signalling for this cell line. For stimulation of Wnt signalling, the 
canonical Wnt-3a ligand was used which showed a concentration-dependent 
increase in β-catenin-dependent transcriptional activity as measured using the TCF 
(T-cell factor) luciferase reporter assay as a readout. 100 ng/ml of Wnt-3a for 6 
hours caused the highest increase in luciferase activity (Figure  5.3; A).  
As a positive control for activation of Wnt signalling, BIO (6-bromo-indirubin-3'-
oxime) was used (Figure  5.2; left). BIO inhibits the GSK-3β enzyme that is 
responsible for phosphorylation of β-catenin, leading to β-catenin ubiquitination 
and degradation by the proteasome (Meijer et al., 2003) (Polychronopoulos et al., 
2004). Therefore, treating cells with BIO stabilizes β-catenin leading to its 
accumulation in the cytoplasm, translocation into the nucleus and transcription of 
downstream genes. The results showed concentration-dependent luciferase 
activity that was highest after treatment with 1 µM of BIO. Higher concentrations 
were toxic to the cells (Figure  5.3; B). As a negative control for activation of Wnt 
signalling, compound 3289-8526 was used (Figure  5.2; right). This compound is a 
dishevelled (Dvl)-PDZ domain inhibitor II that blocks the interaction between the 
scaffolding protein Dvl and the frizzled receptor, leading to inhibition of Wnt 
245 
 
signalling (Grandy et al., 2009). Incubation of HuH-7 cells with this compound 
inhibited Wnt-3a-induced luciferase activity in a concentration-dependent manner 
(Figure ‎5.3; C). 
Growth factor/RTK signalling pathway in HCC 
Growth factors bind to their cognate cell surface receptor tyrosine kinases (RTKs) 
which then transduce the signal predominantly via the RAF/MEK/ERK or the 
PI3K/AKT/mTOR cascades, depending on the growth factor and the cell type. The 
RAF/MEK/ERK axis has been reported to be constitutively activated in HCC as 
evidenced by the increased phosphorylation of MEK1/2 and ERK1/2 (Feng et al., 
2001) (Huynh et al., 2003). Similarly, the PI3K/AKT/mTOR axis is also 
constitutively activated in HCC (Zhou et al., 2011 a) as shown by increased 
phosphorylation of AKT (Boyault et al., 2007) or mTOR and its substrate p70S6 
kinase (Sahin et al., 2004). Also, phosphorylation of either ERK or AKT was found 
to correlate with poor prognosis of patients with HCC (Schmitz et al., 2008) 
(Nakanishi et al., 2005). 
Activation of the growth factor/RTK pathway primarily involves either mutations in 
downstream mediators, or dysregulation of growth factors and their receptors. 
However, pathway mutations are rare in HCC; 3% (18 of 667) for KRAS, 2% (8 of 
422) for NRAS, 0.3% (1 of 383) for HRAS, 3% (2 of 73) for ARAF, 4% (16 of 357) 
for BRAF and 3% (2 of 71) for CRAF, also called RAF1, in the RAF/MEK/ERK axis 
(Tannapfel et al., 2003) (Whittaker et al., 2010) (Wellcome Trust Sanger Institute, 
COSMIC database, 2013), and 6% (40 of 640) for PIK3CA (encoding the p110α 
catalytic subunit of PI3K) and 4% (20 of 452) for PTEN in the PI3K/AKT/mTOR 
axis (Tanaka et al., 2006) (Boyault et al., 2007) (Wellcome Trust Sanger Institute, 
COSMIC database, 2013). In contrast, overexpression of growth factors and their 
RTK receptors is more common in HCC and leads to constitutive activation of 
RAF1 in the RAF/MEK/ERK axis (Gollob et al., 2006) or mTOR in the 
PI3K/AKT/mTOR axis (Villanueva et al., 2008). Dysregulated growth factors 
include FGFs, IGFs and VEGF. 
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The FGF signalling pathway is stimulated by binding of one of the 22 different FGF 
ligands to one of four FGF receptors (FGFR1-4). Overexpression of ligands, such 
as FGF-1 (Hu et al., 1996), FGF-2 (Mise et al., 1996), FGF-9 (Miura et al., 2012), 
FGF-8, FGF-17, and FGF-18 (Gauglhofer et al., 2011), among others, and their 
receptors, FGFR1, FGFR2, FGFR3 or FGFR4 (Hu et al., 1996) (Ho et al., 2009) 
(Gauglhofer et al., 2011) has been reported in HCC. Similarly, the IGF signalling 
pathway, which is activated by IGF-I or IGF-II binding to the receptor IGF-1R, has 
been implicated in hepatocarcinogenesis (Alexia et al., 2004). Dysregulation of the 
IGF pathway is mostly through upregulation of IGF-II, found in 16-40% of HCC 
(Cariani et al., 1988), overexpression of IGF-1R (Breuhahn and Schirmacher, 
2008) or downregulation of IGF-2R, found in about 60% of tumours (De Souza et 
al., 1995) (Yamada et al., 1997). IGF-2R is different from IGF-1R in that it does not 
have cytoplasmic kinase activity and regulates IGF2 degradation through receptor-
mediated endocytosis (Oka et al., 1985). Also, the angiogenic factor VEGF was 
found to be upregulated at the mRNA and plasma protein level in patients with 
HCC (Ng et al., 2001) (Mas et al., 2007), and was associated with poor prognosis 
(Poon et al., 2004). Furthermore, mRNA levels for the VEGF receptors, VEGFR-1 
(or FLT-1) (Ng et al., 2001), VEGFR-2 (or KDR/FLK-1) (Shimamura et al., 2000) 
and VEGFR-3 (Dhar et al., 2002), were found to be increased in HCC tumours. 
A requirement for 6-O sulfation of HS chains for cell-surface signalling by growth 
factors, such as FGF-1 and FGF-2, has been described (Pye et al., 1998) (Pye et 
al., 2000). Using X-ray crystallography analysis, DiGabriele et al., demonstrated a 
direct role for the 6-O sulfation and 2-O sulfation of heparin in its binding to FGF-1 
(DiGabriele et al., 1998), while no such requirement for 6-O sulfation was revealed 
for binding of heparin to FGF-2 (Faham et al., 1996). Nevertheless, the 6-O 
sulfation of HS was shown to be necessary for maximal FGF-2 activity (Guimond et 
al., 1993) (Pye et al., 1998), indicating a role in mediating the interaction between 
HS and FGFR1 (Kan et al., 1993) (Panteliano et al., 1994). In this latter case, HS 
functions as a bridge to form the ternary complex of FGF-2/HS/FGFR (Rusnati et 
al., 1994). Also, it has been shown that both the chain length and sulfation pattern 
(including 6-O sulfation status) of HS may be involved in the differential activation 
of FGF-1/FGF-2 signalling (Pye et al., 2000). These data were further supported by 
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the ability of SULF2 to greatly reduce FGF-1 but not FGF-2 binding to immobilized 
heparin (Uchimura et al., 2006 a).  
Overexpression of SULF2 in the HCC cell line Hep 3B has been shown to increase 
FGF-2 binding to the cell surface, and to enhance the level of phospho-ERK (p-
ERK) and phospho-AKT (p-AKT) (Lai et al., 2008 a). Collectively, these data 
suggest that excess ligand availability, or higher sensitivity to growth factors due to 
overexpression of RTK receptors, could be modulated by SULF2 inhibition in a 
high percentage of HCCs. 
To study the role of SULF2 in the growth factor/RTK signalling pathway, p-ERK 
and p-AKT were used as readouts, and stimulation of ERK and AKT 
phosphorylation was characterised using a range of growth factors to identify the 
optimal concentration and exposure time. For stimulation of this pathway in the 
SNU-182 cell line, five growth factors were chosen: FGF-1, FGF-2, IGF-I, IGF-II 
and VEGF-165. The results showed stimulation of p-ERK and p-AKT in response 
to FGF-1, FGF-2 and IGF-I at concentrations as low as 0.1 nM, with maximum 
activation after 10 min exposure to FGF-1 or FGF-2 and after 5 min exposure to 
IGF-I. IGF-II caused an increase in p-ERK after 5 min of treatment, and in p-AKT 
after 10 min of treatment, but only at 10 nM. VEGF-165 did not affect the level of 
either p-ERK or p-AKT in the SNU-182 cell line even at 10 nM (Figure  5.4) (Figure 
 5.5). HuH-7 and Hep 3B cells showed similar results to SNU-182 cells (G. Beale 
personal communication).  
As a positive control for inhibition of FGF/RTK signalling pathway, the potent and 
selective inhibitor of the FGF receptor kinase activity, PD173074, was used (Figure 
 5.6, left). This compound has an IC50 of 5 and 22 nM against FGFR3 and FGFR1, 
respectively (Mohammadi et al., 1998) (Kunii et al., 2008) (Pardo et al., 2009). 
Using the p-ERK ELISA, concentration-dependent inhibition of basal and FGF-1- 
and FGF-2-induced p-ERK levels was demonstrated in the SNU-182 cell line 
(Figure ‎5.7; A), and the IC50 values for inhibition of FGF-stimulated p-ERK levels by 
PD173074 were 84 nM for FGF-1 and 27 nM for FGF-2 (Figure ‎5.7; B). Also, the 
MEK inhibitor PD0325901 (Barrett et al., 2008) (Figure ‎5.6, right) was used at 1 µM 
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and caused complete inhibition of basal, FGF-1- and FGF-2-induced ERK 
phosphorylation in the SNU-182 cell line (data not shown). 
The biology of SULF1/2 enzymes in HCC 
Two approaches can be used to study the biology of SULF1/2, the first being 
overexpression of the enzymes, and this approach has been studied extensively by 
other groups in HCC and in other types of cancer. For instance, the effect of 
SULF1 overexpression has been studied in myeloma, ovarian cancer, SCCHN, 
breast cancer, pancreatic cancer, ESCC (oesophageal squamous cell carcinoma) 
and gastric cancer (Lai et al., 2004 b) (Lai et al., 2006) (Dai et al., 2005) (Lai et al., 
2003) (Lai et al., 2004 a) (Narita et al., 2007) (Narita et al., 2006) (Li et al., 2005) 
(Liu et al., 2013) (Hur et al., 2012). These studies showed that SULF1 acts a 
tumour suppressor in all these types of cancers except for gastric cancer, where it 
was found to have tumour-promoting activity as discussed in Section 1.5.1. Also, 
SULF2 overexpression was studied in the models of HCC, myeloma, NSCLC and 
gastric cancer (Lai et al., 2008 a) (Lai et al., 2010 a) (Lai et al., 2010 b) (Dai et al., 
2005) (Lemjabbar-Alaoui et al., 2010) (Hur et al., 2012) where it was found to have 
an oncogenic role with the exception of myeloma, as discussed in Section 1.5.2. 
A complimentary approach to studying the biology of SULF1/2 is knockdown of 
SULF1/2 mRNA, also termed gene silencing, which also serves as a positive 
control for SULF2 inhibition using small-molecule inhibitors. For this purpose, 
SULF1/2 shRNA lentiviral particles were used due to the high efficiency of delivery 
and because integration into genomic DNA produces stable expression of the 
shRNA (Stovall et al., 2012). As controls, both untransduced cells and non-
targeting shRNA (NT shRNA)-transduced cells were used. The NT shRNA 
contained four base pair mismatches to any known human or mouse gene, and 
controlled for the effect of transduction with lentiviral particles and for selection with 
the antibiotic puromycin. The shRNA that caused the greatest gene silencing of 
SULF1 or SULF2 was selected from a panel of 5 different shRNAs for each gene. 
For SULF2, SULF2 mRNA levels were measured by RT-qPCR after transient or 
stable transduction of shRNA lentiviral particles at different multiplicities of infection 
(MOIs) in HuH-7 cells and at different time points (Figure  5.8). The specificity of 
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knockdown was confirmed by stably transducing SULF2 shRNA that caused the 
best knockdown of SULF2 into HuH-7, HepG2 and SNU-182 cells and showing the 
lack of any effect on the expression of unrelated genes, including B2M (beta-2-
microglobulin), TP53 and KLF6 (Figure  5.9) (Figure  5.10) (Figure  5.11). The same 
strategy was followed for selecting the shRNA sequence that causes the best gene 
silencing of SULF1 (Figure  5.12). The SNU-182 cell line was chosen for the studies 
on SULF1 as it is the only HCC cell line that expresses this gene at a high level, 
and specificity of SULF1 knockdown was confirmed as for SULF2, i.e. there was 
no effect of transduction of SULF1 shRNA on the expression level of B2M, TP53 or 
KLF6 genes, or SULF2 (Figure  5.13). 
The effects of SULF1/2 suppression were studied in all the HCC cell lines that 
express SULF1/2 (i.e., HuH-7, HepG2, SNU-182, SNU-475) and in addition in one 
pancreatic cancer cell line (BxPC3) that expresses a high level of SULF2 and a low 
level of SULF1. For all of the cell lines a test cascade was followed to define the 
downstream consequences of SULF1/2 knockdown, and each experiment was 
repeated at least 3 times (Figure  5.14). First, the knockdown was confirmed at the 
mRNA level by RT-qPCR and at the protein level by WB. Second, the effect of 
SULF1/2 knockdown on growth factor/RTK (including the two main axes, 
RAF/MEK/ERK and PI3K/AKT/mTOR) and on Wnt signalling pathways was 
investigated by measuring p-ERK and p-AKT levels, or TCF reporter activity, 
respectively. Subsequently, the impact of signalling modulation was evaluated by 
measuring phenotypic effects in vitro and tumourigenicity in vivo. 
Effects of SULF2 knockdown in the HuH-7 cell line  
The downstream consequences of SULF2 knockdown was first studied in the HuH-
7 cell line which is derived from a well differentiated HCC and expresses SULF2 
but not SULF1. HuH-7 has a p53 point mutation at codon 220 position 2 (A → G), 
leading to replacement of tyrosine with cysteine (Hsu et al., 1993) and mutant Rb 
(retinoblastoma). Infecting HuH-7 cells with SULF2 shRNA lentiviral particles 
caused 37-fold downregulation of SULF2 expression in the SULF2 knockdown 
cells compared to NT shRNA-transduced cells (Figure  5.9). Suppression of SULF2 
was confirmed at the protein level by WB using SULF2 Ab (Serotec), which 
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showed complete absence of SULF2 protein in the SULF2 knockdown cells (Figure 
 5.15). Stimulation of HuH-7 cells with FGF-1 or FGF-2 caused an increase in p-
ERK and p-AKT levels (Figure  5.15; A and B), while stimulation with IGF-I caused 
an increase in p-AKT levels, at a high concentration of the ligand (Figure  5.15; C), 
which was also observed with IGF-II (data not shown). However, there was no 
clear effect of SULF2 knockdown on the phosphorylation of either ERK or AKT 
after stimulation with any of these ligands (Figure  5.15), suggesting that SULF2 
suppression does not affect these growth factor/RTK signalling pathways in the 
HuH-7 cell line.  
The effect of SULF2 suppression on Wnt signalling was also studied in HuH-7 
cells, and no significant effect of SULF2 knockdown on the basal level of β-catenin 
transcriptional activity was observed; however, marked inhibition of Wnt-3a-
induced activity was shown using both the TOPflash and 7TFP reporter systems 
with luciferase activity as a readout (Figure  5.16) (Figure  5.17; A). The effect of 
SULF2 suppression on Wnt signalling was found to be predominantly due to 
modulating Wnt-3a upstream signalling as treating cells with the GSK-3β inhibitor 
BIO, that works downstream of Wnt-3a-mediated activation of the frizzled and 
LRP5/6 receptors, activated luciferase activity in a manner that was independent of 
the SULF2 expression level (Figure  5.17; B). The effect of SULF2 knockdown on 
Wnt signalling was confirmed by WB using an antibody against ABC (active β-
catenin), the non-phosphorylated form of β-catenin, which showed that SULF2 
knockdown inhibited Wnt-3a-induced ABC accumulation (Figure  5.18; B). 
However, no change in the level of total β-catenin was observed after SULF2 
knockdown (Figure  5.18; A). The lack of an effect could be due to small changes in 
total β-catenin, as a result of Wnt signalling, being masked by the high levels of β-
catenin present at the cell membrane in HuH-7 cells, where it has a role in cell-cell 
adhesion (Sangkhathat et al., 2006). ICC studies showed that the majority of total 
β-catenin staining was at the cell surface in the HuH-7 cells with no detectable 
translocation of β-catenin to the nucleus after treatment with Wnt-3a or reduction of 
β-catenin staining after SULF2 knockdown (Figure  5.19). Unfortunately, the ABC 
antibody used in the WB experiments did not work for ICC. These results are in 
contrast with those of Lai et al. who have shown that SULF2 suppression in HuH-7 
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cells was associated with reduced basal levels of p-AKT, Wnt-3a, total β-catenin, 
cyclin D1 and GPC3 (Lai et al., 2010 a) (Lai et al., 2010 b), whereas the results 
presented here showed no clear effect on the mRNA or protein levels of these 
genes.  
Phenotypically, SULF2 knockdown in HuH-7 cell line caused inhibition of cell 
growth as measured by the SRB (sulforhodamine B) assay and cell counting, with 
the doubling time of 43 hours for both control untransduced and NT shRNA-
transduced cells increasing to 58 hours in the SULF2 knockdown cells (Figure 
 5.20). The effect of modulators of Wnt signalling on the growth of HuH-7 cells in 
vitro was investigated, and due to the sensitivity of HuH-7 cells to reduced FBS 
(foetal bovine serum) levels the effect of Wnt-3a, BIO and compound 3289-8625 
could be only studied in 10% (v/v) FBS-containing medium. Neither Wnt-3a nor 
BIO had any effect on the growth of HuH-7 cells regardless of the SULF2 
expression level (Figure ‎5.21; A and B), possibly due to other growth factors in the 
FBS masking any effect of Wnt signalling. However, incubating cells with 
compound 3289-8625 completely inhibited the proliferation of control 
untransduced, NT shRNA-transduced and SULF2 shRNA-transduced cells (Figure 
‎5.21; C), indicating that Wnt signalling does have a role in driving the proliferation 
of HuH-7 cells. Importantly, growth inhibition was partially rescued by adding BIO 
but not Wnt-3a (Figure ‎5.21; D and E), presumably because compound 3289-8625 
inhibits the binding of the scaffolding protein dishevelled to the frizzled receptor, 
and hence works downstream of Wnt-3a binding to the cell surface but upstream of 
BIO-induced inhibition of GSK-3β, such that BIO can rescue the phenotypic effects 
of compound 3289-8625. There was also no difference in the growth of BIO-
rescued SULF2 knockdown HuH-7 cells compared to BIO-rescued control 
untransduced or NT shRNA-transduced cells (Figure ‎5.21; E). This result is again 
consistent with SULF2 affecting the binding of Wnt-3a at the cell surface and, as 
BIO acts downstream in Wnt signalling, the effect of SULF2 knockdown is not 
observed. 
In addition to a detrimental effect on cell proliferation in vitro, SULF2 knockdown 
caused complete inhibition of the tumourigenicity of HuH-7 cells in vivo (Figure 
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 5.22) (Figure  5.23; A). Both control untransduced and NT shRNA-transduced HuH-
7 cells formed tumours with no difference in the mean time to reach a tumour size 
of 500 mm3, while none of the mice implanted with the SULF2 knockdown cells 
formed tumours up to 100 days post-implantation (Figure ‎5.23; B). These data are 
in contrast to an independent study showing that SULF2 knockdown HuH-7 cells 
could form tumours in nude mice when 5 x 105 cells/mouse were implanted (Zheng 
et al., 2013), which is 20 times fewer than the number of cells implanted in the 
current study. This discrepancy could be due to the much lower downregulation of 
SULF2 mRNA (3.4-fold) in the cells generated by Zheng and colleagues after 
stable transfection with shRNA and the consequently modest downregulation of 
SULF2 at the protein level as shown by WB (Zheng et al., 2013). The study here 
and two others are consistent in reporting that SULF2 knockdown prevents or 
retards the growth of tumours, with inhibition of Wnt signalling implicated as an 
underlying mechanism (Nawroth et al., 2007) (Lemjabbar-Alaoui et al., 2010). 
SULF2 overexpression in gastric cells or the HCC cell line Hep 3B was found to 
activate Wnt signalling and increase the tumourigenicity of cells in vivo (Lai et al., 
2008 a) (Lai et al., 2010 b) (Hur et al., 2012), and the results presented here 
together with previous data suggest that SULF2 facilitates Wnt signalling in some 
tumour cell lines and that SULF2 inhibition would be detrimental to cell growth in 
vitro and tumourigenicity in vivo. 
Effects of SULF1/2 knockdown in the SNU-182 cell line  
The effects of SULF1/2 knockdown were also investigated in the SNU-182 cell line. 
The SNU-182 cell line was derived from a poorly differentiated HCC and expresses 
both SULF1 and SULF2 at high and comparable levels. SNU-182 cells have wild-
type β-catenin but a p53 mutation S215I (AGT → ATT) leading to the substitution 
of isoleucine for serine (Cagatay and Ozturk, 2002). Knocking down SULF1 and 
SULF2 in this cell line allows comparison of the biology and the roles of SULF1 
and SULF2 in the context of HCC. Infecting cells with SULF1/2 shRNA lentiviral 
particles caused downregulation of SULF2 (16-fold) in the SULF2 shRNA-
transduced cells and downregulation of SULF1 (6.5-fold) in the SULF1 shRNA-
transduced cells, as compared to NT shRNA-transduced cells, after two weeks of 
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selection with antibiotic (Figure  5.24; A). After two months of growing the cells 
under selection pressure, the suppression of gene expression was further 
increased to 56-fold for SULF2 and 9-fold for SULF1 (Figure  5.24; B). Interestingly, 
there was a late effect of SULF1 suppression on the expression of SULF2 as 
shown by a 2-fold downregulation of SULF2 expression in the SULF1 knockdown 
cells (Figure  5.24; B). However, there were no late effects on the expression of the 
other genes tested, namely B2M, TP53 and KLF6, after either SULF1 or SULF2 
knockdown in the SNU-182 cell line. The suppression of SULF1/2 mRNA 
expression was confirmed in all cases at the protein level by WB (Figure  5.25).  
Mechanistically, SULF2 but not SULF1 knockdown in SNU-182 cells caused 
inhibition of FGF-1- and FGF-2-stimulated p-ERK levels as shown by WB (Figure 
 5.25) or p-ERK ELISA (Figure  5.26), but SULF2 knockdown did not affect the basal 
level of p-ERK in this cell line. Two positive controls were used for inhibition of ERK 
phosphorylation, namely, the FGFR inhibitor PD173074 and the MEK inhibitor 
PD0325901. Both compounds inhibited basal and FGF-stimulated levels of p-ERK 
regardless of the SULF2 expression status (Figure  5.25) (Figure  5.26). Also, 
SULF2 but not SULF1 knockdown inhibited IGF-II- but not IGF-I-stimulated p-AKT 
levels, but again there was no effect on the basal level of p-AKT as a result of 
SULF2 knockdown (Figure  5.27). This result is interesting as IGF-II but not IGF-I is 
overexpressed in up to 40% of HCCs (Cariani et al., 1988) (Breuhahn and 
Schirmacher, 2008).  
Previous studies have shown that targeting one of the FGF receptors, FGFR4, 
using antibodies blocks the binding of FGF-1 and FGF-19, and inhibits the growth 
of HCC cells in vitro and in vivo (Bumbaca et al., 2011) (French et al., 2012). Also, 
antibodies against FGFR4 or FGF-19 prevented the development of liver cancer in 
a FGF-19 transgenic animal model of HCC (Desnoyers et al., 2008) (French et al., 
2012). In other animal models of HCC, re-expression of IGF-II coincided with 
disease progression (Schirmacher et al., 1992). Conversely, inhibition of the IGF-II 
pathway by neutralizing antibodies against IGF-II or its receptor IGF-1R in HCC 
cell lines decreased cell proliferation and increased chemotherapeutic agent-
induced apoptosis (Lund et al., 2004). Small molecule inhibitors of growth 
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factor/RTK pathways are already in Phase III clinical trials for HCC including 
BMS582664/brivanib (Bristol-Myers Squibb) that works against FGFR and VEGFR 
(Johnson et al., 2013), TSU-68/orantinib (Pfizer) that targets FGFR, PDGFR and 
VEGFR2 (Kanai et al., 2011) and PI-88 (Progen) that works against FGF-1, FGF-2 
and VEGF (Liu et al., 2009). In addition, more selective inhibitors are now in Phase 
I trials for solid tumours including BGJ398 (Novartis) targeting FGFR1-3 and 
LY2874455 (Eli Lilly) against FGFR1-4 (Brooks et al., 2012). Collectively, these 
studies demonstrate the level of interest in targeting this pathway in the 
management of cancer, and there are potential applications for these and related 
drugs in HCC. Interference with FGF or IGF signalling pathways through inhibiting 
SULF2 could provide an alternative mechanism for preventing tumour growth in 
HCC that is dependent on RTK signalling. 
Wnt signalling was not functional in SNU-182 cells as there was no response to 
exogenous Wnt-3a up to 200 ng/ml as measured by 7TFP luciferase reporter 
activity (Figure  5.28). This result is consistent with an independent study showing 
that TCF activity was not detected in SNU-182 cells and that transient transfection 
of SNU-182 cells with a mutant form of β-catenin lacking the GSK-3β 
phosphorylation site, Ser33, did not induce canonical Wnt signalling (Yuzugullu et 
al., 2009). The lack of response to Wnt-3a in this cell line cannot be attributed to 
the lack of canonical frizzled receptors as FZD1, 5, 7, 9 were shown by RT-PCR to 
be expressed in this cell line (Yuzugullu et al., 2009). Instead, it was proposed that 
SNU-182 cells are resistant to canonical Wnt signalling as a result of the high 
expression of non-canonical Wnt ligands, especially Wnt-5a (Yuzugullu et al., 
2009), which can antagonize the canonical pathway (Liang et al., 2003) (Hu et al., 
2007) (Yuzugullu et al., 2009).   
Interestingly, there was a late but not an early effect of SULF1 and SULF2 
knockdown on the expression of glypican 3 (GPC3), an HSPG that is anchored to 
the cell surface. SULF1 knockdown caused 11-fold and SULF2 knockdown caused 
4-fold downregulation of GPC3 expression (Figure  5.29). However, downregulation 
of GPC3 cannot explain the inhibition of growth factor/RTK signalling in SNU-182 
cells, given the lack of an effect of SULF1 knockdown on this pathway, even 
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though SULF1 knockdown caused greater GPC3 downregulation than SULF2 
knockdown. However, this result does not rule out a possible detrimental effect of 
GPC3 knockdown on other signalling pathways, because either SULF1 or SULF2 
knockdown inhibited the proliferation of SNU-182 cells (Figure  5.30). Unfortunately, 
the effect of SULF1/2 knockdown on the tumourigenicity of SNU-182 cells could 
not be tested due to the inability of SNU-182 cells to form tumours in either nude 
mice or more immunodeficient NSG (NOD scid gamma) mice, despite one report 
that SNU-182 cells are tumourigenic in nude mice (Song et al., 2006). 
Effects of SULF1/2 knockdown in other HCC cell lines and the BxPC3 
pancreatic cancer cell line 
In the HepG2 cell line, which is derived from a well differentiated hepatoblastoma, 
SULF2 was downregulated by only 2.6-fold in the SULF2 knockdown cells as 
compared to NT shRNA-transduced cells (Figure  5.10). HepG2 cells have mutant 
β-catenin, mutant N-Ras at codon 61 position 2 (A → T) and mutant Rb, and 
SULF2 knockdown had no clear effect on the growth factor/RTK signalling pathway 
after stimulation with a range of growth factors (Figure  5.31). HepG2 cells express 
both a wild-type as well as the truncated mutant form of β-catenin produced by an 
interstitial deletion in the domain that is usually phosphorylated by GSK-3β, making 
β-catenin constitutively active (de La Coste et al., 1998) (Cagatay and Ozturk, 
2002). HepG2 cells were found to be responsive to exogenous Wnt-3a (data not 
shown), presumably due to the wild-type allele, and the effect of SULF2 
knockdown was investigated on Wnt-3a-induced β-catenin-dependent TCF activity. 
However, basal TCF activity was very high in the HepG2 cells, compared to the 
activity of the mutated form of the TCF reporter serving as a negative control 
(Figure  5.32), and treatment with Wnt-3a did not increase activity any further. 
Collectively, SULF2 seems not to play a role in the growth of HepG2 cells and this 
was confirmed by SRB growth assays where the SULF2 knockdown cells grew at a 
similar rate to the control untransduced and NT shRNA-transduced cells (Figure 
 5.33). It is most probable that in this cell line, due to the endogenous β-catenin 
mutation and activation of the Wnt signalling pathway, exogenous activation by 
Wnt ligands has no phenotypic effect.  
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SULF2 was also knocked down in the SNU-475 cell line which is derived from a 
poorly differentiated HCC. However, no phenotypic effect of either SULF1 or 
SULF2 knockdown was observed (data not shown). There was low expression of 
SULF1/2 genes in this cell line, and hence the cell line may not depend on 
SULF1/2 activity for proliferation. SULF2 knockdown in a pancreatic cancer cell 
line, BxPC3, that expresses high levels of SULF2 and low levels of SULF1, caused 
12-fold downregulation of SULF2 mRNA levels, complete loss of SULF2 protein 
and reduction of cell growth in vitro and a small delay of tumour growth in vivo, as 
compared to control untransduced and NT shRNA-transduced cells (Figure  7.6). 
This effect of SULF2 knockdown in BxPC3 cells is consistent with the findings of 
an independent study that also showed inhibition of autocrine Wnt signalling 
(Nawroth et al., 2007). No effect of SULF2 knockdown on growth factor/RTK 
signalling pathways was observed in the BxPC cells studied here (data not shown), 
while the effect on Wnt signalling was not studied. A summary of the effects of 
SULF2 knockdown on cell signalling, growth and tumourigenicity is presented in 
Table  8.2. 
 
 
 
 
 
 
 
 
 
 
257 
 
Table ‎8.2: Summary of the effects of SULF2 knockdown on cell signalling, growth 
and tumourigenicity in HCC and BxPC3 pancreatic cancer cell lines. 
Cell line Effect on signalling Effect on 
cell growth 
Effect on 
tumourigenicity 
SNU-182 ↓FGF-1-stimulated p-ERK 
↓FGF-2-stimulated p-ERK 
↓IGF-II-stimulated p-AKT 
No effect  on IGF-I signalling 
No functional Wnt signalling 
↓Growth Not applicable* 
SNU-475 Not tested No effect Not tested 
HuH-7 ↓Wnt-3a-induced β-catenin-
dependent transcriptional activity 
No effect  on FGF-1, FGF-2, IGF-I 
or IGF-II signalling 
↓Growth Complete 
inhibition of 
tumourigenicity 
HepG2 No effect  on FGF-1, FGF-2, IGF-I 
or Wnt signalling 
No effect Not tested 
BxPC3 No effect  on FGF-1, FGF-2, IGF-I 
or IGF-II signalling 
Effect  on Wnt signalling not studied 
↓Growth Minimal delay of 
tumour growth 
* Parental SNU-182 cells are not tumourigenic in nude or NSG mice. 
 
Inducible SULF1/2 knockdown in HCC cell lines 
Due to the detrimental effects of constitutive SULF2 knockdown on the growth of 
both HuH-7 and SNU-182 cells, and to characterise further the downstream 
consequences of SULF1 and SULF2 knockdown on signalling pathways in these 
two cell lines, IPTG (isopropyl β-D-1-thiogalactopyranoside)-inducible shRNAs for 
SULF1 and SULF2 were evaluated. The shRNA sequences that caused the 
highest level of silencing of the SULF1 and SULF2 genes were used and cloned 
into the inducible constructs, designated iSULF1.shRNA and iSULF2.shRNA, 
respectively. Also, an inducible construct for an NT shRNA was used and this was 
called iNT.shRNA. The sequence of the inducible NT shRNA was different from 
that of the constitutive NT shRNA (Table  2.3), but nevertheless did not match any 
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known human gene. These inducible constructs have three LacO sequences in the 
U6 promoter instead of one (Figure  2.4) to ensure tight regulation and minimal 
leakiness of shRNA expression, while allowing the production of shRNA on 
addition of IPTG. Regulation of shRNA expression is based on the lac operator-
repressor gene system, and in the absence of lactose or its analogue IPTG the 
protein encoded by the LacI (lac repressor) binds to the LacO (lac operator) 
sequences that are inserted in the U6 promoter, thus blocking transcription of the 
shRNA. On adding IPTG, the lactose analogue binds to the lac repressor protein 
modifying its affinity for LacO and thus allowing expression of the shRNA. This 
system is proven to work in vitro and in vivo and has the advantage of a fast 
response to IPTG induction that was observed as early as one day post-treatment 
in the two cell lines tested (i.e., HuH-7 and SNU-182) (Figure  6.1). One mM IPTG 
was found to be enough to induce SULF1/2 knockdown, and IPTG was shown to 
be stable in conditioned medium. In addition, it was found that knockdown was 
greater with longer incubation with IPTG (Figure  6.2) (Figure  6.3). Interestingly, 
treatment of SNU-182 cells with IPTG for 8 days caused 5-fold downregulation of 
SULF1 in iSULF2.shRNA-transduced cells and conversely SULF2 was 
downregulated in iSULF1.shRNA-transduced cells (Figure  6.3; B), while no effect 
on SULF1/2 expression was detected after treating iNT.shRNA-transduced cells 
with IPTG. Also, there was no effect of treating iNT.shRNA-, iSULF1.shRNA- or 
iSULF2.shRNA-transduced cells with IPTG on the expression of B2M, indicating 
the specificity of SULF1/2 knockdown (Figure  6.2) (Figure  6.3).    
To confirm the expression of iNT.shRNA after IPTG treatment, and to compare the 
level of the inducible shRNAs expression to that of the constitutive shRNAs, the 
amount of shRNA was analysed using RT-qPCR in the SNU-182 cell line using the 
QuantiMir small RNA quantification system, which converts the shRNA species into 
cDNA. The results showed comparable expression of the inducible iSULF2.shRNA 
after 8 days of treatment with IPTG to that produced by constitutively expressed 
SULF2 shRNA (6.4- vs. 9.3-fold) (Figure  6.4; A). The RT-qPCR data also indicated 
expression of both the inducible iNT.shRNA and the constitutively expressed NT 
shRNA in SNU-182 cells (Figure  6.4; B and C). However, as these two NT shRNAs 
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have different sequences, it was not possible to directly compare their expression 
levels. 
The effect of inducible SULF1/2 knockdown was investigated in the HuH-7 and 
SNU-182 cell lines. Inducing SULF2 knockdown in HuH-7 cells caused reduction of 
the β-catenin-dependent TCF transcriptional activity that was stimulated by Wnt-
3a, but not that stimulated by BIO. No effect of inducing iNT.shRNA expression 
was seen on Wnt signalling (Figure  6.5). However, the effect of inducible SULF2 
knockdown on Wnt signalling was much less than that observed after constitutive 
SULF2 knockdown, and this reduced effect could explain the lack of any impact of 
inducible SULF2 knockdown on the growth of HuH-7 cells in vitro (Figure  6.6). 
Given that the microenvironment in vivo is different from that in cell culture, and 
based on the finding that constitutive SULF2 knockdown caused complete 
inhibition of tumourigenicity of HuH-7 cells, the effect of inducible SULF2 
knockdown in vivo was also investigated. 
Induction of gene expression in vivo in mice has been reported 48 hours after 
adding IPTG to the drinking water, and shown to regulate the expression of the lac 
system in nearly all tissues (Wu et al., 1997) (Cronin et al., 2003) (Smith et al., 
2004). Mice with subcutaneous implants of iNT.shRNA- or iSULF2.shRNA-
transduced HuH-7 cells were split into two groups (n = 10 per group) and half the 
mice in each group received IPTG in the drinking water. However, IPTG treatment 
did not affect the tumourigenicity or change the mean time to reach a tumour 
volume of 500 mm3 among the resulting four groups (Figure  6.7). The induction of 
SULF2 knockdown in the HuH-7 tumours originating from iSULF2.shRNA-
transduced cells by IPTG treatment was investigated by RT-qPCR and a 4.2-fold 
downregulation of SULF2 expression was demonstrated, while there was no 
change in SULF2 expression in the iNT.shRNA group with or without IPTG 
treatment (Figure  6.7; C). This low level of SULF2 knockdown in the tumours could 
be the reason for the lack of an effect on tumourigenicity with inducible SULF2 
knockdown in HuH-7 cells as it is far lower than that achieved using constitutive 
SULF2 knockdown (37-fold) (Figure  5.9). This result is consistent with an 
independent study where a 3.4-fold downregulation of SULF2 mRNA expression in 
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HuH-7 cells did not impede tumourigenicity in nude mice (Zheng et al., 2013). 
Therefore, a high level of SULF2 suppression may be required before any 
phenotypic effect is produced in the HuH-7 cell line. The duration of SULF2 
suppression could also be an important factor as SULF2 was only knocked down 
after implantation in the case of inducible shRNA, while it was already knocked 
down for about two months before implantation in the case of HuH-7 cells with 
constitutive shRNA expression. Thus, prolonged SULF2 loss may be needed to 
inhibit tumourigenicity in HuH-7 cells.  
Neither SULF1 knockdown nor SULF2 knockdown caused any effect on the p-ERK 
levels stimulated by FGF-1 or FGF-2, or on p-ERK or p-AKT levels stimulated by 
IGF-I (Figure  6.8) or IGF-II (data not shown) in the SNU-182 cell line. Also, no 
effect on the growth of these cells was observed after inducible SULF1/2 
knockdown (Figure  6.9). This result is in contrast to the detrimental effects of 
constitutive SULF2 knockdown on growth factor/RTK signalling, and the effect of 
either SULF1 or SULF2 constitutive knockdown on the growth of SNU-182 cells.   
Collectively, these data suggest that SULF1/2 knockdown in HuH-7 and SNU-182 
cell lines must be maintained at a high level and for adequate time period before 
effects on cell growth and tumourigenicity are seen.   
The effect of SULF2 knockdown on gene expression in HCC cell lines 
To extend studies of the effect of SULF1/2 knockdown beyond growth factor/RTK 
and Wnt signalling pathways, microarray gene expression analysis was performed 
in HuH-7 cell lines using Affymetrix human genome U133 plus 2.0 arrays. In 
addition to understanding the biological impact of SULF2 suppression, the 
experiment could identify biomarkers for SULF2 inhibition. More than 54,000 probe 
sets were analysed corresponding to 47,400 transcripts and variants encoded by 
38,500 characterised genes. Samples were provided as biological quadruplicates 
and SULF2 expression was first confirmed by RT-qPCR (Figure  7.1; A). There was 
3-fold upregulation of SULF2 in the NT shRNA-transduced cells as compared to 
control untransduced cells, possibly due to infecting cells with lentiviral particles. In 
SULF2 shRNA-transduced cells, SULF2 expression was downregulated 34- and 
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11-fold compared to NT shRNA-transduced cells and control untransduced cells, 
respectively (Figure  7.1; A).  
The microarray data revealed changes in the expression level of many genes in 
the control untransduced cells as compared to the NT shRNA- and SULF2 shRNA-
transduced cells as shown by the principal component analysis plot (Figure  7.1; B). 
Changes could be due to transduction with lentiviral particles and/or selection with 
puromycin regardless of SULF2 expression status. These results suggest that NT 
shRNA-transduced cells could represent a better control for the effects of SULF2 
knockdown than control untransduced cells. Only genes that were differentially 
expressed in the SULF2 knockdown cells with ≥ 2-fold change and adjusted p 
value ≤ 0.01 compared to both NT shRNA-transduced and control untransduced 
cells and that showed a similar trend in the NT shRNA-transduced and control 
untransduced cells (i.e., upregulation or downregulation in both cell lines) as 
compared to SULF2 knockdown cells were taken into consideration for further 
analysis. These criteria identified 444 differentially expressed probe sets 
representing 322 genes (Figure  7.2) (Appendices A and B). The genes are 
involved in a range of pathways, and pathways with at least two affected genes are 
listed in Table  7.1.  
The most differentially expressed genes were chosen for further analysis (n = 26) 
(Table  7.2), and the expression of genes that have a potential link to cancer was 
confirmed by RT-qPCR (n = 18) (Table  7.2). Subsequently, seven genes that have 
been implicated in hepatocarcinogenesis were studied at the protein level; namely 
ACE2, PCDH20, SLPI, TFPI2, WNT5A, MYCN and DLK1. However, only the 
antibodies for ACE2 and MYCN performed satisfactorily in WB such that the effect 
of SULF2 suppression could be confirmed at the protein level (Figure  7.4).  
ACE2 and Ang-(1-7) 
Microarray data showed that the most highly upregulated gene after SULF2 
knockdown in the HuH-7 cell line was angiotensin I converting enzyme (peptidyl-
dipeptidase A) 2 (ACE2), using two different probe sets. The expression of this 
gene inversely correlated with SULF2 expression as evidenced by microarray and 
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RT-qPCR analyses (Figure  7.3). The relationship was also observed at the protein 
level where ACE2 protein was only detected in the SULF2 knockdown cells (Figure 
 7.4). 
ACE2 is a newly discovered member of the renin-angiotensin system (RAS). In the 
past, RAS was thought to be a simple linear pathway that leads to the formation of 
the final active peptide angiotensin II (Ang II) through the catalytic activity of 
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1 or ACE (Figure  8.1). 
Ang II then acts on the Ang II type 1 receptor (AT1R) (Figure  8.1) to exert its 
effects that were initially thought to be restricted to increasing blood pressure 
through vascular smooth muscle cells, inducing vasoconstriction and regulating 
electrolyte and fluid homeostasis. Subsequently, it was found that the ACE/Ang 
II/AT1R axis is also involved in promoting fibrosis, cell proliferation and 
inflammation (Mezzano et al., 2001) (Suzuki et al., 2003).  
Understanding of the RAS was further revised by the discovery of the ACE 
homologue, ACE2 in 2000 (Donoghue et al., 2000) (Tipnis et al., 2000). ACE2 is a 
zinc metalloprotease with 40% homology to ACE in the catalytic domain and is a 
type I transmembrane ectoenzyme; it has a signal sequence at the N-terminus and 
is anchored to the cell membrane by its C-terminus (Warner et al., 2005). 
Furthermore, the ectodomain of the enzyme can be cleaved post-translationally by 
ADAM17 to give a soluble functional glycoprotein enzyme (Lambert et al., 2005).  
Therefore, to determine the level and localization of ACE2 in the SULF2 
knockdown cells, flow cytometry analysis was performed which demonstrated that 
45% of SULF2 knockdown cells were ACE2-positive with higher fluorescence 
intensity compared to control untransduced and NT shRNA-transduced cells, 
where 10% and 4% of the cells were ACE2-positive, respectively. Also, ACE2 was 
shown to be expressed at the cell surface (Figure  7.7). 
The importance of ACE2 arises from its ability to convert Ang II with very high 
efficiency into the biologically active peptide angiotensin 1-7 (Ang-(1-7)). Ang-(1-7) 
stimulates the Mas receptor (MasR) which is a separate G protein-coupled 
receptor to AT1R with completely opposite properties including vasodilation, anti-
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fibrotic, anti-proliferative and anti-inflammatory effects (Figure  8.1) (Santos et al., 
2003) (Tallant and Clark, 2003) (Tallant et al., 2005). Therefore, this second arm of 
RAS counterbalances effects resulting from the over-activation of the classical arm. 
Also, both Ang II and Ang-(1-7) stimulate to a lesser degree the Ang II type 2 
receptor (AT2R) (Figure  8.1). Activation of the AT2R can induce apoptosis and 
inhibit cell proliferation (Nakajima et al., 1995) (Stoll et al., 1995) (Li et al., 2009).   
To determine whether or not the overexpressed ACE2 enzyme is catalytically 
active in SULF2 knockdown cells, the enzymatic activity of cell lysates was tested 
using two fluorogenic substrates that generate the fluorescent molecule 7-
methoxycoumarin. The assay showed higher activity in SULF2 knockdown cell 
lysates as compared to that of control untransduced and NT shRNA-transduced 
cell lysates (Figure  7.8). Also, the level of ACE2 product, Ang-(1-7), was measured 
by ELISA in the CM of cultures of these cells. The results showed that the level of 
Ang-(1-7) was 56 and 48 pg/ml for CM from control untransduced and NT shRNA-
transduced cell cultures, respectively, which falls within the range of physiological 
levels in the plasma of healthy volunteers of 32 ± 27 pg/ml (Reyes-Engel et al., 
2006). In contrast, the level of Ang-(1-7) was 3-times higher in the CM from SULF2 
knockdown cells (154 pg/ml) (Figure  7.9), confirming that the overexpressed ACE2 
was catalytically active in the SULF2 knockdown cells. 
ACE2 is different to ACE in several ways. First of all, ACE2 has only one active site 
while ACE has two homologous active sites (Donoghue et al., 2000). Secondly, 
ACE2 acts as a carboxymonopeptidase, and hence removes one amino acid from 
the carboxy terminus in substrates like angiotensin I (Ang I) to produce angiotensin 
1-9 (Ang-(1-9)) or Ang II to give Ang-(1-7). In contrast, ACE cleaves the C-terminal 
dipeptide from substrates like angiotensin I (Ang I) to produce Ang II, Ang-(1-9) to 
give Ang-(1-7), or the vasodilator bradykinin (Donoghue et al., 2000) (Tipnis et al., 
2000) (Rice et al., 2004). However, the affinity of ACE2 for Ang I is much lower 
than that of ACE, whereas ACE2 has a high catalytic activity for Ang II that is 400-
fold greater than that for Ang I (Vickers et al., 2002) (Rice et al., 2004). Thirdly, 
ACE2 is not inhibited by ACE inhibitors such as captopril and lisinopril that bind to 
both active sites of ACE (Ehlers and Riordan, 1991) (Donoghue et al., 2000) 
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(Tipnis et al., 2000). Fourthly, ACE2 is particularly expressed in heart, kidney and 
testis whereas the expression of ACE is more widespread in the endothelium of 
somatic tissues (Donoghue et al., 2000). 
ACE2 knockout mice have been generated (Crackower et al., 2002), and the role 
of ACE2 studied in the context of cardiovascular physiology and the pathogenesis 
of cardiovascular disease, not cancer. ACE2 null mice are healthy and fertile with 
normal organ function. However, they show progressive severe contractile 
dysfunction of the heart that subsequently results in reduced blood pressure with 
no signs of cardiac fibrosis or hypertrophy. This effect was attributed to increased 
cardiac hypoxia as evidenced by the upregulation of hypoxia-inducible genes. Ang 
II and Ang I were also increased in ACE2 knockout mice, but no change in ACE 
expression was detected. All these observed changes were reversed in the ACE 
and ACE2 double knockout mice (Crackower et al., 2002), suggesting that the 
effects observed in the ACE2 knockout mice may be the result of dysregulated 
RAS system. 
Role of ACE2 and Ang-(1-7) in liver fibrosis and cirrhosis 
Recently, activation of the classical RAS arm was found to be associated with liver 
injury, fibrosis and cirrhosis (Paizis et al., 2002). It was also found that activated 
human hepatic stellate cells (HSCs), which play an essential role in hepatic 
fibrosis, express high levels of renin and ACE and secrete Ang II, as opposed to 
quiescent HSCs which only express these elements at low levels and do not 
secrete Ang II (Bataller et al., 2003 a). Also, it was shown that Ang II promotes the 
activation of HSCs and their transformation into extracellular matrix-producing 
myofibroblasts (Bataller et al., 2000) (Bataller et al., 2003 b). Administration of Ang 
II during liver injury in rat models caused liver fibrosis that was alleviated by 
blocking the AT1R by AT1R blockers including olmesartan and candesartan 
(Hirose et al., 2007). Furthermore, fibrosis was completely inhibited in AT1R 
knockout mice (Yang et al., 2005), but was enhanced in AT2R knockout mice 
(Nabeshima et al., 2006). These studies reveal the role of the classical RAS arm in 
liver fibrosis.  
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It has been reported that human ACE2 protein, which is usually only weakly 
expressed by endothelial cells, perivenular hepatocytes and bile duct cells in 
healthy livers, was overexpressed by parenchymal cells in cirrhotic livers (Paizis et 
al., 2005). Furthermore, hepatic ACE2 and MasR expression was increased in rats 
with cirrhosis, and plasma Ang-(1-7) levels elevated in rats and patients with 
cirrhosis (Herath et al., 2007) (Lubel et al., 2009). Ang-(1-7) improved fibrosis 
stage in a cirrhotic rat model and decreased expression of the fibrosis marker α-
SMA (alpha-smooth muscle actin). Decreased α-SMA expression was also 
observed after treating rat HSCs with Ang-(1-7) or the MasR agonist AVE-0991, an 
effect that was reversed by the MasR antagonist, [D-Ala7]-Ang (1-7) (also called A-
779) where the amino acid proline in Ang-(1-7) is modified by D-alanine at position 
7 (Lubel et al., 2009). Additionally, ACE2 knockout mice showed increased chronic 
liver damage and fibrosis compared to wild-type littermates, which was attenuated 
by treatment with recombinant human ACE2 (rhACE2) protein (Osterreicher et al., 
2009). Collectively, these data suggest a role of the alternative RAS arm in 
counteracting aberrant RAS over-activation in liver disease.  
Two strategies can be employed to manipulate the RAS system in liver disease. 
The first is to inhibit the classical arm by using an ACE inhibitor (ACEi) or an AT1R 
blocker (ARB). However, there is insufficient evidence to recommend this approach 
in liver fibrosis (Grace et al., 2012). The second strategy is to activate the 
alternative ACE2/Ang-(1-7)/MasR arm by administering ACE2, Ang-(1-7) or MasR 
agonists. In animals, rhACE2 administration was demonstrated to attenuate 
cardiovascular (hypertension) and renal (diabetic nephropathy) disease, and liver 
fibrosis (Oudit et al., 2010) (Wysocki et al., 2010) (Osterreicher et al., 2009). Also, 
in healthy human volunteers, rhACE2 was well-tolerated with no adverse effects in 
Phase I clinical trials (Haschke et al., 2013). Ang-(1-7) has a very short half-life in 
plasma (20 seconds) after intravenous (i.v.) administration in rats (Iusuf et al., 
2008). However, in humans, the half-life is 29 - 30 min after i.v. or subcutaneous 
administration (Kono et al., 1986) (Rodgers et al., 2006). More stable oral 
formulations were developed for Ang-(1-7), such as hydroxypropyl β-cyclodextrin-
coated Ang-(1-7), and this drug was found to have cardioprotective effects 
(Marques et al., 2011). Alternatively, the MasR could be stimulated using the 
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agonist AVE-0991 which has been shown to be effective in models of 
cardiovascular disease when given intraperitoneally or orally (Ferreira et al., 2007) 
(Benter et al., 2007) (Ebermann et al., 2008). 
Role of ACE2 and Ang-(1-7) in cancer 
In addition to treating liver fibrosis and cirrhosis, the alternative RAS arm has 
potential in treating HCC itself. Recent studies have indicated that the alternative 
RAS arm can be used as a treatment for cancer based on its anti-proliferative and 
anti-angiogenic effects. Overexpression of ACE2 in the NSCLC A549 cell line 
reduced invasion and expression of tumour metastasis-promoting enzymes, matrix 
metalloproteinases MMP2 and MMP9, in vitro and inhibited tumour growth and 
downregulated VEGF-A, ACE and AT1R expression in vivo (Feng et al., 2011). 
ACE2 expression was found to be downregulated in pancreatic ductal 
adenocarcinoma (PDAC) compared to normal neighbouring tissues as opposed to 
ACE and AT1R expression, and Ang II levels were higher in PDAC (Arafat et al., 
2007) (Feng et al., 2011). In addition, ACE2 expression was found to be inversely 
related to tumour stage (Zhou et al., 2009). Suppressing ACE2 expression in two 
pancreatic cancer cell lines with siRNA promoted cell proliferation in vitro (Zhou et 
al., 2009), while overexpressing ACE2 in the same cell lines inhibited their 
proliferation, migration and invasion and sensitized them to hypoxia in vitro, and 
reduced the growth of tumour xenografts and VEGF-A expression in vivo. Treating 
established pancreatic tumour xenografts with ACE2-carrying adenovirus reduced 
their growth and further enhanced the survival of the mice when combined with the 
chemotherapeutic agent gemcitabine (Zhou et al., 2011 b). Furthermore, ACE2 
and ACE expression and activity were shown to be downregulated in renal cancer 
(Larrinaga et al., 2010). Lastly, clinical data in HCC showed that ACE2 expression 
was upregulated in 84 cases and downregulated in 196 cases with a deregulation 
ratio of 47% (Center for Bioinformatics and Computational Biology, East China 
Normal University, HCCNet database, 2013).  
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Collectively, studies investigating regulation of ACE2 in different types of cancer 
have shown that ACE2 may be a potential therapeutic target for cancer treatment 
due to its ability to suppress the growth of cancer cells and tumour angiogenesis. 
Ang-(1-7), the main product of ACE2 activity, reduced the growth of three human 
NSCLC cell lines (SK-LU-1, A549 and SK-MES-1) in vitro, an effect that was 
mediated through activation of the MasR that is expressed in these cells; blocking 
the AT1R or AT2R or treatment with Ang II did not alter the inhibitory effect of Ang-
(1-7). Ang-(1-7) treatment also reduced the phosphorylation of ERK in SK-LU-1 
cells which could explain the growth inhibitory effect of Ang-(1-7) in this cell line 
(Gallagher and Tallant, 2004). Treating the A549 cell line with Ang-(1-7) inhibited 
their invasion and migration in vitro which was associated with reduced 
phosphorylation of p38 MAPK and JNK, and MMP2 and MMP9 activity (Ni et al., 
2012). Treating mice with A549 human tumour xenografts with Ang-(1-7) reduced 
tumour growth in vivo which was accompanied by a reduction in cyclooxygenase-2 
expression in the tumour. Thus, the growth inhibitory effect of Ang-(1-7) may be 
mediated through decreased pro-inflammatory prostaglandin synthesis (Menon et 
al., 2007). Treatment of orthotopic human breast tumour-bearing mice with Ang-(1-
7) reduced the growth of stroma myofibroblasts and fibrosis in tumour 
microenvironment, which was associated with (1) reduced TGF-β1 (transforming 
growth factor-β1), that is responsible for fibroblast activation, and (2) increased 
DUSP1 (dual specificity phosphatase 1) which dephosphorylates, and hence 
deactivates ERK (Cook et al., 2010). 
Furthermore, Ang-(1-7) decreased vascular smooth muscle cell growth in vitro and 
in vivo (Freeman et al., 1996) (Strawn et al., 1999), and microvessel density in lung 
tumour xenografts that was associated with a reduction in VEGF-A expression 
(Soto-Pantoja et al., 2009), revealing an important antiangiogenic role. In another 
study, Ang-(1-7) was found to inhibit the proliferation of prostate cancer cell lines 
that express the MasR in vitro and in vivo, and attenuated their metastatic 
potential. The inhibition was associated with a reduction in p-ERK levels, vessel 
density and expression of the two angiogenic factors VEGF-A and PIGF and the 
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FLT-1 receptor, and an increase of the inhibitory secreted form of the receptor 
sFTL-1 in tumour extracts (Krishnan et al., 2013 a) (Krishnan et al., 2013 b).  
All the above studies are consistent with Ang-(1-7) exerting its anti-tumourigenic 
and anti-angiogenic effects through stimulating the MasR. This view was confirmed 
by a further study showing that Ang-(1-7) inhibited angiogenesis in sponge 
implants in mice, where inhibition was not affected by ACEi, ARB or AT2R 
inhibitors (Machado et al., 2001), while the potent and selective MasR antagonist 
A-779 abolished the Ang-(1-7) effect. The effect of Ang-(1-7) on vascularisation 
was found to be mediated by nitric oxide (NO) release as treating mice with NO 
synthase inhibitors attenuated Ang-(1-7) effect (Machado et al., 2001).  
Clinically, Ang-(1-7) has been used in Phase I clinical trials in patients with 
advanced solid tumours. Ang-(1-7) was generally well-tolerated and caused a 
reduction in plasma level of PlGF (placental growth factor) in patients. There was 
also evidence of clinical benefit manifested as stabilization of the disease for more 
than 3 months (Petty et al., 2009).  
In summary, several studies validate the RAS system as a target for cancer 
therapy. In addition, components of this system have been found to be expressed 
in the tumour environment (Ino et al., 2006) (Herr et al., 2008), and the RAS 
system may provide approaches to cancer chemoprevention. For instance, in 
retrospective analyses and follow-up studies of hypertensive patients, it was found 
that long-term use of ACEi reduced the risk of cancer compared to other types of 
antihypertensive drugs (Pahor et al., 1996) (Jick et al., 1997) (Lever et al., 1998) 
(van der Knaap et al., 2008). Moreover, combining ACEi or ARB with 
chemotherapy has been reported to increase the survival of pancreatic cancer and 
NSCLC patients (Wilop et al., 2009) (Nakai et al., 2010), and improve progression-
free survival in pancreatic cancer and renal cell carcinoma (Nakai et al., 2010) 
(Keizman et al., 2011). Also, ACEi or ARB reduced the risk of breast cancer 
recurrence (Chae et al., 2011) and distant metastasis in colorectal cancer patients 
(Heinzerling et al., 2007). Such effects could be due to decreased Ang II 
concentrations or increased Ang-(1-7) levels.  
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There was no effect of Ang II treatment on cell growth of control untransduced, NT 
shRNA-transduced cells or SULF2 knockdown HuH-7 cells (Figure  7.10). This 
result is in line with an independent study showing an increase in HuH-7 cell 
proliferation after treatment with Ang II for 24 hrs that was no longer apparent at 48 
hrs (Itabashi et al., 2008). These data suggest that Ang II has no mitogenic effects 
in HuH-7 cell lines even though AGTR1, the gene encoding Ang II receptor, is 
expressed in HuH-7 cells as analysed by RT-qPCR (Ct value of 25 compared to Ct 
value of 17 for GAPDH). AGTR1 was also shown to be expressed at the protein 
level in HuH-7 cells (Itabashi et al., 2008). Similarly, treatment with Ang-(1-7) did 
not cause any change in cell growth of any of the three cell lines, which could be 
due to the low expression of MAS1, the gene encoding Ang-(1-7) receptor, in HuH-
7 cells (Ct value of 36 compared to Ct value of 17 for GAPDH). 
It is conceivable that expression of the MasR in a tumour may be necessary for 
patients to benefit from Ang-(1-7) or a MasR agonist. However, given that MasR is 
expressed on endothelial cells (Tallant et al., 1997) and Ang-(1-7) directly inhibits 
endothelial cell tubule formation (Soto-Pantoja et al., 2008) (Soto-Pantoja et al., 
2009), tumour cell MasR expression might not be required to inhibit tumour 
angiogenesis. 
The effect of SULF1/2 knockdown on the expression of RAS elements was also 
studied in other cell lines. ACE2 was slightly upregulated (≥ 1.5-fold) after SULF2 
suppression and downregulated (≥ 1.9-fold) after SULF1 suppression in the SNU-
182 cell line. No change in ACE expression was shown, while > 2-fold 
downregulation of AGTR1 was detected after SULF2 knockdown in SNU-182 cells 
(Table  7.3). MMP9 but not MMP2 was found to be downregulated (≥ 1.5-fold) after 
SULF2 knockdown and upregulated (> 2-fold) after SULF1 knockdown in SNU-182 
cells (Table  7.3). In the BxPC3 cell line, ACE2 expression was > 2-fold upregulated 
after SULF2 knockdown (Figure  7.6; A). These data suggest a general effect of 
SULF2 knockdown on the expression of ACE2 in tumour cells; however, the effect 
was only profound in the HuH-7 cell line. 
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Figure ‎8.1: Renin-angiotensin system: The classical arm (ACE/Ang II/AT1 
receptor) in blue leads to pro-inflammatory and pro-fibrotic responses, and the 
alternative arm in red (ACE2/Ang-(1-7)/Mas receptor) has anti-inflammatory and 
anti-fibrotic effects. The AT2 receptor in green can be activated by either Ang II or 
Ang-(1-7), and this often leads to similar effects to those resulting from Mas 
receptor activation. NEP: neprilysin. (Adapted from Grace et al., 2012). 
 
Other genes differentially expressed after SULF2 knockdown 
MYCN (v-myc myelocytomatosis viral related oncogene, neuroblastoma derived 
(avian)) was the other gene that showed changes at the mRNA and protein level 
after SULF2 knockdown in HuH-7 cells. The expression of MYCN correlated with 
the expression of SULF2, with ≥ 4-fold downregulation of MYCN mRNA expression 
(Figure  7.3) and a reduction in MYCN protein levels (Figure  7.4) after SULF2 
knockdown. In the SNU-182 cell line, both SULF1 and SULF2 knockdown also 
caused downregulation of MYCN expression (≥ 1.5-fold) (Table  7.3). MYCN 
encodes the transcription factor N-Myc and overexpression of N-Myc is associated 
with different types of cancer especially neuroblastoma (Cheng et al., 1993). In 
neuroblastoma, MYCN expression has been reported to be related to advanced 
stages and metastasis of the disease, and associated with poor prognosis 
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(Brodeur et al., 1984) (Seeger et al., 1985). Overexpression of MYCN increased, 
and its suppression decreased, cell growth, invasion and migration in 
neuroblastoma cell lines (Burkhart et al., 2003) (Kang et al., 2006) (Tanaka and 
Fukuzawa, 2008). However, no studies have been reported on N-Myc in the 
context of HCC. 
PCDH20 (protocadherin 20) showed ≥ 24-fold upregulation after SULF2 
knockdown in HuH-7 cells (Table  7.2). PCDH20 is a member of the cadherin 
superfamily that encompasses over 80 members involved in cell-cell adhesion. 
However, little is known about protocadherin function and downstream signalling 
(Kim et al., 2011). Involvement of some protocadherins (protocadherin LKC, 
protocadherin 2 and protocadherin-PC) in carcinogenesis has been suggested in 
colon, renal and prostate cancer, and in HCC (Okazaki et al., 2002) (Stassar et al., 
2001) (Chen et al., 2002). In established tumours there is only one study (Imoto et 
al., 2006) where PCDH20 was found to be expressed in normal lung tissues but 
epigenetically silenced in 53% (32 of 59) of NSCLC by promoter hypermethylation. 
Reduced PCDH20 expression was related to poor patient survival, and 
overexpression of PCDH20 in NSCLC cells inhibited cell growth in vitro (Imoto et 
al., 2006), suggesting a potential tumour suppressor role for PCDH20 in cancer.  
SLPI (secretory leukocyte protease inhibitor) showed ≥ 38-fold upregulation after 
SULF2 knockdown in HuH-7 cells (Table  7.2). SLPI is secreted by epithelial and 
inflammatory cells of the digestive, respiratory and genital tracts, and SLPI has 
anti-protease, antibacterial and antiviral activities (Williams et al., 2006). Clinically, 
SLPI was found to be upregulated in 160 cases and downregulated in 203 cases in 
HCC with a deregulation ratio of 56% (Center for Bioinformatics and Computational 
Biology, East China Normal University, HCCNet database, 2013). The role of SLPI 
has been studied in different types of cancer and cancer-type dependent effects 
shown. For instance, in ovarian, lung and colon cancer cell lines, SLPI was found 
to have a tumour-promoting effect, and overexpression of SLPI increased cell 
proliferation in vitro and tumourigenicity in vivo (Devoogdt et al., 2003) (Devoogdt 
et al., 2009) (Amiano et al., 2013). In contrast, in oral squamous cell carcinoma 
(OSCC), SLPI was downregulated and inversely related to tumour progression, 
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with overexpression inhibiting the migration of OSCC cells in vitro (Wen et al., 
2011). SPLI was also found to reduce the metastatic potential of lung carcinoma 
cells (Wang et al., 2006), and overexpression of SLPI in mammary cancer cells 
caused apoptosis in vitro and inhibited their tumourigenicity in vivo (Amiano et al., 
2013). However, no studies have been reported on the role of SLPI in HCC. 
TFPI2 (tissue factor pathway inhibitor 2) showed ≥ 13-fold upregulation after 
SULF2 knockdown in the HuH-7 cell line (Table  7.2). TFPI2 is a serine protease 
inhibitor and was found to inhibit the activation of MMPs (Rao et al., 1999). TFPI2 
was reported to be downregulated in about 90% (38 of 42) of HCCs and silenced 
by promoter methylation in 47% (16 of 34) of HCC and in 62% (31 of 50) of 
colorectal cancers (Wong et al., 2007) (Hibi et al., 2010). Overexpression of TFPI2 
in HCC cell lines (including HepG2 and Hep 3B) inhibited their proliferation and 
invasiveness in vitro (Wong et al., 2007) (Xu et al., 2011). Clinically, elevated 
TFPI2 methylation was detected in the sera of patients with HCC and in the 
tumours of colorectal cancer, especially in advanced cases, suggesting that TFPI2 
may have a role in cancer progression (Hibi et al., 2010) (Sun et al., 2013). Given 
that TFPI2 expression increased after SULF2 knockdown, TFPI2 may be a 
biomarker for SULF2 inhibition. 
Effect of SULF2 suppression on Wnt signalling-related genes  
The microarray and RT-qPCR data for the HuH-7 cell line showed changes in the 
expression level of different Wnt signalling-related genes including the upregulation 
of WNT5A (wingless-type MMTV integration site family, member 5A) (> 5-fold) and 
CTBP2 (> 9-fold), and downregulation of DLK1 (delta-like 1 homolog (Drosophila)) 
(> 6-fold) (Table  7.2). In the SNU-182 cell line, both SULF2 and SULF1 knockdown 
caused ≥ 1.5-fold downregulation of DLK1 expression (Table  7.3). The WNT5A 
gene encodes Wnt-5a ligand that activates the non-canonical Wnt signalling 
pathway, and this ligand has been reported to antagonize the canonical Wnt 
signalling pathway in HuH-7 cells by inhibiting TCF reporter activity (Yuzugullu et 
al., 2009). Downregulation of Wnt-5a protein has been reported in 77% (65 of 85) 
and 81% (92 of 114) of HCCs, and was associated with weak β-catenin 
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membranous staining, high serum α-fetoprotein (AFP) and poor prognosis (Liu et 
al., 2008) (Geng et al., 2012).  
The CTBP2 gene, which encodes the C-terminal binding protein 2 that functions as 
a transcriptional co-repressor of β-catenin-dependent Wnt signalling, has similar 
effects (Valenta et al., 2003) (Hamada and Bienz, 2004), and blocking DLK1 with 
an anti-DLK1 antibody also suppresses Wnt signalling (Zhu et al., 2012). Therefore 
the downregulation of DLK1 and upregulation of WNT5A and CTBP2 after SULF2 
knockdown could also contribute to the inhibition of canonical Wnt signalling 
pathway that was observed in the HuH-7 cell line, in addition to the inhibition of 
Wnt-3a binding to its receptors at the cell surface, as a result of SULF2 
suppression. 
SULF2 knockdown in HuH-7 cells was shown to markedly inhibit Wnt-3a-induced 
β-catenin-dependent transcriptional activity as measured by both the TOPflash and 
7TFP luciferase activity assays, and analysis of ABC levels by WB (Figure  5.16) 
(Figure  5.17; A) (Figure  5.18; B). Inhibition of Wnt signalling could be the cause of 
the inhibition of HuH-7 cell growth and proliferation in vitro (Figure  5.20) and 
tumourigenicity in vivo (Figure  5.22) (Figure  5.23) after SULF2 suppression. HuH-7 
are a heterogeneous population of cells, and a subpopulation of HuH-7 cells can 
be sorted as a side population (SP) that behave as cancer stem cells. These cells 
divide asymmetrically in vitro and in vivo and have high tumourigenic potential; 
1,000 of these cells forming tumours in comparison to 1,000,000 non-SP cells 
(Chiba et al., 2006). Canonical Wnt signalling has been implicated in the self-
renewal of stem cells and in the malignant proliferation of some types of cancer 
cells, and HCC may arise from cancer stem/progenitor cells with dysregulated Wnt 
signalling (Reya and Clevers, 2005) (Ji and Wang, 2012). Thus, it is possible that 
SULF2 knockdown may have a particularly detrimental effect on HuH-7 cells in 
vitro and in vivo as a result of the inhibition of Wnt signalling in the cancer stem 
cells.  
DLK1 is a transmembrane and secreted protein that is expressed in foetal but not 
neonatal or adult liver, except in hepatic stem/progenitor cells derived from adult 
livers, suggesting that DLK1 could be a potential marker of these cells (Oertel et 
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al., 2008) (Tanaka et al., 2009) (Xu et al., 2012). Sorted DLK1-positive HuH-7 cells 
(which constituted 4% of total cell population) formed larger colonies in vitro and 
were substantially more tumourigenic when 10,000 cells were injected into 
NOD/SCID mice (5/5 mice) as compared to DLK1-negative cells injected into the 
opposite flank of the same mice (1/5 mice) (Xu et al., 2012). DLK1-positive HuH-7 
cells expressed other stem cell markers and were able to self-renew and 
regenerate the DLK1-negative cells in vitro and in vivo. Also, treating HCC cell 
lines (HuH-7, HepG2 and Hep 3B) with different chemotherapeutic drugs increased 
the percentage of DLK1-positive cells 5-fold, suggesting that they are more chemo-
resistant (Xu et al., 2012). 
DLK1 was found to be upregulated in hepatocytes and hepatic stellate cells after 
partial hepatectomy in mice (Zhu et al., 2012), and expression was upregulated at 
the mRNA level in 73% (60 of 82), and at the protein level in 57% (50 of 88) 
(Huang et al., 2007) and 72% (41 of 57) (Yu et al., 2010) of HCC cases, in addition 
to overexpression in other types of cancer including colon, pancreatic and NSCLC 
(Yanai et al., 2010). Overexpression of DLK1 was shown to promote cell growth 
and increase tumourigenicity of HCC cell lines (Huang et al., 2007) (Yu et al., 
2010), while its knockdown by shRNA in HuH-7, HepG2 and Hep 3B cell lines was 
found to inhibit their growth in vitro. Also, DLK1 knockdown almost completely 
inhibited tumourigenicity of HuH-7 cells in nude mice in vivo, with 8/8 tumours 
developing after implantation of empty vector-transfected cells, and 2/8 and 0/8 
tumours after implantation of two different DLK1 shRNA-transfected clones (Huang 
et al., 2007). Therefore, downregulation of DLK1 as a result of SULF2 knockdown 
in HuH-7 could reduce tumourigenicity.  
In summary, 7 genes underwent marked changes after SULF2 knockdown in HuH-
7 cells, and these are summarized in Table  8.3 with their expression changes after 
SULF2 knockdown and potential role in cancer, as indicated in the literature. 
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Table ‎8.3: Summary of genes that underwent changes after SULF2 knockdown in 
cancer cells studied in the thesis. 
Gene Fold change * Role in cancer ** 
ACE2 ↑ ≥ 67-fold (HuH-7) 
↑ ≥ 1.5-fold (SNU-182) 
↑ ≥ 2.2-fold (BxPC3) 
Overexpression reduces invasion in vitro and 
inhibits tumour growth in vivo (NSCLC cells). 
Suppression promotes cell proliferation and 
overexpression inhibits proliferation, migration 
and invasion and sensitizes cells to hypoxia 
in vitro, and reduces tumour growth in vivo 
(pancreatic cancer cells). 
Expression inversely correlates with tumour 
stage (pancreatic cancer). 
Expression is upregulated in 84 and 
downregulated in 196 of cases (HCC). 
MYCN ↓ ≥ 4-fold (HuH-7) 
↓ ≥ 1.5-fold (SNU-182) 
Promotes growth, invasion and migration 
(neuroblastoma cells). 
Expression correlates with advanced stages, 
metastasis and poor prognosis 
(neuroblastoma). 
PCDH20 ↑ ≥ 24-fold (HuH-7) Overexpression inhibits growth in vitro 
(NSCLC cells). 
Reduced expression correlates with poor 
patient survival (NSCLC). 
SLPI ↑ ≥ 38-fold (HuH-7) Overexpression increases cell proliferation in 
vitro and tumourigenicity in vivo (ovarian, lung 
and colon cancer cells). 
Overexpression inhibits migration in vitro 
(OSCC cells). 
Overexpression reduces the metastatic 
potential (lung carcinoma cells). 
Overexpression causes apoptosis in vitro and 
inhibits tumourigenicity in vivo (mammary 
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cancer cells). 
Expression inversely correlates with tumour 
progression (OSCC). 
Expression is upregulated in 160 and 
downregulated in 203 of cases (HCC). 
TFPI2 ↑ ≥ 13-fold (HuH-7) Overexpression inhibits proliferation and 
invasiveness in vitro (HCC). 
Expression downregulated in ~ 90% (HCC). 
Silenced by promoter methylation in 47% 
(HCC) and in 62% (colorectal cancer). 
Elevated methylation detected in the sera of 
(HCC) or tumours (colorectal cancer) of 
patients. 
Potential biomarker for SULF2 inhibition. 
WNT5A ↑ ≥ 5.2-fold (HuH-7) Protein downregulation in 77% - 81% (HCC). 
Downregulation is associated with high AFP 
level and poor prognosis (HCC). 
DLK1 ↓ ≥ 6.7-fold (HuH-7) 
↓ ≥ 1.5-fold (SNU-182) 
Overexpression promotes and knockdown 
inhibits cell growth in vitro and tumourigenicity 
in vivo (HCC cells). 
Upregulation at the mRNA level in 73% and 
at the protein level in 57% - 72% (HCC) 
*Fold change values of gene expression in SULF2 knockdown cells as compared 
to control untransduced and NT shRNA-transduced cells measured by RT-qPCR. 
**References are included in the text. 
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Summary and Future Work 
 
A. Summary 
• SULF2 has higher expression in 3/6 HCC cell lines at the mRNA and protein 
levels. 
• SULF2 is catalytically active as shown by arylsulfatase and endosulfatase 
activity assays using SULF2-Ab IPs of HCC cell lysates. 
• Recombinant SULF2 protein is expressed and catalytically active, and can 
be used for screening of small-molecule inhibitors. 
• Commercially available sulfatases are enzymatically active and can be used 
for counter-screening of SULF2 inhibitors. 
• Constitutive SULF2 knockdown inhibits Wnt signalling and proliferation in 
vitro and tumourigenicity in vivo in the HuH-7 cell line. 
• Constitutive SULF2 but not SULF1 knockdown inhibits FGF-1, FGF-2 and 
IGF-II signalling, while either SULF1 or SULF2 knockdown can inhibit 
proliferation in the SNU-182 cell line. 
• Inducible SULF2 knockdown failed to reproduce the detrimental effects of 
constitutive SULF2 suppression in HCC cell lines. 
• SULF2 suppression dramatically upregulates ACE2 and increases the level 
of the anti-proliferative, anti-angiogenic peptide, Ang-(1-7) in the HuH-7 cell 
line. 
• SULF2 is a promising target for HCC therapy 
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B. Future Work 
Screening of small-molecule inhibitors of SULF2 using the optimised assays 
according to the following test cascade: 
1) SULF1/2 inhibition using recombinant SULF1/2 proteins. 
2) Counter-screening of inhibitors using commercially available sulfatases: 
ARSA, ARSB and ARSC for the initial screening and IDS, ARSD, ARSF, 
ARSG and GNS for selected inhibitors. 
3) Cell-based mechanistic studies (effect on FGF-1-stimulated p-ERK 
levels in the SNU-182 cell line using the p-ERK ELISA and Wnt-3a-
induced β-catenin-dependent transcriptional activity in the HuH-7 cell line 
using the TCF luciferase reporter assay). 
4) Cell-based phenotypic investigations (effect on proliferation using the 
SRB assay and cell counting, migration by measuring the number of 
cells traversing a porous membrane using cultrex 96-well cell migration 
assay (R and D systems), and invasion by monitoring cell movement 
through extracellular matrices using cultrex cell invasion assay (R and D 
systems). 
5) In vitro ADME (plasma protein binding assessed by the rapid equilibrium 
dialysis method (BD Biosciences), metabolic stability analysed by 
incubating test compounds with liver microsomes (BD Biosciences), P-
glycoprotein-mediated transport assessed by Caco-2 permeability (BD 
Biosciences) and cytochrome P450 inhibition (BD Biosciences)).  
6) In vivo PK (bioavailability, half-life, Cmax, Tmax, clearance, elimination) and 
PD (turnover of sulfation of HSPGs, reduction of p-ERK and p-AKT 
levels or translocation of β-catenin to the nucleus, increase in Ang-(1-7) 
level in plasma) properties. 
7) In vivo efficacy using HuH-7 cell tumour xenografts as a model and 
toxicity studies. 
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Investigation of the role of the alternative arm of RAS in mediating the effect of 
SULF2 knockdown on HuH-7 tumourigenicity in vivo: 
1) Stimulation of the Mas receptor using the MasR agonist, AVE-0991, in 
mice bearing untransduced HuH-7 cell tumour xenografts as a model to 
evaluate the anti-tumour effect of AVE-0991. 
2) Inhibition of ACE2 enzyme using MLN-4760 in SULF2 knockdown HuH-7 
cells as a model to test the pro-tumourigenic effect of MLN-4760 by 
demonstrating the ability of SULF2 knockdown cells to form tumours in 
mice following inhibition of ACE2, at doses associated with an increase 
of Ang II and reduction in Ang-(1-7) levels in plasma.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
280 
 
Appendices  
 
Appendix A 
Differentially expressed probe sets (n = 146, representing 111 genes) that were 
downregulated in the SULF2 knockdown HuH-7 cells with ≥ 2-fold change and 
adjusted p value ≤ 0.01 as compared to both NT shRNA and control untransduced 
HuH-7 cells (alphabetically ordered). Data generated using Affymetrix microarray 
gene expression analysis as described in Section 2.22 
 
CTRL: control untransduced cells 
NT: NT shRNA-transduced cells 
S2: SULF2 knockdown cells 
Ave Expr: average expression 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
242110_at --- --- --- -5.08 -15.85 -3.12 8.14 0.0000000005 
230413_s_at --- --- --- -1.26 -3.28 -2.60 5.27 0.0000460556 
228835_at --- --- --- -2.64 -5.84 -2.21 6.61 0.0000000000 
242051_at --- --- --- -1.65 -3.65 -2.21 5.46 0.0000000098 
242096_at --- --- --- -1.88 -4.09 -2.18 5.33 0.0000000126 
240655_at --- --- --- -3.08 -6.45 -2.09 5.81 0.0000000007 
228734_at --- --- --- 1.01 -2.05 -2.08 6.78 0.0000010959 
239253_at --- --- --- -1.20 -2.44 -2.04 7.07 0.0000000584 
205997_at ADAM28 ADAM metallopeptidase domain 28 10863 -3.44 -6.97 -2.03 4.63 0.0000000001 
210929_s_at AHSG alpha-2-HS-glycoprotein 197 1.06 -4.87 -5.14 10.41 0.0000000000 
204551_s_at AHSG alpha-2-HS-glycoprotein 197 1.07 -4.58 -4.87 8.64 0.0000000000 
201952_at ALCAM activated leukocyte cell adhesion molecule 214 -1.80 -4.02 -2.23 10.55 0.0000000000 
203300_x_at AP1S2 adaptor-related protein complex 1, sigma 2 subunit 8905 -1.34 -2.81 -2.10 7.27 0.0000000149 
228415_at AP1S2 adaptor-related protein complex 1, sigma 2 subunit 8905 -1.75 -3.63 -2.08 7.85 0.0000000001 
230264_s_at AP1S2 adaptor-related protein complex 1, sigma 2 subunit 8905 -1.45 -2.94 -2.02 8.25 0.0000000002 
205216_s_at APOH apolipoprotein H (beta-2-glycoprotein I) 350 -1.52 -3.21 -2.11 10.89 0.0000000000 
217936_at ARHGAP5 Rho GTPase activating protein 5 394 -3.08 -10.22 -3.32 10.29 0.0000000000 
233849_s_at ARHGAP5 Rho GTPase activating protein 5 394 -2.86 -9.13 -3.19 10.46 0.0000000000 
235635_at ARHGAP5 Rho GTPase activating protein 5 394 -2.37 -6.65 -2.81 8.37 0.0000000000 
228889_at ARHGAP5-AS1 ARHGAP5 antisense RNA 1 (non-protein coding) 84837 -3.03 -8.55 -2.82 6.57 0.0000000000 
224797_at ARRDC3 arrestin domain containing 3 57561 1.05 -2.43 -2.56 8.17 0.0000000021 
206743_s_at ASGR1 asialoglycoprotein receptor 1 432 -1.89 -5.30 -2.80 7.23 0.0000000000 
212599_at AUTS2 autism susceptibility candidate 2 26053 -1.79 -4.10 -2.29 4.65 0.0000000039 
235007_at BBS7 Bardet-Biedl syndrome 7 55212 -1.22 -2.52 -2.07 5.90 0.0000000605 
218332_at BEX1 brain expressed, X-linked 1 55859 -1.59 -20.07 -12.63 7.56 0.0000000000 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
221478_at BNIP3L BCL2/adenovirus E1B 19kDa interacting protein 3-
like 
665 -1.42 -2.93 -2.07 10.43 0.0000000001 
224719_s_at C12orf57 chromosome 12 open reading frame 57 113246 -1.38 -2.98 -2.16 9.20 0.0000000001 
227158_at C14orf126 chromosome 14 open reading frame 126 112487 -4.37 -9.89 -2.26 9.31 0.0000000000 
1553801_a_at C14orf126 chromosome 14 open reading frame 126 112487 -4.73 -10.52 -2.22 6.93 0.0000000000 
218802_at CCDC109B coiled-coil domain containing 109B 55013 -2.22 -4.90 -2.21 6.29 0.0000000828 
220115_s_at CDH10 cadherin 10, type 2 (T2-cadherin) 1008 13.55 4.85 -2.80 5.53 0.0000000000 
214803_at CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 1004 -4.96 -20.73 -4.18 6.94 0.0000000000 
205532_s_at CDH6 cadherin 6, type 2, K-cadherin (fetal kidney) 1004 -2.41 -7.15 -2.97 6.62 0.0000000001 
226274_at CLCN5 chloride channel, voltage-sensitive 5 1184 -8.77 -22.90 -2.61 6.38 0.0000000000 
226273_at CLCN5 chloride channel, voltage-sensitive 5 1184 -8.11 -17.10 -2.11 5.07 0.0000000003 
223507_at CLPX ClpX caseinolytic peptidase X homolog (E. coli) 10845 -1.05 -2.09 -2.00 7.51 0.0000000055 
225664_at COL12A1 collagen, type XII, alpha 1 1303 -1.00 -2.05 -2.05 7.46 0.0000000290 
201990_s_at CREBL2 cAMP responsive element binding protein-like 2 1389 -1.50 -3.07 -2.04 6.57 0.0000000398 
205927_s_at CTSE cathepsin E 1510 1.03 -9.19 -9.47 7.57 0.0000000085 
201372_s_at CUL3 cullin 3 8452 -1.79 -4.27 -2.39 4.64 0.0000000024 
217028_at CXCR4 chemokine (C-X-C motif) receptor 4 7852 -2.67 -8.51 -3.18 7.56 0.0000000008 
228915_at DACH1 dachshund homolog 1 (Drosophila) 1602 -2.91 -23.59 -8.09 5.31 0.0000000000 
205471_s_at DACH1 dachshund homolog 1 (Drosophila) 1602 -3.24 -6.73 -2.08 4.55 0.0000000583 
205472_s_at DACH1 dachshund homolog 1 (Drosophila) 1602 -3.01 -6.10 -2.03 4.07 0.0000000102 
239425_at DCUN1D5 DCN1, defective in cullin neddylation 1, domain 
containing 5 (S. cerevisiae) 
84259 -1.16 -2.38 -2.05 4.10 0.0000026347 
209560_s_at DLK1 delta-like 1 homolog (Drosophila) 8788 1.82 -3.78 -6.89 5.37 0.0000000000 
227708_at EEF1A1 /// 
LOC100653236 
eukaryotic translation elongation factor 1 alpha 1 /// 
uncharacterized LOC100653236 
100653236 
/// 1915 
-1.30 -2.87 -2.21 9.50 0.0000000001 
207257_at EPO erythropoietin 2056 1.06 -2.02 -2.15 5.26 0.0000002349 
224833_at ETS1 v-ets erythroblastosis virus E26 oncogene homolog  2113 -4.91 -10.26 -2.09 5.04 0.0000000005 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
205774_at F12 coagulation factor XII (Hageman factor) 2161 -9.04 -18.16 -2.01 6.89 0.0000000000 
219427_at FAT4 FAT tumor suppressor homolog 4 (Drosophila) 79633 -1.25 -2.95 -2.36 6.17 0.0000000031 
215245_x_at FMR1 fragile X mental retardation 1 2332 -1.43 -4.70 -3.29 9.45 0.0000000000 
203689_s_at FMR1 fragile X mental retardation 1 2332 -1.41 -3.88 -2.74 8.98 0.0000000000 
230645_at FRMD3 FERM domain containing 3 257019 -1.34 -2.95 -2.21 5.53 0.0000000034 
207345_at FST follistatin 10468 -1.22 -3.68 -3.01 7.38 0.0000000008 
226847_at FST follistatin 10468 -1.18 -3.27 -2.77 9.00 0.0000000000 
204948_s_at FST follistatin 10468 -1.35 -3.10 -2.30 9.55 0.0000000000 
223257_at G2E3 G2/M-phase specific E3 ubiquitin protein ligase 55632 -2.75 -6.80 -2.48 8.42 0.0000000000 
223256_at G2E3 G2/M-phase specific E3 ubiquitin protein ligase 55632 -2.56 -5.22 -2.04 8.90 0.0000000000 
223255_at G2E3 G2/M-phase specific E3 ubiquitin protein ligase 55632 -2.57 -5.15 -2.00 8.93 0.0000000001 
222943_at GBA3 glucosidase, beta, acid 3 (cytosolic) 57733 -21.11 -57.35 -2.72 5.92 0.0000000000 
201667_at GJA1 gap junction protein, alpha 1, 43kDa 2697 -1.27 -2.55 -2.01 11.79 0.0000000002 
226510_at HEATR5A HEAT repeat containing 5A 25938 -3.47 -8.53 -2.45 9.42 0.0000000000 
209398_at HIST1H1C histone cluster 1, H1c 3006 -5.33 -18.15 -3.40 8.89 0.0000000000 
214290_s_at HIST2H2AA3 /// 
HIST2H2AA4 
histone cluster 2, H2aa3 /// histone cluster 2, 
H2aa4 
723790 /// 
8337 
-5.29 -14.39 -2.72 9.15 0.0000000000 
218280_x_at HIST2H2AA3 /// 
HIST2H2AA4 
histone cluster 2, H2aa3 /// histone cluster 2, 
H2aa4 
723790 /// 
8337 
-4.48 -9.63 -2.15 8.01 0.0000000000 
206697_s_at HP haptoglobin 3240 -1.02 -2.27 -2.23 5.53 0.0000000524 
208470_s_at HP /// HPR haptoglobin /// haptoglobin-related protein 3240 /// 
3250 
-1.03 -2.09 -2.04 5.30 0.0000002489 
227361_at HS3ST3B1 heparan sulfate (glucosamine) 3-O-
sulfotransferase 3B1 
9953 -1.00 -4.16 -4.16 7.26 0.0000000006 
230031_at HSPA5 heat shock 70kDa protein 5 (glucose-regulated 
protein, 78kDa) 
3309 -1.25 -2.93 -2.33 7.46 0.0000000027 
211406_at IER3IP1 immediate early response 3 interacting protein 1 51124 -1.35 -3.39 -2.51 6.34 0.0000003940 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
223071_at IER3IP1 immediate early response 3 interacting protein 1 51124 -1.75 -3.94 -2.25 9.66 0.0000000000 
202490_at IKBKAP inhibitor of kappa light polypeptide gene enhancer 
in B-cells, kinase complex-associated protein 
8518 -1.32 -3.04 -2.30 5.49 0.0000000110 
212859_x_at LOC100505584 
/// MT1E 
metallothionein-2-like /// metallothionein 1E 100505584 
/// 4493 
-1.68 -3.74 -2.22 7.98 0.0000000000 
238632_at LOC100505946 uncharacterized LOC100505946 1.01E+08 1.09 -2.02 -2.20 6.59 0.0000011850 
230057_at LOC285178 uncharacterized LOC285178 285178 -1.43 -2.94 -2.06 6.93 0.0000008596 
230930_at LOC338620 uncharacterized LOC338620 338620 -1.31 -3.49 -2.67 7.70 0.0000000001 
235497_at LOC643837 uncharacterized LOC643837 643837 -2.29 -4.58 -2.00 4.47 0.0000000011 
202998_s_at LOXL2 lysyl oxidase-like 2 4017 -1.91 -4.08 -2.14 6.40 0.0000000014 
204036_at LPAR1 lysophosphatidic acid receptor 1 1902 -1.05 -3.38 -3.23 5.64 0.0000000103 
226884_at LRRN1 leucine rich repeat neuronal 1 57633 -2.78 -5.97 -2.14 4.28 0.0000000056 
239960_x_at LYRM7 Lyrm7 homolog (mouse) 90624 -1.12 -2.59 -2.30 4.94 0.0041715506 
210302_s_at MAB21L2 mab-21-like 2 (C. elegans) 10586 -5.13 -21.28 -4.14 5.97 0.0000000000 
213627_at MAGED2 melanoma antigen family D, 2 10916 -1.06 -2.62 -2.48 6.05 0.0000000047 
212741_at MAOA monoamine oxidase A 4128 -8.13 -23.41 -2.88 6.90 0.0000000000 
204388_s_at MAOA monoamine oxidase A 4128 -7.47 -16.35 -2.19 6.01 0.0000000000 
224507_s_at MGC12916 uncharacterized protein MGC12916 84815 -1.21 -3.26 -2.70 5.46 0.0000000353 
217165_x_at MT1F metallothionein 1F 4494 -1.38 -2.86 -2.08 7.55 0.0000000039 
204326_x_at MT1X metallothionein 1X 4501 -1.67 -3.65 -2.19 7.81 0.0000000001 
208581_x_at MT1X metallothionein 1X 4501 -1.45 -3.10 -2.14 7.93 0.0000000003 
212185_x_at MT2A metallothionein 2A 4502 -1.11 -2.29 -2.07 9.33 0.0000000005 
209757_s_at MYCN v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived (avian) 
4613 1.13 -4.17 -4.73 8.31 0.0000000000 
225355_at NEURL1B neuralized homolog 1B (Drosophila) 54492 -1.59 -4.10 -2.58 5.97 0.0000000018 
220176_at NUBPL nucleotide binding protein-like 80224 -3.02 -8.48 -2.81 8.07 0.0000000000 
230883_at NXPH2 neurexophilin 2 11249 1.11 -3.41 -3.79 4.83 0.0000000058 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
228959_at PDK3 pyruvate dehydrogenase kinase, isozyme 3 5165 -3.57 -20.30 -5.69 7.34 0.0000000000 
230085_at PDK3 pyruvate dehydrogenase kinase, isozyme 3 5165 -2.97 -7.53 -2.53 5.01 0.0000000000 
221957_at PDK3 pyruvate dehydrogenase kinase, isozyme 3 5165 -1.40 -2.83 -2.02 5.50 0.0000285828 
219165_at PDLIM2 PDZ and LIM domain 2 (mystique) 64236 -1.07 -2.69 -2.52 7.36 0.0000000005 
213469_at PGAP1 post-GPI attachment to proteins 1 80055 -1.70 -4.48 -2.64 6.49 0.0000000002 
241801_at PGAP1 post-GPI attachment to proteins 1 80055 -1.55 -3.80 -2.45 5.79 0.0000004795 
214717_at PKI55 DKFZp434H1419 150967 -1.26 -2.76 -2.19 7.21 0.0000000017 
235758_at PNMA6A /// 
PNMA6B /// 
PNMA6C /// 
PNMA6D 
paraneoplastic Ma antigen family member 6A /// 
paraneoplastic Ma antigen family member 6B /// 
paraneoplastic Ma antigen family member 6C /// 
paraneoplastic Ma antigen family member 6D 
100287428 
100287466 
/// 728513 
/// 84968 
-1.10 -2.33 -2.13 6.52 0.0000000057 
232424_at PRDM16 PR domain containing 16 63976 -2.36 -5.21 -2.20 3.66 0.0000000230 
205880_at PRKD1 protein kinase D1 5587 -1.22 -3.21 -2.62 7.98 0.0000000005 
201300_s_at PRNP prion protein 5621 -1.86 -3.76 -2.03 5.14 0.0000002133 
238852_at PRRX1 paired related homeobox 1 5396 -2.69 -6.24 -2.32 4.72 0.0000000547 
205174_s_at QPCT glutaminyl-peptide cyclotransferase 25797 -2.76 -7.07 -2.56 5.21 0.0000000005 
229300_at RAB3C RAB3C, member RAS oncogene family 115827 -1.14 -2.31 -2.02 4.43 0.0000018907 
212706_at RASA4 /// 
RASA4B 
RAS p21 protein activator 4 /// RAS p21 protein 
activator 4B 
100271927 
/// 10156 
1.07 -2.50 -2.68 4.61 0.0000001951 
222026_at RBM3 RNA binding motif (RNP1, RRM) protein 3 5935 -2.28 -5.05 -2.22 6.69 0.0000000001 
208873_s_at REEP5 receptor accessory protein 5 7905 -1.23 -3.34 -2.72 8.96 0.0000000000 
204319_s_at RGS10 regulator of G-protein signaling 10 6001 -1.09 -2.25 -2.06 5.55 0.0000042374 
213397_x_at RNASE4 ribonuclease, RNase A family, 4 6038 -1.83 -4.43 -2.42 8.06 0.0000000000 
205158_at RNASE4 ribonuclease, RNase A family, 4 6038 -1.86 -4.14 -2.22 7.27 0.0000000000 
226885_at RNF217 ring finger protein 217 154214 -1.83 -5.46 -2.99 5.30 0.0000000069 
240806_at RPL15 Ribosomal protein L15 6138 -1.29 -2.79 -2.15 5.81 0.0000050770 
216247_at RPS20 ribosomal protein S20  26795 -1.59 -3.38 -2.13 5.03 0.0000000118 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
228176_at S1PR3 sphingosine-1-phosphate receptor 3 1903 -5.01 -23.73 -4.74 6.81 0.0000000000 
212425_at SCAMP1 secretory carrier membrane protein 1 9522 -1.09 -2.27 -2.08 4.92 0.0000042523 
238078_at SEC22A SEC22 vesicle trafficking protein homolog A (S. 
cerevisiae) 
26984 -1.15 -2.33 -2.03 5.52 0.0000060618 
227038_at SGMS2 sphingomyelin synthase 2 166929 -3.48 -8.07 -2.32 4.46 0.0000002306 
225056_at SIPA1L2 signal-induced proliferation-associated 1 like 2 57568 -6.91 -14.69 -2.13 6.11 0.0000000000 
227506_at SLC16A9 solute carrier family 16, member 9 (monocarboxylic 
acid transporter 9) 
220963 -1.38 -4.25 -3.08 6.37 0.0000000012 
235763_at SLC44A5 solute carrier family 44, member 5 204962 -2.26 -11.43 -5.06 5.71 0.0000000005 
1569112_at SLC44A5 solute carrier family 44, member 5 204962 -1.87 -4.00 -2.14 5.03 0.0000000006 
223748_at SLC4A11 solute carrier family 4, sodium borate transporter, 
member 11 
83959 -1.39 -3.13 -2.25 6.74 0.0000000004 
226550_at SLC9A7 solute carrier family 9, subfamily A (NHE7, cation 
proton antiporter 7), member 7 
84679 -3.88 -12.03 -3.10 4.88 0.0000000008 
1558105_a_at SLC9A7 solute carrier family 9, subfamily A (NHE7, cation 
proton antiporter 7), member 7 
84679 -4.74 -9.89 -2.09 4.35 0.0000000006 
230782_at SORD sorbitol dehydrogenase 6652 -2.28 -4.98 -2.19 5.80 0.0000000011 
222557_at STMN3 stathmin-like 3 50861 -1.33 -3.84 -2.88 6.57 0.0000000457 
213413_at STON1 stonin 1 11037 -1.14 -2.37 -2.08 4.55 0.0000000276 
224724_at SULF2 sulfatase 2 55959 2.61 -6.43 -16.79 6.29 0.0000000000 
233555_s_at SULF2 sulfatase 2 55959 3.07 -2.00 -6.13 5.22 0.0000000003 
227480_at SUSD2 sushi domain containing 2 56241 -1.23 -2.65 -2.15 6.07 0.0000002287 
232760_at TEX15 testis expressed 15 56154 -1.36 -3.77 -2.77 7.87 0.0000000120 
214476_at TFF2 trefoil factor 2 7032 -1.11 -2.97 -2.68 7.36 0.0000000441 
203786_s_at TPD52L1 tumor protein D52-like 1 7164 -1.36 -3.31 -2.43 7.14 0.0000000003 
202242_at TSPAN7 tetraspanin 7 7102 -2.98 -14.73 -4.95 5.37 0.0000000003 
235561_at TXNL1 thioredoxin-like 1 9352 -2.45 -5.34 -2.18 5.20 0.0000000010 
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Gene 
Fold Change 
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p value NT vs 
CTRL 
S2 vs 
CTRL 
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NT 
238462_at UBASH3B ubiquitin associated and SH3 domain containing B 84959 -3.25 -6.75 -2.08 5.66 0.0000000000 
1556095_at UNC13C unc-13 homolog C (C. elegans) 440279 -2.93 -7.16 -2.44 4.69 0.0000000109 
1556096_s_at UNC13C unc-13 homolog C (C. elegans) 440279 -2.61 -5.67 -2.17 6.63 0.0000000000 
227399_at VGLL3 vestigial like 3 (Drosophila) 389136 -3.25 -9.82 -3.02 6.36 0.0000000001 
239680_at WDR76 WD repeat domain 76 79968 -1.54 -3.39 -2.20 5.38 0.0000000082 
243024_at ZNF394 zinc finger protein 394 84124 -1.28 -4.58 -3.57 5.62 0.0000000177 
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Appendix B 
Differentially expressed probe sets (n = 298, representing 211 genes) that were 
upregulated in the SULF2 knockdown HuH-7 cells with ≥ 2-fold change and 
adjusted p value ≤ 0.01 as compared to both NT shRNA and control untransduced 
HuH-7 cells (alphabetically ordered). Data generated using Affymetrix microarray 
gene expression analysis as described in Section 2.22 
 
CTRL: control untransduced cells 
NT: NT shRNA-transduced cells 
S2: SULF2 knockdown cells 
Ave Expr: average expression 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
235152_at --- --- --- 1.48 3.03 2.05 4.34 0.0000001040 
236750_at --- --- --- 1.53 3.24 2.12 4.58 0.0000012971 
239914_at --- --- --- 1.11 2.55 2.29 3.17 0.0000018992 
222288_at --- --- --- 2.39 5.60 2.34 6.08 0.0000000137 
237400_at --- --- --- 1.72 4.24 2.47 4.21 0.0000000125 
232827_at --- --- --- 1.13 3.18 2.81 4.48 0.0000000030 
239767_at --- --- --- 1.04 2.99 2.88 3.65 0.0000005319 
1558871_at --- --- --- -1.27 2.28 2.88 4.09 0.0000002019 
1561195_at --- --- --- -1.35 2.18 2.95 5.88 0.0001746303 
1563494_at --- --- --- -1.22 2.66 3.25 4.03 0.0000006241 
231035_s_at --- --- --- 1.36 5.61 4.12 5.43 0.0000046434 
242967_at --- --- --- -1.04 23.58 24.57 4.50 0.0000000000 
209993_at ABCB1 ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 
5243 1.42 6.34 4.47 8.66 0.0000000000 
209994_s_at ABCB1 /// 
ABCB4 
ATP-binding cassette, sub-family B (MDR/TAP), 
member 1 /// ATP-binding cassette, sub-family B 
(MDR/TAP), member 4 
5243 /// 
5244 
1.37 5.71 4.18 8.99 0.0000000000 
1554918_a_at ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4 
10257 2.95 7.51 2.55 5.92 0.0000000000 
1555039_a_at ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 4 
10257 1.63 4.91 3.01 4.29 0.0000000002 
222257_s_at ACE2 angiotensin I converting enzyme (peptidyl-
dipeptidase A) 2 
59272 -1.39 31.80 44.21 6.57 0.0000000000 
219962_at ACE2 angiotensin I converting enzyme (peptidyl-
dipeptidase A) 2 
59272 -1.51 63.03 95.13 6.45 0.0000000000 
206262_at ADH1C alcohol dehydrogenase 1C (class I), gamma 
polypeptide 
126 -1.33 2.75 3.66 3.90 0.0000000255 
222458_s_at AKIRIN1 akirin 1 79647 1.32 2.63 2.00 7.59 0.0000069899 
215241_at ANO3 anoctamin 3 63982 1.05 2.57 2.45 6.39 0.0000000015 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
208323_s_at ANXA13 annexin A13 312 -3.08 2.42 7.43 5.92 0.0000000001 
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like 3B 
9582 2.81 7.05 2.51 5.88 0.0000000000 
205980_s_at ARHGAP8 /// 
PRR5-
ARHGAP8 
Rho GTPase activating protein 8 /// PRR5-
ARHGAP8 readthrough 
23779 /// 
553158 
-1.11 2.66 2.95 3.80 0.0000023559 
37117_at ARHGAP8 /// 
PRR5-
ARHGAP8 
Rho GTPase activating protein 8 /// PRR5-
ARHGAP8 readthrough 
23779 /// 
553158 
-1.13 4.27 4.83 4.10 0.0000000000 
242230_at ATXN1 ataxin 1 6310 1.82 3.66 2.01 5.96 0.0000000858 
225612_s_at B3GNT5 /// 
LOC100505668 
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 /// uncharacterized 
LOC100505668 
100505668 
/// 84002 
1.04 3.06 2.95 7.56 0.0000000095 
210347_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 53335 1.04 2.14 2.07 4.78 0.0000010982 
222891_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 53335 1.09 2.49 2.28 4.82 0.0000001175 
219497_s_at BCL11A B-cell CLL/lymphoma 11A (zinc finger protein) 53335 1.12 2.70 2.41 4.20 0.0000000566 
205780_at BIK BCL2-interacting killer (apoptosis-inducing) 638 -1.30 3.30 4.28 6.04 0.0000000001 
223631_s_at C19orf33 chromosome 19 open reading frame 33 64073 -1.31 2.38 3.11 7.50 0.0000000040 
228865_at C1orf116 chromosome 1 open reading frame 116 79098 1.48 3.44 2.32 4.83 0.0000001162 
219476_at C1orf116 chromosome 1 open reading frame 116 79098 1.35 4.38 3.25 4.09 0.0000000000 
238965_at C21orf2 Chromosome 21 open reading frame 2 755 -1.17 2.14 2.51 5.90 0.0000000492 
1552575_a_at C6orf141 chromosome 6 open reading frame 141 135398 -1.18 2.15 2.54 5.23 0.0000017441 
1552390_a_at C8orf47 chromosome 8 open reading frame 47 203111 -1.15 2.76 3.18 6.76 0.0000000110 
1552389_at C8orf47 chromosome 8 open reading frame 47 203111 -1.17 3.39 3.96 5.16 0.0000000587 
209301_at CA2 carbonic anhydrase II 760 -1.29 2.25 2.90 8.40 0.0000000006 
204865_at CA3 carbonic anhydrase III, muscle specific 761 -1.13 5.07 5.71 3.45 0.0000000152 
206208_at CA4 carbonic anhydrase IV 762 -1.19 6.94 8.26 7.17 0.0000000000 
206209_s_at CA4 carbonic anhydrase IV 762 -1.27 13.51 17.19 7.34 0.0000000000 
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Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
225627_s_at CACHD1 cache domain containing 1 57685 -1.14 2.37 2.69 6.53 0.0000000077 
212763_at CAMSAP2 calmodulin regulated spectrin-associated protein 
family, member 2 
23271 1.10 2.25 2.05 6.23 0.0000003004 
205114_s_at CCL3 /// 
CCL3L1 /// 
CCL3L3 
chemokine (C-C motif) ligand 3 /// chemokine (C-C 
motif) ligand 3-like 1 /// chemokine (C-C motif) 
ligand 3-like 3 
414062 /// 
6348 /// 
6349 
1.03 8.86 8.62 4.75 0.0000000005 
1553043_a_at CD300LF CD300 molecule-like family member f 146722 -1.01 3.34 3.38 4.47 0.0000000000 
201925_s_at CD55 CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
1604 1.14 2.27 2.00 7.14 0.0000004828 
218451_at CDCP1 CUB domain containing protein 1 64866 1.07 2.94 2.76 5.11 0.0000000212 
207149_at CDH12 cadherin 12, type 2 (N-cadherin 2) 1010 5.67 37.04 6.53 4.74 0.0000000000 
209847_at CDH17 cadherin 17, LI cadherin (liver-intestine) 1015 -6.42 5.77 37.09 8.54 0.0000000000 
235287_at CDK6 cyclin-dependent kinase 6 1021 1.21 2.96 2.44 4.20 0.0000013778 
226187_at CDS1 CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
1040 -1.27 2.52 3.20 5.85 0.0000000426 
226185_at CDS1 CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
1040 -1.29 3.20 4.12 7.05 0.0000000000 
205709_s_at CDS1 CDP-diacylglycerol synthase (phosphatidate 
cytidylyltransferase) 1 
1040 -1.29 4.31 5.56 6.81 0.0000000016 
206387_at CDX2 caudal type homeobox 2 1045 -1.12 2.62 2.94 6.05 0.0000000019 
211657_at CEACAM6 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen) 
4680 1.02 10.29 10.11 5.47 0.0000000002 
203757_s_at CEACAM6 carcinoembryonic antigen-related cell adhesion 
molecule 6 (non-specific cross reacting antigen) 
4680 1.04 10.98 10.57 4.19 0.0000000000 
211848_s_at CEACAM7 carcinoembryonic antigen-related cell adhesion 
molecule 7 
1087 -1.11 3.16 3.51 4.08 0.0000000007 
206198_s_at CEACAM7 carcinoembryonic antigen-related cell adhesion 
molecule 7 
1087 -1.01 4.43 4.45 2.97 0.0000000106 
206199_at CEACAM7 carcinoembryonic antigen-related cell adhesion 
molecule 7 
1087 -1.09 42.22 46.09 4.71 0.0000000000 
203973_s_at CEBPD CCAAT/enhancer binding protein (C/EBP), delta 1052 -1.13 2.17 2.45 9.51 0.0000000028 
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Probe Set ID Gene Symbol Gene Title 
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Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
202790_at CLDN7 claudin 7 1366 1.61 4.47 2.78 5.84 0.0000000387 
213317_at CLIC5 chloride intracellular channel 5 53405 1.00 4.36 4.34 3.48 0.0000000046 
217404_s_at COL2A1 collagen, type II, alpha 1 1280 3.12 6.48 2.08 7.31 0.0000000000 
215076_s_at COL3A1 collagen, type III, alpha 1 1281 1.44 4.08 2.83 6.60 0.0000000000 
201852_x_at COL3A1 collagen, type III, alpha 1 1281 1.40 4.00 2.86 5.94 0.0000000000 
211980_at COL4A1 collagen, type IV, alpha 1 1282 1.50 3.07 2.05 4.90 0.0000001012 
205713_s_at COMP cartilage oligomeric matrix protein 1311 2.63 8.09 3.08 5.15 0.0000000000 
206212_at CPA2 carboxypeptidase A2 (pancreatic) 1358 -1.17 3.70 4.33 6.46 0.0000000004 
210262_at CRISP2 cysteine-rich secretory protein 2 7180 2.01 6.13 3.05 4.64 0.0000000002 
201219_at CTBP2 C-terminal binding protein 2 1488 -1.29 2.69 3.48 4.59 0.0000000073 
201220_x_at CTBP2 C-terminal binding protein 2 1488 -1.86 3.22 6.00 6.41 0.0000000037 
210554_s_at CTBP2 C-terminal binding protein 2 1488 -2.40 4.50 10.79 6.48 0.0000000001 
210835_s_at CTBP2 C-terminal binding protein 2 1488 -2.74 4.63 12.66 5.96 0.0000000000 
201218_at CTBP2 C-terminal binding protein 2 1488 -3.10 5.20 16.14 5.26 0.0000000000 
206085_s_at CTH cystathionase (cystathionine gamma-lyase) 1491 1.81 3.85 2.13 5.93 0.0000000080 
225647_s_at CTSC cathepsin C 1075 1.16 2.42 2.08 8.60 0.0000000067 
202901_x_at CTSS cathepsin S 1520 3.08 6.55 2.12 4.95 0.0000000040 
202902_s_at CTSS cathepsin S 1520 3.46 9.95 2.87 6.61 0.0000000000 
207852_at CXCL5 chemokine (C-X-C motif) ligand 5 6374 1.39 2.89 2.08 3.65 0.0000000893 
215101_s_at CXCL5 chemokine (C-X-C motif) ligand 5 6374 2.49 6.66 2.67 8.43 0.0000000001 
242138_at DLX1 distal-less homeobox 1 1745 1.47 4.24 2.88 4.11 0.0000000107 
204455_at DST /// 
LOC100652766 
dystonin /// dystonin-like 100652766 
/// 667 
1.31 3.42 2.61 6.40 0.0000000006 
225275_at EDIL3 EGF-like repeats and discoidin I-like domains 3 10085 -1.02 14.08 14.34 7.51 0.0000000000 
222802_at EDN1 endothelin 1 1906 1.08 2.73 2.54 8.88 0.0000000169 
218995_s_at EDN1 endothelin 1 1906 -1.03 2.53 2.62 9.12 0.0000000077 
  
 
2
9
3
 
Probe Set ID Gene Symbol Gene Title 
Entrez 
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p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
204271_s_at EDNRB endothelin receptor type B 1910 17.99 57.85 3.22 8.00 0.0000000005 
206701_x_at EDNRB endothelin receptor type B 1910 10.58 36.31 3.43 6.47 0.0000000011 
201842_s_at EFEMP1 EGF containing fibulin-like extracellular matrix 
protein 1 
2202 1.03 2.21 2.14 9.94 0.0000000005 
210827_s_at ELF3 E74-like factor 3 (ets domain transcription factor, 
epithelial-specific ) 
1999 1.03 2.34 2.26 7.01 0.0000000002 
227803_at ENPP5 ectonucleotide 
pyrophosphatase/phosphodiesterase 5 (putative) 
59084 1.89 4.01 2.13 4.80 0.0000000264 
214053_at ERBB4 v-erb-a erythroblastic leukemia viral oncogene 
homolog 4 (avian) 
2066 -1.38 3.41 4.71 5.09 0.0000000001 
219121_s_at ESRP1 epithelial splicing regulatory protein 1 54845 1.09 4.27 3.91 4.17 0.0000000013 
225846_at ESRP1 epithelial splicing regulatory protein 1 54845 1.11 9.45 8.53 4.72 0.0000000000 
224453_s_at ETNK1 ethanolamine kinase 1 55500 -1.01 2.36 2.39 5.22 0.0000000715 
224454_at ETNK1 ethanolamine kinase 1 55500 -1.04 2.88 2.98 4.09 0.0000002352 
1554576_a_at ETV4 ets variant 4 2118 1.13 2.41 2.14 6.86 0.0000000038 
230147_at F2RL2 coagulation factor II (thrombin) receptor-like 2 2151 1.20 4.29 3.58 5.39 0.0000000002 
218510_x_at FAM134B family with sequence similarity 134, member B 54463 2.17 8.52 3.93 5.52 0.0000000000 
218532_s_at FAM134B family with sequence similarity 134, member B 54463 2.63 11.06 4.20 5.69 0.0000000000 
223204_at FAM198B family with sequence similarity 198, member B 51313 -1.97 7.06 13.87 6.93 0.0000000000 
202766_s_at FBN1 fibrillin 1 2200 -1.82 2.10 3.83 8.49 0.0000000000 
232064_at FER fer (fps/fes related) tyrosine kinase 2241 1.39 2.85 2.05 5.26 0.0003999943 
239178_at FGF9 fibroblast growth factor 9 (glia-activating factor) 2254 1.09 2.18 2.00 2.83 0.0000056468 
206404_at FGF9 fibroblast growth factor 9 (glia-activating factor) 2254 1.29 3.55 2.75 4.36 0.0000000237 
204437_s_at FOLR1 folate receptor 1 (adult) 2348 1.55 4.97 3.21 4.79 0.0000000003 
227475_at FOXQ1 forkhead box Q1 94234 -1.23 2.28 2.80 6.66 0.0000000845 
208782_at FSTL1 follistatin-like 1 11167 1.55 3.24 2.08 10.52 0.0000000000 
203988_s_at FUT8 fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 2530 1.08 2.19 2.02 7.90 0.0000000080 
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1554930_a_at FUT8 fucosyltransferase 8 (alpha (1,6) 
fucosyltransferase) 
2530 1.07 2.57 2.41 6.25 0.0000001497 
209602_s_at GATA3 GATA binding protein 3 2625 1.81 3.99 2.20 3.16 0.0000000460 
202832_at GCC2 GRIP and coiled-coil domain containing 2 9648 1.22 18.68 15.34 7.98 0.0000000000 
221577_x_at GDF15 growth differentiation factor 15 9518 1.14 2.32 2.03 10.01 0.0000000004 
204472_at GEM GTP binding protein overexpressed in skeletal 
muscle 
2669 -1.67 2.55 4.25 4.56 0.0000000017 
214071_at GNAL guanine nucleotide binding protein (G protein), 
alpha activating activity polypeptide, olfactory type 
2774 2.18 5.07 2.33 5.84 0.0000000020 
204115_at GNG11 guanine nucleotide binding protein (G protein), 
gamma 11 
2791 1.14 2.96 2.60 6.34 0.0000000231 
204324_s_at GOLIM4 golgi integral membrane protein 4 27333 1.19 2.62 2.21 7.08 0.0000542395 
217771_at GOLM1 golgi membrane protein 1 51280 -2.31 4.37 10.11 8.38 0.0000000000 
207174_at GPC5 glypican 5 2262 -1.41 2.07 2.90 3.85 0.0000001952 
235733_at GXYLT2 glucoside xylosyltransferase 2 727936 2.62 5.36 2.04 5.47 0.0000000001 
235371_at GXYLT2 glucoside xylosyltransferase 2 727936 2.44 6.21 2.55 5.78 0.0000000002 
214500_at H2AFY H2A histone family, member Y 9555 1.05 2.12 2.02 6.02 0.0000000098 
205659_at HDAC9 histone deacetylase 9 9734 -1.17 2.18 2.55 8.06 0.0000000034 
242601_at HEPACAM2 HEPACAM family member 2 253012 1.51 3.25 2.15 4.05 0.0000001032 
203903_s_at HEPH hephaestin 9843 -1.88 19.74 37.14 4.51 0.0000000000 
232271_at HNF4G hepatocyte nuclear factor 4, gamma 3174 1.09 2.40 2.20 7.64 0.0000000017 
239153_at HOTAIR HOX transcript antisense RNA (non-protein coding) 1E+08 -1.28 3.65 4.67 3.72 0.0000000016 
213150_at HOXA10 homeobox A10 3206 -1.91 2.11 4.03 5.69 0.0000000017 
209905_at HOXA10-
HOXA9  
HOXA10-HOXA9 readthrough /// homeobox A9 100534589 
/// 3205 
-1.70 2.50 4.23 6.09 0.0000000023 
214651_s_at HOXA10-
HOXA9 /// 
MIR196B  
HOXA10-HOXA9 readthrough /// homeobox A9 /// 
microRNA 196b 
100534589 
/// 3205 /// 
442920 
-1.67 2.80 4.67 6.70 0.0000000007 
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231786_at HOXA13 homeobox A13 3209 -1.43 3.39 4.84 3.76 0.0000000171 
213844_at HOXA5 homeobox A5 3202 -1.37 2.13 2.91 4.67 0.0000001983 
228904_at HOXB3 homeobox B3 3213 1.02 9.80 9.58 4.12 0.0000000000 
205366_s_at HOXB6 homeobox B6 3216 -1.16 5.81 6.74 4.18 0.0000000000 
204778_x_at HOXB7 homeobox B7 3217 -1.09 4.57 4.97 5.17 0.0000000017 
216973_s_at HOXB7 homeobox B7 3217 1.12 12.70 11.39 4.22 0.0000000000 
204779_s_at HOXB7 homeobox B7 3217 1.02 18.06 17.74 4.16 0.0000000000 
229667_s_at HOXB8 homeobox B8 3218 1.10 2.46 2.24 2.89 0.0000001374 
226461_at HOXB9 homeobox B9 3219 1.10 3.67 3.33 3.94 0.0000000008 
205975_s_at HOXD1 homeobox D1 3231 1.42 11.18 7.85 5.72 0.0000000000 
229400_at HOXD10 homeobox D10 3236 -1.21 3.80 4.60 4.55 0.0000000017 
205522_at HOXD4 homeobox D4 3233 1.12 4.65 4.16 5.82 0.0000000002 
242042_s_at HOXD-AS1 HOXD cluster antisense RNA 1 (non-protein 
coding) 
401022 1.12 4.91 4.40 4.34 0.0000000005 
228601_at HOXD-AS1 HOXD cluster antisense RNA 1 (non-protein 
coding) 
401022 1.11 4.89 4.40 6.14 0.0000000005 
229493_at HOXD-AS2 HOXD cluster antisense RNA 2 (non-protein 
coding) 
1.01E+08 -1.30 3.49 4.53 5.38 0.0000000001 
206172_at IL13RA2 interleukin 13 receptor, alpha 2 3598 1.34 11.34 8.45 4.02 0.0000000000 
206693_at IL7 interleukin 7 3574 -1.43 2.86 4.07 3.84 0.0000000299 
205376_at INPP4B inositol polyphosphate-4-phosphatase, type II, 
105kDa 
8821 -1.03 2.24 2.32 3.00 0.0000016223 
235046_at INPP4B inositol polyphosphate-4-phosphatase, type II, 
105kDa 
8821 1.31 4.59 3.50 3.76 0.0000000359 
225303_at KIRREL kin of IRRE like (Drosophila) 55243 6.46 14.17 2.19 5.64 0.0000000000 
209211_at KLF5 Kruppel-like factor 5 (intestinal) 688 1.08 2.85 2.63 8.94 0.0000000004 
209212_s_at KLF5 Kruppel-like factor 5 (intestinal) 688 -1.02 3.72 3.78 7.99 0.0000000001 
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204734_at KRT15 keratin 15 3866 1.05 2.22 2.11 4.54 0.0000022952 
202267_at LAMC2 laminin, gamma 2 3918 -1.36 5.20 7.08 6.14 0.0000000000 
205569_at LAMP3 lysosomal-associated membrane protein 3 27074 1.70 5.83 3.42 5.78 0.0000000043 
1554679_a_at LAPTM4B lysosomal protein transmembrane 4 beta 55353 1.40 3.19 2.28 10.56 0.0000000002 
242006_at LCA5 Leber congenital amaurosis 5 167691 1.68 3.62 2.16 4.94 0.0000000491 
244401_at LCA5 Leber congenital amaurosis 5 167691 1.53 4.40 2.88 5.28 0.0000001128 
212325_at LIMCH1 LIM and calponin homology domains 1 22998 -1.57 2.40 3.78 6.29 0.0000000905 
1561367_a_at LINC00540 long intergenic non-protein coding RNA 540 1.01E+08 1.99 7.86 3.95 4.92 0.0000000000 
209465_x_at LOC100287705 
/// PTN 
uncharacterized LOC100287705 /// pleiotrophin 100287705 
/// 5764 
1.76 6.13 3.49 6.15 0.0000000003 
209466_x_at LOC100287705 
/// PTN 
uncharacterized LOC100287705 /// pleiotrophin 100287705 
/// 5764 
1.36 5.18 3.82 6.92 0.0000000001 
211737_x_at LOC100287705 
/// PTN 
uncharacterized LOC100287705 /// pleiotrophin 100287705 
/// 5764 
1.74 6.89 3.96 7.20 0.0000000000 
227452_at LOC100499467 uncharacterized LOC100499467 1E+08 2.02 5.83 2.89 7.66 0.0000000000 
227880_s_at LOC100506234 
/// TMEM185A 
uncharacterized LOC100506234 /// 
transmembrane protein 185A 
100506234 
/// 84548 
-1.37 2.47 3.39 5.56 0.0000000893 
1560425_s_at LOC100506247 uncharacterized LOC100506247 1.01E+08 1.59 3.56 2.24 3.55 0.0000000009 
232504_at LOC285628 /// 
MIR146A 
uncharacterized LOC285628 /// microRNA 146a 285628 /// 
406938 
-1.02 2.09 2.14 3.59 0.0003179666 
204298_s_at LOX lysyl oxidase 4015 4.60 10.76 2.34 8.05 0.0000000000 
227688_at LRCH2 leucine-rich repeats and calponin homology (CH) 
domain containing 2 
57631 1.83 8.96 4.91 4.41 0.0000000002 
231861_at LRP10 low density lipoprotein receptor-related protein 10 26020 1.10 2.26 2.05 6.46 0.0000000886 
219631_at LRP12 low density lipoprotein receptor-related protein 12 29967 9.04 19.44 2.15 6.28 0.0000000000 
220253_s_at LRP12 low density lipoprotein receptor-related protein 12 29967 6.12 15.24 2.49 5.49 0.0000000000 
220254_at LRP12 low density lipoprotein receptor-related protein 12 29967 4.37 11.53 2.64 4.77 0.0000000000 
220622_at LRRC31 leucine rich repeat containing 31 79782 -2.00 4.71 9.43 5.52 0.0000000026 
  
 
2
9
7
 
Probe Set ID Gene Symbol Gene Title 
Entrez 
Gene 
Fold Change 
Ave 
Expr 
Adjusted 
p value NT vs 
CTRL 
S2 vs 
CTRL 
S2 vs 
NT 
233499_at LRRC7 leucine rich repeat containing 7 57554 -1.04 2.81 2.92 3.27 0.0000008869 
218918_at MAN1C1 mannosidase, alpha, class 1C, member 1 57134 1.21 3.23 2.68 5.03 0.0000000041 
221884_at MECOM MDS1 and EVI1 complex locus 2122 -1.08 2.13 2.29 8.13 0.0000013594 
206000_at MEP1A meprin A, alpha (PABA peptide hydrolase) 4224 1.02 5.40 5.30 9.38 0.0000000000 
225478_at MFHAS1 malignant fibrous histiocytoma amplified sequence1 9258 -1.01 2.87 2.91 8.99 0.0000000000 
213457_at MFHAS1 malignant fibrous histiocytoma amplified sequence1 9258 -1.10 2.97 3.27 8.90 0.0000000001 
225102_at MGLL monoglyceride lipase 11343 1.14 6.64 5.84 8.05 0.0000000000 
211026_s_at MGLL monoglyceride lipase 11343 1.29 8.47 6.56 8.01 0.0000000000 
207233_s_at MITF microphthalmia-associated transcription factor 4286 -2.65 2.10 5.55 5.32 0.0000000001 
226066_at MITF microphthalmia-associated transcription factor 4286 -3.63 2.97 10.76 5.18 0.0000000005 
204918_s_at MLLT3 myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 3 
4300 3.06 14.26 4.65 5.38 0.0000000002 
204917_s_at MLLT3 myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 3 
4300 2.08 10.42 5.01 6.97 0.0000000000 
1569652_at MLLT3 myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 3 
4300 1.45 8.41 5.80 4.69 0.0000000015 
209708_at MOXD1 monooxygenase, DBH-like 1 26002 -1.24 2.18 2.71 6.73 0.0000000004 
1554474_a_at MOXD1 monooxygenase, DBH-like 1 26002 -1.22 2.26 2.76 6.72 0.0000000042 
205675_at MTTP microsomal triglyceride transfer protein 4547 1.13 2.26 2.00 10.92 0.0000000014 
222712_s_at MUC13 mucin 13, cell surface associated 56667 1.06 8.02 7.58 4.24 0.0000000000 
218687_s_at MUC13 mucin 13, cell surface associated 56667 -1.14 9.13 10.42 6.43 0.0000000000 
220196_at MUC16 mucin 16, cell surface associated 94025 2.26 5.79 2.56 4.88 0.0000000013 
206797_at NAT2 N-acetyltransferase 2 (arylamine N-acetyltransferase) 10 1.25 3.51 2.81 6.42 0.0000000001 
206964_at NAT8B N-acetyltransferase 8B (GCN5-related, putative, 
gene/pseudogene) 
51471 -1.15 2.83 3.24 5.55 0.0000000076 
211466_at NFIB nuclear factor I/B 4781 1.29 3.05 2.36 3.70 0.0000150754 
223218_s_at NFKBIZ nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 
64332 -1.03 2.20 2.27 10.23 0.0000000071 
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223217_s_at NFKBIZ nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, zeta 
64332 -1.09 2.85 3.11 8.61 0.0000000090 
202238_s_at NNMT nicotinamide N-methyltransferase 4837 -2.11 4.78 10.10 6.64 0.0000000000 
202237_at NNMT nicotinamide N-methyltransferase 4837 -3.41 4.85 16.57 7.21 0.0000000000 
229233_at NRG3 neuregulin 3 10718 -1.07 2.10 2.25 4.36 0.0000000352 
215020_at NRXN3 neurexin 3 9369 1.46 3.05 2.09 4.12 0.0000000001 
229649_at NRXN3 neurexin 3 9369 5.26 13.06 2.48 6.86 0.0000000000 
205795_at NRXN3 neurexin 3 9369 3.25 8.06 2.48 5.40 0.0000000006 
206291_at NTS neurotensin 4922 -10.33 -4.18 2.47 11.59 0.0000000000 
205552_s_at OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa 4938 1.64 4.21 2.57 4.77 0.0000000005 
1554524_a_at OLFM3 olfactomedin 3 118427 1.70 3.60 2.12 4.01 0.0000000003 
217525_at OLFML1 olfactomedin-like 1 283298 1.19 2.71 2.27 4.31 0.0000000077 
226140_s_at OTUD1 OTU domain containing 1 220213 1.35 7.01 5.18 8.20 0.0000000000 
203058_s_at PAPSS2 3'-phosphoadenosine 5'-phosphosulfate synthase 
2 
9060 1.03 2.46 2.39 9.15 0.0000000672 
242871_at PAQR5 progestin and adipoQ receptor family member V 54852 1.71 7.29 4.27 6.27 0.0000000000 
232054_at PCDH20 protocadherin 20 64881 1.51 26.92 17.82 5.47 0.0000000000 
205535_s_at PCDH7 protocadherin 7 5099 -2.01 2.41 4.83 4.44 0.0000000027 
239443_at PCDHB6 protocadherin beta 6 56130 -1.09 2.03 2.22 5.83 0.0000006945 
216867_s_at PDGFA platelet-derived growth factor alpha polypeptide 5154 -1.23 2.02 2.50 6.20 0.0000000147 
218273_s_at PDP1 pyruvate dehyrogenase phosphatase catalytic 
subunit 1 
54704 1.34 4.23 3.16 4.52 0.0000064423 
203691_at PI3 peptidase inhibitor 3, skin-derived 5266 -1.87 6.97 13.02 6.67 0.0000000000 
41469_at PI3 peptidase inhibitor 3, skin-derived 5266 -1.82 8.33 15.19 6.17 0.0000000000 
216218_s_at PLCL2 phospholipase C-like 2 23228 1.42 3.28 2.32 5.49 0.0000000065 
219756_s_at POF1B premature ovarian failure, 1B 79983 1.12 2.59 2.30 4.05 0.0000008710 
1552670_a_at PPP1R3B protein phosphatase 1, regulatory subunit 3B 79660 1.08 2.17 2.01 4.84 0.0000002397 
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219127_at PRR15L proline rich 15-like 79170 -1.57 2.07 3.25 5.54 0.0000008616 
216470_x_at PRSS2 protease, serine, 2 (trypsin 2) 5645 1.27 4.73 3.72 5.82 0.0000000014 
205402_x_at PRSS2 protease, serine, 2 (trypsin 2) 5645 1.17 4.47 3.83 6.21 0.0000000008 
207463_x_at PRSS3 protease, serine, 3 5646 1.96 21.14 10.78 6.88 0.0000000000 
213421_x_at PRSS3 protease, serine, 3 5646 1.72 19.87 11.53 6.98 0.0000000000 
215395_x_at PRSS3P2 protease, serine, 3 pseudogene 2 154754 1.30 2.92 2.24 6.03 0.0000000118 
222611_s_at PSPC1 paraspeckle component 1 55269 1.23 2.51 2.04 6.05 0.0000007085 
205171_at PTPN4 protein tyrosine phosphatase, non-receptor type 4 
(megakaryocyte) 
5775 1.33 3.06 2.31 7.84 0.0000000005 
214043_at PTPRD protein tyrosine phosphatase, receptor type, D 5789 20.59 51.00 2.48 5.99 0.0000000000 
205712_at PTPRD protein tyrosine phosphatase, receptor type, D 5789 1.68 4.18 2.49 3.70 0.0000000019 
213362_at PTPRD protein tyrosine phosphatase, receptor type, D 5789 3.47 9.94 2.86 5.30 0.0000000003 
243001_at RBFA ribosome binding factor A (putative) 79863 1.09 2.62 2.42 5.66 0.0000000685 
203498_at RCAN2 regulator of calcineurin 2 10231 1.66 3.83 2.30 5.66 0.0000009286 
218723_s_at RGCC regulator of cell cycle 28984 1.41 3.56 2.53 5.33 0.0000000020 
202388_at RGS2 regulator of G-protein signaling 2, 24kDa 5997 -1.06 2.37 2.52 9.26 0.0000000037 
241703_at RUNDC3B RUN domain containing 3B 154661 1.28 3.71 2.89 5.50 0.0000000168 
215321_at RUNDC3B RUN domain containing 3B 154661 -1.03 3.09 3.20 4.39 0.0000000034 
1552367_a_at SCIN scinderin 85477 -1.22 2.64 3.22 3.91 0.0000029479 
1552365_at SCIN scinderin 85477 -1.30 4.60 5.98 4.00 0.0000000002 
223449_at SEMA6A sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6A 
57556 -1.34 2.06 2.76 6.51 0.0000000029 
225660_at SEMA6A sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6A 
57556 -1.72 2.29 3.95 6.73 0.0000000023 
215028_at SEMA6A sema domain, transmembrane domain (TM), and 
cytoplasmic domain, (semaphorin) 6A 
57556 -1.95 2.28 4.43 5.24 0.0000000211 
202376_at SERPINA3 serpin peptidase inhibitor, clade A (alpha-1 
antiproteinase, antitrypsin), member 3 
12 1.78 5.29 2.97 6.31 0.0000000000 
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223196_s_at SESN2 sestrin 2 83667 1.19 2.37 2.00 6.91 0.0000000684 
206664_at SI sucrase-isomaltase (alpha-glucosidase) 6476 -11.37 5.18 58.88 6.06 0.0000000000 
239345_at SLC19A3 solute carrier family 19, member 3 80704 -1.36 3.10 4.22 8.17 0.0000000001 
220736_at SLC19A3 solute carrier family 19, member 3 80704 -1.17 4.35 5.09 7.12 0.0000000003 
206143_at SLC26A3 solute carrier family 26, member 3 1811 -1.81 2.11 3.82 5.71 0.0000000193 
206354_at SLCO1B3 solute carrier organic anion transporter family, 
member 1B3 
28234 -4.62 2.01 9.30 5.63 0.0000000012 
226743_at SLFN11 schlafen family member 11 91607 1.39 19.46 13.98 4.46 0.0000000000 
1553423_a_at SLFN13 schlafen family member 13 146857 1.12 3.35 3.00 3.82 0.0000013893 
203021_at SLPI secretory leukocyte peptidase inhibitor 6590 -1.28 11.36 14.50 6.75 0.0000000000 
1568574_x_at SPP1 Secreted phosphoprotein 1 6696 1.66 3.97 2.39 3.33 0.0000335438 
209875_s_at SPP1 secreted phosphoprotein 1 6696 3.29 10.30 3.13 10.49 0.0000000000 
204011_at SPRY2 sprouty homolog 2 (Drosophila) 10253 1.43 2.90 2.03 9.42 0.0000000006 
233888_s_at SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 57522 1.03 2.57 2.50 6.18 0.0000000576 
1554473_at SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 57522 -1.10 2.49 2.74 3.96 0.0000001127 
227484_at SRGAP1 SLIT-ROBO Rho GTPase activating protein 1 57522 1.12 3.85 3.44 7.35 0.0000000003 
231969_at STOX2 storkhead box 2 56977 -1.02 2.14 2.19 5.77 0.0000000362 
203767_s_at STS steroid sulfatase (microsomal), isozyme S 412 1.65 3.30 2.00 7.74 0.0000000003 
203768_s_at STS steroid sulfatase (microsomal), isozyme S 412 1.41 2.99 2.12 5.79 0.0000000368 
219992_at TAC3 tachykinin 3 6866 1.33 3.34 2.51 6.07 0.0000000362 
209277_at TFPI2 tissue factor pathway inhibitor 2 7980 1.05 6.75 6.43 5.74 0.0000000002 
209278_s_at TFPI2 tissue factor pathway inhibitor 2 7980 -1.00 8.71 8.72 7.41 0.0000000000 
203167_at TIMP2 TIMP metallopeptidase inhibitor 2 7077 1.34 3.10 2.30 6.62 0.0000000002 
224560_at TIMP2 TIMP metallopeptidase inhibitor 2 7077 -1.08 2.17 2.35 8.38 0.0000000002 
231579_s_at TIMP2 TIMP metallopeptidase inhibitor 2 7077 -1.10 2.20 2.43 8.89 0.0000000002 
206271_at TLR3 toll-like receptor 3 7098 1.98 4.30 2.17 4.37 0.0000001751 
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220639_at TM4SF20 transmembrane 4 L six family member 20 79853 -1.36 2.91 3.97 4.42 0.0000000054 
226489_at TMCC3 transmembrane and coiled-coil domain family 3 57458 3.89 8.71 2.24 6.38 0.0000000000 
1554105_at TMEM185A transmembrane protein 185A 84548 1.07 2.86 2.68 5.30 0.0000000003 
226226_at TMEM45B transmembrane protein 45B 120224 -2.40 3.87 9.28 7.66 0.0000000003 
230323_s_at TMEM45B transmembrane protein 45B 120224 -5.62 4.69 26.38 6.68 0.0000000000 
228574_at TMTC2 transmembrane and tetratricopeptide repeat 
containing 2 
160335 1.45 3.50 2.41 4.80 0.0000000253 
235775_at TMTC2 transmembrane and tetratricopeptide repeat 
containing 2 
160335 1.26 3.38 2.68 3.13 0.0000001297 
201688_s_at TPD52 tumor protein D52 7163 1.04 2.47 2.38 9.21 0.0000000007 
243952_at TPTEP1 transmembrane phosphatase with tensin homology 
pseudogene 1 
387590 1.09 3.86 3.55 7.24 0.0000000000 
202504_at TRIM29 tripartite motif containing 29 23650 1.14 2.44 2.14 4.33 0.0000004942 
210159_s_at TRIM31 tripartite motif containing 31 11074 1.74 5.69 3.27 5.99 0.0000000003 
215444_s_at TRIM31 tripartite motif containing 31 11074 3.22 15.07 4.68 6.16 0.0000000001 
208170_s_at TRIM31 tripartite motif containing 31 11074 2.97 17.99 6.06 5.32 0.0000000000 
203824_at TSPAN8 tetraspanin 8 7103 -3.09 2.27 7.01 9.32 0.0000000000 
227388_at TUSC1 tumor suppressor candidate 1 286319 6.34 14.53 2.29 6.75 0.0000000000 
211184_s_at USH1C Usher syndrome 1C (autosomal recessive, severe) 10083 -2.54 2.09 5.29 5.87 0.0000000002 
205139_s_at UST uronyl-2-sulfotransferase 10090 1.05 2.10 2.00 2.97 0.0000004782 
218806_s_at VAV3 vav 3 guanine nucleotide exchange factor 10451 1.41 5.42 3.84 4.45 0.0000000003 
218807_at VAV3 vav 3 guanine nucleotide exchange factor 10451 1.82 7.76 4.27 6.15 0.0000000000 
220528_at VNN3 vanin 3 55350 -1.33 2.26 3.02 6.82 0.0000000070 
210861_s_at WISP3 WNT1 inducible signaling pathway protein 3 8838 -1.28 2.10 2.69 7.30 0.0000000083 
221958_s_at WLS wntless homolog (Drosophila) 79971 -2.02 2.80 5.65 7.37 0.0000000000 
228949_at WLS wntless homolog (Drosophila) 79971 -2.22 3.04 6.74 5.00 0.0000000032 
228950_s_at WLS wntless homolog (Drosophila) 79971 -2.00 3.65 7.30 5.35 0.0000000008 
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213425_at WNT5A wingless-type MMTV integration site family, 
member 5A 
7474 -1.99 3.26 6.48 4.18 0.0000000017 
205990_s_at WNT5A wingless-type MMTV integration site family, 
member 5A 
7474 -2.60 3.27 8.50 5.02 0.0000000000 
1555800_at ZNF385B zinc finger protein 385B 151126 1.46 3.69 2.53 3.92 0.0000001228 
1555801_s_at ZNF385B zinc finger protein 385B 151126 1.93 5.82 3.01 3.99 0.0000000024 
228988_at ZNF711 zinc finger protein 711 7552 13.99 29.98 2.14 5.33 0.0000000000 
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Appendix C 
Affymetrix microarray gene expression analysis procedure:  
For transcriptional profiling, Affymetrix Human Genome U133 plus 2.0 arrays were 
used, and this was preformed by the Center of Physiology and Pathophysiology, 
Institute of Neurophysiology, Cologne, Germany. The reagents and instrumentation 
regarding microarrays were acquired from Affymetrix (Affymetrix, Santa Clara, CA, 
USA, http://www.affymetrix.com). For biotin-labelling and RNA amplification, 100 
ng total RNA was used with GeneChip 3’ IVT Express kit according to the 
manufacturer’s instructions (Affymetrix). The amplified RNA (aRNA) was purified 
using magnetic beads and 15 μg of aRNA was fragmented in fragmentation buffer. 
For hybridization (Affymetrix HWS kit) 12.5 μg fragmented aRNA was hybridized 
with Affymetrix GeneChip Human Genome U133 plus 2.0 arrays along with 
hybridization cocktail solution and then placed in Genechip Hybridization Oven-645 
(Affymetrix), rotating at 60 rpm at 45°C for 16 hours (hrs). For staining with 
streptavidin-phycoerythrin and washing, the Affymetrix HWS kit was used 
according to the manufacturer’s washing and staining protocol using a Genechip 
Fluidics Station-450 (Affymetrix). The stained arrays were scanned with Affymetrix 
GeneChip Scanner-3000-7G and the quality control analysis were performed with 
Affymetrix GCOS software. 
To analyse the data, background correction, normalization and summarization 
were performed using Robust Multi-array Average (RMA) normalization method. 
Differential expression of probe sets has been determined by the linear model 
implementation of R Limma Package followed by a Benjamini Hochberg multiple 
testing correction and the corrected p value were provided as adjusted p value. 
Fold change value calculation between the conditions were provided in normal 
scale.  
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